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Abstract 
Age-related macular degeneration (AMD) is the leading cause of blindness 
worldwide, affecting an estimated 50 million individuals aged over 65 years. 
Environmental and genetic risk-factors contribute to the development of AMD. An 
AMD-risk locus on chromosome 10q26 spans two genes, ARMS2 and HTRA1, and 
controversy exists as to which variants are responsible for increased risk of disease. 
Recent work suggests that HTRA1 expression levels ar  ignificantly increased in 
carriers of the risk haplotype associated with AMD. However, relatively little is 
known about the interactions, substrate specificity and roles in disease played by this 
secreted serine protease.   
This thesis aims to elucidate the potential role played by HTRA1 in AMD 
pathogenesis. A combination of tandem affinity purification (TAP) and yeast two-
hybrid techniques was used to identify interacting partners of HTRA1. A number of 
proteins, with diverse roles in the alternative complement pathway, cell signaling, 
cell-matrix interactions, inflammation, angiogenesis and fibrosis, were identified. 
These are attractive candidates for further study as such processes are disturbed in 
AMD, implicating HTRA1 and its binding partners in disease development.  
One interacting partner, Complement Factor D (CFD), is a key activator in 
the alternative complement pathway. CFD, a 24 kDa serine protease, is expressed as 
an inactive zymogen, from which a signal peptide and ctivation peptide are cleaved 
before release of the mature, active protein into the circulation. In vitro studies show 
that CFD interacts with, and can be a substrate for, HTRA1. The interacting domain 
between the two proteins is localised to a region of 30 amino acids at the N-terminal 
end of proCFD. The 5 amino acid pro-peptide of CFD appears to be both necessary 
and sufficient for proteolysis of CFD by HTRA1.  
Investigation of the functional relevance of the interaction between HTRA1 
and CFD shows that proCFD is cleaved by HTRA1, whilst mature CFD is not 
subjected to proteolysis. HTRA1-mediated cleavage of CFD forms an active 
protease, leading to activation of factor B in the alt rnative complement pathway in 
in vitro assays. Furthermore, a normal complement response is restored to CFD-
depleted serum by addition of proCFD activated by HTRA1. Thus, an HTRA1-
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mediated increase in alternative complement pathway activity may explain a 
proportion of the AMD-risk attributed to the chr10q26 locus.  
Genetic and protein-based approaches were used to study the potential role of 
CFD in AMD pathogenesis, independent of an interaction with HTRA1. An intronic 
SNP, rs3826945, was significantly associated with increased risk of AMD in two 
British case-control cohorts, and in a combined meta-analysis with 4 additional 
cohorts from North America and Europe (p-value = 0.032, Odds Ratio = 1.112 in 
4765 cases and 2693 controls). Assessment of copy number variation and 
sequencing of CFD did not identify any functional vriants which may explain the 
association with disease. However, plasma levels of CFD were measured by ELISA 
in 751 AMD cases and 474 controls, and were found to be significantly elevated in 
AMD cases compared to controls (p-value = 0.00025). This further implicates 
complement activation in AMD pathogenesis, and makes CFD an attractive 
candidate for therapeutic intervention. An alteration in the level of activated CFD, 
possibly mediated via an interaction with HTRA1, eith r at the systemic or local 
tissue level, may play a role in disease development and progression. 
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1.1            Age-related macular degeneration (AM D) 
Age-related macular degeneration (AMD) is the leading cause of blindness in people 
aged over 65 years in developed countries (VanNewkirk et al. 2000; Friedman et al. 
2004). AMD leads to the progressive impairment of central vision as the macula 
degenerates over time. Loss of central vision has profound consequences on an 
individual, affecting the ability to perform tasks such as reading and writing. As life 
expectancy increases, the burden placed by AMD upon individuals, their carers and 
society will increase. Due to the increasing number of affected individuals 
worldwide and the current lack of treatment options, a comprehensive understanding 
of this disease is very important.  
 
1.1.1  Global prevalence of AMD  
In the UK, it has been estimated that 3.7% of peopl aged over 75 years suffer from 
visual impairment as a consequence of AMD (Evans et al. 2004). This proportion 
rises steeply to affect 14.4% of individuals aged over 90 years (Evans et al. 2004). 
Similar studies in the USA have found that 30% of peo le aged over 75 years show 
signs of maculopathy, with 6-8% affected by advanced AMD (Klein et al. 1992; 
Friedman et al. 2004). 
This suggests that in the UK and the USA, more than2 million people aged 
over 75 years are afflicted by visual impairment as a result of severe AMD, with 
many millions more affected by early stages of age-related maculopathy (ARM). As 
the elderly population in developed countries continues to grow, the prevalence of 
AMD can be expected to rise.  
 
1.1.2   The eye 
The major features of the human eye are shown schematically in cross-section in 
Figure 1.1. Maintenance of homeostasis in the eye and correct functioning of the 
cellular phototransduction pathway requires a highly ordered tissue structure and 
normal cell-cell relationships. In AMD, retinal pigment epithelial cell dysfunction 
leads to photoreceptor cell death, and the disruption of tissue structure. 






Figure 1.1  A cross-section of the human eye.  
The eye is made up of three layers, enclosing the aqu ous humour, the vitreous and 
the lens. The cornea and sclera form the outermost layer, overlying the iris, ciliary 
body and the choroid. The retina is the innermost layer. The photoreceptor cells of 
the neural retina are separated from the blood supply in the choroid by the retinal 
pigment epithelium (RPE), resting on the collagen-rich Bruch’s membrane. The 
macula is a region of the retina approximately 6 mmin diameter that contains a high 








Figure 1.2 Structure of the vertebrate retina. 
Light enters the eye through the lens. Light must then travel through several layers of 
cells in the retina to reach the light-senstive photoreceptors. In the photoreceptors, 
photosensitive pigments including rhodopsin are activ ted, and signal transduction 
from the photoreceptor cells to the bipolar cells and ganglion cells is induced. 
Ganglion cell axons in the optic nerve transmit the impulse to the brain where the 
image is formed. 
 
Source: http://thalamus.wustl.edu/course/eye3.gif 
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1.1.2.1 The retina 
As shown in Figure 1.1, the retina lines the majority of the back of the eye. The 
retina is a multilayered neural structure (Figure 1.2), and processes light which enters 
the eye. Axons transmit nerve impulses initiated in the retinal photoreceptors to the 
brain via the optic nerve, except at the “blind spot” where the optic nerve enters the 
eye. Directly behind the lens at the posterior pole of the eye, the macula is a region of 
the retina approximately 6 mm in diameter that has a high concentration of densely 
packed photoreceptor cells known as cones (Figure 1.1). The fovea is the central 
region of the macula, and contains only cones. These specialised neurons receive 
visual stimuli, initiate phototransduction and are responsible for visual acuity 
(McIlwain, 1996).  
As shown in Figure 1.1 and 1.2, the photoreceptor cells of the retina are 
separated from their blood supply in the choroid by the retinal pigment epithelium 
(RPE), resting on the collagen-rich Bruch’s membrane in the extracellular matrix 
(ECM).  
 
1.1.2.1.1  Photoreceptor cells 
The photoreceptor cells of the retina (rods and cones) contain light-sensitive 
pigments which allow the absorption of light and transduction of nerve impulses in 
response. Cones are responsible for colour vision, and contain several different 
pigments derived from vitamin A and opsins, each detecting distinct wavelengths of 
light. Rods contain the pigment rhodopsin (11-cis retinaldehyde and opsin), and this 
is important in night vision. Light must pass through several layers of cells before 
reaching the photoreceptors (Figure 1.2). At the fov a, the anterior retinal layers are 
thinner than at the periphery, allowing more light to reach the cones at this location. 
 Vertebrate photoreceptors have a specialised cilium known as the outer 
segment which consists of large numbers of disc-like lamellae (Figure 1.2). These 
contain the photo-sensitive pigments of the rods and cones. The outer segment is 
connected to the inner segment by the ciliary stalk or connecting cilium. The inner 
segment guides light photons to the pigments in the out r segment, and also contains 
the numerous mitochondria required to meet the metabolic demands of the 
   
6 
 
photoreceptor. The inner segment is connected to the cell body in the outer nuclear 
layer (ONL), and from here to the synaptic terminal from which impulses are 
transmitted, through bipolar cells in the inner nuclear layer and ganglion cells in the 
ganglion cell layer (Figure 1.2). Ganglion cells transmit the nerve impulse to the 
brain in the optic nerve (McIlwain 1996). 
 
1.1.2.1.2 Retinal pigment epithelium (RPE) 
RPE cells are pigmented cells which form a monolayer, s parating the neural retina 
from the blood supply in the choroid (Figure 1.2). Outer segments of photoreceptor 
cells interdigitate with apical microvilli of the RPE. The basolateral RPE plasma 
membrane forms one of the five layers of the Bruch’s membrane.  
RPE cells have a crucial role in maintaining the blood-retinal barrier (Strauss 
2005). Furthermore, the RPE maintains exchange of oxygen and nutrients from the 
choroid to the photoreceptors, phagocytoses shed photoreceptor outer segments, and 
re-isomerises all-trans-retinal into 11-cis-retinal (Figure 1.3). The metabolic support 
of the RPE cells is vital to photoreceptors. Dysfunctional RPE may lead to the 
development of drusen deposits between the monolayer RPE and the underlying 
Bruch’s membrane, a hallmark of AMD (Penfold et al. 2001). Accumulation of 
waste products and debris in drusen over time may le d to inflammation (Hageman 
et al. 2001).  
 
1.1.2.1.3 Bruch’s membrane 
The pentalaminar Bruch’s membrane (BM) separates th RPE cells from the choroid 
(Figure 1.1, 1.2), and is involved in the exchange of biomolecules between these 
tissues. BM also has roles in adhesion of RPE cellsvia integrin cell-surface receptors 
and anchoring plaques (Marshall et al. 1992; Del Priore and Tezel 1998) and in 
restricting migration of cells in the RPE and choroid.  
 
 






Figure 1.3  The visual cycle. 
The visual cycle involves cycling of retinoids betwen the rod outer segments (OS; 
upper panel) and the RPE (lower panel). The visual cycle begins in the outer 
segment. Light activates rhodopsin, causing the release of all-trans retinal and 
initiating signal transduction. All-trans retinol is transported across the sub-retinal 
space by the carrier protein IRBP, and enters the RPE. All-trans-retinol is converted 
to all-trans-retinyl ester, then into 11-cis-retinol and finally into11-cis-retinal. The 
regenerated chromophore is transported back to the photoreceptors for further use.  
Source: (Rattner et al. 2000). 
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1.1.2.1.3.1 The layers of Bruch’s membrane 
The five layers of BM are the basement membrane of the RPE, the inner collagenous 
layer (ICL), the elastin layer (EL), the outer collagenous layer (OCL) and the 
basement membrane of the choriocapillaris. The diffrent components of these 
layers, indicated in Figure 1.4, are thought to be expressed mainly by the RPE and 
choroidal cells (van Soest et al. 2007; Booij et al. 2009).  
The basement membrane of both the RPE and choroid are rich in collagens 
type IV, fibronectin (FN)(Pauleikhoff et al. 1992), laminin (Aisenbrey et al. 2006) 
and heparin sulphate proteoglycans (HSPG (Hewitt et al. 1989)). The basement 
membrane of the choriocapillaris also contains collagens type V and VI. These are 
thought to play a role in platelet aggregation and epithelial cell migration (Narayanan 
and Page 1983) and in attaching BM to the choroidal endothelium (Marshall et al. 
1994) respectively. 
The ICL and the OCL are multi-layered grids, consisting of collagens type I, 
III and V. These layers of BM also contain glycosaminoglycans (Hewitt et al. 1989) 
and complement and coagulation proteins.  
The elastin layer is rich in elastin fibres, forming a layered sheet with 
perforations of approximately 1 µm forming between the elastin fibres. Collagen 
type VI is also present, along with collagen fibres extending from the collagenous 
layers to either side. TIMP3 (tissue inhibitor of metalloproteases 3) has also been 
identified in the EL (Booij et al. 2009). In a recent study of 121 donor eyes, the EL in 
the macular region was found to be up to six times thinner than the EL at the 
periphery in human eyes from all ages (Chong et al. 2005). This does not appear to 
correlate with topographical differences in expression of the elastin gene (although 
other components are expressed at a lower level in the macular region; van Soest et 
al. 2007), which suggests that BM may have regional differences in structure, 










Figure 1.4 Bruch’s membrane structure and compositi on. 
A schematic drawing of the layered Bruch’s membrane (BM), indicating the major 
proteins in each layer and the corresponding genes xpressed in RPE and choroidal 
cells. The DNA encoding these genes in the RPE and choroidal cells is shown as a 
double helix shape. The basement membranes of the RPE and choroid are 
abbreviated as bm RPE and bm choroid respectively.  
Source: Booij et al. (2010). 
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1.1.2.1.3.2  Diffusion of molecules across Bruch’s membrane 
Biomolecules such as oxygen, vitamin A and serum coponents move from the 
choroid to the RPE, and oxidised lipids and waste products are removed from the 
RPE across the BM. This is a largely passive process (Strauss 2005). Diffusion of 
these components is dependent on the pore size of BM layers, upon hydrostatic 
pressure and binding to BM components. This is influenced by the structure and 
composition of BM, and is further altered during agein  (Huang et al. 2007). 
  
1.1.2.1.3.3  Changes to the Bruch’s membrane during  normal ageing 
The structure and composition of BM changes during normal ageing. There is an 
increase in thickness of BM (van der Schaft et al. 1992; Ramrattan et al. 1994). This 
is partly due to more collagen cross-linking and differential turnover of 
proteoglycans such as heparan sulphate and chondroiti  sulphate (Hewitt et al. 1989; 
Inatani and Tanihara 2002). This also has implications for regulating inflammation, 
as heparan sulphate may have anti-inflammatory properties through its interaction 
with Complement Factor H (CFH; (Meri and Pangburn 1994). BM is further 
modified by deposition of calcium (van der Schaft et al. 1992), iron (Hahn et al. 
2003) and zinc (Lengyel et al. 2007) during ageing. Advanced glycation end 
products (AGEs) - chemically modified oxidised and glycosylated proteins and fats - 
accumulate on structural proteins in BM, causing age-related damage (Gugliucci et 
al. 2007). Lipids, including cholesterol, also accumulate in BM with age (Huang et 
al. 2007) and may build up preferentially in the macul r region compared to the 
periphery (Holz et al. 1994), although there is substantial variability between 
individuals.    
 As a consequence of BM thickening, the elasticity and permeability of the 
BM are compromised. This can lead to the accumulation of waste material between 
the BM and the RPE. These are called drusen deposits, and are classified by location, 
size and shape (de Jong 2006). Soft, confluent drusen are a major risk factor for 
AMD.   Thus, normal age-related changes in the BM may contribute to AMD 
pathology (Figure 1.5). 
 








Figure 1.5 Age-related changes in the retina. 
A comparison of the retina of a 3 year old child (left panel) and an 80 year old person 
(right panel) shows that there is an increase in thickness of the Bruch’s membrane, 
development of lipofuscin granules and accumulation of waste material in drusen 
between the BM and the RPE. In some individuals, these changes contribute to the 
development of AMD, by causing RPE and photoreceptor cell dysfunction and death. 
Source: de Jong (2006). 
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1.1.3   Clinical features of AMD 
Early or intermediate forms of macular degeneration, cli ically defined by small 
numbers of drusen deposits and pigment abnormalities, ar  considered as age-related 
maculopathy (ARM). These individuals often maintain normal visual acuity. AMD 
refers to more advanced cases of the disease, in which large confluent drusen, 
geographic atrophy (GA) or neovascularisation are observed (Figure 1.6).  
 
1.1.3.1  Dry AMD 
Over 80% of AMD cases are “dry” or atrophic, with progressive degeneration of 
RPE and photoreceptor cells causing central geographic trophy (GA). GA is 
characterized by hypopigmentation as a result of RPE cell death. Overlying 
photoreceptor cells die as a result of the loss of metabolic support provided by the 
RPE. This leads to blurring and gradual loss of central vision. Disease progression 
involves formation of sub-RPE drusen deposits, inflammation and lipofuscin 
accumulation (involving oxidative stress), as shown in Figure 1.5. Dry AMD may 
progress to exudative AMD in which neovascularisation occurs. 
  
1.1.3.1.1 Changes in the Bruch’s membrane 
During normal ageing, the Bruch’s membrane thickens, becomes less permeable and 
sub-RPE deposits are formed. The changes observed during normal ageing can 
contribute towards AMD pathology in a variety of ways (Figure 1.5).  Genetics and 
environmental factors can further contribute to these changes. 
Increased BM thickness affects the diffusion of biomolecules from the RPE 
and choroid, and leads to sub-RPE drusen deposits frming. Accumulation of AGEs 
may promote AMD (Yamada et al. 2006), whilst collagen cross-linking reduces 
turnover of BM components by decreasing the access of proteases to the 
pentalaminar structure (Ramrattan et al. 1994). This creates further thickening of the 
BM, exacerbating the restrictions in metabolite exchange and causing further drusen 
deposition. An increase in the proportion of heparan sulphate relative to other 
proteoglycans may alter the local regulation of inflammation (Meri and Pangburn 
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1994). Calcification of the BM has been correlated with AMD (Spraul et al. 1999), 
and has been proposed to make the EL brittle and susceptible to breaking, which may 
aid neovascularisation. Retinal degeneration can be i duced by oxidative stress 
caused by iron accumulation (Kurz et al. 2007). Furthermore, both iron and zinc may 
be involved in oligomerisation of CFH (Nan et al. 2008), a key regulator of the 
alternative complement pathway with a known role in AMD pathogenesis.        
 
1.1.3.1.2 Drusen 
In early stages of AMD, basal laminar deposits (BlamD) and basal linear deposits 
(BlinD) develop (Green and Enger 1993). BlamD are diffuse deposits between the 
plasma membrane and basal lamina of the RPE, whilst Bl nD develop within the ICL 
of Bruch’s membrane (Curcio and Millican 1999). The composition of these deposits 
differs; BlamD are composed of collagenous material and basement membranes, and 
BlinD are composed of vesicular matter. BlinD develop after BlamD, and are 
markers for AMD progression (Curcio and Millican 1999; Sarks et al. 2007). The 
third class of sub-RPE deposit characteristic of AMD are drusen. Drusen are focal 
deposits, positioned between the basement membrane of th RPE and the Bruch’s 
membrane (Figures 1.5 and 1.6).  
The characteristics of drusen vary, although they tend to develop in the 
macular region, and can be classified based on size, shape and colour as either hard 
or soft. Hard drusen are clinically defined as small, yellow punctate deposits that are 
<63 µm in diameter. Small numbers of hard drusen ar not a risk factor for AMD, 
and appear to increase in number during normal ageing (Fine et al. 2000). Soft 
drusen are larger (≤125 µm) amorphous deposits with less defined edges than hard 
drusen (Figure 1.6). Soft drusen are a significant risk factor for advanced AMD, 
especially if accompanied by alterations in pigmentation in the macular region (Klein 
et al. 2002).  
Drusen are considered the hallmark of AMD. Although the exact role of 
drusen in disease pathogenesis remains unclear, these deposits are likely to disrupt 
RPE and photoreceptor cells directly, and also by the activation of inflammatory 
responses (Anderson et al. 2002). The molecular composition of drusen has been 
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analysed by proteomic and immunohistochemical approaches, with more than 100 
proteins identified (Mullins et al. 2000; Russell et al. 2000; Hageman et al. 2001; 
Anderson et al. 2002; Crabb et al. 2002; Johnson et al. 2002). These proteins include 
components of the complement pathway, acute-phase inflammatory molecules, 
fibronectin, lipids, apolipoproteins B and E, glycopr teins and amyloid β (Crabb et 
al. 2002; Johnson et al. 2002). As many as 65% of the proteins identified are 
common to drusen from AMD and disease-free aged eyes, and many components are 
found in both hard and soft drusen  (Mullins et al. 2000; Anderson et al. 2002; Crabb 
et al. 2002; Johnson et al. 2002; Nozaki et al. 2006a). Dendritic cell processes have 
been identified in drusen deposits (Hageman et al. 2001). High levels of zinc have 
been detected in drusen deposits, and have been suggested to have a role in the 
accumulation and aggregation of deposits, such as has been observed in Alzheimer’s 
disease and Parkinson’s disease (Lengyel et al. 2007).  
Constituents of drusen appear to be produced by photoreceptor cells, RPE 
cells, choroidal cells and from the serum (Booij et al. 2009). Components of the 
complement pathway, including CFH and the membrane attack complex (MAC), are 
present in drusen. This implicates the alternative complement pathway and the innate 
immune response in the formation of drusen, disruption of the BM, and degeneration 
of RPE and photoreceptor cells observed in AMD (Anderson et al. 2002). This has 
been subsequently confirmed using genetic approaches. 
 
1.1.3.1.3 Lipofuscin deposits 
The development of lipofuscin deposits is thought to arise as a consequence of age-
related RPE cell dysfunction (Figure 1.5; (Feeney-Burns et al. 1984)). This prevents 
the transport of vitamin A derivatives required forthe visual cycle (Figure 1.3) and 
the phagocytosis of shed rod outer segments (Strauss 2005). Lipofuscin deposits are 
composed of oxidised lipids and proteins from photoreceptors, phagosomes and 
lysosomes. Oxidation of these proteins, including the cellular retinoid binding 
protein CRALBP, occurs as a result of exposure to high oxygen levels in the eye and 
to UVA and visible light (Sparrow and Boulton 2005; Warburton et al. 2005). 
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Lipofuscin contains the bisretinoid fluorophore A2E (N-retinylidene-N-
retinylethanolamine), a remnant of photoreceptor outer segments. A2E is a potent 
inducer of reactive oxidant species (ROS) and has cytotoxic properties, damaging 
proteins, lipids and DNA (Sparrow and Boulton 2005). A2E inhibits degradation of 
proteins by the lysosome in cultured RPE cells, consistent with lipofuscin generation 
as a result of incomplete digestion of rod outer segm nts.  
 
  
1.1.3.2 Choroidal neovascularisation in wet AMD 
In more severe cases of “wet” or exudative AMD, shown in Figure 1.6, 
neovascularisation occurs in the choroid of the sub-macular region. The adult retina 
has a high metabolic rate, and the highest relative oxygen requirement in the body. 
To meet these requirements the retina is provided with oxygen and nutrients from 
two circulatory systems, arising from the retina (supplying the inner 2/3 of the retina) 
and the choroid. Under normal conditions, the outer third of the retina contains no 
blood vessels, but obtains metabolites and oxygen from the choroidal vessels (Figure 
1.1). However, when there is a pathogenic increase in pro-angiogenic signalling 
(involving the balance of pro-angiogenic vascular endothelial growth factor (VEGF) 
to anti-angiogenic pigment epithelium derived factor (PEDF)) in the sub-retinal 
region, choroidal neovascularisation (CNV) can occur (Figure 1.6). New blood 
vessels originate from the choroid, penetrate the BM and spread into the subretinal 
space. Local inflammation may promote CNV formation in AMD, promoting 
secretion of VEGF by the RPE and injuring the BM. Bleeding through the fragile 
neovascular membrane leads to irreversible loss of central vision and fibrovascular 
scarring (Fine et al. 2000). Interestingly, wet AMD is more prevalent in Asian 
populations, often arising without any of the characteristic features of dry AMD, 
such as drusen (Klein et al. 2006). 
 




Figure 1.6 Clinical characteristics of age-related macular 
degeneration. 
A five stage grading criterion is often used for characterising age-related 
maculopathy (ARM) and age-related macular degeneration (AMD). (1) A healthy 
retina with no drusen. ARM is characterised by (2a) several small drusen (yellow 
spots) and no RPE changes; (2b) RPE alteration, but no drusen; (2c) both small 
drusen and RPE changes; (3a) several intermediate-size and large drusen; (3b) 
drusenoid RPE detachment. Late-stage AMD is characterised by (4) geographic 
atrophy or (5b) choroidal neovascularisation.  
Source: (Seddon et al. 2006b).   
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1.1.4   Therapeutic options for treatment of AMD 
At the present time, effective treatments for dry AMD are lacking. High doses of  
antioxidant and zinc supplements slowed AMD progression in a 5 year study 
involving 3640 AMD  cases (OR 0.72, 99% C.I. 0.52-0.98; (Age-Related Eye 
Disease Study Research 2001)). Recently, high dietary intake of zinc and other anti-
oxidants was found to reduce the hazard ratio of AMD for individuals with high 
genetic susceptibility (Ho et al. 2011). 
Therapeutic options for wet AMD, including anti-angio enic agents such as 
VEGF inhibitors, and photodynamic therapy, are aimed at preventing further loss of 
sight rather than reversing the course of the disease. VEGF-inhibitors are now the 
most commonly used therapy. Lucentis and Avastin (monoclonal antibodies against 
full-length VEGF, and a fragment of VEGF, respectively) have very similar 
beneficial responses in a recent clinical trial (CATT 2011).  
An increased understanding of the biological mechanisms behind AMD may 
provide new therapeutic targets, whilst identification of genetic risk-factors may aid 
in the early identification of at-risk individuals, allowing therapeutic intervention 
before photoreceptor death occurs. 
 
1.1.5   Underlying mechanisms of disease 
During the course of normal ageing, changes occur in the eye. These affect the 
metabolic activity and function of the RPE, photoreceptor survival, Bruch’s 
membrane structure and permeability and development of basal deposits and drusen. 
In some individuals, these changes contribute to the development of AMD 
pathology. Although the switch from normal ageing to disease processes is multi-
factorial, the underlying mechanisms of AMD which result in RPE dysfunction and 
photoreceptor cell death appear to be shared. 
 
1.1.5.1 Oxidative damage 
The combination of constant light exposure, high oxygen consumption and 
photoreactive compounds in the visual cycle means the retina is exposed to 
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substantial oxidative stress. Outer segments of photoreceptors are constantly 
phagocytosed by RPE cells (Tate et al. 1995). The retina is somewhat protected from 
oxidative damage by anti-oxidant enzymes including superoxide dismutase and 
glutathione peroxidase (Tate et al. 1995; Frank et al. 1999; Beatty et al. 2000). 
However, both the photoreceptors and RPE are highly susceptible to oxidative 
damage of DNA, proteins and lipids. This can cause cell death and has significant 
consequences on the structure and function of the retina, contributing to the 
pathogenesis of AMD.  
 
1.1.5.2  Mitochondrial dysfunction 
Mitochondria have been implicated in AMD and other age-related neurodegenerative 
diseases, such as Alzheimer’s disease (Lin and Beal 2006). Impaired energy 
metabolism and generation of reactive oxygen species is observed in dysfunctional 
mitochondria during aging, with a decrease in number of mitochondria seen in AMD 
retinas compared to controls (Feher et al. 2006). Deletions in the mitochondrial 
genome accumulate in the retina with age (Barron et al. 2001) and mutations in 
mitochondrial proteins are known to play a role in neurodegenerative eye diseases, 
including AMD (Carelli et al. 2004; Canter et al. 2008). Defective mitochondrial 
function may lead to apoptosis (Liang and Godley 2003) of RPE cells, and cause 
photoreceptor cell death as a result of diminished m tabolic support (Wallace 2005).  
 
1.1.5.3 Inflammation 
The innate immune system has been implicated in the pathogenesis of AMD for 
many years (Penfold et al. 1985; Hageman et al. 2001). Characterisation of the 
constituents of drusen showed that many proteins involved in the immune response 
were localised to these deposits, including immunoglobulins (IgG), complement 
component C5 and the terminal component of the comple ent pathway, the MAC 
(Crabb et al. 2002). Based on the high level of IgGdetected in the eyes of AMD 
cases, drusen formation was suggested to occur as a consequence of an immune 
response against antigens derived from the RPE (Johnson et al. 2000). The 
identification of acute-phase proteins such as C-reactive protein (CRP) and 
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vitronectin, activators of the complement pathway (C5, C5b-9, C3b and C3d) and the 
complement regulators membrane co-factor (CD46) and complement receptor 1 
(CR1), in drusen further implicated local inflammation (Hageman et al. 2001; 
Anderson et al. 2002). In addition to the immune-reactivity of drusen, the study by 
Anderson and colleagues of 400 AMD eyes also showed that some RPE cells had a 
build up of CRP and C5 in the cytoplasm, and that tis corresponded to dying cells 
(Anderson et al. 2002).  
These findings led to the hypothesis that RPE cell dysfunction is the primary 
event in AMD pathology, causing the accumulation of cellular debris. This acts as a 
trigger for pro-inflammatory signalling, inducing local expression of pro-
inflammatory molecules, recruitment of inflammatory cells, and activation of the 
alternative complement pathway. During this process, such molecules are deposited 
alongside the cellular debris to form drusen (Hageman et al. 2001, Anderson et al. 
2002). However, the exact mechanism of drusen biogenesis remains undetermined. 
 Subsequent work has identified a number of molecules derived from the RPE 
that are antigenic. A2E, a component of lipofuscin, is recognised as a non-self 
molecule (Zhou et al. 2006) and activates the comple ent cascade. Likewise, 
amyloid β co-localises with activated components of the comple ent pathway in 
drusen, and can trigger a local immune response throug  an interaction with 
Complement Factor I (Johnson et al. 2002; Wang et al. 2008). Carboxyethylpyrrole 
(CEP), an oxidatively modified fragment of the polyunsaturated fatty acid 
docosahexaenoic acid, can also promote a local immune response (Hollyfield et al. 
2008). Together, this suggests activation of the innate immune response as a result of 
complement-activating components of drusen may exacerb te RPE cell dysfunction 
by inducing bystander damage and leading to AMD. 
 
1.1.5.4 Phagocytes in AMD 
Phagocytes including macrophages, microglia and denritic cells are present in the 
healthy adult retina. Resident microglial cells contribute to neuronal homeostasis and 
immunoregulation (Langmann 2007). These cells are present in the retina since 
embryological development. Injury and degeneration of the retina activates the 
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microglia and leads to proliferation. The activated c lls secrete pro-inflammatory 
molecules, migrate to sites of injury and phagocytose debris (Langmann 2007). 
These cells are involved in the clearance of sub-RPE debris (Chen et al. 2002 ) and 
are detected in macular lesions in AMD eyes (Gupta et al. 2003). 
 
1.1.5.4.1  Macrophages in AMD 
 Macrophages are recruited from the blood supply in the choroid to clear the sub-
retinal deposits in the AMD eye (Forrester 2003). These cells have been localised to 
deposits in AMD eyes using electron microscopy (Killingsworth et al. 1990). 
Macrophages have also been identified near sites of RPE atrophy, CNV and in areas 
of Bruch’s membrane damage in AMD eyes (Penfold et al. 1985; Lopez et al. 1993; 
Dastgheib and Green 1994; Green 1999; Penfold et al. 2001; Grossniklaus et al. 
2002; Coleman et al. 2008) using histopathology.  
 The role of macrophages in CNV remains to be clarified. It seems that some 
macrophages combat CNV. Interleukin-10 deficient mice show decreased 
susceptibility to laser-induced CNV as a result of increased recruitment of 
macrophages to the site of injury (Apte et al. 2006). However, other macrophages 
appear to have a causative role in CNV (Espinosa-Heidmann et al. 2003; Sakurai et 
al. 2003). The uptake of dichloromethylene diphosphnate (Cl2MD)-containing 
liposomes causes macrophage death in mice. These mice show impaired macrophage 
recruitment to sites of laser injury on the retina, and this correlates with less severe 
CNV at these lesions.  
These contradictory findings are consistent with macrophages existing as two 
subtypes: pro-inflammatory M1 macrophages, and anti-inflammatory M2 
macrophages (Mantovani et al. 2004). M2 macrophages have been suggested to 
perform scavenging and tissue-remodelling, and may be recruited beneficially to 
clear drusen. Recruitment of M1 macrophages may be to the detriment of the tissue, 
inducing and worsening inflammation by expression of pr -inflammatory cytokines 
and promoting development of CNV (Mantovani et al. 2004).  
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1.1.5.5 Tissue metalloproteases and other proteases  
The balance between pro-angiogenic and anti-angiogen c signals is crucial to 
maintaining the appropriate vasculature for a healty tissue. Over-expression of pro-
angiogenic VEGF is necessary, but not sufficient, to induce neovascularisation from 
the choroid into the subretinal space. Additional ijury to the Bruch’s membrane 
appears to be required (Schwesinger et al. 2001). Matrix metalloproteinases (MMPs) 
are known to degrade components of the extracellular matrix (ECM), and appear to 
be required during angiogenesis.  
MMPs and the tissue inhibitor of metalloproteinases-3 enzyme (TIMP3) have 
been implicated in pathological processes underlying AMD (Guo et al. 1999; Kamei 
and Hollyfield 1999). Drusen deposits are lacking i MMP activity, suggesting 
proteolytic degradation of drusen may be compromised n AMD individuals (Leu et 
al. 2002). However, MMP9 has been reported to be elevated in plasma from 33 
AMD cases compared to 17 controls (Chau et al. 2007). In experimental models of 
laser-induced CNV, metalloproteinases MMP2 and MMP9 influence the severity of 
choroidal neovascularisation (Lambert et al. 2002; Lambert et al. 2003). A 
microsatellite polymorphism in the promoter of MMP9 was identified as a potential 
susceptibility factor for wet AMD (Fiotti et al. 2005). However, this study was small 
(107 cases and 223 controls) and the association has ot been replicated. 
Mutations in the gene encoding TIMP-3 cause Sorsby’s fundus dystrophy. 
This is a rare inherited form of macular degeneration associated with deposits in the 
Bruch’s membrane and sub-retinal neovascularisation (Weber et al. 1994). Large 
genome-wide association studies have identified an AMD-susceptibility locus near 
TIMP3 (Chen et al. 2010; Yu et al. 2011). The precise mechanism by which these 
proteases may be involved in AMD remains to be determined, although degradation 
of the ECM and the Bruch’s membrane may be important. 
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1.2   Risk factors for AMD 
AMD is a disease with complex etiology, arising through the interaction of genetic 
and environmental factors.  
 
1.2.1   Epidemiological risk factors 
Epidemiological studies have identified advanced age, smoking, ocular pigmentation, 
race, high blood pressure and diet as risk factors, along with family history (Klein et 
al. 2004). Increasing age undoubtedly has a substantial influence upon risk of 
developing AMD (Klein et al. 1997; Friedman et al. 2004). Cigarette smoking also 
greatly increases the risk of developing the disease (Christen et al. 1996; Seddon et 
al. 1996; Tomany et al. 2004). Caucasians are more susceptible to AMD, especially 
wet AMD, than Hispanic or black populations (Sommer et al. 1991; Cruickshanks et 
al. 1997). Obesity and high fat diets are both associated with increased risk of AMD 
(Mares-Perlman et al. 1995; Cho et al. 2001; Seddon et al. 2003b). Conversely, 
dietary factors such as antioxidants and omega-3-fatty acids, are protective (Seddon 
et al. 1994; Age-Related Eye Disease Study Research 2001; Seddon et al. 2003c). 
The contribution of other risk factors such as hypertension, high cholesterol levels, 
and sunlight exposure remains unclear.  
The combination of environmental risk factors acting to induce oxidative 
stress, or inflammation, over a lifetime is likely to contribute to the age-associated 
increase in AMD-risk.  
 
1.2.2   Genetic risk factors 
Familial aggregation studies indicate that as much as 25% of AMD cases have a 
genetic contribution (Klaver et al. 1998). First degree relatives of AMD cases have a 
50% risk of AMD, compared to 12% for relatives of disease-free controls (Klaver et 
al. 1998). A combination of linkage and association studies has elucidated the 
contribution of several genes to AMD.  
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1.2.2.1  Linkage studies 
Linkage analysis performed in multiple families and sibling-pairs suggest that 
susceptibility loci for AMD may be found on most chromosomes in the human 
genome. However, only two genomic regions have been stro gly replicated in such 
studies - a region on chromosome 1q25-31 (Majewski et al. 2003; Iyengar et al. 
2004) and another on chromosome 10q26 (Kenealy et al. 2004 ; Jakobsdottir et al. 
2005). Meta-analysis performed by Fisher et al. (2005) further implicated risk loci on 
chromosome 1q and chromosome 10q. Chromosomes 2p, 3p, 4q, 12q and 16q also 
showed evidence for linkage with AMD (Fisher et al. 2005). 
 
1.2.2.2  Association studies 
Recent advances in AMD genetics have been made using population-based 
association studies, utilising unrelated AMD cases and disease-free control subjects 
to identify causative alleles of genetic markers (such as single nucleotide 
polymorphisms, SNPs) or variants in linkage disequilibrium (LD) with disease-
causing alleles. A Manhattan plot summarising the peaks of association identified in 
the most recent genome-wide association scan for AMD in shown in Figure 1.7. 
 
1.2.3  Complement Factor H (CFH) 
Complement Factor H (CFH) on chromosome 1q31 was proposed as a candidate 
gene based on such analyses.  Klein et al. (2005) performed a genome-wide 
association scan of 96 cases and 50 controls for polymorphisms associated with 
AMD.  An intronic variant (rs380390) with a p-value less than 10-7, that increased 
the likelihood of developing AMD by a factor of 7.4 in homozygotes (95% 
confidence interval (C.I.) 2.9 -19) was identified. Re-sequencing of the CFH gene 
identified a T-C transition in exon 9 that was in linkage disequilibrium (LD) with 
rs380390, and results in a tyrosine to histidine change at position 402 of CFH. This 
region of the protein binds heparin and C-reactive protein (CRP) and controls the 
activity of CFH in regulation of the complement system (Klein et al. 2005). The 
association between AMD and the Y402H polymorphism in CFH was replicated in 
independent studies, all attributing a significantly increased risk of AMD to this 
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variant in heterozygotes (Edwards et al. 2005; Hageman et al. 2005; Haines et al. 
2005). Y402H is estimated to account for as much as 50% of the population-
attributable risk for AMD (Edwards et al. 2005).  
Hageman et al. (2005) also found an association between increased AMD 
susceptibility and I62V (rs800292) in CFH in two independent cohorts from North 
America (p=1.1 × 10-4 and p=3.2 × 10-7). The I62V variant is located in an exon 
splice enhancer (Wang et al. 2004). Li et al. (2006) found that 20 polymorphisms in 
and around CFH were more strongly associated with AMD than the Y402H variant 
in their cohort of 726 AMD cases and 286 controls. No single polymorphism was 
responsible for the increase in susceptibility; rather, haplotypes, including non-
coding variants, were formed which influenced risk (Li et al. 2006). The common, 
noncoding variant rs1410996 in CFH was also found to be associated with AMD 
(Maller et al. 2006). Thus it appears that there are several AMD-susceptibility alleles 
in and around the CFH gene on chromosome 1, including non-coding variants 
(Figure 1.8). Interestingly, allele frequencies of these variants in CFH differ 
substantially in Asian populations, and do not apper to confer the same risk of AMD 
(Gotoh et al. 2006).  
Membranoproliferative glomerulonephritis type II (MPGN II) is a disease 
with ocular manifestations identical to those observed in AMD (Mullins et al. 2001 ). 
In their analysis of CFH in 900 AMD cases and 400 controls, Hageman et al. (2005) 
also identified several common SNPs as risk factors associated with both AMD and 
MPGN II. Protective haplotypes for both diseases were also identified. Furthermore, 
CFH was detected in the macula and in drusen, providing evidence for a role for 
CFH in AMD pathogenesis (Hageman et al. 2005). Additional studies subsequently 
confirmed a role for CFH in AMD development (Conley et al. 2005; Magnusson et 
al. 2005; Zareparsi et al. 2005a).  
 









Figure 1.7  Major susceptibility loci for AMD ident ified in association 
studies. 
Genetic loci that substantially alter AMD-risk have b en identified by linkage and 
association studies. Recently, genome-wide associati n scans performed in 
thousands of AMD cases and controls have confirmed pr viously reported loci in 
CFH, CFI, CFB, C3 and ARMS2/HTRA1, and have identified new susceptibility loci 
near COL10A1, COL8A1, TIMP3, LIPC and VEGF.  In the Manhattan Plot shown 
above, SNPs showing a genome-wide significant associati n (threshold p-value 
shown by red line) with AMD are highlighted in red. Chromosomal position is 
indicated on the x-axis.  
Source: Yu et al. (2011). 
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1.2.4  Genetic association of additional complement  genes with 
AMD  
As a result of the identification of a major susceptibility factor in CFH, inflammation 
is considered to play an important role in the degen ration of the macula and in 
AMD pathogenesis. Several other components of the complement pathway (Figure 
1.10) have subsequently been implicated in AMD, providing further evidence for the 
damage caused by aberrant regulation of inflammatory processes in the eye. 
 
1.2.4.1 CFHR1 and CFHR3 
CFHR1 and CFHR3 genes, which are homologous to and located adjacent to CFH 
on chromosome 1q23, are deleted in a common protective haplotype (Figure 1.8). 
This results in a loss of detectable protein in the serum of homozygous carriers of the 
risk haplotype (Hughes et al. 2006); the functional consequence of this remains 
unclear. The protective effect of CFHR1 and CFHR3 deletion is independent of 
genotype at CFH Y402H (Hughes et al. 2006; Schmid-Kubista et al. 2009), but is 
slightly reduced by genotype at the intronic CFH SNP rs10737680 (Raychaudhuri et 
al. 2010), as shown in Figure 1.8. 







Figure 1.8  CFH, CFHR1 and  CFHR3 are associated with AMD 
susceptibility . 
CFHR1 and CFHR3 genes are homologous to, and located adjacent to, CFH on 
chromosome 1q23. (a) Variants in CFH, including Y402H and rs10737680, are 
significantly associated with AMD, and CFHR1 and CFHR3 are deleted in a 
common protective haplotype. (b) Raychaudhuri et al (2010) identified 7 haplotypes 
with frequencies >1%. Haplotypes are composed of the CFH Y402H proxy 
rs10801555, CFH rs10737680, deletion status of CFHR1–CFHR3 (empty circle, 
deleted; filled circle, not deleted), rs7542235 and rs800292 (CFH I62V). H1 is 
presented as the reference haplotype. SNP genotypes shaded in blue are the same as 
in H1, SNP genotypes different from H1 are shaded white. The observed frequency 
in controls and affected individuals and the odds ratio of disease for each haplotype 
relative to that of the most common haplotype, H1 is shown to the right.  
Source: Raychaudhuri et al. (2010). 
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1.2.4.2  Complement Factor B and C2 
The genes encoding Complement Factor B (BF/CFB) and complement component 2 
(C2) are located 500 bp apart on chromosome 6p21 in the major histocompatibility 
complex (MHC) class III region. In a study of 898 affected individuals and 389 
controls from two independent cohorts, two variants i  each gene were significantly 
associated with AMD (Gold et al. 2006). The L9H variant in CFB  and the E318D 
variant in C2 are located on the same protective haplotype for AMD (p=3.4 × 10−6, 
OR = 0.36 (95% confidence interval (C.I.) = 0.23–0.56)). A second highly protective 
haplotype consists of the R32Q allele in CFB and rs547154 in intron 10 of C2 and 
(p=2.1 × 10−7, OR = 0.45 (95% C.I. = 0.33–0.61)). A common risk haplotype was 
also identified (p=0.0013, OR = 1.32). High LD in this region makes it difficult to 
separate the relative contribution of the SNPs on these haplotypes, and to identify the 
gene responsible for increased risk. However, functio al studies of some of the 
coding changes in factor B show decreased enzyme activity, ability to form the 
convertase and activity in assays of complement activity for the protective variants 
(Lokki and Koskimies 1991; Montes et al. 2009). 
 
1.2.4.3  Complement component C3 ( C3) 
A variant in the complement C3 gene was recently associated with risk of developing 
AMD (Yates et al. 2007). In a study of 847 AMD cases and 701 unaffected controls, 
heterozygotes for the S/F variant (Arg102Gly) in theC3 gene had a 70% increased 
risk for AMD, whilst individuals homozygous for the F variant are at more than 
twice the risk of developing AMD. This may be responsible for an estimated 22% of 
population-attributable risk for the disease. Interestingly, like polymorphisms in CFH 
(Hageman et al. 2005; Montes et al. 2008), this variant has also been associated with 
MPGN II (Finn and Mathieson 1993). Functional studies have shown that the 102G 
variant activates the alternative complement pathway more efficiently than R102 
(Heurich et al. 2011). 
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1.2.4.4  Complement Factor I ( CFI) 
A variant 2781 bp downstream of the 3’ UTR of the gene encoding Complement 
Factor I (CFI) has also shown association with AMD. Located within a linkage peak 
on chromosome 4 (Fisher et al. 2005), the non-coding SNP rs10033900 was first 
significantly associated with AMD in a study of 1228 AMD cases and 825 controls 
(p=9.11 × 10−8; (Fagerness et al. 2009). Subsequent studies have replicated the 
association between rs10033900 and AMD in smaller groups of Caucasian (Ennis et 
al. 2009) and Japanese (Kondo et al. 2010) cases and controls. The causal variant in 
CFI has yet to be identified. 
 
1.2.5  The chromosome 10q26 risk locus 
Chromosome 10q26 has been shown by numerous groups t  contain AMD risk loci 
with an equivalent impact on AMD risk as CFH (Majewski et al. 2003; Seddon et al. 
2003d; Weeks et al. 2004; Fisher et al. 2005; Jakobsd ttir et al. 2005). Three genes, 
PLEKHA1, LOC387715 (ARMS2) and HTRA1 (also known as PRSS11) lie in a 200 
kb region of strong linkage disequilibrium, shown in Figure 1.9. Identification of the 







Figure 1.9  The chromosome 10q26 locus.   
Location of variants on chromosome 10 which are associated with AMD 
susceptibility in relation to candidate genes (not drawn to scale). Coding sequences 
of candidate genes are shaded in grey; untranslated regions are shown in black. 
Nucleotide positions and distances along chromosome 10 are derived from the NCBI 
Entrez Gene database. Figure adapted from (Allikmets and Dean 2008). 
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1.2.5.1  PLEKHA1  
Jakobsdottir et al. (2005) genotyped numerous SNPs in a region of chromosome 10 
spanning PLEKHA1, LOC387715 (ARMS2) and HTRA1 (Figure 1.9). SNP analysis 
in 612 AMD cases, 184 unrelated controls and 323 families suggested that variants in 
PLEKHA1, encoding TAPP1, a protein which may act in local lymphocyte 
activation, were responsible for increased susceptibility to AMD (Jakobsdottir et al. 
2005). 
 
1.2.5.2  ARMS2/LOC387715  
Rivera et al. (2005) studied the same region of chromosome 10q in two independent 
cohorts of AMD case-controls, and found that the strongest association with AMD 
(p= 10-34) arose from rs10490924, a coding change from alanine to serine at position 
69 (A69S) in the hypothetical locus LOC387715 (Figure 1.9). The A69S variant in 
LOC387715 was subsequently reported as a second major susceptibility allele for 
AMD following multi-variate analyses performed using A69S, smoking and the 
Y402H variant of CFH to test gene-gene and gene-environment interactions 
(Schmidt et al. 2006). However, no plausible role in AMD pathogenesis was 
proposed as there was an absence of any functional information for LOC387715 
(Rivera et al. 2005). The lack of functional information, together with the subsequent 
removal of LOC387715 from the GenBank database, led to the strong association on 
chromosome 10q26 being attributed to promoter variants in HTRA1, which are in 
complete LD with risk variants in LOC387715 and which may affect gene expression 
(Dewan et al. 2006). 
 
1.2.5.3  HTRA1  
Wet AMD is more prevalent in Asian populations than Caucasian, where 
approximately 10% of AMD cases have this more aggressiv  form of the disease. 
Dewan et al. (2006) performed a whole genome associati n scan of 96 wet AMD 
cases and 130 age-matched controls in a Chinese populati n to identify variants that 
increased susceptibility to the wet AMD phenotype. A single A-to-G SNP, 
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rs11200638, in complete LD with the SNP in LOC387715 previously associated with 
AMD, was identified (Rivera et al. 2005; Dewan et al. 2006). This variant, associated 
with a 10-fold increased risk for wet AMD in individuals homozygous for the A 
allele, lies in the promoter region of HTRA1 (Figure 1.9), in putative binding sites for 
transcription factor AP2α and serum response factor (SRF). Transcription of HTRA1 
was shown to be upregulated by the AA genotype, suggesting that the increased 
susceptibility to AMD arises as a result of increased HTRA1 expression and activity 
(Dewan et al. 2006). This theory gained support when increased HTRA1 mRNA and 
protein were detected in RPE from 4 AMD-affected inividuals carrying the AA risk 
allele (Yang et al. 2006). 
Yang et al. (2006) found that the promoter polymorphism in HTRA1 was also 
associated with AMD in Caucasians, causing an estimated 49.3% population-
attributable risk for AMD.   Furthermore, this varint also increases risk of 
developing dry AMD, and HTRA1 has been detected in rusen deposits in AMD-
affected eyes. Carrying a risk allele in either CFH or chromosome 10q26 accounts 
for an estimated 71.4% population-attributable riskof AMD, whilst possessing risk 
alleles in both HTRA1 and CFH increases the susceptibility to developing AMD by 
40-fold (Yang et al. 2006; Cameron et al. 2007). 
 
1.2.5.4 The contribution of LOC387715/ARMS2  to association at 
chromosome 10q26 
As reported by Dewan et al. (2006), LOC387715 was removed from the GenBank 
database, leading to a shift in focus to variants i HTRA1 which were associated with 
AMD. However, LOC387715 has subsequently been reinstated to the database, using 
the symbol ARMS2 (age-related maculopathy susceptibility 2). 
 
1.2.5.4.1  The SNP rs10490924 
Variants in LOC387715/ARMS2 have recently been gaining support as the true risk 
alleles for AMD on chromosome 10q26. Kanda et al. (2007) provided contradictory 
evidence to that of Dewan et al. (2006) as to the up-regulation of HTRA1 expression 
in individuals homozygous for the A allele at rs11200638. The region surrounding 
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rs11200638 was also shown not to bind the transcription factor AP2α, as 
hypothesised by Dewan et al. (2006). Furthermore, using logistic regression analysis 
to evaluate the contribution of multiple SNPs across a 220 kb region spanning 
PLEKHA1, LOC387715 (ARMS2) and HTRA1 to the strong association with AMD, 
Kanda and colleagues find that when rs10490924, the A69S variant in ARMS2, was 
included, no other SNPs showed evidence of significant association to the disease. 
This led to the suggestion that a single variant (rs10490924 or an ungenotyped 
variant in complete LD) is responsible for the large effect on disease susceptibility on 
chromosome 10q26 (Kanda et al. 2007). 
 
1.2.5.4.2 The ARMS2 3’ UTR indel 
A recent discovery of a combination of a 372 base pair deletion and a 54 base pair 
insertion in the 3’ UTR of the ARMS2 gene, which is significantly associated with 
AMD in 760 AMD cases and 549 controls (p = 4.1 x10-29), adds further weight to the 
argument for ARMS2 playing a role in AMD risk (Fritsche et al. 2008). This variant 
(in/del in Figure 1.9) is tightly linked to rs10490924 and several other SNPs, forming 
a risk haplotype with an 8.1-fold increased risk of AMD for homozygous individuals. 
The deletion removes a polyadenylation signal, whilst the insertion of an AU-rich 
element appears to lead to rapid mRNA decay in indiv duals with the indel 
polymorphism. As a consequence, expression of ARMS2 is not detected in 
homozygous carriers of the indel variant in some studies (Fritsche et al. 2008; Yang 
et al. 2010). 
Yang et al. (2010) also showed that a second coding change in ARMS2 – 
R38X – results in reduced ARMS2 mRNA and protein. This mutation is weakly 
protective for AMD, suggesting that loss of ARMS2 protein may be necessary but 
not sufficient to cause AMD. 
Wang et al. (2010) showed that the 3’ UTR indel consists of two adjacent 
indels, 17 base pairs apart. The indel was in strong LD with rs10490924 (D’ 0.99). 
As in previous reports, the indel was strongly associated with AMD (p=10-13). 
However, in this study the stability of the ARMS2 transcript did not appear to be 
affected by the indel. Furthermore, the indel was not associated with lower levels of 
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ARMS2 mRNA in retina or white blood cells. This led to further speculation that 
A69S is the causal variant at the chromosome 10q26 locus, although the functional 
consequences remain unknown. Mechanisms by which the proteins encoded by 
ARMS2 and HTRA1 may affect processes leading to AMD are outlined in Section 
1.4. 
 
1.2.6  Additional genetic risk factors remain to be  found 
In addition to the major risk loci in CFH and ARMS2/HTRA1, other loci which 
convey smaller risk effects have shown association or linkage with AMD. Such loci 
include VEGF, Fibulin 5, CST3, CX3CR1, TLR4, LRP6 and MMP9 genes (Stone et 
al. 2004; Tuo et al. 2004; Fiotti et al. 2005; Goverdhan et al. 2005; Zareparsi et al. 
2005b; Churchill et al. 2006; Haines et al. 2006). Most of these associations have not 
been replicated in subsequent (larger) studies. For example, TLR4, and other 
members of the toll-like receptor family, are unlike y to be involved in AMD 
susceptibility (Edwards et al. 2008). In the last year, genome-wide association scans 
performed in highly powered case-control cohorts comprising several thousand 
individuals have not found association with common variants in these genes. 
However, these large studies have identified associati n between AMD and variants 
in or near TIMP3, COL10A1, COL8A1, CETP, LIPC, LDL and ABCA1 (Chen et al. 
2010; Yu et al. 2011). The proteins encoded by these g nes have roles in the ECM 
(structural or degradation) and in lipid metabolism. Although replication of such 
associations has proved difficult, these and other unidentified susceptibility loci may 
play roles in drusen formation, neovascularisation and angiogenesis or in the 
inflammatory process.  
 
1.3   The Complement Systems 
The complement system is part of the innate immune system, providing protection 
against bacterial infection, clearing inflammatory debris and “complementing” 
adaptive immunity (Walport 2001). More than 30 plasm  and cell surface proteins 
are involved in the three pathways of Complement (Figure 1.10). Activation of the 
classical pathway, the alternative pathway and the mannose-binding lectin (MBL) 
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pathway induces an enzymatic cascade, cleaving C3, and leading to the formation of 
inflammatory mediators and the membrane attack complex (MAC). These processes 
result in cell lysis, inflammation and phagocytosis. Under normal conditions, 
complement pathways are tightly regulated to target invading microorganisms, whilst 
minimising deposition of complement on normal cells. Dysregulation of the 
complement pathways can have detrimental effects, as een in the alternative 
complement pathway in AMD. 
 
1.3.1  Activation of the alternative complement pat hway 
The alternative complement pathway is activated in response to bacteria, viruses, 
fungi and tumour cells. In plasma, C3 is spontaneously cleaved at low levels to form 
C3b. C3b contains an activated thioester bond which binds to hydroxyl groups on 
proteins and carbohydrates on target surfaces. This identifies surfaces as foreign, 
leading to further recruitment of C3b to the surface (Walport 2001, Figure 1.10). 
When C3b is deposited on the foreign surface, it can bind factor B, forming the 
C3bB pro-C3 convertase. When Factor B is bound to C3b, Factor D (CFD) binds this 
complex and cleaves factor B to Bb and Ba. The Ba fragment is released. The Bb 
fragment remains associated with C3b to form the unstable C3bBb complex (Xu et 
al. 2001). Properdin stabilises this complex (Walport 2001). This is the C3 
convertase of the alternative complement pathway which results in an amplification 
loop of C3b formation, and deposition on the foreign surface. The C5-convertase 
(C3bBbC3b) is subsequently formed, triggering formation of the MAC and cell lysis. 
 




Figure 1.10 The Complement Pathway.  
The Complement pathway is part of the innate immune system, and comprises of 
three pathways. Activation of the classical pathway, the alternative pathway and the 
mannose-binding lectin (MBL) pathway induces an enzymatic cascade, cleaving C3, 
and leading to the formation of inflammatory mediators and the membrane attack 
complex (MAC). Components of the alternative pathway, including Factor H, C3 
and Factor B, have been implicated in AMD. Source: Walport (2001). 
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1.3.2   Regulation of the alternative complement pa thway 
Dependent on the glycoproteins in the surrounding environment, immobilised C3b 
may bind to the plasma protein CFH rather than factor B. This is a crucial step in 
recognition of self, rather than foreign membranes, and in regulating complement 
activation (Pangburn et al. 2000). Host cell membranes contain polyanions such as 
sialic acid, which enables CFH to bind C3b with a higher affinity than factor B. 
Microorganisms do not have polyanions on their surface, and so factor B has higher 
affinity for C3b (Pangburn et al. 2000). When bound C3b interacts with CFH, C3b is 
catabolised to inactive products (iC3b and C3f) by factor I. Factor I is a regulatory 
protease which requires CFH as a co-factor. The cell membrane proteins complement 
receptor type 1 (CD35), and membrane cofactor protein (CD46) are also involved in 
decay of C3b (Riley-Vargas et al. 2004). Decay accelerating factor (DAF; CD55) 
dissociates the convertase complex (Kim and Song 2006). 
CFH is the only fluid-phase regulator of the alternative complement pathway, 
and is vital for the appropriate regulation of the pathway. CFH not only binds and 
inactivates C3b, but also immobilises complement cascade triggers, including CRP 
(Rodríguez de Córdoba et al. 2004). Thus, CFH modulates complement activation, 
dampening the inflammatory response. This reduces chronic inflammation that can 
cause tissue damage. CFH deficiency leads to MPGN II and hemolytic-uremic 
syndrome (Levy et al. 1986). 
 
1.3.3  Dysregulation of alternative complement path way in AMD 
The strong genetic association of alternative comple ent pathway genes, together 
with the identification of complement proteins in drusen by immunohistochemistry 
and proteomic approaches, clearly implicates this pathway in disease development. 
More recent studies have shown that alternative comple ent pathway components in 
plasma are also altered, consistent with activation of the pathway in AMD cases 
(Hakobyan et al. 2008; Scholl et al. 2008; Reynolds et al. 2009; Hecker et al. 2010). 
AMD risk-associated coding variants in CFH affect protein function. The 
402H risk variant appears to influence binding to surfaces containing sialic acid 
(Herbert et al. 2007; Prosser et al. 2007).  The protective CFH 62I variant binds C3b 
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more strongly than the V variant, and promotes inact v tion by factor I (Tortajada et 
al. 2009).  A protective variant in factor B, 32Q, forms the C3 convertase with C3b 
less efficiently than the wild-type protein, resulting in less activation of complement 
(Tortajada et al. 2009). The C3b fragment generated from the AMD-risk variant in 
C3 (102G) binds CFH less strongly than the non-risk 102R form of the protein, 
decreasing catabolism by factor I and enhancing C3 convertase activity by extending 
the lifetime of the convertase (Heurich et al. 2011).  
The role of non-coding variants, and the deletion of CFHR1 and CFHR3, is 
less clear, although these are likely to affect gene xpression. 
 
1.3.4 Animal models of AMD involving complement and  
inflammation 
Although mice lack a macula, the structure of the retina and function of the RPE 
cells is highly conserved between mouse and man. The use of mouse models in 
studying AMD is complicated by the shorter life-span of mice, and the differences in 
the immune systems of mice and humans. Another complication is that common 
polymorphisms associated with AMD in humans tend not to result in a complete loss 
of gene function, such as is studied in knock-out mice. Furthermore, AMD is a multi-
factorial disorder, and replicating genetic haplotypes and environmental risk factors 
is difficult. Despite this, mice have been used to study the role of genetic variants in 
AMD. A variety of such models have been reported to reproduce pathological 
features of AMD, implicating inflammation, oxidative stress and lipid metabolism in 
the disease (Zeiss 2010), although many of these findings are controversial.  
 
1.3.4.1   The Cfh–/– mouse 
In humans, a total deficiency of CFH causes systemic activation of the alternative 
complement pathway. This causes MPGN II (Levy et al. 1986).  This phenotype is 
replicated in the Cfh–/–mouse. These animals have significantly reduced systemic C3 
levels, develop glomerulonephritis and die by age of 12 - 15 months (Pickering et al. 
2002). Systemic C3 depletion caused by the loss of Cfh can be prevented by 
introduction of a second mutation in factor B (Pickering et al. 2002). Aged Cfh–/–
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mice (2 years) have been reported to have elevated lev ls of complement C3 
deposition in the photoreceptor layer. This was proposed to contribute to oxidative 
stress, photoreceptor loss and reduced rod photoreceptor function (Coffey et al. 
2007). In contrast to the characteristic Bruch’s membrane thickening and drusen 
observed in human AMD, the Cfh–/– mice have reduced Bruch’s membrane thickness 
and reduced sub-RPE deposits, indicating that this is not a true AMD-like phenotype.  
 
1.3.4.2  C3aR1–/– and C5aR1–/– mice 
Anderson et al. (2002) identified the complement pathw y activation products of C3 
and C5 cleavage (C3a and C5a) in drusen in AMD eyes.  These fragments are 
anaphylatoxins, and promote inflammation, chemotaxis, cytotoxic oxygen radical 
production and secretion of VEGF. The receptors C3aR and C5aR are crucial to 
mediating the biological effects of C3a and C5a. Mice deficient in these receptors 
show a reduction in chemotactic recruitment of leukocytes and lowered VEGF 
expression (Nozaki et al. 2006a). No AMD-like features arise spontaneously in these 
mice. Following laser-induced injury to the C3aR1–/– or C5aR1–/– mice, choroidal 
neovascularisation was reported to be less severe than in wild-type mice. Small 
molecule antagonists of the receptors or neutralising antibodies against C3a or C5a 
reproduced the protective effects of genetic ablation of the receptors (Nozaki et al. 
2006).  Variants in these receptors have not been implicated in altering AMD-risk in 
humans. Inflammatory processes resulting from comple ent C3a and C5a deposition 
in drusen may contribute to AMD progression.  
 
1.3.4.3  Inflammatory cytokine models 
Migration of leukocytes during inflammation is direct d by cytokines called 
chemokines. The CXC and CC subfamilies of chemokines ( amed according to the 
arrangement of the first two of four conserved cysteine residues) mediate chemotaxis 
via binding to G protein–coupled receptors (Graves and Jiang 1995).  
Macrophages are recruited from the circulation to remove complement 
components from sites of complement deposition, by the combined action of CCL2 
(chemokine, CC motif, ligand 2) and its receptor CCR2.  
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Macrophages in Cc12–/– or Ccr2–/– mice show defects in chemotaxis. Cc12–/– 
or Ccr2–/–mice aged over 16 months have been reported to exhibit pathology similar 
to that seen in AMD, including deposits in the BM and RPE (containing C3a, C5a 
and A2E), RPE and photoreceptor atrophy and CNV (Ambati et al. 2003). More 
recently, the drusen-like deposits reported in Cc12–/– mice were shown to be sub-
retinal, rather than sub-RPE, and to result from the accelerated, normal age-related 
accumulation of lipofuscin-containing macrophages (Luhmann et al. 2009).  
Leukocytes such as microglia and macrophages possess th  G protein–
coupled receptor CX3CR1 (chemokine, CX3C motif, receptor 1). Upon binding of 
the ligand CX3CL1, the receptor mediates adhesion and migration of leukocytes to 
inflamed tissues. Indeed, CX3CR1-positive cells detect d in drusen are microglia 
(Chan et al. 2008). Variants in CX3CR1 have been associated with increased 
susceptibility to AMD (Tuo et al. 2004; Combadière et al. 2007) although replication 
has not been achieved in larger genome-wide studies (Chen et al. 2010; Yu et al. 
2011). Aged Cx3cr1–/– mice reportedly show subretinal accumulation of microglia, 
drusen-like deposits, photoreceptor degeneration and CNV after laser injury 
(Combadière et al. 2007). However, subretinal accumulation of autofluorescent 
microglia occurs during normal ageing, and could be confused with drusen-like 
deposits (Xu et al. 2008).  
 Double mutant Cc12-/-/Cx3cr1-/- mice have been reported to develop AMD-
like pathology, including drusen-like deposits, BM thickening, atrophy of RPE and 
photoreceptors (Ross et al. 2008). These changes are apparent after only 6 weeks, 
compared to 16-18 months for the single knock-out anim ls (Tuo et al. 2007; Chan et 
al. 2008). However, it seems likely that the drusen-like deposits reported in these 
animals are subretinal accumulations of autofluoresent macrophages and microglia, 
rather than drusen. These are unlikely to be informative models of AMD, as these 
cells accumulate during normal ageing in the eyes of healthy wildtype mice. 
 
1.4  Proposed mechanisms of disease for the candida tes on 
chromosome 10 
Understanding the pathogenic mechanisms by which ARMS2/HTRA1 are involved in 
AMD development is an ongoing process. As discussed in Section 1.2.5.4, it is not 
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clear whether variants in ARMS2 or those in HTRA1 are responsible for an increased 
susceptibility to AMD. Due to the strong linkage disequilibrium in this locus on 
chromosome 10q26, it is not possible to identify the causative variant by allele 
frequency differences. It is therefore important to understand the functional role 
played by both proteins, and to investigate whether either protein (or both) 
contributes to the pathophysiology of AMD. 
 
1.4.1   ARMS2 
ARMS2 is a 12 kDa protein of unknown function, contai ing no known domains, 
and no sequence homology to other proteins. ARMS2 is conserved only in higher 
primates (Kanda et al. 2007), and has proved difficult to study. Both Kanda et al. 
(2007) and Fritsche et al. (2008) used immunostaining to show that ARMS2 is 
localised to mitochondria, with intense staining in the photoreceptor layer of the 
retina. Mitochondrial dysfunction has been implicated in AMD (Barron et al. 2001; 
Feher et al. 2006; Carelli et al. 2004; Canter et al. 2008). A role for ARMS2 in 
mitochondrial homeostasis, modulating oxidative strss and apoptosis, was proposed 
(Fritsche et al. 2008) However, recent work identified ARMS2 as a secreted protein, 
present at high levels in the choroid (Kortvely et al. 2010). ARMS2 expression was 
reported to be restricted to only the placenta and the retina (Jakobsdottir et al. 2005; 
Fritsche et al. 2008), but ubiquitous expression of ARMS2 in 18 human tissues 
screened by RT-PCR has now been reported (Wang et al. 2010b). This merely 
highlights the current controversy and lack of understanding regarding the true roles 
of ARMS2 in AMD susceptibility. 
 
1.4.2  HTRA1 
HTRA1 is a member of the mammalian HtrA (high temperature requirement A) 
serine protease family, first identified in Escherichia coli as a heat shock protein 
required for survival at high temperatures (Clausen et al. 2002). Four members of 
this highly conserved family of peptidases have been described in humans. Each 
member of the family has a characteristic trypsin-like catalytic domain paired with 
one or more C-terminal PDZ domains (Hu et al. 1998; Gray et al. 2000; Clausen et 
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al. 2002; Nie et al. 2003). Additionally, HTRA1 also has an N-terminal secretory 
signal sequence, an insulin-like growth factor or Mac25 domain, followed by a 
Kazal-type serine protease inhibitor domain (Zumbrunn and Trueb 1996). PDZ 
domains mediate protein-protein interactions by binding to 4-6 amino acid motifs, 
generally found at the C-terminus of target proteins (Hung and Sheng 2002). 
Peptidase activity of HTRA1 is regulated by ligand binding to the PDZ domain for 
some substrates (Murwantoko et al. 2004) but not all (Truebestein et al. 2011). Auto-
activation of HTRA1 may occur via N-terminal cleavage of the Kazal inhibitory 
domain (Hu et al. 1998; Chien et al. 2006). The domain structure of HTRA1 is 
shown in Figure 1.11.  
 
 
Figure 1.11 Domain structure of HTRA1. 
HTRA1 is a member of the highly conserved mammalian HtrA (high temperature 
requirement A) serine protease family. HTRA1 has an N-terminal secretory signal 
sequence (SP), an insulin-like growth factor binding domain (IGFBP), a Kazal-type 
serine protease inhibitor domain (which may be involved in self-regulation), a 
characteristic trypsin-like catalytic domain and a C-terminal PDZ domain.  
 
1.4.2.1 Expression of HTRA1 
HTRA1 is a secreted protein, widely expressed in a range of human tissues 
(Zumbrunn and Trueb 1996; De Luca et al. 2003). The highest expression levels 
have been reported in the placenta (particularly during the third trimester), mature 
layers of epidermis, liver and in kidney tubules (De Luca et al. 2003). 
 
1.4.2.2  Function of HTRA1 
Ingenuity pathway analysis performed by Gilicze et al. (2007) found that HTRA1 
was involved in two gene networks, one pertaining to enes involved in cell death 
and cancer, and the other to genes involved in the dev lopment and function of 
bones, muscles and connective tissue.   
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The ingenuity pathway analysis found that the only genes with a direct 
relationship to HTRA1 were Tgf-βI (transforming growth factor- β) and Bmp4 (bone 
morphogenetic protein 4), a member of the TGF-β family (Gilicze et al. 2007). TGF-
β is a known regulator of extracellular matrix depositi n and angiogenesis; cellular 
activities that are disrupted by AMD. Oka et al. (2004) previously reported that 
HTRA1 was able to inhibit TGF-β signalling, acting to regulate the availability of 
insulin-like growth factors (IGFs) by cleaving IGF-binding proteins. HTRA1 can 
also directly cleave pro-TGF-β, limiting the amount of mature TGF-β available under 
normal conditions (Shiga et al. 2011). 
Negative regulation of BMP signalling has also been attributed to HTRA1 
(Oka et al. 2004). Further evidence as to the inhibtion of signalling pathways by 
HTRA1 was provided by Canfield et al. (2007), who found BMP-2 induced matrix 
mineralisation was inhibited by overexpression of HTRA1. 
 Although some interacting partners of HTRA1 have be n reported, the 
HTRA1 interactome, and range of substrates for this serine protease, are not well 
characterised. In terms of ECM components, collagens have been identified as 
binding partners of HTRA1 using a combination of approaches. A yeast two-hybrid 
screen performed using the PDZ domain of mouse HTRA1 (96% identical to human 
HTRA1) identified interactions with C-propeptides of fibrillar collagens 
(Murwantoko et al. 2004). HTRA1 was also shown to interact with collagen fibres in 
the extracellular matrix in a study of HTRA1 expression in the placenta (De Luca et 
al. 2004). On the basis of HTRA1 distribution in both the extracellular space and the 
cytosol, De Luca et al. (2004) speculated that HTRA1 may act on intracellular 
growth factors or extracellular matrix proteins, depending on the precise sub-cellular 
location of HTRA1. In vitro, HTRA1 can also degrade matrix proteins, including 
matrix Gla protein and decorin, and inhibits signalli g to regulate physiological and 
pathological matrix mineralisation (Canfield et al. 2007). 
 Using quantitative proteomics, An et al. (2010) recently identified additional 
substrates for HTRA1 in the RPE secretome. These substrates - clusterin, vitronectin, 
and fibromodulin; proteins involved in complement regulation - may be of particular 
relevance to AMD pathogenesis if HTRA1 does play a role in development of this 
disease. 




1.4.2.3  HTRA1 in diseases other than AMD 
HTRA1 is down-regulated in ovarian cancer and melanoma (Baldi et al. 2002; Chien 
et al. 2004), and may act as a tumour suppressor by p omoting serine-protease-
mediated cell death. This is supported by the observation that over-expression of 
HTRA1 inhibits cell growth and proliferation i vitro (Baldi et al. 2002). Recently, 
over-expression of HTRA1 has been suggested to play a role in survival in 
mesothelioma patients (Baldi et al. 2008).  
 Expression of HTRA1 is also up-regulated in osteoarthritis and in skeletal 
muscle in Duchenne muscular dystrophy, conditions in which degradation of the 
ECM may be important (Bakay et al. 2002; Grau et al. 2006).  Proteomic 
investigation of cartilage tissue extracts identified aggregan as a substrate for 
HTRA1 (Chamberland et al. 2009). Aggrecan is the major structural proteoglycan of 
cartilage. Aggregan fragments produced by HTRA1 activity were significantly more 
abundant in cartilage from osteoarthritic joints than in healthy joints, implicating 
HTRA1 in cartilage degeneration in this disease. 
 Down-regulation of HTRA1 has been reported in the hippocampal region of 
brains affected by Alzheimer’s disease, relative to disease-free controls (Li et al. 
2003). Association studies have not shown a significant contribution of variants in 
HTRA1 to risk of Alzheimer’s disease (Li et al. 2003; Ozturk et al. 2005). However, 
the protease can degrade amyloid-β in vitro (Grau et al. 2005). This is a major 
constituent of amyloid plaques, the pathological hallm rk of Alzheimer’s disease. 
HTRA1 also co-localises with amyloid plaques in thebrain (Grau et al. 2005). 
CARASIL (cerebral autosomal recessive arteriopathy with subcortical 
infarcts and leukoencephalopathy) is an autosomal recessive disorder caused by 
mutations in HTRA1 (Hara et al. 2009). CARASIL is characterised by ischemic, non-
hypertensive, cerebral small-vessel disease with associated alopecia and spinal 
osteoarthritis (Fukutake and Hirayama 1995). Arteriosclerosis appears to result from 
intimal thickening in the cerebral small vessels by deposition of dense collagen fibres 
(Hara et al. 2009). Non-sense and mis-sense mutations in HTRA1 identified in 
CARASIL patients reduce activity of the protease, leading to uncontrolled TGF-β 
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signalling (Hara et al. 2009; Shiga et al. 2011). TGF-β signalling plays a variety of 
roles in angiogenesis and vascular remodelling (reviewed by (ten Dijke and Arthur 
2007)). 
 
1.4.2.4 HTRA1 in AMD 
HTRA1 is expressed in human RPE, and the HTRA1 protein has been detected in 
drusen in the eyes of AMD-affected individuals (Figure 1.12; Dewan et al. 2006; 
Yang et al. 2006). Although the role of HTRA1 in AMD pathogenesis is not yet 
known, a combination of effects may contribute to disease. HTRA1 binds and 
degrades components of the ECM (Murwantoko et al. 2004; Grau et al. 2006; 
Canfield et al. 2007), as well as complement regulators (An et al. 2010). HTRA1 
negatively regulates TGF-β signalling (Shiga et al. 2011); this may have implications 
in extracellular matrix deposition, neuronal survival (Launay et al. 2008) and 
angiogenesis. Yang et al. (2006) suggest that HTRA1 overexpression could promote 
the growth of choroidal capillaries across the extracellular matrix of Bruch’s 
membrane leading to CNV, although this does not seem to occur spontaneously in 
mice over-expressing HTRA1 in the RPE (Vierkotten et al. 2011).  
 HTRA1 may be involved in neovascularisation, in wound healing 
following chronic inflammation and in remodelling the Bruch’s membrane. 
However, much work remains to be done before the biological significance of 
HTRA1 activity in normal and disease states can be fully understood. 
 





Figure 1.12  HTRA1 expression in the AMD eye. 
HTRA1 is expressed by RPE cells and has been detected in drusen. This is shown by 
HTRA1 immunoreactivity in the AMD lesion (circle) and in residual RPE cells 
(arrow; top left corner) from a human eye  (Ding et al. 2009). 
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1.5.4   Animal models of HTRA1 and ARMS2 
There is considerable debate about whether ARMS2 or HTRA1 is the AMD-
susceptibility gene located on chromosome 10q26. To date, there have been no 
published reports of mouse models of HTRA1 over-expression to recreate the 
proposed functional consequence of the risk haplotye on human chromosome 10. 
ARMS2 is conserved only in higher primates, which may correlate with development 
of the macula (Kanda et al. 2007). Thus, rhesus macaques have been used to study 
the contribution of HTRA1 and ARMS2 to macular degeneration. A rhesus 
homologue of the chromosome 10q26 AMD-susceptibility locus contains ARMS2 
and HTRA1 (Francis et al. 2008). As in humans, both proteins are expressed in the 
retina and RPE of macaques. A promoter polymorphism in HTRA1 which was 
associated with macular degeneration in these animals resulted in over-expression of 
HTRA1 in in vitro studies (Francis et al. 2008). A second study on independent 
research colonies of macaques found similar associati n between the HTRA1 
promoter polymorphism and macular degeneration, and no association with ARMS2 
(Singh et al. 2009). 
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1.6  Aims of the study 
The aims of this study were to determine whether HTRA1 is likely to play a role in 
AMD pathogenesis, by: 
 
• Identifying interacting partners of HTRA1, using yeast two-hybrid screening 
and tandem affinity purification. 
 
• Studying candidate interactors of HTRA1 which may be relevant to AMD, 
using genetic and molecular approaches. 
 
• Validating and characterising the roles of interactions involving HTRA1 in 














2: Chapter 2 
 
Materials and Methods 
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2.1  Introduction 
This chapter describes the experimental methods and t tistical approaches used to 
generate the data that are subsequently presented. Unless otherwise noted, 
consumables were obtained from HGU Technical Servics.  
  
2.2  Cell culture procedures 
Human cell culture lines HEK293T, hTERT-RPE1 and THP-1, bacterial cells and 
yeast cells were used. Procedures for culturing and manipulating cells are described.  
 
2.2.1  Mammalian cells 
2.2.1.1 Standard culture conditions for mammalian c ells 
Mammalian cell cultures were maintained at 37°C in 5% CO2. HEK293T cells were 
grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) supplemented with 
10% fetal calf serum (FCS) and penicillin/ streptomycin. hTERT-RPE1 (RPE1) cells 
were grown in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 
(DMEM/F-12; Gibco) containing 15 mM HEPES, 2 mM L-Glutamine and 0.348% 
sodium bicarbonate (Gibco), 10% FCS and 100 µg/ml streptomycin, 100 U/ml 
penicillin. THP-1 cells were grown as a suspension culture in RPMI 1640 (Gibco) 
supplemented with 2 mM GlutaMAX, 10 mM HEPES (Gibco), 1 mM sodium 
pyruvate (Gibco), 4.5 g/l glucose, 100 µg/ml streptomycin, 100 U/ml penicillin, 0.05 
mM 2-mercaptoethanol (Sigma) and 10% FCS.  
THP-1 cells were passaged when cell density reached between 6-8x105 
cells/ml, by diluting 1 in 10 in fresh media. RPE1 and HEK293T cells were passaged 
at 70-90% confluence. A 25 cm2 tissue culture flask of cells was washed twice with 
phosphate buffered saline (PBS; 3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 
135 mM NaCl, pH 7.4), and then 2.5 ml of a 1:1 mix of trypsin (2 g/l trypsin in PBS, 
0.2% Phenol Red) and versene (0.4 g/l EDTA in PBS, 0.2% Phenol Red) was added. 
The flask was incubated at 37°C for 2-3 minutes or until the cells detached. 7.5 ml of 
culture media was added to neutralise the trypsin. When appropriate, cells were 
counted using a haemocytometer.  Cells were seeded as a 1 in 10 dilution in a new 
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tissue culture flask with the appropriate volume of media. Volumes were adjusted for 
flask/plate size.  
All cell cultures were negative for mycoplasma infection (tested by HGU 
Technical Services). 
 
2.2.1.2  Transfection of mammalian cells  
HEK293T and RPE1 cells were transfected using microporation performed using an 
MP-100  machine (Digital Bio).  At 70-90% confluency, HEK293T cells were 
transfected with pDEST HTRA1-CTAP or pDEST EV-CTAP. 5.6 x 106 cells were 
mixed with 5 µg of the appropriate construct. Microporation was performed using 
the MP-100 (Digital Bio) with 100 µl tips and Buffer E2 electrode buffer. 
Microporation parameters were 1300 V/ 10 ms/ 3 pulses. For each construct, ten 14 
cm plates were seeded with 2 microporation reactions (~10x 106 cells, 10 µg DNA) 
in 10 ml of DMEM supplemented with 10% FCS, without antibiotics, and grown at 
37°C for 48 hours. Transformation efficiency and cell viability were initially 
confirmed by fluorescence microscopy 12 hours following transfection of HEK293T 
cells with pEGFP DNA.  
Optimal electric field, pulse width and pulse number for effective transfection 
of RPE1 cells were determined using a procedure supplied by the manufacturer 
(Digital Bio). RPE1 cells were grown to 70-90% confluency and harvested by 
trypsinisation. 2.4 x 105 cells were centrifuged at 1200 rpm for 3 minutes, washed in 
PBS and then resuspended in 288 µl Buffer R (Digital Bio). For each microporation 
reaction, 0.5 µg of pmaxGFP DNA (Amaxa) was added. Microporation was 
performed using the MP-100 with 10 µl tips and Buffer E electrode buffer. 
Microporation parameters are shown in Table 2.1.  
Following microporation, each reaction was seeded in a well of a 24-well 
plate. Each well contained 500 µl of antibiotic-free media. The plate was incubated 
at 37°C for 24 hours. Fluorescence and light microscopy was used to determine the 
optimal parameters for microporation by assessment of cell viability in relation to 
untransfected RPE1 cells, and by assessment of transfection efficiency by 
observation of GFP-positive cells. Subsequently, the three optimal protocols were 
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scaled up for use with 14 cm plates. 5.6 x 106 cells were mixed with 5 µg of the 
pmaxGFP construct and microporation performed using the MP-100 with 100 µl tips 
and Buffer E2 electrode buffer. Microporation parameters tested were: 1400 Volts/ 
20 ms/ 1 pulse, 1500 Volts/ 20 ms/ 1 pulse and 1600 Volts/ 20 ms/ 1 pulse. For each 
condition tested, a 14 cm plate was seeded with 2 microporation reactions (~10x 106 
cells, 10 µg DNA) in 10 ml of antibiotic-free media. Transfection efficiency and cell 
viability were assessed as described previously. Optimised parameters (1500 Volts/ 
20 ms/ 1 pulse) were used for transfection of RPE1 cells with pDEST HTRA1-CTAP 







width Pulse number  
1 Control without microporation 
2 1400 20 1 
3 1500 20 1 
4 1600 20 1 
5 1700 20 1 
6 1100 30 1 
7 1200 30 1 
8 1300 30 1 
9 1400 30 1 
10 1000 40 1 
11 1100 40 1 
12 1200 40 1 
13 1100 20 2 
14 1200 20 2 
15 1300 20 2 
16 1400 20 2 
17 900 30 2 
18 1000 30 2 
19 1100 30 2 
20 1200 30 2 
21 1300 10 3 
22 1400 10 3 
23 1500 10 3 
24 1600 10 3 
 
Table 2.1 Microporation parameters tested during op timisation of 
transfection of RPE1 cells. 
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2.2.1.3 Treating RPE1 cells to induce stress 
2.2.1.3.1 Cell viability assay 
The cytotoxic effects of a range of concentrations f H2O2 (250-2,000 µM; Sigma) or 
LPS (1.25-80 µg/ml; Sigma) upon RPE1 cells in culture was assessed. 8,000 RPE1 
cells/well were seeded in a 96-well plate in standard culture media. After 24 hours, 
media was removed and the cells washed in PBS. Serum-free media containing H2O2 
(250-2,000 µM) or LPS (1.25-80 µg/ml) was added, the cells were grown for a 
further 24 hours and the media removed. Cell viability was quantified using an MTT 
assay. 100 µl of 5 mg/ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; Sigma) in PBS was added to each well, and incubated 
at 37°C for 4 hours. The MTT solution was removed and replaced with an equal 
volume of MTT Solvent (4 mM HCl (Fisher), 0.1% Nondet P-40 (NP40; ICN 
Biomedicals) in isopropanol (Fisher)). The plate was rapped in foil, and incubated 
at room temperature on an orbital shaker for 15 minutes. Absorbance was measured 
at 590 nm with a reference filter of 620 nm (Multiskan Spectrum, Thermo Electron).  
All assay points were determined in triplicate and ll experiments were repeated 
three times. Cell viability was calculated relative to untreated cells, and corrected for 
background in the absence of cells in the well.  
 
2.2.1.3.2 Optimised assay for non-cytotoxic stress in RPE1 
RPE1 cells were cultured in 6-well plates (0.5x106 cells/well) for 24 hours until 
confluent. Media was removed and replaced with 250 µM H2O2 or 10 µg/ml LPS in 
serum-free media for 24 hours. Conditioned media was collected and used to 
measure CFD by ELISA. Cells were lysed and RNA extracted. 
 
2.2.1.4 Differentiation of THP-1 cells 
Monocyte THP-1 cells were induced to differentiate into macrophage-like adherent 
cells by addition of 200 nM PMA (phorbol myristate acetate; Sigma) in DMSO 
(Sigma) for 72 hours. Morphological changes were apparent under light microscopy 
(Leica DM1L). After 4 days in culture in serum-free media, conditioned media was 
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collected and protein measured by Bradford assay for analysis by Western blotting. 
Cells were lysed and RNA extracted using the RNeasy Kit (Qiagen). 
 
2.2.2  Bacterial cells  
2.2.2.1  Standard culture conditions for bacterial cells 
Escherichia coli cultures were used to produce recombinant human proteins and for 
propagation of plasmids. E. coli cultures were incubated at 37°C, either on Luria-
Bertani (LB) agar plates supplemented with the appro riate antibiotic, or in liquid 
culture in LB rotated at 225 rpm. LB was supplied by HGU Technical Services. 
Bacterial clones were obtained from Invitrogen (CFD Ultimate ORF) or made by 
transfection of E. coli with DNA constructs made in the lab or provided as gifts. 
Glycerol stocks of all bacterial cultures were stored at -80°C.  Expression constructs 
and their antibiotic resistance are shown in Table 2.2. 
 
2.2.2.2  Plasmid amplification in E. coli 
50 µl of freshly thawed E. coli TOP10 cells (Invitrogen) were mixed with 1µl of 
plasmid and incubated on ice for 30 minutes. Cells were heat-shocked at 42ºC for 30 
seconds, then placed on ice for 2 minutes. 250µl Super Optimal broth with Catabolite 
repression (SOC) medium (Invitrogen) was added before incubation at 37ºC with 
shaking for 1 hour. 50-200 µl of the cell suspensio were spread on LB-agar plates 
containing 100 µg/ml ampicillin (provided by HGU technical services) or 50 µg/ml 
kanamycin, as appropriate (Table 2.2). Plates were incubated overnight at 37ºC. 
Individual colonies were amplified overnight at 37ºC in 5 ml LB under antibiotic 
selection. Cell pellets were collected by centrifugation at 2500 rpm for 10 minutes. 
Plasmid DNA was purified from the cell pellets using the QIAprep Spin 
Miniprep Kit (Qiagen), following the manufacturer’s instructions and supplied 
buffers. Centrifugation steps were performed using a bench-top microcentrifuge 
(Thermo Scientific). The cell pellet was resuspended in 250 µl Buffer P1 plus RNase 
A and mixed with 250 µl Buffer P2 by inversion. 350 µl Buffer N3 was added. After 
mixing by repeated inversion, the mixture was centrifuged at 13,000 rpm for 10 
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minutes. The supernatant was spun through a QIAprep spin column. The column was 
washed with 0.5 ml Buffer PB and then with 0.75 ml Buffer PE. After the second 
wash, an additional centrifugation step removed any residual wash buffer. 
Centrifugation was performed at 13,000 rpm for 60 seconds. The flow-through was 
discarded after each spin. Plasmid DNA was eluted from the column in 30 µl dH2O 
or in TE Buffer (10 mM Tris-Cl, 1 mM EDTA, pH 7.5). 
 
2.2.2.3  Protein expression in E. coli 
100 µl of E.coli BL21 (DE3) pLysS cells (Stratagene) were transformed with 0.5 µl 
of one of the expression vectors shown in Table 2.2. Cells were transformation by 
incubating the bacteria and DNA on ice for 30 minutes, followed by 45 seconds at 
42°C and 2 minutes on ice. Transformed bacteria were grown in SOC media and 
plated on LB agar as described in Section 2.1.2.2. Individual colonies were used to 
make glycerol stocks, and to inoculate 10 ml overnight starter cultures. The 
following day, 400ml of LB medium containing 100 µg/ l ampicillin and 34 µg/µl 
chloramphenicol was inoculated with the starter culture and grown at 37oC until the 
OD600 reached 0.6–0.8 (UV1101 Biotech Photometer, WPA). 1 mM isopropyl β-D 
thiogalactoside (IPTG) was added to induce protein production. After incubation at 
25°C for 4 hours, the cells were harvested by centrifugation at 4,000 x g for 20 
minutes and frozen at -20°C prior to protein purificat on. 
 
2.2.3   Yeast cells 
2.2.3.1 Yeast two-hybrid screening for HTRA1-bindin g proteins 
A GAL4-based yeast two-hybrid system (Matchmaker, Clontech) was used to screen 
a human oligo-dT primed placental cDNA library (in pAD_GAL4_2.1/DEST vector) 
for proteins interacting with HTRA1 in PJ69-4α yeast cells. Full-length HTRA1 was 
fused to the DNA binding domain in the pYes-Dest52 vector to create a bait plasmid, 
which was transformed into PJ69-4A yeast cells using the lithium acetate procedure 
(Becker and Lundblad, 1994). Cell-to-cell mating of PJ69-4α cells, containing the 
bait plasmid, with the mating library, containing human oligo-dT primed placental 
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cDNA fused to an activation domain, was  >5% efficient. Transformation and cell-
to-cell mating was performed by Dr. Elod Kortvely. Resultant diploid cells were 
cultured on selection plates lacking tryptophan, leucine, histidine and adenine (-
WLHA) at 30°C. Yeast capable of growing on selective medium were positive 
clones. 
 Plasmid DNA was extracted from positive clones following culture for 2 days 
at 30°C in 2ml of SD-tryptophan-leucine (SD-WL) media supplemented with 1% 
glucose, to select for the pAD_GAL4_2.1/DEST prey plasmid. Yeast cells were 
pelleted by centrifugation at 3,000 x g for 5 minutes, and resuspended in 250 µl of 
Buffer A1 (Macherey-Nagel) supplemented with 570 µg/ml Lyticase (Sigma) and 
400 µg/ml RNAse I (Macherey-Nagel). Cell lysis was achieved by incubation at 
37°C for 2 hours with vigorous shaking. Plasmid DNA was purified using the 
NucleoSpin Multi-96 Plus Plasmid kit (Macherey-Nagel) and used to transform E. 
coli DH5α cells. Bacterial cells were plated on L-AMP plates using glass beads, and 
grown at 37°C overnight. Plasmid DNA was purified as described previously using 
the NucleoSpin Multi-96 Plus Plasmid kit (Macherey-Nagel) and processed for DNA 
sequencing using the primer pACT2_7848F, which annels to the GAL4 activation 
domain sequence within the pACT2-AD vector backbone. 
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Table 2.2  Details of DNA constructs used. 
DNA Construct Name Vector Backbone Insert Tag Expression 
Bacterial 
resistance 
pDEST HTRA1 CTAP pDEST CTAP 
full-length HTRA1 (amino acids 
1-480) 
C-terminal Strep-Strep-
FLAG Mammalian Ampicillin 
pDEST EV pDEST CTAP No insert 
C-terminal Strep-Strep-
FLAG Mammalian Ampicillin 
pmaxGFP pmax No insert GFP Mammalian Kanamycin 
CFD Ultimate ORF pDONR221  
full-length preproCFD (amino 
acids 1-253) - - Kanamycin 
pENTR proCFD pDONR221  proCFD (amino acids 21-253) - - Kanamycin 
pENTR ∆N HTRA1 pDONR221  
∆N HTRA1 (amino acids 157-
480) - - Kanamycin 
pENTR HTRA1 ∆C pDONR221  
∆C HTRA1 (amino acids 21-
160) - - Kanamycin 
pENTR CTGF pDONR221  full-length CTGF - - Kanamycin 
GST ∆N HTRA1 pDEST15 
∆N HTRA1 (amino acids 157-
480) N-terminal GST Bacterial Ampicillin 
GST ∆N HTRA1 S328A pDEST15 
∆N HTRA1 (amino acids 157-
480) N-terminal GST Bacterial Ampicillin 
His6 ∆N HTRA1 pDEST17  
∆N HTRA1 (amino acids 157-
480) N-terminal His6 Bacterial Ampicillin 
GST HTRA1 ∆C pDEST15 
∆C HTRA1 (amino acids 21-
160) N-terminal GST Bacterial Ampicillin 
GST CTGF pDEST15 full-length CTGF N-terminal GST Bacterial Ampicillin 
GST pGEX 6-P-1 No insert N-terminal GST Bacterial Ampicillin 
GST-cleavable-proCFD 
pGEX6P1-DEST 




modified) placental cDNA library 
GAL4-activation domain 
fusion S. cerevisiae Ampicillin 
pDBD DEST HTRA1 pYes-Dest52  
full-length HTRA1 (amino acids 
1-480) 
GAL4-DNA binding 
domain fusion S. cerevisiae Ampicillin 
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2.3  DNA and RNA procedures 
2.3.1  Agarose gel electrophoresis  
Agarose gel electrophoresis was used to separate and purify DNA. Agarose gels were 
made with 1% or 2% agarose, depending on the size of DNA being resolved. To 
make a 1% agarose gel, 1 g agarose (biogene) was added to 100 ml 0.5x TBE buffer 
(1 litre of 20x stock: 216 g Tris base, 110 g boric acid, 18.6 g EDTA, dH2O) and 
heated until boiling to dissolve the agarose. 0.2 mg/ml ethidium bromide (VWR 
International) was added when the liquid had cooled to approximately 60°C. The 
agarose solution was allowed to set in a gel tray for at least 1 hour, prior to 
immersion in 0.5x TBE buffer and loading of the DNA samples. DNA samples were 
mixed with 6x loading buffer (Promega) before loading. Gels were run at 150 Volts. 
DNA size markers were used in combination: 100 bp ladder (Promega), 1 kb ladder 
(Promega), DNA marker III (Roche). 
 
2.3.2   Gel purification 
The QIAquick PCR Purification Kit (Qiagen) was used to purify DNA from agarose 
gel slices, following the manufacturer’s instructions and supplied buffers. 3 volumes 
of buffer PB was added to 1 volume of gel slice containing DNA in an eppendorf 
tube. The gel was dissolved by incubating at 50°C for 10 minutes, and then added to 
the QIAquick column. After centrifugation for 1 minute, the column was washed 
with 0.5 ml Buffer QG and then with 0.75 ml Buffer PE. After each wash, the 
column was centrifuged at 13,000 rpm for 60 seconds. After the second wash, an 
additional 60 second spin removed any residual wash buffer. The flow through was 
discarded after each spin. Plasmid DNA was eluted from the column in 30 µl dH2O. 
 
2.3.3   DNA constructs 
Gateway cloning technology (Invitrogen) was used to generate vectors for the 
expression of HTRA1 and interacting proteins in E.coli. Sequences encoding 
HTRA1 and CTGF were amplified by PCR from human retinal Marathon-Ready 
cDNA (BD Biosciences) using gene-specific attB PCR primers (Table 2.3). The 
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proCFD sequence was amplified using the CFD Ultimate ORF (Invitrogen) as the 
template for amplification. Constructs for the expression of CTAP-HTRA1 and the 
empty vector in mammalian cells were generated previously, using vectors provided 
by Dr. Johannes Gloeckner. 
 
2.3.3.1           PCR amplification of attB-flanked  gene-specific sequences 
A 50 µl PCR mixture contained 1 µl cDNA, 1x Phusion HF buffer (1.5 mM MgCl2), 
0.2 mM dNTPs, 0.5 µM each of forward and reverse primers, 0-10% DMSO and 1 U 
of Phusion High Fidelity DNA polymerase (Finnzymes). Samples were denatured at 
98°C for 30 seconds, and then subjected to 35 cycles of 98°C for 10 seconds, 
annealing at 54°C for 30 seconds, extension at 72°C for 45 seconds, followed by a 
final extension cycle of 72°C for 10 minutes. Annealing temperature, extension time
and % DMSO for specific primer pairs is shown in Table 2.3.  Following successful 
amplification, the PCR product was purified from a 1% TBE Agarose gel using the 
QIAquick gel extraction kit (Qiagen) to remove attB primers and primer-dimers. 
 
2.3.3.2 Gateway BP recombination  
The gene-specific attB-flanked PCR products were used in Gateway BP 
recombination reactions. 150 ng of attP containing donor vector (pDONR221) was 
incubated at 25°C for 4 hours with the PCR product and 2 µl of BP Clonase 
(Invitrogen) in TE Buffer, pH 8. 1 µl of Proteinase K (Invitrogen) was added and the 
reaction incubated at 37°C for 10 minutes to terminate the reaction. The BP 
recombination reaction mix was used to transform chemically competent TOP10 E. 
coli (Invitrogen) The transformed cells were grown overnight at 37°C on L-KAN (50 
µg/ml) agar plates to select for entry clones containing the kanamycin resistance 
gene encoded by pDONR221 vector. The presence of the insert in the entry vector 
was verified by PCR, using primers and thermocycling conditions shown in Table 
2.3. Clones containing the appropriate insert were used to propagate the plasmid, 
which was then quantified using the ND-1000 Spectrophotometer (NanoDrop). The 
inserts were sequenced using M13 primers and gene-specific primers (Table 2.3). 
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2.3.3.3 Gateway LR recombination 
AttL-containing entry clones were used in Gateway LR recombination reactions. The 
destination vectors used are shown in Table 2.2. 150 ng of destination vector was 
added to 150 ng of entry clone and incubated with LR Clonase II (Invitrogen) at 
25°C for 1 hour. The reaction was stopped by adding Proteinase K, and used to 
transform TOP10 E. coli. Clones were selected on L-AMP plates (100 µg/ml 
ampicillin), and the insert verified by PCR. Restriction digests were used to confirm 
the insert into the vector. Appropriate restriction enzymes were identified using 
NEBCutter2 (tools.neb.com/NEBcutter2/). Digests were performed at overnight at 
37°C using 1 U of ApaI or MluI, in specific buffers supplied with the enzymes 
(NEB).  
 
2.3.3.4  Site-directed mutagenesis of DNA construct s 
The active site serine residue of HTRA1 was mutated to an alanine residue (S328A), 
using the QuikChange Site-Directed Mutagenesis kit (Stratagene) and HPLC-
purified primers containing the mutated residue: 
HTRA1_S328A  5'-ccatcatcaactatggaaacgcgggaggcccgttag-3' 
HTRA1_S328A_antisense 5'-ctaacgggcctcccgcgtttccatagttgat atgg-3'  
The site-directed mutagenesis of the GST ∆N HTRA1 expression construct was 
performed by Dr. Elod Kortvely, following the manufacturer’s instructions. Samples 
were denatured at 95°C for 30 seconds, and then subjected to 12 cycles of 95°C for 
30 seconds, annealing at 55°C for 1 minute and extension at 68°C for 14 minutes. 
The plasmid template was digested by 10 U DpnI at 37°C for 1 hour. 50 µl of XL1-
Blue supercompetent E.coli cells were transformed with 1 µl of DNA, and 
subsequently grown on L-AMP plates overnight at 37°C. 5 ml overnight culture was 
established from 5 separate colonies and used for to amplify the plasmid, which were 
subsequently purified using the QIAprep Spin Miniprep Kit (Qiagen). The mutation 
was verified by sequencing using HTRA1-specific primers (Table 2.3). 
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    PCR conditions 
























1100 10 54 45 seconds Phusion 
SP-HtrA1_F 
GGGGACAAGTTTGTACAAAAAAGCAGGCT




500 10 54 45 seconds Phusion 
ARMS2 3' UTR indel genotyping primers 
ARMS2 indel F TGTCACTGCATTCCCTCCTGTCAT 
ARMS2 indel R AAGCTTCTTACCCTGACTTCCAGC 
200/600  10 58 60 seconds Platinum Taq 
CFD resequencing primers 
CFD-ex1-F CGACTCTGGTGTGAGTCTGG 
CFD-ex1-R  TTTCAGCGTTCAGAGCCTTC 
383 5 59 60 seconds Platinum Taq 
CFD-ex2-F AGAGCTGGGATCCCGTCAG 
CFD-ex2-R GCCCAGGAGAACCTGCAC 
353 10 67 60 seconds Platinum Taq 
CFD-ex3-F            CTGGAGGACGCGTGAGTG 
CFD-ex3-R                    GTGAGGGTGTGGGGGTTG 
387 10 65 60 seconds Platinum Taq 
CFD-ex4-F            AGCCTAGCGGCATTCTCC 
CFD-ex4-R                      CTGGGCCCTGTTCCTACTTG 
425 10 57 60 seconds ReddyMix 
CFD-ex5-F          ATTAACACGGGAGGGATGAG 
CFD-ex5-R           CCATGCTGATCTCGAACTCC 
431 10 62 60 seconds ReddyMix 








55 20 seconds Platinum Taq 




55 20 seconds Platinum Taq 




59 20 seconds Platinum Taq 




59 20 seconds Platinum Taq 




55 20 seconds Platinum Taq 
Sequencing primers 
CFD_Seq_F   gctacagctgtcggagaagg           
CFD_Seq_R        cagcactggcaagagcac           
CTGF_Seq_F1 Gtgagcctcgtgctggac           
CTGF_Seq_R1 acgtgcactggtacttgcag           
CTGF_Seq_F2   gttccaagacctgtgggatg           
CTGF_Seq_R2  tggagattttgggagtacgg           
HTRA1 IntF CAAGGGCAGGAAGATCCCAA           
HTRA1 IntR AGTTGCGGAGCCCCAGCTCT           
Htra1 IntF2  Gctcttctcccgctgctg           
Htra1 IntR2         ggaagcttgcgaaacaattc           
Htra1 IntF3 ccgttttcccttcaaaacac           
Htra1 IntR3 acgtcgttttccttgagacc           
Htra1 IntF4       caaagccaaagagctgaagg           
M13 F CACGACGTTGTAAAACGAC           
M13 R GGATAACAATTTCACACAGG           
pACT2_7848F CTATCTATTCGATGATGAAG           
 
Table 2.3  Primers and PCR conditions.
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2.3.4  DNA Sequencing 
Plasmid DNA and PCR products were sequenced in both directions using primers 
shown in Table 2.3. DNA sequencing was performed by HGU Technical Services 
using BigDye Terminator Cycle Sequencing on an ABI PRISM 3100 (Applied 
Biosystems). Sequence fidelity was confirmed using Sequencher (Gene Code) for 
analysis. Variants in CFD were identified using Mutation Surveyor (Soft Genetics).  
 
2.3.5  Cases and controls for genetic association a nalysis  
DNA samples were obtained from six cohorts and were g notyped to test for an 
association between AMD-susceptibility and variants i  CFD. The characteristics 
and demographic information for the AMD case-control series used in this study are 
shown in the results in Chapter 4, Table 4.2. AMD cases were graded using the 
Clinical Age-Related Maculopathy Grading System (Bird et al. 1995). Controls were 
examined and free from AMD. All individuals were reported as Caucasian. Blood 
samples were collected at ophthalmic clinics, and genomic DNA isolated from 
peripheral blood leukocytes. Written consent from the individuals and appropriate 
ethical approval were obtained prior to the study. 
 
2.3.6   SNP Genotyping  
2.3.6.1  TaqMan 5’ nuclease assay 
SNPs in CFD were genotyped in the UK1, UK2 and Nijmegen cohorts using 
TaqMan genotyping technologies (Applied Biosystems). Genotyping assays for 
rs3826945, rs1683563 and rs1683564 were pre-validated by the supplier. 5µl 
reactions were set up in 384-well plates, using TaqMan Universal PCR Master Mix, 
No AmpErase UNG (Applied Biosystems) with 7.5 ng DNA, 1 µM of each primer, 
and 0.2 µM of probe. The thermal cycling reactions (95°C for 10 minutes, followed 
by 40 cycles at 92°C for 15 seconds and 60°C for 1 minute) were run and analyzed 
on a 7900HT Sequence Detection System (Applied Biosystems) with Applied 
Biosystems Genotyper software (SDS system, version 2.2). As controls, each plate 
contained multiple blank wells without DNA. The USA2 series were genotyped 
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using the same TaqMan assays in the laboratory of Dr. Dwight Stambolian at the 
University of Pennsylvania. 
 
2.3.6.2  Alternative methods of SNP genotyping 
Genotyping for the USA1 and USA3 series was performed using alternative 
methods. The USA3 series was genotyped for rs3826945 using the Sequenom iPLEX 
assay (Yu et al. 2011) in the laboratory of Dr. Johanna Seddon at Tufts University 
School of Medicine, USA. The USA1 case-control series was genotyped for 
rs1683563 and rs3826945 using direct sequencing. This was performed in the 
laboratory of Dr. Anand Swaroop at the University of Michigan, USA. The following 
primers were used for PCR:  
rs1683563 :  Forward primer 5’AGTGTGGCCTTCTCCGACAG 
Reverse primer 5’AAATCTCTCCTGCTGCACTGA.  
rs3826945: Forward primer 5’CACGTGTTAGACCCCCTCAC  
Reverse primer 5’TGGAAGAGCAGGAATGAGGT.  
Standard PCR conditions using TaKaRa Ex Taq polymerase (TAKARA BIO INC., 
Japan) were used to amplify ~100 ng DNA. Samples were d natured at 94°C for 2 
minutes, and then subjected to 35 cycles of 94°C for 30 seconds, annealing at 60°C 
for 30 seconds, extension at 72°C for 30 seconds; followed by extension at 72°C for 
7 minutes. PCR products were sequenced at the University of Michigan core facility. 
 
2.3.7  Measuring copy number variation  
Copy number variation at the CFD locus was assessed using a TaqMan copy number 
assay (Hs01536182_cn; Applied Biosystems) run simultaneously with a TaqMan 
Copy Number Reference Assay for RNAseP in a duplex real-time polymerase chain 
reaction. The CFD probe was FAM-labelled and the endogenous control was VIC- 
labelled. 10 µl reactions were set up in 384-well plates, using TaqMan Universal 
PCR Master Mix, No AmpErase UNG (Applied Biosystems) with 10 ng genomic 
DNA, 1 µM of each primer, and 0.2 µM of probe. The t rmal cycling reactions 
(95°C for 10 minutes, followed by 40 cycles at 92°C for 15 seconds and 60°C for 1 
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minute) were run on a 7900HT Sequence Detection System (Applied Biosystems). 
Samples were analysed in triplicate, and each platecontained multiple blank wells 
without DNA as no template controls. The relative copy number of CFD, normalised 
to the copy number of the RNAseP reference sequence, was calculated using Applied 
Biosystems Copycaller software.  
 
2.3.8  PCR amplification of CFD for sequencing 
Primers spanning the 5 exons, intron-exon boundaries nd 200 bases of the promoter 
of CFD (ENSG00000197766, Ensembl) were designed using Primer3 
(frodo.wi.mit.edu/primer3/). Primer sequences are shown in Table 2.3. Primers were 
used to amplify specific sequences from genomic DNA of 95 AMD cases and 95 
controls. Exons 1-3 were amplified using Platinum Taq. A 20 µl PCR mixture 
contained 1 µl  10 ng/ml DNA, 1 x PCR Buffer (Minus Mg), 1.5 mM MgCl2, 0.2 
mM dNTPs, 0.2 µM each of forward and reverse primers, 5-10% DMSO and 1 U of 
Platinum Taq polymerase (Invitrogen). Samples were d natured at 94°C for 30 
seconds, and then subjected to 35 cycles of 94°C for 30 seconds, annealing at 59-
67°C for 30 seconds and extension at 72°C for 60 seconds. Annealing temperature 
and % DMSO for specific primer pairs is shown in Table 2.3.  Exons 4 and 5 were 
amplified using ReddyMix PCR Mix (Thermo Scientific). A 20 µl PCR mixture 
contained 1 µl  10 ng/ml DNA, 75 mM Tris-HCl, 20 mM (NH4)2SO4, 1.5 mM 
MgCl2, 0.2 mM dNTPs, 1.25 U of Thermoprime Plus DNA Polymerase and 0.2 µM 
each of forward and reverse primers. PCR was carried out in 0.2 ml semi-skirted 96-
well plates (ABgene).  PCR products were sequenced by HGU Technical Services. 
Sequence analysis was performed using Mutation Surveyo  to identify variants 
compared to the reference sequence ENSG00000197766 (converted to .gbk). 
 
2.3.9  Genotyping of indel in ARMS2 3’UTR 
The indel in the 3’ UTR of ARMS2 was genotyped by PCR using primers designed to 
span the indel (Wang et al. 2010b).  Primers (Table 2.3) were used to PCR amplify 
specific sequences from genomic DNA from 15 AMD cases using Platinum Taq, as 
described in Section 2.3.8. Annealing temperature and % DMSO are shown in Table 
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2.3. Following amplification, the PCR products were analysed on a 2% agarose gel, 
alongside a 100 bp DNA ladder (Promega). The wild-type sequence generates a band 
of 600 bp; the indel generates a band of 200 bp. 
 
2.3.10  RNA isolation, cDNA synthesis and RT-PCR 
RNA was extracted from RPE1 and THP-1 cells using the RNeasy Mini kit (Qiagen), 
following the manufacturer’s instructions and supplied buffers. <1 x 107 RPE1 cells 
or THP-1 cells differentiated by treatment with PMA were lysed directly in the 
culture plate, by adding 350 µl of Buffer RLT. THP-1 cells grown in suspension 
were centrifuged at 1200 rpm for 3 minutes to form a cell pellet, which was then 
lysed by addition of Buffer RLT. The cell lysate was homogenised by passing 
through a QIAshredder column (Qiagen). 350 µl of 70% ethanol (Fisher) was added 
to the homogenized lysate and mixed. The mixture was transferred to an RNeasy 
spin column, centrifuged for 15 seconds at 8,000 x g, then washed with 350 µl Buffer 
RW1. After centrifugation and removal of flow-through, on-column DNase digestion 
was performed using 10 µl RNase-Free DNase I (Qiagen) mixed with 70 µl Buffer 
RDD and incubating for 15 minutes at room temperature. 350 µl Buffer RW1 was 
added and the column centrifuged for 15 seconds at 8,000 x g. The column was 
washed twice with 500 µl Buffer RPE, and then centrifuged for 2 minutes at 8,000 x 
g. RNA was eluted in 30 µl RNase-free water by centrifugation at 8,000 x g for 1 
minute. RNA was quantified by quantitated using the NanoDrop ND-1000 
Spectrophotometer.  
The Transcriptor High Fidelity cDNA Synthesis Kit (Roche) was used for 
synthesising cDNA from 1 µg RNA, following the manufacturer’s protocol and 
supplied buffers and enzymes. 1200 pmol of random hexamer primer was denatured 
at 65oC for 10 minutes with 1 µg RNA (or without RNA, as  control) in a final 
volume of 11.4 µl, before chilling on ice. The reaction volume was increased to 20 µl 
by addition of Transcriptor High Fidelity Reverse Transcriptase Reaction Buffer (1x, 
8 mM MgCl2), Protector RNase Inhibitor (20 U), 1 mM dNTPs, 5 mM DTT and 10 
U Reverse Transcriptase (RT). A control lacking Reverse Transcriptase (-RT) was 
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performed. After incubation at 45oC for 30 minutes to allow cDNA synthesis, 
Reverse Transcriptase was inactivated by heating to 85oC for 5 minutes. 
 50-250 ng of cDNA was amplified by PCR using Platinum Taq and gene-
specific intron-spanning primers to test for expression of transcripts for HTRA1, 
CFD, C3, MASP1 and GAPDH. Primers, annealing temperatures and extension times 
are shown in Table 2.3. Following amplification, the PCR products were analysed on 
a 2% agarose gel, alongside a 100 bp DNA ladder. 
 
2.4  Protein procedures 
2.4.1  Bradford Assay 
The concentration of protein in solution was determined using the Bradford Assay. 
Protein standards were prepared in the same buffer as the samples to be assayed.  A 
10 mg/ml BSA (96%, Sigma) solution was subjected to oubling dilutions into an 
appropriate diluent (such as PBS or distilled water) to obtain seven standard 
solutions with the following range of concentrations of BSA: 0, 0.078, 0.156, 0.313, 
0.625, 1.25 and 2.5 mg/ml. 0.98 ml of 1x Bradford reagent (5x; BioRad) diluted in 
distilled water was mixed with 20 µl of either standard sample or protein solution in 
disposable 1 ml cuvettes. Colour was allowed to develop for 10 minutes at room 
temperature. The OD595 of each sample and standard was measured using the 
UV1101 Biotech Photometer. A standard curve was created from the OD595 of the 
standard solutions, allowing the concentrations of pr tein solutions to be determined. 
 
2.4.2  Protein separation by polyacrylamide gel ele ctrophoresis 
For reducing gels, samples were mixed with 1 x Reducing Agent (Invitrogen) and 4 x 
NuPAGE LDS (lithium dodecyl sulfate) Sample Buffer (Invitrogen) and denatured 
by heating to 70oC for 10 minutes. Samples run under non-reducing coditi ns were 
mixed with 4 x NuPAGE LDS Sample Buffer and loaded irectly on the gel, without 
heating.  Gel electrophoresis was performed using pre-cast 10%, 12% or 4-12% Bis-
Tris NuPAGE gels (Invitrogen), depending on the required resolution of proteins. 
Gels were run using the XCell SureLock Mini-Cell system (Invitrogen). Running 
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buffer was either 1 x MOPS (3-(N-morpholino)propanesulfonic acid; Invitrogen) or 
1 x MES (2-(N-morpholino)ethanesulfonic acid; Invitrogen). Gels were run at 200V 
for 55 minutes. SeeBlue Plus 2 pre-stained molecular weight marker (Invitrogen) 
was the protein standard used on all gels. 
 Gels were silver-stained, Coomassie-stained or transferred to Hybond-P 
PVDF membrane (GE Healthcare) for Western blotting. 
 
2.4.3  Coomassie staining 
Following electrophoresis, gels were either stained with Gelcode Blue stain reagent 
(Pierce) or with InstantBlue stain (Expedeon). For Gelcode Blue-staining, the gel 
was rinsed 3 times in 100 ml of ultrapure water for 5 minutes. 20 ml of Gelcode Blue 
stain reagent was then added to the gel, and incubated for 1 hour at room temperature 
with gentle shaking a rotary shaker. After 1 hour, the staining solution was removed 
and destaining of the gel background was achieved by washing in ultrapure water for 
an hour or more. For gel staining using InstantBlue, th re was no wash step in 
ultrapure water prior to immersion of the gel in 20 ml of stain reagent for 1 hour at 
room temperature with gentle shaking on a rotary shaker. After 1 hour, the staining 
solution was removed and destaining of the gel background was achieved by 
washing in ultrapure water for an hour or more.  
 
2.4.4  Silver staining 
Silver staining was performed using the SilverQuest Silver staining kit (Invitrogen). 
The gel was fixed in Fixing Solution (40% ethanol (Fisher), 10% acetic acid 
(Sigma)) for 20 minutes, and then washed for 10 minutes in 30% ethanol. In order to 
increase the sensitivity and contrast of the stain, he gel was incubated in Sensitizing 
solution (30% ethanol, 10% Sensitizer (Invitrogen)) for 10 minutes. The gel was 
washed twice, firstly with 30% ethanol and then with ultrapure water for 10 minutes 
each. The gel was stained in Staining solution for 15 minutes, washed for 1 minute in 
ultrapure water, and then developed in Developer solution (Invitrogen) until the 
required band intensity was obtained. 
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2.4.5  Western Blotting 
Samples were subjected to gel electrophoresis and then transferred to Hybond-P 
PVDF membrane (GE Healthcare) in 1 x NuPAGE Transfer Buffer (Invitrogen) 
containing 10% methanol (Fisher) using the XCell SureLock Mini-Cell Blot Module 
system (Invitrogen). The PVDF membrane was cut to the appropriate size, wetted in 
methanol and then placed directly on the gel. The gel and membrane was sandwiched 
between two pieces of Whatman filter paper, and then  transfer apparatus 
assembled. Transfer was performed for 1 hour at 30V. Following transfer of proteins 
from the gel to the membrane, membranes were blocked in 5% non-fat milk in PBST 
(Phosphate-buffered Saline-Tween 20; 3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM 
KCl, 135 mM NaCl, 0.05% Tween 20, pH 7.4) for 1 hour at room temperature, or 
overnight at 4°C. Antibodies used in the following steps are shown in Table 2.4. 
Membranes were incubated with primary antibody diluted in PBST for 1 hour 
at room temperature, followed by three 5-minute washes in PBST. Membranes were 
incubated in horseradish peroxidase (HRP)-conjugated secondary antibody, diluted 
1:5,000 in PBST, for 1 hour followed by three more washes in PBST. The secondary 
antibodies were detected by addition of Enhanced Chemiluminescence (ECL) 
Western blotting detection reagents (GE Healthcare) for 1 minute. The membrane 
was exposed to Kodak BioMax XAR film (Sigma) in an X-ray film exposure cassette 
for sufficient time to detect an ECL signal. The film was developed using a 
phosphorimager X-ray machine (Konica Minolta). Densitometry analysis of scanned 
films was performed using ImageQuantTL software (GEHealthcare). 
   
69 
 
Antibody Raised in Clonality Supplier 
Stock 
concentration Application Dilution 
anti-Bb Mouse Monoclonal Quidel 1 mg/ml Western Blot primary 1 in 1000 
anti-C3 (B-9) Mouse Monoclonal Santa Cruz Biochemicals 0.2 mg/ml Western Blot primary 1 in 2000 
anti-CFD (C-16) Goat Polyclonal Santa Cruz Biochemicals 0.2 mg/ml Western Blot primary 1 in 2000 
anti-CFD  Mouse Monoclonal R&D Systems 0.72 mg/ml ELISA Capture 1 in 180  
biotinylated anti-
CFD  Goat Polyclonal R&D Systems 0.036 mg/ml ELISA Detection 1 in 180  
anti-CFD 
MAB#255719 Mouse Monoclonal R&D Systems 0.5 mg/ml Serum depletion - 
anti-CFD GAU 008-
01 Mouse Monoclonal Antibody Shop 1 mg/ml Serum depletion - 
anti-CTGF (L-20) Goat Polyclonal Santa Cruz Biochemicals 0.2 mg/ml Western Blot primary 1 in 2000 
anti-FLAG M2 Mouse Monoclonal Sigma-Aldrich 2 mg/ml Western Blot primary 1 in 4000 
anti-GST-HRP 
conjugate Rabbit Polyclonal Sigma-Aldrich 9 mg/ml Western Blot 1 in 1000 
anti-His6 Mouse Monoclonal Veronica van Heynigen ND Western Blot 1 in 100 
anti-HTRA1 PDZ Rabbit Polyclonal Michael Erhmann ND Western Blot primary 1 in 1000 








hybridoma Monoclonal Jeremy Chien ND ELISA Detection N/A 
anti-THBS1 Rabbit Polyclonal Abcam 1 mg/ml Western Blot primary 1 in 400 
- Western Blot secondary 1 in 5000 anti-mouse IgG 
HRP 
Rabbit Polyclonal Sigma-Aldrich 
- ELISA secondary Detection 1 in 12500 
anti-rabbit IgG HRP Donkey Polyclonal Amersham Pharmacia - Western Blot secondary 1 in 5000 
anti-goat IgG HRP Donkey Polyclonal Santa Cruz Biochemicals 0.4 mg/ml Western Blot secondary 1 in 5000 
 
Table 2.4  Antibodies used for Western blotting, se rum depletion and ELISA.
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2.4.6  Purification of bacterially expressed recomb inant proteins 
Bacterial cells were induced to express recombinant proteins as described in Section 
2.2.2.3. Proteins were affinity purified using the N-terminal tags. 
 
2.4.6.1 Purification of GST-tagged recombinant prot eins  
The bacterial cell pellet was resuspended in STE Buffer (50 mM Tris-HCl pH 7.5, 
150 mM NaCl, 1 mM EDTA, 10 mM DTT (Sigma)) with 1 mg/ml of lysozyme 
(Novagen) and rotated on an end-on-end shaker at 4°C for 1 hour to achieve lysis. 
Subsequently, Sarcosyl (Sigma) was added to a final concentration of 1% and the 
cells disrupted by sonication for 6 x 10 seconds at 24 µ. Triton X-100 (Sigma) was 
added to a final concentration of 1% prior to clearing of the lysate by centrifugation 
at 10,000 x g for 20 minutes at 4°C.  Soluble material was incubated for 2 hours at 
4°C with glutathioine-agarose (GE Healthcare), previously equilibrated with STE 
Buffer. The agarose was washed with 60 bed volumes of STE Buffer + 0.5% Triton 
X-100, prior to elution of bound GST-tagged proteins i  200 µl fractions using GST-
Elution Buffer (200 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.1% Triton 
X-100 and 100 mM reduced glutathione (Sigma)). For on-column cleavage of the 
GST tag from proCFD, after washing the resin to remove contaminating proteins, 
Prescission protease was added to the resin in Cleavag  Buffer (20 mM Tris pH 7.0, 
150 mM NaCl, 1 mM DTT) and incubated for 2 hours at 4°C. Free proCFD was 
collected in the flow-through and dialysed into TBS. 
 
2.4.6.2 Purification of His 6-tagged recombinant HTRA1 
Bacterial cells were resuspended in His6-Lysis Buffer (50 mM NaH2PO4, 300 mM 
NaCl, 5 mM imidazole (Acros), pH 8.0) and lysozyme was added to 1 mg/ml. The 
suspension was rotated end-on-end at 4oC for 1 hour to achieve lysis. Cells were then 
further disrupted by sonication for 6 x 10 seconds at 100% power. Insoluble material 
was removed by centrifugation at 10,000 x g for 20 minutes at 4oC. The cleared 
lysate (soluble fraction) was applied to a Ni-NTA (Ni2+-nitrilotriacetate)-agarose 
(Qiagen) column, pre-equilibrated by washing with 10 bed volumes of His6-Lysis 
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Buffer. The lysate was incubated on the column for 2 hours at 4oC. The column was 
washed twice with His6-Lysis Buffer, before elution of bound His6 ∆N HTRA1 from 
the column in 0.5 ml fractions with His6-Elution Buffer (50 mM NaH2PO4, 300 mM 
NaCl, 250 mM imidazole pH 8.0). 
 
2.4.6.3 Assessment of protein purity 
Protein fractions were quantified by Bradford assay, and 2-5 µg of protein was 
analysed by reducing and denaturing gel electrophoresis, followed by Coomassie 
staining. Fractions containing pure protein were identified and pooled for dialysis 
into Storage Buffer (50 mM Tris pH 8, 150 mM NaCl, 10% glycerol (Fisher), and in 
some cases, 0.1% Triton X-100). Proteins were also as essed by Western blotting 
using antibodies specific to the protein and the tag (Table 2.4). 
 
2.4.7  Zymography of recombinant forms of the HTRA1  protease 
Proteolytic activity of recombinant HTRA1 was assessed using zymography, using 
premade buffers and following a protocol provided by BioRad. Briefly, 5 µg of each 
GST ∆N HTRA1, GST ∆N HTRA1 S328A and His6 ∆N HTRA1 was mixed with an 
equal volume of Zymogram sample buffer (62.5 mM Tris-HCl, pH 6.8, 4% SDS, 
25% glycerol, 0.01% Bromophenol Blue). Samples were loaded on a 12% 
Zymogram gel with casein as a substrate (BioRad) an ru  for 90 minutes at 100 V 
in Zymogram Running Buffer (25 mM Tris, 192 mM glycine, 0.1% SDS).  
Proteins were renatured within the gel by incubating in Renaturation Solution 
(2.5% Triton X-100) for 30 minutes at room temperatu e. Subsequent incubation in 
Development Solution (50 mM Tris, 200 mM NaCl, 5 mM CaCl2, 0.02% Brij-35 
(Pierce), pH 7.5) overnight at 37ºC allowed proteolysis of the casein contained in the 
gel. The gel was stained with Coomassie Brilliant Blue R-250 staining solution (40% 
methanol. 10% acetic acid. 0.5% Coomassie Blue R-250 (BDH)) for 1 hour at room 
temperature. Destaining was performed in a solution of 40% methanol and 10% 
acetic acid, for 1 hour until clear bands were apparent.   
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2.4.8  Protein interaction assays 
2.4.8.1 Tandem Affinity Purification (TAP) 
48 hours post-transfection, media was removed from t ansfected RPE1 or HEK293T 
cells (Section 2.2.1.2), and centrifuged at 1200 rpm for 10 minutes to remove cell 
debris. Each 14 cm plate of cells was scraped in 1 ml of Lysis Buffer (50 mM Tris-
HCl pH 7.5, 150 mM NaCl, 1 % NP40, 1 mM EDTA, 1 PhosStop phosphatase 
inhibitor tablet (Roche)/10 ml). Cell lysis was achieved by snap-freezing in liquid 
nitrogen. Media was snap-frozen in liquid nitrogen for storage at -80°C. Upon 
thawing, media was concentrated approximately 10-fold to a final volume of 5 ml, by 
centrifugation in a Sorvall Legend RT centrifuge using a Centriprep centrifugal filter 
device (Amicon; 3 kDa MW cut-off) at 3,000 x g at 4oC. Cell lysates were 
centrifuged at 1,0000 rpm for 10 minutes to remove cell debris.  
Streptactin Superflow beads (IBA Technologies) were pre-equilibrated by 
washing with 1 ml of Lysis Buffer (details as above), and 2 x 1 ml of Wash Buffer 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 % NP40, 1 mM EDTA). Cell lysate or 
concentrated media was added to 20 µl settled volume of Streptactin Superflow 
beads per 14 cm plate and incubated, on an end-on-end shaker, for 2 hours at 4oC. 
Subsequently, beads were washed 3 times in 0.5 ml of Wash Buffer. Bound proteins 
were eluted by resuspension of Streptactin Superflow beads in 0.5 ml of Elution 
Buffer (2 mM D-Desthiobiotin; IBA Technologies) for 10 minutes at 4 oC. The 
elution mixture was transferred to Illustra Microspin columns (GE Healthcare). 
Eluates were recovered by centrifugation at 2,000 rpm for 5 seconds and incubated 
for 2 hours at 4°C with 30 µl settled volume of pre-equilibrated anti-FLAG M2 
Agarose beads (Sigma) per construct in Microspin columns. 
Anti-FLAG M2 Agarose beads were washed 3 times with 0.5 ml of Wash 
Buffer before elution with 200 µl of 200 µg/ml FLAG peptide (Sigma) by gentle 
mixing for 10 minutes. Eluates were concentrated by centrifugation using Microcon 
centrifugal filter devices (3kDa MW cut-off; Millipore) at 10,000 rpm for ~100 
minutes at 4 oC. 
Eluates were precipitated and analysed by mass spectrometry, performed by 
Dr. Karsten Boldt at the Helmholtz Zentrum, Munich. 
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2.4.8.2 Protease Activity Assay 
The protease activity of GST ∆N HTRA1 was assayed by incubation of recombinant 
HTRA1 (0.1-5 µg) with other recombinant proteins (proCFD, GST-CTGF), synthetic 
peptides (CFD_Y2H, GeneCust; 20 µg) or proteins purified from human plasma 
(THBS1 (Affinity Bioreagents), C3 (Sigma), CFB (Calbiochem); CFD (Sigma); 0.5-
5 µg). Assays were performed in a 20 µl mixture containing 50 mM Tris-HCl, pH 8, 
150 mM NaCl for 3-18 hours at 37°C. GST only and GST ∆N HTRA1 S328A were 
incubated with potential substrates under the same conditions and served as controls.  
The reaction was terminated by the addition of 10 µl of LDS loading buffer 
(Invitrogen), and where appropriate, reducing agent.  For denaturing gels, the 
mixture was boiled for 5 minutes. Proteins were separated by gel electrophoresis and 
stained with Coomassie Blue, silver stained or analysed by Western blot.  
 
2.4.8.3 GST Pull-downs 
For pull-down assays using GST-tagged proteins, equimolar amounts of a GST-
tagged protein (GST ∆N HTRA1, GST HTRA1 ∆C, GST CTGF or GST alone) were 
incubated together with a potential binding partner (His6 ∆N HTRA1, CFD, C3, 
THBS1).GST-tagged proteins and interactors were bound to 25 µl of glutathione-
Sepharose beads (GE Healthcare) in 500 µl TEN150 buffer (50 mM Tris-HCl, pH 
7.5, 150 mM NaCl) for 2 hours at 4°C. Beads were washed with 4 x 1ml of TEN150 
buffer containing 0.1-0.5% NP40 and resuspended in 4 x LDS loading buffer and 10 
x Reducing Agent. Samples were heated at 70°C for 10 minutes. Eluted proteins 
were then analysed by LDS-PAGE and Western blotting using a tibodies specific to 
the protein and/or the tag (Table 2.4). 
 
2.4.9  Mass spectrometry  
2.4.9.1 Identification of interactors from TAP expe riments 
Eluates from tandem affinity purification were analysed by liquid chromatography 
coupled with tandem mass spectrometry (LC-MS/MS) to identify components of the 
purified complexes following tryptic digestion. Mass pectrometry was performed by 
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Dr. Karsten Boldt at the Helmholtz Zentrum, Munich, according to the published 
protocol (den Hollander et al. 2007). Peptides were identified using the MASCOT 
search engine (Matrix Science in the GPS Explorer software (Applied Biosystems) to 
search the Swiss Prot database. Positive identification of proteins required 
representation by one or more unique peptides with a MASCOT confidence interval 
>90%. 
 
2.4.9.2 Peptide Mass Fingerprinting of proCFD  
Following overnight incubation of HTRA1 with proCFD at 37°C, the digested and 
untreated proCFD were subjected to reducing gel electrophoresis, and the gel was 
Coomassie stained.  Bands corresponding to CFD and proCFD were excised from the 
gel using sterile razor blades. The gel slices were frozen and sent to Dundee Cell 
Products for peptide mass fingerprinting. Gel slice were destained and in-gel digests 
using the V8 Protease (NEB) in buffer containing 50 mM Tris-HCl, 0.5 mM Glu-
Glu, pH 8.0 was performed overnight at 37°C. Peptide fragments were separated by 
HPLC using the Dionex Ultimate 3000 nanoflow LC-System with a reverse-phase 
ReproSil-Pur C18-AQ 3 µm column, using a gradient of 10-60% solvent B over 100 
minutes with a constant flow of 200 nL/minute. The HPLC system was coupled to an 
LTQ-Orbitrap mass spectrometer (ThermoFisher Scientific) to detect peptides. Data 
were acquired using the Xcalibur software, and peptid s quantitated using MS-Quant 
(http://msquant.sourceforge.net) and identified using Protein Center (Proxeon 
Bioinformatics) proteomics data mining and management software.  
 
2.4.10  Plasma and serum 
2.4.10.1 Plasma 
Plasma samples used in the CFD and HTRA1 ELISAs were collected from 751 cases 
and 474 controls from the UK1 and UK2 AMD case-contr l cohorts. 208 plasma 
samples were obtained from the SOCCS disease-free control series (Prof. Malcolm 
Dunlop). Blood samples were collected in dipotassium EDTA-coated tubes. Plasma 
was separated from blood cells by centrifugation within 3 hours of collection and 
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was frozen in aliquots at -80°C until use. Human blood and blood products were 
handled following protocols for Containment Level 2.  
 
2.4.10.2 Serum 
2.4.10.2.1 Normal Sera 
Blood samples from 5 healthy Caucasian volunteers wre processed to produce 
normal sera. After clotting for 1 hour at room temperature, sera were separated by 
centrifugation for 25 minutes at 3,000 rpm. Separated serum was collected, pooled 
for all samples and frozen immediately then stored at −80 °C. This represents normal 
serum in the subsequent assays. Normal serum was heat-inactivated at 65°C for 25 
minutes to remove alternative complement pathway activity.   
 
2.4.10.2.2 CFD-depleted serum 
Normal human serum was thawed and used to test protocols for depleting sera of 
CFD on affinity columns. CFD-depleted human serum was also obtained from 
Quidel.  
 
2.4.10.2.2.1 CFD-depletion using antibodies 
0.2 µg of the monoclonal CFD-specific antibodies GAU-008-01 (Antibody Shop) or 
MAB#255719 (R&D Systems) were coupled to 0.2 ml of CNBr-activated Sepharose 
4B (GE Healthcare). Prior to coupling, the Sepharose was swelled in 1 mM HCl for 
20 minutes at room temperature, collected by centrifugation at 500 x g for 10 
minutes at 4°C and then washed 3 times with 10 ml of 1 mM HCl. The beads were 
washed twice more with Borate Buffered Saline (BBS; 200 mM H3BO3, 150 mM 
NaCl, pH 8) containing 0.02% sodium azide (Sigma). Beads were resuspended in 
antibody solution containing 0.2 mg/ml antibody in BBS and incubated end-on-end 
overnight at 4°C. The beads were washed three times with BBS, and excess reactive 
sites blocked by incubation in 1M ethanolamine (Sigma) for 2 hours at room 
temperature. Beads were washed three times with BBS and equilibrated by extensive 
washing in veronal buffered saline (VBS; 2.8 mM barbituric acid, 145.5 mM NaCl, 
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0.8 mM MgCl2, 0.3 mM CaCl2, 0.9 mM sodium barbital, pH 7.2 (Lonza)). Beads 
were transferred to Microspin columns and incubated for 1 hour with freshly thawed 
serum at 4°C. Serum was passed over the column and collected. The column was 
washed with VBS, and then with 50 mM glycine-HCl (Fisher) to remove bound 
proteins, before re-equilibrating in VBS. The serum was passed over the column a 
second time, and the least dilute fractions of deplet d sera, assessed visually by 
colour, were collected and pooled for each antibody. 
 
2.4.10.2.2.2 BioRex70 chromatography 
0.2 g of BioRex70 cation-exchange resin (BioRad) was equilibrated by repeated 
washing in VBS until pH 7.2 was maintained. 1 ml of n rmal serum was incubated 
for 1 hour at 4°C with the resin. CFD-depleted-serum was recovered from the resin 
by centrifugation at 10,000 x g for 10 minutes. 
 
2.4.10.2.2.3 Testing depletion of CFD in sera 
CFD-depleted sera were tested using CFD-specific ELISA, Western blotting of 1 µl 
of sera with anti-CFD, and by assessing haemolytic activity using a red cell lysis 
assay in the presence and absence of 0.1 µg of exogenous human CFD.  
 
2.4.10.2.3 CARASIL Sera  
Sera obtained from three Japanese CARASIL patients, a d two healthy Japanese 
controls, were provided by Professor Osamu Onodera (Niigata University, Japan) 
These samples were collected and processed as described p eviously. Samples were 
shipped on dry ice, and immediately stored at -80 °C upon arrival.  
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2.4.10.3 An ELISA for CFD 
2.4.10.3.1 Optimisation of the CFD Duoset for measu ring CFD in 
plasma 
The DuoSet ELISA development kit for human Complement Factor D (R&D 
Systems) was optimised for use in plasma. Following the manufacturer’s 
recommended protocol, the ability of the assay to measure CFD in a plasma dilution 
series was assessed. Serial dilutions of three internal control plasma samples (P1, P2 
and P3), ranging from 1/400 to 1/4,000, were made in 1% BSA (98%, Sigma) in 
PBS. A standard curve was made by serial dilutions of recombinant human CFD, 
ranging from 0 - 2.5 ng/ml. Plasma dilutions and standards were mixed end-on-end 
for 10 minutes to ensure proper mixing before additional dilution or use in the assay. 
All samples and standards were performed in duplicate or triplicate during the 
optimisation assays. At the end of the assay, absorbance was measured at 450 nm, 
corrected for background at 540 nm. Mean absorbance valu s (minus background 
absorbance of the zero standard) were used to create a standard curve, and 
subsequently calculate plasma CFD concentration in the three plasma samples for all 
dilutions. The most suitable plasma dilution to detect CFD in the range of 1-3 µg/ml 
was determined.  
The internal control plasma samples P3, P6 and P9 were measured multiple 
times within the same assay to assess intra-assay variation, and measured multiple 
times in different assays to assess inter-assay variation.  
 
2.4.10.3.2 Optimised protocol for measuring CFD in plasma 
Round-bottomed ELISA plates (Greiner-Bio) were coated overnight at room 
temperature with 50 µl of 4.0 µg/ml mouse anti-human Complement Factor D 
capture antibody diluted in PBS. The wells were washed three times with 200 µl of 
PBST and then blocked in 1% BSA in PBS for 2 hours. The wells were washed three 
times with 200 µl of PBST, and then 50 µl of standards and plasma samples, diluted 
1:4,000 in 1% BSA in PBS, were added for 2 hours. The wells were washed three 
times with 200 µl of PBST. Captured CFD was detected by incubation with 50 µl of 
200 ng/ml of the biotinylated goat anti-human Complement Factor D detection 
   
 78 
antibody in 1% BSA in PBS for 2 hours. The wells were washed three times with 
200 µl of PBST, and 50 µl of a 1 in 200 dilution of Streptavidin-HRP in 1% 
BSA/PBS was added for 20 minutes. The wells were washed three times with 200 µl 
of PBST, followed by incubation with 50 µl of TMB (Tetramethylbenzidine) 
substrate (Sigma). Colour was allowed to develop for 20 minutes before the reaction 
was stopped by adding 25 µl of 1N sulphuric acid (Fsher). Incubation steps were 
performed at room temperature on an orbital shaker. Absorbance was measured at 
450 nm, corrected for background at 540 nm. A CFD standard curve (0-2.5 ng/ml) 
was made by serial dilution of 110 ng/ml recombinant human Complement Factor D, 
which was included on each plate. The mean absorbance for each standard (minus 
the background absorbance from the zero standard) was used to create the standard 
curve in Microsoft Excel. The equation of the line of best fit was obtained by 
polynomial regression  and used to calculate the concentration of CFD in plasma 
samples (accounting for the dilution factor) from the UK1 and UK2 AMD case-
control series. AMD cases and control samples were included on each plate and all 
samples and standards were measured in duplicate. CFD was measured without prior 
knowledge of disease status for each sample. 
 
2.4.10.3.3 Measuring CFD in cell culture supernatan ts 
The CFD ELISA protocol outlined above was used to measure CFD in the cell 
culture supernatants collected from RPE1 cells that had been treated with LPS or 
hydrogen peroxide, or from untreated cells. 50 µl of conditioned media was used 
undiluted, alongside a standard curve of 0-2.5 ng/ml recombinant CFD. 
 
2.4.10.4 An ELISA for HTRA1  
2.4.10.4.1 Antibodies 
An HTRA1-specific sandwich ELISA was developed using a mouse monoclonal 
capture antibody (MAb 10) and a polyclonal detection antibody (HTRA1**). 
Antibodies were gifts from Dr Jeremy Chien (Mayo Clinic, Rochester, USA). 
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2.4.10.4.2 Optimisation of the HTRA1 ELISA 
2.4.10.4.2.1 Testing antibodies in an indirect ELIS A 
Purified recombinant protein (0.3-5 ng/ml) was diluted in Coating Buffer (50 mM 
carbonate buffer, pH 10.6) and incubated overnight at 4oC in an ELISA plate to 
allow binding of antigens to the microplate. The wells were washed three times with 
200 µl of Tris-buffered saline (50 mM Tris, 150 mM NaCl, 2 mM KCl, pH 7.4) 
containing 0.05% Tween-20 (TBST) and blocked in 5% non-fat dried milk in TBST 
for 2 hours. After washing three times,  primary antibodies (HTRA1** diluted 1:100, 
mixed monoclonals 1:1, MAb 10 diluted 1:2 or MAb 4.1 diluted 1:2 in 1% BSA in 
TBST) were added for 2 hours to bind to the immobilised antigen. The wells were 
washed three times with 200 µl of TBST. Detection was performed using HRP-
conjugated IgG from rabbit or mouse as appropriate for the primary antibody to 
process the TMB substrate. Absorbance was measured at 450 nm and corrected for 
background by subtraction of absorbance at 540 nm and absorbance measured at 450 
nm for the zero standard (1% BSA in TBST). 
 
2.4.10.4.2.2 Capture Antibody HTRA1** Optimisation 
Dilutions of the polyclonal capture antibody HTRA1 ** (1:100, 1:250, 1:500, 
1:1,000, 1:5,000, 1:10,000) were used in a sandwich ELISA to determine the optimal 
dilution for detection of recombinant GST ∆N HTRA1 S328A (0.78-50 ng/ml). 
Dilutions of the capture antibody were made in TBS, and were mixed end-on-end for 
10 minutes before use. 50 µl of each antibody dilution was added to the plate in 
duplicate, and incubated at 4oC overnight with shaking on an orbital platform. The 
wells were washed three times with 200 µl of TBST and then blocked in 5% NFDM 
in TBST for 2 hours. The wells were washed three times, and then the recombinant 
protein – diluted in 1% BSA in TBST, and each concentration added in duplicate for 
each capture antibody dilution - was added for 2 hours. After repeating the wash 
procedure, the monoclonal detection antibody MAb 10 was added to the plate. For 
optimisation of the capture antibody, the detection antibody was diluted 1:2 in 1% 
BSA in TBST. 50 µl of detection antibody was added to each well and incubated for 
2 hours, with shaking. Washing was repeated and then 50 µl of anti-mouse IgG HRP 
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(Sigma) diluted 1:5,000 in 1% BSA in TBST was added to the wells for 30 minutes. 
The wells were washed three times, and then 50 µl of TMB substrate was added. 
After 30 minutes, colour development was stopped by addition of 25 µl of 1N 
sulphuric acid. Absorbance was measured, corrected for background, and used to 
determine the dilution of capture antibody which was not saturated by 50 ng/ml of 
HTRA1. 
 
2.4.10.4.2.3 Detection Antibody MAb 10 Optimisation  
The capture antibody was diluted 1:100 in TBS, and 50 µl was added to each well of 
the plate. The plate was incubated at 4oC overnight. Following the protocol outlined 
previously, the plate was washed, blocked and then washed again. A dilution series 
of GST ∆N HTRA1 S328A (0.78-50ng/ml) was prepared and added to the plate 
before incubation for 2 hours. After repeating the wash procedure, 50 µl of the 
monoclonal detection antibodies MAb 10, MAb 4.1 or a mix of MAb 10 and MAb 
4.1 were added to the plate for 2 hours. The hybridoma supernatants containing the 
monoclonal antibodies were tested undiluted, or diluted 1:2, 1:5, 1:10, 1:25 in 1% 
BSA in TBST, with each antibody dilution assayed in duplicate for each 
concentration of HTRA1 detected. After washing three times, 50 µl of anti-mouse 
IgG HRP diluted 1:5,000 in 1% BSA in TBST was added to the wells for 30 minutes. 
The wells were washed three times, and then 50 µl of TMB substrate was added. 
After 30 minutes, colour development was stopped by addition of 25 µl of 1N 
Sulphuric acid. Absorbance was measured, corrected for background, and used to 
determine the dilution of detection antibody which was not saturated by 50 ng/ml of 
HTRA1. 
 
2.4.10.4.2.4 Anti-mouse IgG HRP Optimisation 
Two internal control plasma samples, P8 and P9, were diluted 1:10 in 1% BSA in 
TBST and assayed for HTRA1 using the optimised antibody dilutions for capture 
and detection, following the procedure outlined above. Following wash steps after 
the incubation with the detection antibody,  a dilution series of anti-mouse HRP-
conjugated IgG was used to detect binding of MAb10 to HTRA1 from plasma which 
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had been captured by HTRA1**. The IgG-HRP was diluted as follows in 1% BSA in 
TBST: 1:5,000, 1:10,000, 1:25,000, 1:50,000, 1:75,000  1:100,000. 50 µl of each 
dilution was assayed in duplicate for each plasma dilution. After 30 minutes, the 
wells were washed and TMB added. Colour development was stopped after 30 
minutes and the absorbance was measured. A range of dilutions of IgG-HRP giving 
rise to identical plasma HTRA1 concentrations were identified, and used for the 
selection of the optimal IgG-HRP dilution for subsequ nt assays. 
 
2.4.10.4.2.5 Plasma dilution optimisation 
The ability of the optimised antibody dilutions to capture and detect HTRA1 in 
plasma was assessed. Three internal control plasma sa ples were assayed following 
the procedure outlined above. 50 µl of each sample was assayed in duplicate, 
undiluted or diluted 1:3, 1:10, 1:50 and 1:100 in 1% BSA in TBST. When 
absorbance was measured, it was apparent that lowerabso bance readings were 
obtained when the plasma was less dilute. The apparent inhibition of the assay was 
tested by making an HTRA1 standard curve, ranging from 0.312 to 50 ng/ml of GST 
∆N HTRA1 S328A in either the standard dilution buffer (1% BSA in TBST) or 
diluted in plasma (P7), diluted either 1:10 or 1:50 in 1% BSA in TBST. The 
optimised HTRA1 ELISA was performed to measure HTRA1 in these samples, and 
to determine the plasma dilution at which the ELISA was not inhibited.  
 
2.4.10.4.3 Optimised protocol for measuring HTRA1 i n plasma 
Round-bottomed ELISA plates (Greiner-Bio) were coated with a 1:100 dilution of 
the polyclonal capture antibody in 50 µl TBS overnight at 4°C. The wells were 
washed three times with 200 µl of TBST and then blocked in 5% NFDM in TBST 
for 2 hours. The wells were washed three times with200 µl of TBST, and then 50 µl  
of plasma samples, diluted 1:50 in 1% BSA in TBST, and standards were added for 2 
hours. The wells were washed three times with 200 µl of TBST, and captured 
HTRA1 was detected by incubation with 50 µl of a 1:10 dilution of the mouse 
monoclonal detection antibody in 1% BSA in TBST for 2 hours. The wells were 
washed three times with 200 µl of TBST, followed by incubation with 50 µl of anti-
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mouse IgG HRP, diluted 1:25,000 in 1% BSA in TBST for 30 minutes. The wells 
were washed three times with 200 µl of TBST. 50 µl of TMB substrate was added, 
and the plate incubated for 30 minutes to allow colour to develop. The reaction was 
stopped by adding 25 µl of 1N sulphuric acid. All ass y incubations were performed 
at 20°C on an orbital shaker. Absorbance was measurd at 450 nm, corrected for 
background at 540 nm. Plasma HTRA1 concentrations were calculated relative to a 
recombinant HTRA1 S328A standard curve (0-2.5 ng/ml), ade by serial dilution 
and included on each plate. The inter-assay coeffici nt of variation, as determined by 
two internal standard plasma samples included on each ELISA plate, was below 
10%. HTRA1 was measured without prior knowledge of disease status or genotype 
for each sample. All samples and standards were measur d in duplicate. The mean 
absorbance for each standard (minus the background absorbance from the zero 
standard) was used to create the standard curve in Microsoft Excel. The equation of 
the line of best fit was obtained by linear regression  and used to calculate the 
concentration of HTRA1 in plasma (accounting for the dilution factor). 
HTRA1 was measured without prior knowledge of genotype for each sample, 
and without knowledge of disease status for the AMD case-control series. 
 
2.4.10.5 Assays of complement activation  
The functional consequence of HTRA1-mediated cleavage of proCFD was assessed 
using assays of alternative complement pathway activation in vitro. In the following 
assays, recombinant proCFD was incubated with GST ∆N HTRA1 overnight at 37°C 
to allow cleavage of the activation peptide to occur.  
 
2.4.10.5.1 Reconstitution Assay 
1 µg of purified Cobra Venom Factor (CVF; Quidel) was incubated overnight at 
37°C with combinations of purified human factor B (1 µg; Calbiochem), CFD (0.2 
µg; Sigma), recombinant proCFD (0.2 µg) and recombinant GST ∆N HTRA1 (0.1 
µg). The final volume was 20 µl, in TBS containing 5 mM MgCl2 and 5 mM CaCl2, 
The reaction was stopped by adding 4 x LDS Loading Buffer. Proteins were 
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separated by non-reducing gel electrophoresis on 4–12% Bis-Tris gels in 1xMOPS 
Buffer. Gels were stained with InstantBlue (Expedeon).  
 
2.4.10.5.2 Cleavage of factor B in human sera 
 1 µl of normal human serum (pooled serum, collected from healthy volunteers) or 
CFD-depleted serum (Quidel) were supplemented with combinations of 1µg CVF, 
0.2µg CFD, 0.2 µg proCFD and 0.1 µg HTRA1. The final re ction volume was 10 
µl, in TBS containing 5 mM MgCl2 and 5 mM CaCl2.  Factor B cleavage in 
CARASIL sera was assessed by incubating 1-3 µl of CARASIL sera (or 1 µl of 
control sera) with 1 µg of  CVF in the presence of increasing concentrations of 
MgCl2 (0-5 mM). Mixtures were incubated at 37°C for 3 hours, then 4 x LDS 
Loading Buffer was added.  Samples were separated by non-reducing gel 
electrophoresis and transferred to PVDF for immunoblotting with anti-Bb antibody 
to detect Factor B cleavage.  
 
2.4.10.5.3 Haemolysis Assays 
Erythrocytes from 2 ml of sheep’s blood in Alsevers solution (TSC Biosciences) 
were washed in PBS containing 0.5 mM EDTA, and then twice in 10 ml of 
Incubation Buffer (10 mM sodium phosphate, 140 mM NaCl, pH5.5). The cells were 
counted and resuspended to a concentration of 1×109 cells/ml. Following the 
protocol described by Carroll et al. (2009), 2.5 units of neuraminidase from 
Clostridium perfringens (Sigma) were added for every 1×1010 cells and incubated 
with gentle shaking at 37oC for 1 hour. Erythrocytes were recovered by 
centrifugation at 3,000 rpm for 10 minutes and washed with PBS containing 0.5 mM 
EDTA. Neuraminidase-treated erythrocytes and untreated erythrocytes (used in 
reactive lysis assays with CVF) were then washed twice in 10mM ethylene glycol-
bis(2-aminoethylether)-N,N,N,N’-tetraacetic acid (EGTA), 7 mM MgCl2, 2.1 mM 
sodium barbital, 59 mM NaCl, 2.08% (w/v) glucose, 0.08% (w/v) gelatin, pH 7.4 
(DGVB-MgEGTA) and resuspended to a concentration of 109 cells/ml in DGVB-
MgEGTA. Lysis of 108 neuraminidase-treated cells in DGVB-MgEGTA in 20 µl of 
normal, heat-inactivated or CFD-depleted human sera, with and without the addition 
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of 0.05 µg CFD, 0.2 µg proCFD and 0.1 µg HTRA1 was tested. The alternative 
complement pathway-specific reactive lysis of untreated red blood cells was also 
tested by mixing 108 erythrocytes in DGVB-MgEGTA with 20 µl of normal, heat-
inactivated or CFD-depleted human sera, with and without the addition of 1 µg CVF, 
0.05 µg CFD, 0.2 µg proCFD and 0.1 µg HTRA1. Reactive lysis was also assessed 
in 20 µl of sera from CARASIL patients and Japanese controls. Following incubation 
at 37°C for 1 hour, cells were pelleted by centrifugation, the supernatant transferred 
to a 96-well ELISA plate (Greiner Bio), and the absorbance at 412 nm (or 541 nm for 
neuraminidase-treated cells) was measured. Background haemolysis (0%) was 
monitored by incubating erythrocytes in DGVB-MgEGTA buffer only. 100% lysis 
was achieved by addition of 20 µl of H2O to 10
8 erythrocytes in DGVB-MgEGTA. 
The absorbance of the serum dilution was accounted for by correcting for absorbance 
measured in heat-inactivated serum. 
 
2.4.11  Synthetic peptide assays 
2.4.11.1 Protease assay with CFD_Y2H fragment 
The CFD_Y2H peptide (PPRGRILGGREAEAHARPYMASVQLNGAHL), obtained 
from GeneCust, was resuspended in H2O to a stock concentration of 2 mg/ml. 
Subsequent dilutions were made in TBS.  0.1 - 1 µg recombinant HTRA1 (wild-type 
or S328A) was incubated with 20 µM of CFD_Y2H  in a 20 µl mixture containing 
50 mM Tris-HCl pH 7.5, 150 mM NaCl for 16 h at 37°C. The reaction was 
terminated by adding 4 x LDS loading buffer and 10 x Reducing Agent and boiling 
for 5 minutes. Samples were separated under reducing co ditions in 12% Bis-Tris 
gels in 1xMES Buffer and stained with InstantBlue. The degree of cleavage of CFD 
Y2H peptide by HTRA1 was quantified using ImageQuantTL, expressed as a 
percentage reduction compared with CFD Y2H peptide incubated with inactive 
HTRA1±SD in two independent experiments. 
 
2.4.11.2 AMC assay with MCA-peptides 
Fluorogenic substrates were synthesised corresponding to the activation peptide 
(PPRGR-MCA) or the last 5 amino acids of mature CFD (DSVLA-MCA), linked to 
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a C-terminal MCA moiety (GeneCust). Peptides were rsuspended in H2O to a stock 
concentration of 2 mg/ml, and subsequently diluted in TBS.  Fluorescence measured 
from an 7-amino-4-methyl coumarin (AMC; Calbiochem) standard curve ranging 
from 0.049-200 µM was prepared by serial dilution in TBS. The standard curve was 
used to calculate the amount of free AMC released by cleavage of the synthetic 
substrates.  
The optimal pH for the reaction was determined by incubating the protease 
and synthetic substrate (20 µM) in TBS, in the pH range 6- 8.5, in a final volume of 
50 µl at 37°C for 6-24 hours. Specificity of the assay was validated by comparing the 
relative fluorescence generated by HTRA1-mediated cl avage of PPRGR-MCA with 
DSVLA-MCA. 
Recombinant HTRA1 (0-200 nM) was incubated in TBS pH 7.5, in a final 
volume of 50 µl at 37°C with the synthetic substrate (0 - 240 µM). Thrombin, 
purified from plasma (Sigma), was used as a positive control for the assay in the 
same concentration range. Fluorescence was monitored at excitation and emission 
wavelengths of 355 nm and 460 nm using a VICTOR plate reader (PerkinElmer). 
Non-specific background fluorescence was measured in the absence of enzyme, 
which was used to calculate AMC release due to protease activity.  
Enzyme kinetics were calculated using the Michaelis-Menten equation: 
 
 [S] is substrate concentration, V is reaction rate, Vmax is the maximum rate achieved 
at saturating substrate concentration, and Km (the Michaelis constant) is the [S] at 
which the reaction rate is half of Vmax. Kinetic data (1/V and 1/[S]) were used to draw 
a Lineweaver-Burk plot in Microsoft Excel. 
  
2.5  Statistical analysis 
For all analyses, a p-value ≤0.05 was considered statistically significant. Unless 
otherwise noted, statistics were performed using Microsoft Excel software. 
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2.5.1 Statistical Analysis of CFD SNP association and copy 
number variation 
Genotyping, copy number variation and plasma CFD measurements were maintained 
using SPSS Version 17, a statistical analysis and dta management software (SPSS 
Inc.) used for subsequent analyses.  
SNP genotyping was assessed for deviation from Hardy-Weinberg 
equilibrium in AMD cases and controls using a Chi2 test. The association of SNPs in 
CFD with AMD was tested using logistic regression analysis to model the 
probability of disease occurrence, including known risk factors - age, sex and 
smoking history - as variables along with SNP genotype in the analyses. Using a 
dominant genotypic model for regression, SNP genotype was categorised as 0 = 
major allele homozygote, or 1 = minor allele homozygote or heterozygote. Age was 
included as a continuous variable. Sex and smoking history (ever/never) were 
considered as categorical values. Correction for multiple testing was not necessary. 
Each cohort was analysed individually, and in a combined meta-analysis.  Cohorts 
were also stratified by gender. In these analyses, SNP genotype, age and smoking 
status were included as variables. Stepwise logistic regression was also performed to 
investigate interactions between rs3826945 and smoking (ever/never), rs3826945 and 
age, rs3826945 and sex and rs3826945 and BMI (categoris d as <25, 25-29.99, or 
>30). Odds ratios (OR) and 95% confidence intervals (C.I.) for association were 
calculated by the software. A Forest plot for OR and 95% confidence intervals for 
each cohort was constructed using GraphPad Prism 5.  
Association of AMD with copy number variation (defined as either deletion 
or duplication) at the CFD locus was evaluated using Fisher’s exact test. 
 
2.5.2  Statistical Analysis of plasma CFD 
The coefficient of variation (CV; the ratio of the standard deviation σ observed in 
replicates for the same sample to the mean µ) was used to estimate variation 
observed between measurements of the same sample to determine inter-assay and 
intra-assay variability. CV was calculated as follows: 
CV (%) = (σ/µ) x 100 
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 Normalising for experimental variables which affected assay performance was 
performed using the following calculation: 
  Normalised measurement = (A/B) actual measurement 
A is the mean of the means of the three internal control plasmas measured across all 
plates (>30). B is the mean of the means of the three internal controls obtained from 
one assay. 
The Mann-Whitney U Test performed in SPSS was used to assess differences 
between median values of CFD measured in plasma for AMD cases (GA, CNV and 
total AMD) and controls. Logistic regression, contrlling for age (<65 years of age/ 
65-80 years of age, and aged >80 years), gender and smoking (ever/never), was 
performed to compare the first and fourth quartiles of plasma CFD values in AMD 
cases and controls, and to calculate ORs and 95% confidence intervals. BMI (<25, 
25-29.9, >30) was included as a covariate in analysis of the UK2 cohort. 
 
2.5.3  Statistical Analysis of plasma HTRA1  
Assessment of inter- and intra- assay variability, and normalisation of plasma 
HTRA1 measurements was performed as described for the CFD ELISA. 
Demographic, genotyping and HTRA1 ELISA data were maintained and analysed 
using SPSS Version 19. SNP genotyping was assessed for deviation from Hardy-
Weinberg equilibrium in AMD cases, in AMD-free individuals and in the combined 
series using a Chi2 test. Differences in mean age and BMI between genotype groups 
were assessed by t-tests. Fisher’s exact test was used to assess difference in gender, 
smoking history and % AMD between genotype groups. Non-parametric tests 
including the Mann-Whitney U test, Kruskal-Wallis tes , median test and test of 
extreme outliers were used to determine whether alted distribution of raw plasma 
HTRA1 was associated with genotype (GG or GT/TT), and demographic 
characteristics including BMI (<25, 25-29.99, >30) and age (<65 years, 65-80 years, 
>80 years).  
The association between each plasma HTRA1 quartile nd the risk allele of 
rs10490924 (GT/TT) was tested using logistic regression, including age and BMI as 
continuous variables in the analyses. Odds ratios and 95% confidence intervals for 
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association were also calculated in AMD cases, in AMD-free individuals and in the 
combined series.  
 
2.5.4  Power calculations 
The Genetic Power calculator (http://pngu.mgh.harvard.edu/~purcell/gpc/cc2.html; 
Purcell et al., 2003) was used to estimate the requir d number of cases and controls 
for the well-powered replication of the CFD SNP association study, using the effect 
size observed in the discovery cohort. The probability of detecting an effect of a 
given size (power) is calculated as 1- β, where β is the probability of a false-negative 
or type II error. The required level of statistical significance (α, the false-positive or 
type I error) influences the calculated sample size. Power was calculated for 
dominant and additive models of AMD-susceptibility related to SNP genotype, 
accounting for linkage disequilibrium between rs3826945 and rs1683563.  
 The power to detect a significant difference in plasma CFD between AMD 
cases and controls, and in plasma HTRA1 between genotype groups was 
retrospectively assessed using an Altman Nomogram (Figure 2.1) and the 
standardised difference. Use of the Altman Nomogram requires normally distributed 
data. The plasma CFD measurements were normalised by log-transformation. The 
plasma HTRA1 measurements were normalised by cube-root transformation of 
detectable HTRA1. Transformation was performed in SPS . Standardised 
differences were calculated as follows: 
 
Standardised difference = difference in means between groups/standard deviation 
 
The standardised difference was found on the left-hand axis of the Altman 
Nomogram, and used to determine the required sample size to detect a statistically 
significance (p=0.05) difference of that magnitude with 80% power (right-hand axis). 





Figure 2.1 Altman Nomogram. 
The Altman Nomogram was used to calculate the statistical power of a two-sample 
study to detect a significant difference in a continuous variable, relating sample size 
to the standardised difference. Standardised difference is shown on the y-axis at the 
left-hand side, N= sample size (Altman 1980). 
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2.6  Bioinformatic analyses 
2.6.1  Analysis of Prey Sequences 
Analysis of the prey sequences was performed using NCBI BLAST (Basic Local 
Alignment Search Tool; //blast.ncbi.nlm.nih.gov/Blast.cgi).  Nucleotide sequences of 
the isolated prey DNA were used to search a nucleotid  database for sequences of 
highly significant similarity (BLASTN). Nucleotide sequences were also translated 
and used to search a protein database (BLASTX) for regions of similarity. Multiple 
sequences showing significant similarity to the same gene/protein were aligned using 
ClustalW (www.ebi.ac.uk/clustalw/) to identify the minimal sequence required for a 
positive interaction between bait and prey. 
 
2.6.2  Data-mining for components of the HTRA1 inte ractome 
The Human Protein Reference Database (www.hprd.org) was used to identify 
previously reported interactions for the proteins identified as putative interactors of 
HTRA1. A proposed extracellular interactome for HTRA1 was constructed based on 
these data, and including novel interactors identified in yeast two-hybrid screening or 
by tandem affinity purification.  








3: Chapter 3 
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3.1  Introduction  
An AMD risk locus on chromosomal region 10q26 (chr10q26) spans two genes - 
ARMS2 and HTRA1 - and controversy exists as to whether one or bothgenes 
contribute to AMD. The purpose of this study is to investigate the protein interaction 
network of the serine protease HTRA1 (high temperature requirement A 1), to 
elucidate its role in AMD pathogenesis. 
 HTRA1 is a secreted protein expressed in a variety of issues, but 
expression appears to be strongest in placenta (Zumbrunn and Trueb 1996; De Luca 
et al. 2003). In this tissue, HTRA1 is proposed to have a role in extracellular matrix 
remodelling and trophoblast migration and invasion (Ajayi et al. 2008; Lorenzi et al. 
2009).Elsewhere, HTRA1 expression increases with age (Ly et al. 2000), and 
degradation of the ECM by HTRA1 has been implicated in arthritis (Grau et al. 
2006). In AMD, HTRA1 expressed by the RPE (Yang et al. 2006; Chan et al. 2007), 
may remodel extracellular matrix proteoglycans in the Bruch’s membrane, along 
with collagenases and matrix metalloproteinases. ECM components, including 
collagens, interact with HTRA1 in vitro and in vivo (De Luca et al. 2004; 
Murwantoko et al. 2004). Other ECM components, including matrix Gla protein and 
decorin, are degraded by HTRA1 in vitro (Canfield et al. 2007). This is further 
supported by recent work that shows HTRA1 over-exprssion in mouse RPE results 
in fragmentation of the Bruch’s membrane (Vierkotten et al. 2011). However, it 
remains unclear how HTRA1 activity contributes to AMD-susceptibility, as these 
mice do not appear to develop AMD-like features.  
This chapter describes work undertaken to identify interacting partners of HTRA1 
that may contribute to the development of AMD pathology. A modified method of 
tandem affinity purification was performed (Puig et al. 2001; Kumar et al. 2004; 
Gloeckner et al. 2007). Additionally, a yeast two-hybrid screen using full-length 
human HTRA1 as bait in a placental cDNA library was undertaken in collaboration 
with Dr. Elod Kortvely in the laboratory of Professor Marius Ueffing at the 
Helmholtz Zentrum, Munich. These approaches are complimentary to one another, 
and greatly expand upon the previously reported interactome of HTRA1.  
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3.2   Identification of proteins interacting with H TRA1 by yeast 
two-hybrid screening 
To elucidate the role of this secreted serine protease, a yeast two-hybrid screen was 
performed using full-length human HTRA1 as the baitprotein to identify novel 
interacting proteins. As HTRA1 is expressed highly in the placenta (De Luca et al. 
2004), a cDNA library derived from this tissue was utilised in the screen. The 
principles of the yeast two-hybrid system are shown schematically in Figure 3.1. 
The bait construct consisted of the sequence for full-length HTRA1 (active 
protease) fused to the GAL4 transcription factor DNA-binding domain. Prior to 
screening for interacting proteins, auto-activation of the bait plasmid was assessed by 
co-transformation with HTRA1 and the empty prey plasmid (pACT2 
AD_GAL4_2.1/DEST). The pACT2 AD_GAL4_2.1/DEST is a Gateway-cassette 
modified version of the pACT2 vector (Clontech), created by Dr. Elod Kortvely, and 
subsequently referred to as pACT2. After 2 weeks, no yeast cells grew on triple 
dropout medium (-tryptophan, leucine, histidine; -WLH), indicating auto-activation 
did not occur.  
Cell-to-cell mating of yeast containing the bait plasmid to the placental 
cDNA library was performed. Diploid cells in which t ere was a positive interaction 
between bait and prey grew on selective media lacking tryptophan, leucine, histidine 
and adenine (-WLHA).  Of the 480 colonies which grew on selective medium          
(-WHLA), 389 clones were successfully isolated from yeast. The sequences 
recovered identified 64 proteins as potential interactors of HTRA1, of which the 
majority were extracellular (Figure 3.2). Table 3.1shows the interacting proteins for 
which multiple clones were identified, and their cellular localisation. Potential 









Figure 3.1  GAL4-based  yeast two-hybrid screening.  
Yeast two-hybrid screening was utilised to identify interactions between HTRA1 and 
proteins expressed in the human placenta. HTRA1 was fused to the GAL4 
transcription factor DNA-binding domain (DBD) to create a bait plasmid. Placental 
cDNAs were expressed as a fusion protein with the GAL4 activation domain (AD). 
When the HTRA1 bait and placental cDNA library fusion proteins interact (HTRA1 
and A), the proximity of DBD and AD activates transcription of the reporter genes; 
HIS3, ADE2, lacZ and MEL1 are used for selection of positive clones. If two pr teins 
do not interact (HTRA1 and B), there is no expression of the reporter gene. In this 
assay, ADE2 and HIS3 reporters were used for stringent selection of positive clones 
by nutritional selection on -WHLA media. 
 
 
                                                                                                                                                                                                              





Potential interactor Gene name 
Number of 
clones Cellular localisation Molecular Function Biological  process 
Chorionic somatomammotropin hormone 1  CSH1 127 Extracellular  Peptide hormone  
Cell communication; signal 
transduction 
Collagen, type III, alpha 1 COL3A1 100 Extracellular  
Extracellular matrix 
structural constituent  
Cell growth and/or 
maintenance 
Collagen, type I, alpha 1  COL1A1 12 Extracellular  
Extracellular matrix 
structural constituent  
Cell growth and/or 
maintenance 
Telomeric repeat binding factor (NIMA-
interacting) 1 TERF1 9 Nucleus Inhibitor of telomerase 
Regulation of nucleic acid 
metabolism 
ADAM metallopeptidase domain 12 (meltrin 
alpha) ADAM12 9 Plasma membrane  Metallopeptidase activity  Protein metabolism 
Eukaryotic translation initiation factor 3, subunit 
F EIF3F 8 Cytosol (Ribosome) 
Translation initiation factor 
activity Protein metabolism 
HLA-B associated transcript 3  BAT3 8 Nucleus 
Molecular function unknown 
(apoptosis) Apoptosis 
CutC copper transporter homolog (E. coli)  CUTC 6   Nucleolus Copper homeostasis  Unknown 
Tuberous sclerosis 2 TSC2 6 Cytoplasm/Membrane GTPase activator activity 
Cell communication; signal 
transduction 
Fibulin 1  FBLN1 5 Extracellular  
Extracellular matrix 
structural constituent  
Cell growth and/or 
maintenance 
Solute carrier family 2 (facilitated glucose 
transporter) 1  SLC2A1 5 Plasma membrane  
Auxiliary transport protein 
activity  Transport 
Connective tissue growth factor CTGF 4 Extracellular  
Extracellular matrix 
structural constituent  
Cell growth and/or 
maintenance 
Follistatin-like 3  FSTL3 4 Extracellular  
Extracellular matrix 
structural constituent  Unknown 
Growth differentiation factor 15 GDF15 4 Extracellular  Growth factor activity  
Cell communication; signal 
transduction 
Wilms tumor 1 interacting protein WTIP 4 Nucleus Transcription regulator  
Regulation of gene 
expression, epigenetic 
Pleckstrin homology-like domain, family B, 
member 3 PHLDB3 4 Unknown Unknown Unknown 
Collagen, type V, alpha 2 COL5A2 3 Extracellular  
Extracellular matrix 
structural constituent  
Cell growth and/or 
maintenance 
Secreted protein, acidic, cysteine-rich 
(osteonectin) SPARC 3 Extracellular  
Extracellular matrix 
structural constituent  
Cell growth and/or 
maintenance 
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Complement factor D  CFD 3 Extracellular  
Serine-type peptidase 
activity    Immune response 
Golgi autoantigen, golgin subfamily a, 2 GOLGA2 3 Golgi apparatus Vesicular transport 
Cell growth and/or 
maintenance 
Mitochondrion, complete genome   3 Mitochondria     
Zinc finger and AT hook domain containing  ZFAT 3 Nucleus/Cytoplasm Transcriptional regulation Unknown 
Protein phosphatase 4, regulatory subunit 1, PPP4R1 2   Centrosome  Signal transduction 
Cell communication; signal 
transduction 
Calcium regulated heat stable protein 1 CARHSP1 2 Cytoplasm Calcium ion binding  
Cell communication; signal 
transduction 
ATG4 autophagy related 4 homolog B (S. 
cerevisiae) ATG4B 2 Cytoplasm 
Cysteine protease 
(Autophagy) Proteolysis 
FERM domain containing 4B FRMD4B 2 Cytoplasm Insulin receptor signaling Unknown 
Histamine N-methyltransferase HNMT 2 Cytoplasm  
Inactivates histamine by N-
methylation Amino acid metabolism 
Eukaryotic translation initiation factor 4A EIF4A1 2 Cytosol (Ribosome) Translation initiation Protein metabolism 
Selenoprotein P, plasma, 1, SEPP1 2 Extracellular  Peroxidase activity 
Metabolism; Energy 
pathways 
Flotillin 1 FLOT1 2 Integral to membrane  Unknown Unknown 
Transmembrane protein 87A TMEM87A 2 Integral to membrane  Unknown Unknown 




exchange factor  
Cell communication; signal 
transduction 
Forkhead box J3 FOXJ3 2 Nucleus Unknown 
Regulation of nucleic acid 
metabolism 
Zinc finger protein 302  ZNF302 2 Nucleus  Transcriptional regulation 
Regulation of nucleic acid 
metabolism 
Chromosome 9 open reading frame 97 C9orf97 2 Unknown Unknown Unknown 
 
 
Table 3.1 Potential multi-hit interactors of HTRA1 identified by yeast two-hybrid screening in a 
placental cDNA library.  
Proteins are arranged by the frequency with which they were identified by sequencing of the isolated prey plasmids in a 
yeast two-hybrid screen. The Human Protein Referenc database (www.hprd.org) was used to assign cellular ocalisation 
and molecular function to each protein. Extracellular proteins are shaded in orange. 
 
 




Potential interactor Gene name 
Number of 
clones Cellular localisation Molecular Function Biological  process 
A kinase (PRKA) anchor protein 10 AKAP10 1 Mitochondria 
Cytoskeletal anchoring 
activity 
Cell communication ; 
Signal transduction 
Absent in melanoma 1-like AIM1L 1 Unknown Unknown Unknown 
Ankyrin repeat domain 33 ANKRD33 1 Unknown Unknown Unknown 
BCL2-like 12 (proline rich) BCL2L12 1 Cytoplasm Unknown Apoptosis 
CAP, adenylate cyclase-associated protein, 2 CAP2 1 Plasma membrane Unknown 
Cell communication ; 
Signal transduction 
Centaurin, delta 2 CENTD2 1 Cytoplasm/ Golgi  GTPase activator activity 
Cell communication ; 
Signal transduction 
Chromosome 1 open reading frame 172 C1orf172 1 Unknown Unknown Unknown 
Chromosome 10 open reading frame 10 C10orf10 1 Mitochondria Unknown Unknown 
C-type lectin domain family 3, member B CLEC3B 1 Extracellular  Unknown Unknown 
Inhibitor of DNA binding 1, dominant negative 
helix-loop-helix protein ID1 1 Nucleus  Inhibitor of DNA binding Nucleic acid metabolism 
Inosine triphosphatase (nucleoside 
triphosphate pyrophosphatase) ITPA 1 Cytoplasm Hydrolase activity 
Metabolism ; Energy 
pathways 
Junction plakoglobin JUP 1 Cytoplasm 
Cell adhesion molecule 
activity 
Cell communication ; 
Signal transduction 
Macrophage erythroblast attacher MAEA 1 Integral to membrane  
Cell adhesion molecule 
activity Cell adhesion 
Mediator complex subunit 12 MED12 1 Nucleus Transcriptional regulation 
Cell communication ; 
Signal transduction 
NADH dehydrogenase (ubiquinone) Fe-S 
protein 1 NDUFS1 1 Mitochondria Electron transport 
Metabolism ; Energy 
pathways 
Nuclear receptor subfamily 2, group F, member 
6 NR2F6 1 Nucleus Transcription factor Nucleic acid metabolism 
Polymerase (RNA) III (DNA directed) 
polypeptide F POLR3F 1 Nucleus 
DNA-directed RNA 
polymerase activity Nucleic acid metabolism 
PRP8 pre-mRNA processing factor 8 homolog 
(S. cerevisiae) PRPF8 1 Nucleus RNA binding Nucleic acid metabolism 
Son of sevenless homolog 2 (Drosophila) SOS2 1 Cytoplasm 
guanine nucleotide 
exchange factor  
Cell communication ; 
Signal transduction 
Spectrin repeat containing, nuclear envelope 2 SYNE2 1 Nucleus/Cytoplasm 
  Structural constituent of 
cytoskeleton 
Cell growth and/or 
maintenance 
TBC1 domain family, member 12 TBC1D12 1 Intracellular GTPase activator activity 
Cell communication ; 
Signal transduction 
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Topoisomerase (DNA) III beta TOP3B 1 Nucleus DNA topoisomerase Nucleic acid metabolism 
Transmembrane 7 superfamily member 2 TM7SF2 1 Integral to membrane  Cholesterol biosynthesis 
Metabolism ; Energy 
pathways 
Ubiquinol-cytochrome c reductase, Rieske iron-
sulfur polypeptide 1 UQCRFS1 1 Mitochondria Electron transport 
Metabolism ; Energy 
pathways 
USP6 N-terminal like USP6NL 1   Cytoplasm GTPase activator activity 
Cell communication ; 
Signal transduction 
Zinc finger, X-linked, duplicated A ZXDA 1 Nucleus Transcription factor Nucleic acid metabolism 
 
Table 3.2 Potential single-hit interactors of HTRA1  identified by yeast two-hybrid screening in a 
placental cDNA library.  
Proteins identified only once by sequencing of the isolated prey plasmids in a yeast two-hybrid screen. The Human Protein 
Reference database (www.hprd.org) was used to assign cellular localisation and molecular function to each protein. 
Extracellular proteins are shaded in orang
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3.2.1  HTRA1 interacts with CSH1, a placental lacto gen 
The most common interaction to be identified was betwe n HTRA1 and the placental 
lactogen, chorionic somatomammotropin hormone 1 (CSH1; 127 clones). CSH1 is a 
secreted peptide hormone, which, like HTRA1, is highly expressed in the placenta 
during the third trimester (Sciarra et al. 1963; De Luca et al. 2004). CSH1 has been 
postulated to play a role in insulin growth factor (IGF) signalling during pregnancy, 
influencing fetal growth and metabolism (Handwerger 1991). This is interesting in 
terms of a role for HTRA1 during development, but the interaction between CSH1 
and HTRA1 is unlikely to influence AMD and was not investigated further. 
 
3.2.2 HTRA1 interacts with extracellular matrix com ponents  
The majority of interacting proteins identified by yeast two-hybrid are extracellular, 
including a number of extracellular matrix (ECM) components (Figure 3.2). One of 
the most common interactions detected is a previously reported interaction with 
collagen type 3A1 (Table 3.1; (Murwantoko et al. 2004). A representative back-
transformation to verify the interaction between COL3A1 and HTRA1 is shown in 
Figure 3.3. Collagen type 1A1 (COL1A1) and collagen type 5A2 (COL5A2) were 
also identified as interacting with HTRA1 (Table 3.1), in agreement with a proposed 
role for HTRA1 in the degradation of collagen-rich extracellular membranes 
(Murwantoko et al. 2004). 
Other proteins found to interact with HTRA1 are also localised to the ECM. 
Of these, connective tissue growth factor (CTGF), fibulin-1 (FBLN1) follistatin-like 
3 and osteonectin, together with the collagens COL1A1, COL3A1 and COL5A2, are 
all extracellular matrix structural constituents, a defined by the AmiGo Gene 
Ontology database (amigo.geneontology.org/). C-type lectin domain family 3, 
member B (also known as tetranectin) is also a secret d protein, found as a 
component of plasma and the extracellular matrix (Table 3.2). The function of 
CLEC3B is unknown.  
ECM components bind one another, and secreted proteins. An HTRA1 
interactome in the extracellular matrix was proposed (Figure 3.8) based on these data 
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and previously published information (available from the Human Protein Reference 




Figure 3.2 Interactors of HTRA1 identified by yeast  two-hybrid 
screening are enriched for extracellular proteins. 
The interactors of HTRA1 that were identified by yeast two-hybrid screening in a 
placental cDNA library were classified according to cellular localisation using the 
Human Protein Reference Database (www.hprd.org). Extracellular proteins made up 
the greatest proportion of interactors, accounting for 70% of the 389 positive clones 
that were screened (upper chart). The most frequently identified extracellular 
interactors of HTRA1 were a placental lactogen, CSH1, and the extracellular matrix 













Figure 3.3  COL3A1 interacts with HTRA1 in a yeast two-hybrid 
screen. 
Of the numerous interactors of HTRA1 identified by sequencing of the prey plasmid 
in an initial yeast two-hybrid screen, several candidates were selected for back-
transformation to confirm the interaction. Prey vectors for COL3A1 (pACT2-
COL3A1) were co-transformed with the pBD-DEST-HTRA1 bait plasmid into yeast 
cells. Double transformants were grown on SD-WL plates (under no selection for an 
interaction). Individual colonies for COL3A1 were subsequently streaked onto 
selective media of increasing stringency (-WLH and -WLHA) to confirm the 
interaction. Supplements missing from the SD media are tryptophan (W), leucine 
(L), histidine (H) and adenine (A). Images and back-transformations were produced 
by Elod Kortvely. 
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3.2.3   HTRA1 interacts with proteins involved in a ngiogenesis, 
inflammation and scarring 
Interactions between HTRA1 and components of the extracellular matrix have 
previously been reported (De Luca et al. 2004; Murwantoko et al. 2004; Canfield et 
al. 2007; An et al. 2010). In addition to these, several novel interactors with potential 
relevance to the development and progression of AMD were identified by yeast two-
hybrid screening. 
 
3.2.3.1  An interaction between HTRA1 and Complemen t Factor D 
(CFD) 
CFD was identified as a potential interactor of HTRA1 in the yeast two-hybrid 
screen (Table 3.1, Figure 3.8). This links the alternative complement pathway - 
known to be dysregulated in AMD - and HTRA1, and was considered an attractive 
candidate for further study. Additional work to characterise the functional relevance 
of an interaction between HTRA1 and CFD is described in Chapter 5. 
 
3.2.3.2  An interaction between HTRA1 and Connectiv e Tissue 
Growth Factor (CTGF) 
CTGF was identified as a potential interactor of HTRA1 in the yeast two-hybrid 
screen (Table 3.1, Figure 3.8. Four CTGF clone sequences were aligned to the 
human full-length CTGF cDNA reference sequence (NM_001901.2), using Clusta W 
(www.ebi.ac.uk/clustalw/). Although three clones contai ed the complete CTGF 
cDNA sequence, one clone contained only 477 nucleotid s of the cDNA sequence 
(data not shown). This defined the minimal sequence required for a positive 
interaction between the active HTRA1 bait and CTGF prey sequences as spanning 
the first 159 amino acids of CTGF, including the Insulin growth factor-binding 
protein (IGFBP) and von Willebrand factor (vWF) type C domains, shown 
schematically in Figure 3.15A. 
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3.3   Tandem Affinity Purification of HTRA1 and int eracting 
proteins 
To identify proteins which interact with HTRA1 in a n tive, functional state, a fusion 
protein of HTRA1, tagged at the C-terminal end with the tandem affinity purification 
tag (CTAP), was expressed in HEK293T cells and in hTERT-RPE1 cells. The TAP 
procedure is shown schematically in Figure 3.4.  
 
3.3.1   Tandem Affinity purification of HTRA1 in HE K293T cells 
HEK293T cells are a transformed human embryonic kidney cell-line, which can be 
readily transfected. Endogenous HTRA1 is present in HEK293T cells, as 
demonstrated by the detection of an immunoreactive band of ~51 kDa when 
untransfected HEK293T cell lysate is subjected to Western blotting with an anti-
HTRA1 antibody (Figure 3.5, lane 1). HEK293T cells were transfected with a 
construct encoding HTRA1 with a C-terminal TAP tag or with a corresponding 
empty vector (EV). 48-72 hours post transfection, cell lysates and concentrated 
conditioned media were subjected to tandem affinity purification (TAP). The TAP 
procedure is shown schematically in Figure 3.4. 
Western blotting analysis, using antibodies against the FLAG tag, show that 
both HTRA1-CTAP (~57 kDa) secreted into the media from the transfected 
HEK293T cells and intracellular HTRA1-CTAP was successfully purified using 
TAP (Figure 3.5).  Whole eluates were analysed by liquid chromatography coupled 
with tandem mass spectrometry (LC-MS/MS). This was performed by Karsten Boldt 
at the Helmholtz Zentrum in Munich. 
 







Figure 3.4 Tandem Affinity Purification of HTRA1.  
An overview of the TAP procedure, using a C-terminally t gged form of full-length 
HTRA1 (HTRA1-CTAP). Mass spectrometry was used to identify interactors of 
HTRA1 in the whole eluate following purification ofthe tagged protein from the 
conditioned media and cell lysates of HEK293T and RPE1 cells. HTRA1-interacting 
proteins are indicated in green; proteins that bind non-specifically to the tags and 
resin are shown in black.  
 
   
 105 
 
Figure 3.5  HEK293T cells transfected with HTRA1-CT AP express 
tagged-HTRA1. 
HEK293T cells endogenously express HTRA1 (lane 1). HEK293T cells were 
transfected with the HTRA1-CTAP construct for use in tandem affinity purification. 
Expression of the tagged HTRA1 construct was verified by Western blotting of cell 
lysate and conditioned media from transfected cells, probed with anti-FLAG 
antibody to detect FLAG-tagged HTRA1. HTRA1-CTAP was detected in both cell 
lysate (lane 2), and more abundantly, in conditioned m dia of transfected cells (lane 
5). The CTAP FLAG and Strep2 tag adds approximately 6 kDa to the molecular 
weight of HTRA1. The FLAG peptide (1 kDa) produced by HEK293T cells which 
were transfected with the empty vector EV was not detected by Western blotting. 
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 3.3.2   Tandem Affinity purification of HTRA1 in h TERT RPE1 cells 
 Dysfunction and cell death of retinal pigment epithelial (RPE) cells is considered to 
have an important role in the pathogenesis of AMD. For this reason, proteins 
interacting with HTRA1 in the physiologically relevant cell line hTERT-RPE1 were 
also investigated. 
  
3.3.2.1  Optimisation of microporation conditions f or transfection 
of hTERT-RPE1 
Parameters for the transfection of the hTERT-RPE1 cell line using microporation had 
not previously been described. Therefore, the optimal conditions for high 
transfection efficiency and cell viability were determined in a series of experiments. 
 
3.3.2.1.1  Assessment of transfection efficiency an d cell viability in 
24-well plates 
1x105 cells/well of a 24-well plate were subjected to microporation using the MP-
100 (Digital Bio), with 0.5 µg pmaxGFP plasmid DNA in a 10 µl gold tip. A range 
of pulse voltages, pulse widths and pulse number were tested to determine 
microporation parameters with optimal transfection efficiency and cell viability 
(Table 3.3).  
After 24 hours of growth at 37oC, transfection efficiency was determined by 
assessing the proportion of GFP-positive cells. Viability was assessed by comparison 
to cells which were not microporated. The optimal parameters for microporation, 
producing cell viability comparable to untransfected c lls and transfection efficiency 
>75% of viable cells, were  1500 Volts/ 20 ms pulse/ 1 pulse and 1600 Volts/ 20 ms 
pulse/ 1 pulse. 
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Table 3.3  Optimisation of microporation parameters  for the 
transfection of RPE1 cells.  
1x105 cells/well of a 24-well plate were subjected to microporation with 0.5 µg  
pmaxGFP in a 10 µl gold tip using a range of pulse voltages, pulse widths and pulse 
number. Transfection efficiency was determined 24 hours post-microporation by 
assessing the proportion of GFP-positive cells. For cell viability, +++ is cell viability 
comparable to untransfected cells; ++ is cell viability less than 80% of untransfected 
cells and + is cell viability less than 50% of untransfected cells. For transfection 
efficiency, +++ indicates that more than 75% of viable cells are transfected, ++ 
indicates between 50-75% of viable cells are transfected, and + indicates that less 
than 50% of viable cells are transfected. 
 
 







number Cell viability  
Transfection 
efficiency 
1 Control without microporation +++ - 
2 1400 20 1 ++ +++ 
3 1500 20 1 +++ +++ 
4 1600 20 1 +++ +++ 
5 1700 20 1 +++ ++ 
6 1100 30 1 +++ + 
7 1200 30 1 +++ + 
8 1300 30 1 +++ ++ 
9 1400 30 1 ++ ++ 
10 1000 40 1 +++ + 
11 1100 40 1 +++ + 
12 1200 40 1 +++ + 
13 1100 20 2 +++ + 
14 1200 20 2 +++ ++ 
15 1300 20 2 +++ ++ 
16 1400 20 2 ++ ++ 
17 900 30 2 +++ + 
18 1000 30 2 ++ + 
19 1100 30 2 ++ ++ 
20 1200 30 2 +++ ++ 
21 1300 10 3 +++ ++ 
22 1400 10 3 +++ ++ 
23 1500 10 3 ++ ++ 
24 1600 10 3 + ++ 
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3.3.2.1.2  Assessment of transfection efficiency an d cell viability in 
14 cm plates 
The microporation parameters which gave high transfection efficiency and high 
levels of cell viability in a small-scale microporation reaction (Table 3.3) were tested 
in large-scale reactions for use in 14 cm plates.  
5 x 106 RPE1 cells were mixed with 5 µg of the pmaxGFP construct.  
Microporation was performed using the MP-100 (Digital Bio) with 100 µl tips and 
Buffer E2 electrode buffer. Transfection efficiency and cell viability were confirmed 
by fluorescence microscopy 24 hours post transfection. As shown in Figure 3.6, the 
conditions which gave optimal transfection efficiency were 1500 Volts for one pulse 
of 20 ms duration.  
Subsequent transfection of RPE1 cells was performed using these parameters. 
Each 14 cm plate was seeded with 10x 106 cells microporated with 10 µg DNA. 
Transfected cells were grown at 37°C for 48-72 hours before collection of 
conditioned media and cell lysates.  
  
3.3.2.2 Identification of interacting proteins of H TRA1 by TAP in 
hTERT-RPE1  
Endogenous HTRA1 was detected in the conditioned meia of untransfected RPE1 
cells (Figure 3.7). This is consistent with reports of HTRA1 expression in primary 
human RPE cells (Yang et al. 2006; An et al. 2010). RPE1 cells were transfected 
with a construct encoding HTRA1-CTAP or with a corresponding empty vector 
(EV). Cell lysates and concentrated conditioned media were collected 48-72 hours 
after transfection, and subjected to TAP. Immunoblotting, using antibodies against 
the FLAG tag, show that HTRA1-CTAP (~57 kDa) is secreted into the media from 
the transfected RPE1 cells. Secreted HTRA1-CTAP and intracellular HTRA1-CTAP 
were successfully purified by TAP and were identified, along with putative 
interactors, in the whole eluates analysed by LC-MS/MS.  
 




Figure 3.6  Optimised microporation parameters for transfection of 
RPE1 cells. 
Transfection reactions were scaled-up for 5x106 RPE1 cells in a 14cm cell culture 
dish, using 5 µg  pmaxGFP in a 100 µl gold tip. Three microporation parameters, 
found to give high cell viability and transfection efficiencies in small-scale 24-well 
plate transfection were tested to determine microporation parameters with optimal 
transfection efficiency and cell viability for larger scale reactions. After 24 hours of 
growth at 37oC, transfection efficiency was determined by assessing the proportion 
of GFP-positive cells. Viability was assessed by comparison to cells which were not 
subjected to microporation. The greatest cell survival and highest transfection 
efficiency was obtained by microporating the cells at 1500 Volts for one pulse of 20 
ms duration. 




Figure 3.7  RPE1 cells transfected with HTRA1-CTAP express tagged-
HTRA1. 
RPE1 cells endogenously express HTRA1. RPE1 cells wre transfected with the 
HTRA1-CTAP construct for use in tandem affinity purification. Expression of the 
tagged HTRA1 construct was verified by Western blotting of conditioned media 
from transfected cells, probed with anti-FLAG antibody to detect FLAG-tagged 
HTRA1. The CTAP FLAG and Strep2 tag adds approximately 6 kDa to the 
molecular weight of HTRA1. The identities of the hig er molecular weight bands are 
unknown. The FLAG peptide (1 kDa) produced by HEK293T cells which were 
transfected with the empty vector (EV) was not detect d by Western blotting. 
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 3.3.3   Interactors of HTRA1 identified by TAP 
Proteins which bind non-specifically to the affinity resins or to the TAP tag in 
conditioned media and cell lysate were identified by mass spectrometry analysis of 
the empty vector control (data not shown). Proteins that interact specifically with 
HTRA1 (or the binding partners of HTRA1, in the case of indirect interactions) in 
the extracellular environment in three separate TAP experiments are shown in Table 
3.4. Table 3.5 contains the HTRA1 binding partners with a primarily intracellular 
localisation, also in three experiments. Cellular localisation, molecular function and 
biological process for each protein were obtained by ata-mining in the Human 
Protein Reference Database (www.hprd.org, accessed January and February 2009). 
 
3.3.3.1  ECM structural constituents interact with HTRA1 
Extracellular proteins were enriched in the interactome identified by TAP in 
conditioned media. Of these proteins, collagen 12A1, laminin alpha 4, tenascin, 
agrin, fibronectin-1, thrombospondin-1 and connective ssue growth factor have a 
structural role in the ECM (Table 3.4). Only fibronectin was identified as a potential 
interactor of HTRA1 in multiple TAP experiments (performed in media from 
HEK293T cells). Connective tissue growth factor was identified as a binding partner 
of HTRA1 in only one of the TAP experiments (performed in HEK293T cells), but 
was also identified by yeast two-hybrid screening.  
 
3.3.3.2  Protease inhibitors interact with HTRA1 
Four protease inhibitors were found to interact with the serine protease HTRA1 
extracellularly. Serpin B3 and Serpin B12 were detect d only in TAP performed in 
HEK293T cells. Serpin C1 was detected as an interactor only in RPE1 cells. Alpha-
2-macroglobulin was detected in TAP experiments performed in both HEK293T 
cells and in RPE1 cells (Table 3.4), reflecting a previously reported interaction (An 
et al. 2010). Whether these various protease inhibitors represent a tissue-specific 
method of regulating HTRA1, or simply reflect over-expression of an active protease 
is unknown.  
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Protein Name Gene Name  
Cellular 







Alpha-2-macroglobulin  A2M Extracellular 
Protease inhibitor 
activity  Protein metabolism Y  Y 
Cochlin precursor  COCH Extracellular Unknown Unknown Y   
Collagen alpha-1(XII) 
chain COL12A1 Extracellular 
Extracellular matrix 
structural constituent  
Cell growth and/or 
maintenance   Y 
Thrombospondin-1  THBS1 Extracellular 
Extracellular matrix 
structural constituent  
Cell growth and/or 
maintenance Y  Y 
Uncharacterized protein 
ENSP00000332963 FOLR4 Extracellular Unknown Unknown  Y  
Agrin  AGRN Extracellular  
Extracellular matrix 
structural constituent  
Cell growth and/or 
maintenance   Y 
Antithrombin-III  SERPINC1 Extracellular  
Protease inhibitor 
activity  Protein metabolism   Y 
Complement C3  C3 Extracellular  Complement activity  Immune response  Y Y 
Connective tissue 
growth factor  CTGF Extracellular  
Extracellular matrix 
structural constituent  
Cell growth and/or 
maintenance  Y  
Fibronectin precursor  FN1 Extracellular  
Extracellular matrix 
structural constituent  
Cell growth and/or 
maintenance Y Y  
Hemoglobin alpha 1-2 
hybrid HBA1 Extracellular  Transporter activity Transport   Y 
Hemoglobin subunit 
beta  HBB Extracellular  Transporter activity Transport  Y  
Hemoglobin subunit 
delta  HBD Extracellular  Transporter activity Transport   Y 
Isoform 2 of Serum 
albumin  ALB Extracellular  Transporter activity Transport   Y 
Lactoferroxin C LTF Extracellular  Transporter activity Transport   Y 
Laminin subunit alpha-4 LAMA4 Extracellular  
Cell adhesion 
molecule activity  
Cell growth and/or 
maintenance   Y 
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Lysozyme g-like protein 
1  LYG1 Extracellular  Unknown Unknown   Y 
Tenascin  TNC Extracellular  
Extracellular matrix 
structural constituent  
Cell communication; 
Signal transduction   Y 




activity  Protein metabolism  Y  




activity  Protein metabolism  Y  











 Table 3.4 Extracellular interactors of HTRA1 ident ified by tandem affinity purification. 
Proteins identified by LC-MS/MS analysis in the eluates of tandem affinity purification of HTRA1-CTAP from the cell lysates and 
conditioned media of either HEK293T or RPE1 cells. The Human Protein Reference Database was used to assign cellular 
localisation and molecular function to each protein. 
 
 




Protein Name Gene Name  
Cellular 





TAP3          
(RPE1) 
Acetyl-CoA carboxylase 1 ACACA Cytoplasm Ligase activity 
Metabolism;  
Energy pathways   Y Y 
S100-A8 S100A8 Cytoplasm Calcium ion binding 
Cell communication; 
Signal transduction Y   
Cytoplasmic dynein 1 
heavy chain 1 DYNC1H1 Cytoplasm ATPase activity 
Metabolism;  
Energy pathways   Y 
Heat shock 70 kDa 
protein 1 HSPA1A Cytoplasm Chaperone activity Protein metabolism  Y  
Neutrophil defensin 1  DEFA1 Cytoplasm 
Defense/immunity 
protein activity Immune response  Y  
Protein S100-A7 S100A7 Cytoplasm Calcium ion binding 
Cell communication; 
Signal transduction  Y  
Titin TTN Cytoplasm 
Structural molecule 
activity Muscle contraction  Y Y 
Beta-actin-like protein 2 ACTBL2 
Cytoplasm/Cyt




oskeleton Unknown Cell differentiation   Y 





Cell growth and/or 
maintenance  Y  
Dimethylaniline 
monooxygenase [N-
oxide-forming] 3 FMO3 
Endoplasmic 
reticulum Catalytic activity Drug metabolism   Y 
78 kDa glucose-
regulated protein 
precursor GRP 78 
Endoplasmic 
reticulum Chaperone activity Protein metabolism Y Y  




Heat shock protein 
activity Protein metabolism  Y  




protein 9 TMED9 
Endoplasmic 
reticulum Unknown Unknown  Y  
Transmembrane emp24 
domain-containing 
protein 10 TMED10 
Golgi 
apparatus 
membrane Transporter activity Transport Y   
Transmembrane emp24 
domain-containing 
protein 2 TMED2 
Golgi 
apparatus 
membrane Transporter activity Transport Y   
C-type lectin domain 
family 7 member A CLEC7A 
Integral to 






Cell growth and/or 
maintenance   Y 






Signal transduction  Y  
Roundabout homolog 2 
precursor ROBO2 
Integral to 
membrane Receptor activity Signal transduction  Y  
Astrotactin 2 ASTN2 
Integral to 




membrane Unknown Unknown  Y  
Protein dispatched 
homolog 2 DISP2 Membrane Unknown 
Cell communication; 
Signal transduction   Y 




Energy pathways  Y  
Trifunctional enzyme 
subunit beta, 
mitochondrial HADHB Mitochondrion Catalytic activity 
Metabolism;  
Energy pathways  Y  
ATP synthase subunit 
beta, mitochondrial ATP5B Mitochondrion Transporter activity 
Metabolism;  
Energy pathways  Y  
Trifunctional enzyme 
subunit alpha, 
mitochondrial HADHA Mitochondrion Catalytic activity 
Metabolism;  
Energy pathways Y Y  






of nuclear pore Protein transport  Y  
Heat shock cognate 71 
kDa protein HSPA8 Nucleolus 
Heat shock protein 
activity Protein metabolism  Y  
Coiled-coil domain-
containing protein 48 CCDC48 Nucleus Unknown Unknown  Y  
General transcription 





metabolism Y   
Methylcytosine 
dioxygenase TET1 TET1 Nucleus DNA binding 
Regulation of 
nucleic acid 
metabolism   Y 
Probable histone-lysine 
N-methyltransferase 





metabolism  Y  
Ribonucleases P/MRP 
protein subunit POP1 POP1 Nucleus RNA processing 
Regulation of 
nucleic acid 
metabolism    
RNA-binding protein 
Raly RALY Nucleus RNA binding 
Regulation of 
nucleic acid 
metabolism  Y  
Cell cycle checkpoint 
protein RAD17 RAD17 Nucleus Unknown 
Regulation of cell 
cycle  Y  
Chromodomain-
helicase-DNA-binding 
protein 3 CHD3 Nucleus DNA binding 
Regulation of 
nucleic acid 
metabolism   Y 
Component of gems 4 GEMIN4 Nucleus Unknown 
Reproductive 
behavior  Y  
Disrupted in 
schizophrenia 1 protein DISC1 Nucleus Unknown Unknown  Y  
Exportin-2 CSE1L Nucleus Transporter activity Transport  Y  
Lamin-A/C LMNA Nucleus 
Signal transducer 
activity 
Cell growth and/or 
maintenance   Y 
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Signal transduction  Y  
B(0,+)-type amino acid 












Signal transduction  Y  
Ephrin-A5 EFNA5 
Plasma 
membrane Receptor binding 
Cell communication; 
Signal transduction   Y 















pathways  Y  
Plasma membrane 
calcium-transporting 
ATPase 3 ATP2B3 
Plasma 
membrane Transporter activity Transport  Y  






Cell growth and/or 
maintenance  Y  
Vascular endothelial 






Signal transduction  Y  
Double-strand-break 
repair protein rad21-like 
protein 1 RAD21L1 Unknown Unknown Unknown  Y  
NGFRAP1 like 1 BEX5 Unknown Unknown Unknown Y   
Tetratricopeptide repeat 
protein 21B TTC21B Unknown Unknown Unknown   Y   
 
Table 3.5 Potential intracellular interactors of HT RA1 identified by tandem affinity purification. 
Proteins identified by LC-MS/MS analysis in the eluates of tandem affinity purification of HTRA1-CTAP from the cell lysates and 
conditioned media of either HEK293T or RPE1 cells. The Human Protein Reference Database was used to assign cellular 
localisation and molecular function to each protein.
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3.3.3.3  Complement component C3 is a potential int eractor of 
HTRA1 
In addition to the extracellular matrix proteins identified by TAP, complement C3 
was detected as an interacting partner in TAP experiments performed in both 
HEK293T and RPE1 cells (Table 3.4). C3 is an extracellular protein with an 
important role in complement activity, and genetic variants of the C3 gene have been 
shown to confer increased susceptibility to AMD (Yates et al. 2007).  
 
3.3.3.4 Intracellular interactors of HTRA1 
Although HTRA1 is a secreted protein, the protease has been proposed to play a role 
in intracellular signalling pathways. Potential intracellular binding partners of 
HTRA1 that were identified using TAP are shown in Table 3.5.  
 
3.3.3.4.1  Membrane proteins 
Proteins that are localised to the plasma membrane, or are integral components of the 
plasma membrane, were detected by mass spectrometry of the TAP eluates (Table 
3.5). Of these, the vascular endothelial growth factor receptor 2 (VEGFR2) may be 
of interest due to the previous association of VEGF with AMD.  
A largely uncharacterised family of integral membrane proteins is represented 
multiple times as interacting with HTRA1 in TAP eluates - the emp24 domain 
containing proteins 2, 9 and 10 (Table 3.5). Despit only being detected in HEK293T 
cells, the detection of more than one member of this family of proteins may indicate 
a significant biological role for HTRA1 in relation to emp24 domain-containing 
proteins. These proteins are relatively uncharacterised, but may have a transporter 
function. 
 
3.3.3.4.2  Chaperone proteins 
Chaperone proteins (as determined by GO ontology terms) feature strongly in the list 
of potential intracellular interactors of HTRA1 identified by TAP (Table 3.5). These  
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include the 78 kDa glucose regulated protein (GRP78), heat shock cognate 71 kDa 
protein (HSPA8), and heat shock 70 kDa protein 1 (HSPA1A). This may be a 
consequence of over-expression of HTRA1 in cell culture,  or may reflect the role of 
HTRA1 as a stress-responsive protein which may functio  as a chaperone (Runyon 
et al. 2007). 
 
3.3.3.4.3  Cytoskeleton proteins 
Intracellular proteins which are localised to the cytoskeleton were identified as 
interactors of HTRA1 in the TAP experiments (Table 3.5). Of these, Beta-actin-like 
protein 2 (ACTBL2) and Keratinocyte proline-rich protein (KPRP) have an unknown 
function within the cell. Tubulin alpha-1A is a structural constituent of the 
cytoskeleton, and has been previously reported as an interactor and substrate for 
HTRA1 (Chien et al. 2009a; Chien et al. 2009b; Campioni et al. 2011). Tubulins are 
also components of drusen and amyloid plaques, chara teristic of AMD and 
Alzheimer’s disease respectively (Booij et al. 2010). 
 
3.3.3.4.4  Mitochondrial proteins 
AMD has been proposed as a disease of mitochondrial dysfunction; HTRA1 is 
shown to interact with several proteins that are localised to the mitochondria (Table 
3.5). The alpha and beta subunits of the trifunctioal enzyme acetyl-CoA 
acyltransferase were detected. Although the alpha subunit was detected in both of the 
TAP experiments performed in HEK293T cells, the trifunctional enzyme has no 
obvious connection to the AMD phenotype, playing a catalytic role in the β-
oxidation of long chain fatty acids in the mitochondria. Cytochrome b is a 
component of the respiratory chain complex III, and s has a role in electron transfer 
and ATP generation. The electron transfer chain is a key source of free-radical 
superoxide ions and cause of oxidative stress, which is thought to contribute to AMD 
(Hollyfield et al. 2008). The beta subunit of ATP synthase, the final component of 
the mitochondrial electron transport chain, was also detected in the analysis of the 
TAP eluate. The physiological relevance of these int ractions is unclear as HTRA1 is 
not reported to be localised to the mitochondria. 
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3.3.3.4.5  Proteins with a role in innate immunity 
Proteins with a role in pro-inflammatory processes and the innate immune response 
were identified as interactors of HTRA1 in TAP experiments. Neutrophil defensin-1, 
DEFA1, is an alpha-defensin with anti-microbial proerties and was identified as an 
interactor of HTRA1 in an experiment performed in HEK293T cells. S100A7 and 
S100A8 were also identified as interactors of HTRA1 in HEK293T cells. These are 
calcium-binding proteins, with a suggested role in pro-inflammatory processes. 
S100A8 is elevated in the macular region of AMD eyes (Yuan et al. 2010). 
 
3.4   A proposed extracellular interactome for HTRA 1 
A large number of potential interactors of HTRA1 were identified by the yeast two-
hybrid screening and TAP. The focus of this study was on extracellular interactors of 
HTRA1 with a possible role in AMD. The cellular localisation of the putative 
interactors was used to filter proteins with a primarily extracellular localisation. A 
proposed extracellular HTRA1 interactome was constructed, incorporating these data 
and previously reported interactions from HPRD, STRING and NCBI PubMed 
databases. The interaction network for HTRA1 is shown in Figure 3.8. This 
reinforces the overlap between these data and previously reported HTRA1-
interactors (for example, with COL1A1, COL3A1, fibronectin, and indirectly with 
TGF-β). Novel interactions were also identified (Figure 3.8). These suggest roles for 
HTRA1 in angiogenesis, fibrovascular scarring, inflammation and the alternative 
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Figure 3.8   A proposed extracellular interaction n etwork for HTRA1. 
An extracellular interactome for HTRA1 was construced using data from yeast two-hybrid and tandem affinity purification, together with 
data-mining for previously reported interactions in the Human Protein Reference Database (www.hprd.org), STRING string-db.org) and 
NCBI PubMed (www.ncbi.nlm.nih.gov/pubmed).  
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3.5 Verification of interactions identified by yeas t two-hybrid 
screening or TAP 
A number of putative extracellular interactors were selected for verification of an 
interaction with HTRA1 using additional in vitro approaches. Recombinant HTRA1 
was expressed and purified from bacteria, and used to confirm interactions in GST-
pulldown assays, and to identify substrates in protease assays. 
 
3.5.1  Recombinant forms of HTRA1 
Recombinant GST-tagged HTRA1 encoding amino acids 157-480 of the full-length 
protein was produced in E. coli. The pDEST17 construct is an E. coli expression 
vector, encoding a GST-tag at the N-terminus of the recombinant protein, with an 
IPTG-inducible lacIq promoter controlling expression. The expression vector for 
GST ∆N HTRA1 was a kind gift of Dr. Elod Kortvely.   
GST ∆N HTRA1 lacks the N-terminal insulin-like growth factor-binding 
protein and serine protease inhibitor domain (shown schematically in Figure 3.9). 
This form of HTRA1 is thought to be physiologically relevant as HTRA1 undergoes 
auto-proteolysis to generate N-terminal truncations. A catalytically inactive mutant 
of HTRA1 was generated by site-directed mutagenesis (performed by Elod Kortvely) 
of the active site serine residue 328 to alanine (S328A). Confirmation of the 
necessary coding change by the alteration of the codon for serine (TCG) to alanine 
(GCG) is shown in Figure 3.10. 
A His6-tagged form of HTRA1, encoding amino acids 157-480 of the full-
length protein was also produced in E. coli. The pDEST15 construct is an E. coli 
expression vector, encoding a His6-tag at the N-terminus of the recombinant protein, 
with an IPTG-inducible lacIq promoter controlling expression. Gateway cloning 
technology was used to insert the sequence of ∆N HTRA1 into the expression vector.  




Figure 3.9  Domain structure and recombinant forms of HTRA1. 
HTRA1 is a secreted serine protease, with an N-terminal secretory signal sequence, 
an insulin-like growth factor domain, and a Kazal-type serine protease inhibitor 
domain, a trypsin-like serine peptidase domain and a C-terminal PDZ domain. Full-
length HTRA1 contains 480 amino acids and is 51 kDa. GST HTRA1∆C is a 
recombinant form of the protein containing the two N-terminal domains. GST ∆N 
HTRA1 is a recombinant form of the protease, lacking the two N-terminal domains 
and with an N-terminal GST tag. An inactive mutant of HTRA1 replaces the active 




Figure 3.10   Verification of the T to G coding change in HTRA1 
sequence to generate the S328A inactive HTRA1 mutan t. 
Site-directed mutagenesis was used to alter an amino acid codon in HTRA1 from 
TCG (Serine) to GCG (Alanine) and generate an inactive mutant of the enzyme. The 








1                                                                                480 aa. 
   
 124 
3.5.1.1 Expression of recombinant GST ∆N HTRA1 and His 6 ∆N 
HTRA1 
The E.coli strain BL21 (DE3) pLysS was used for the expression of His6 ∆N 
HTRA1, GST ∆N HTRA1 or GST ∆N HTRA1 S328A.  
 
3.5.1.2 Purification of recombinant GST ∆N HTRA1 
Recombinant GST ∆N HTRA1 or GST ∆N HTRA1 S328A was purified from the 
soluble fraction of the bacterial cell lysate using the affinity of the GST-tag for 
Glutathione Sepharose resin. Following extensive washing of the immobilised 
protein, the GST ∆N HTRA1 was eluted. Steps in the purification procedure of GST 
∆N HTRA1 and GST ∆N HTRA1 S328A are shown in Figure 3.11A and Figure 
3.12 respectively.  
The purity of GST ∆N HTRA1 (~64 kDa) was assessed by SDS-PAGE 
(Figure 3.11B). All bands observed in the Coomassie tained gel (lane 1) were 
recognised by the polyclonal anti-HTRA1 PDZ antibody (lane 2) or the anti-GST-
HRP antibody (lane 3). Lower molecular weight bands are due to proteolytic activity 
of the recombinant protease, as these bands are not observed in purified GST ∆N 
HTRA1 S328A (Figure 3.12).  
 
3.5.1.3  Purification of recombinant His 6 ∆N HTRA1 
Recombinant His6 ∆N HTRA1 was purified using the affinity of the His6-tag for Ni-
NTA agarose. Purity of the eluted His6 ∆N HTRA1 (~51 kDa)
 was assessed by SDS-
PAGE and Coomassie-staining (data not shown), priorto dialysis into TBS to 
remove Imidazole. 
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         1      2      3  
 
Figure 3.11 A representative purification procedure  for GST ∆N 
HTRA1. 
A. A representative Coomassie-stained gel showing stage  in the purification of 
GST ∆N HTRA1. The band at ~64 kDa corresponding to HTRA1 is induced 
by IPTG, and purified from the soluble fraction of the bacterial cell lysate. 
Following extensive washing, GST ∆N HTRA1 is eluted from Glutathione 
Sepharose in successive elution steps E1-E6.  
B. Lower molecular weight bands apparent in the Coomassie-stained gel are 
fragments of HTRA1, as shown by immunoreactivity with either anti-HTRA1 
PDZ or anti-GST antibodies. 
 
 






Figure 3.12  A representative purification procedur e for GST ∆N HTRA1 
S328A. 
A Coomassie-stained gel showing steps in the purificat on procedure for GST ∆N 
HTRA1 S328A. Expression of HTRA1 is induced by IPTG, and purified from the 
soluble fraction of the bacterial cell lysate (Input) sing the affinity of the GST tag 
for Glutathione Sepharose. After extensive washing, pure GST ∆N HTRA1 S328A 
(~64 kDa) was eluted from the resin.   
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3.5.2  HTRA1 interacts with Thrombospondin-1 (THBS1 ) 
As shown in Figure 3.13A, thrombospondin-1 is a multi-domain protein of 129 kDa. 
Thrombospondin-1 is secreted by a variety of cell types and is a component of the 
extracellular matrix with diverse physiological roles. An interaction between HTRA1 
and thrombospondin-1 was detected by TAP performed in HEK293T cell media 
(Table 3.4).  
 
3.5.2.1  Thrombospondin-1 is a substrate for HTRA1 in vitro  
Purified thrombospondin-1 is cleaved by recombinant GST ∆N HTRA1 in an in vitro 
protease activity assay (Figure 3.13B). Following icubation of 1 µg of GST ∆N 
HTRA1 with 2.25 µg of thrombospondin-1 at 37ºC for 18 hours, fragments ranging 
from approximately 80 kDa to 129 kDa were observed in a silver stained gel (Figure 
3.13B). A higher molecular weight band of approximately 180 kDa which is not 
recognised by anti-THBS1, but is likely to represent a  acetylated and glycosylated 
modified form of thrombospondin-1 (post-translational modifications are indicated in 
Figure 3.13A), appears to be particularly susceptible o proteolysis by GST ∆N 
HTRA1 (*). There was no degradation of thrombospondin-1 following incubation at 
37ºC for 18 hours in the absence of the protease (ln  3, Figure 3.13B). 
 
3.5.2.2  Thrombospondin-1 interacts directly with H TRA1 in vitro  
The HTRA1/thrombospondin-1 interaction detected by TAP was validated using in 
vitro pull-down techniques. Full-length thrombospondin-1, purified from human 
platelets, was tested for the ability to associate wi h GST ∆N HTRA1 (Figure 3.9). 
Thrombospondin-1 generated an immunoreactive band with a molecular weight of 
~129 kDa when subjected to Western blotting with an anti-THBS1 antibody (lane 3, 
Figure 3.13C). This band represents 10% input to the GST-pulldown assay. A 
thrombospondin-1-specific band was detected following pull-down with the GST ∆N 
HTRA1 fusion protein (lane 6). No binding to Glutathione Sepharose resin or to GST 
alone was observed (lane 4 and lane 5, Figure 3.13C)




Figure 3.13  Thrombospondin interacts with, and is a substrate for, 
HTRA1 in vitro . 
A. Thrombospondin-1 is a multi-domain matrix glycoprotein (N- and O-
glycosylation sites indicated by green dots), which forms as a disulphide-linked 
(indicated by red dots) homotrimer. Domains are: Thrombospondin N-terminal -like 
domain (TSPN), von Willebrand factor (vWF) type C domain (VWC), 
Thrombospondin type 1 repeats (TSP1), Calcium-binding EGF-like domain 
(EGFCA) and Epidermal growth factor-like domain (EGF).   
Source: www.hprd.org. 
B. Thrombospondin-1 is cleaved by HTRA1 in an in vitro protease assay, generating 
fragments ranging from 80-129 kDa (lane 2, **). Unmodified thrombospondin-1 is 
129 kDa; glycosylated thrombospondin-1 has a higher molecular weight (*). 
C. Thrombospondin-1 interacts with GST ∆N HTRA1 in a GST-pulldown assay. 
10% input to the assay is shown in lanes 1-3 of the Western blots. Upper panel is 
probed with anti-thrombospondin-1; lower panel is probed with anti-GST HRP. 
There was no interaction between Glutathione Sepharose and thrombospondin-1 
(lane 4), or GST and thrombospondin-1 (lane 5). A strong interaction between GST 
∆N HTRA1 and thrombospondin-1 was detected (lane 6).  
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3.5.3  An interaction between HTRA1 and C3 could no t be verified 
in vitro  
Complement component C3 has a key role in the alterna ive complement pathway. 
The putative interaction between C3 and HTRA1 identifi d by TAP was selected for 
validation. A commercially available C3, purified from human plasma, was used in 
in vitro assays with recombinant GST ∆N HTRA1. 
 
3.5.3.1  C3 is not a substrate for HTRA1 in vitro  
Purified C3 was tested as a substrate for HTRA1 in an i  vitro protease assay. As 
shown in Figure 3.14, there was no cleavage or degradation of 2 µg of C3 following 
incubation with 0.2 µg of GST ∆N HTRA1 at 37ºC for 18 hours, analysed by SDS-
PAGE. 
 
Figure 3.14  C3 is not a substrate for HTRA1 in an in vitro protease 
assay. 
C3 purified from human plasma (comprising C3 alpha and C3 beta subunits) is not 
subject to proteolysis by GST ∆N HTRA1, as shown in lane 4 of the Coomassie-
stained gel of the protease assay. 
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3.5.3.2 Non-specific binding of C3 prevented verifi cation of an 
interaction in GST-pulldown assay 
Recombinant GST ∆N HTRA1 was used in a series of GST pulldown assays to 
verify an interaction between HTRA1 and C3 in vitro. High background binding of 
C3 to Glutathione Sepharose resin was observed across a range of increasingly 
stringent wash conditions (0-2M NaCl; 0-2% NP40; data not shown). This prevented 
the verification of a direct interaction between C3 and HTRA1.   
 
3.5.4   HTRA1 interacts with CTGF in vitro  
An interaction between CTGF and HTRA1 was identified in the yeast two-hybrid 
screen and in a TAP experiment (Table 3.1, Table 3.4, Figure 3.8). The domain 
structure of CTGF is shown in Figure 3.15A. A direct interaction between these two 
proteins was verified using recombinant purified proteins in in vitro assays. 
 
3.5.4.1  Generation of recombinant GST-tagged CTGF 
The sequence encoding full-length CTGF (Figure 3.15A) was cloned from human 
retinal cDNA. Using Gateway technology, CTGF was sub-cloned into the bacterial 
expression vector pDEST17, to produce CTGF with a GST-tag at the N-terminus of 
the recombinant protein. The E.coli strain BL21 (DE3) pLysS was used for protein 
expression. Recombinant GST CTGF (63 kDa) w s purified from the soluble 
fraction of the bacterial cell lysate. The purity of the eluted protein was assessed by 
SDS-PAGE followed by Coomassie staining prior to dialysis into TBS. GST CTGF 
alone is shown in Figure 3.15B (lane 3). 
 
3.5.4.2  CTGF is a substrate for HTRA1 in vitro  
Recombinant GST-tagged CTGF and ∆N HTRA1 were incubated together for 16 
hours at 37°C. CTGF was cleaved by HTRA1 to generate additional lower molecular 
weight bands (Figure 3.15B). These additional bands were observed when the 
recombinant proteins were incubated together (lane 2), but not seen in each protein 
alone (lane 1, lane 3).  
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3.5.4.3  CTGF interacts directly with HTRA1 in vitro 
GST CTGF was used in a GST-pulldown with His6 ∆N HTRA1 (Figure 3.15C). An 
interaction was observed between GST CTGF and His6 ∆N HTRA1 (lane 6). This 
confirms an interaction between CTGF and HTRA1 initially identified in tandem 
affinity purification experiments and by yeast two-hybrid screening. Non-specific 
interactions between His6 ∆N HTRA1 and Glutathione Sepharose resin alone, or 
between His6 ∆N HTRA1 and GST alone, were not seen. 




Figure 3.15  Connective tissue growth factor  (CTGF ) interacts with, and 
is a substrate for, HTRA1 in vitro . 
A.The CTGF protein (38 kDa) contains four distinct domains; an N-terminal insulin-
like growth factor binding protein domain (IB; a domain also found in HTRA1), the 
Von-Willebrand factor (VWC) motif (implicated as a binding site for TGF-β), a 
thrombospondin type 1 (TSP-1) motif, and a cysteine k ot (CT). Image from 
www.hprd.org. 
B. A GST-tagged form of CTGF (64 kDa) is susceptible to proteolysis by GST ∆N 
HTRA1 in vitro. Following incubation with the protease (lane 2), fragments of GST 
CTGF are observed in the Coomassie-stained gel (*). The band at 38 kDa is likely to 
represent CTGF cleaved from the GST-tag (25 kDa). 
C. GST CTGF interacts with His6 ∆N HTRA1 (39 kDa) in a GST-pulldown assay 
(lane 6). There is no interaction between Glutathione Sepharose, or GST alone, and 
His6 ∆N HTRA1 (lanes 4 and 5 respectively). The Western blot of the pulldown 
assay was probed with anti-CTGF, anti-GST HRP and with anti-HTRA1. 
C B 
A 
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3.6  Discussion 
The serine protease HTRA1 has been implicated in the pathobiology of a variety of 
diseases, including AMD, Alzheimer’s disease and osteoarthritis (Hu et al. 1998; 
Grau et al. 2005; Grau et al. 2006; Yang et al. 2006). HTRA1 is a stress-induced 
serine protease with a poorly characterised interacome and substrate specificity in 
healthy or diseased tissues. As such, the role of the protease and its substrates in the 
development of disease pathogenesis is not well understood. In this chapter, putative 
interactors of HTRA1 were identified by yeast two-hybrid screening and by tandem 
affinity purification. Candidates with a proposed role in the pathogenesis of AMD 
were identified, and suggest that HTRA1 may be involved in a number of pathways 
which are implicated in AMD. 
A number of intracellular proteins of interest in AMD were identified as 
potential interactors of HTRA1 (Table 3.1, Table 3.2, Table 3.5). These included 
previously reported interactions, for example, with Tubulin alpha1 (Chien et al. 
2009a; Chien et al. 2009b), and novel putative interactions with proteins involved in 
innate immunity and inflammatory response (DEFA1, S00 A8). However, HTRA1 
is a secreted serine protease, and so the attention of this study was focussed on the 
extracellular interactors (Figure 3.8). Several of these will be discussed further, 
including those for which an interaction was successfully validated in this chapter. 
Using a combination of a yeast two-hybrid screen and t dem affinity 
purification of a tagged-HTRA1 protein from HEK293T  or RPE1 cells and 
conditioned media, components of the ECM have been identified as novel binding 
partners of HTRA1. As seen in Figure 3.8, an interactome for HTRA1 in the 
extracellular environment has been proposed based on these findings (although 
replication and verification of all interactors is still required).  The combined results 
of the HTRA1 interactome screen showed that this protease interacts with a broad 
range of predominantly extracellular matrix proteins. These include proteins with a 
structural role in the ECM, such as type 1, 3 and 5 collagen chains (COL1A1, 
COL3A1, COL5A2, COL12A1). COL1A1 and COL3A1 have previously been 
reported as interactors of HTRA1 (De Luca et al. 2004; Murwantoko et al. 2004) and 
are constituents of Bruch’s membrane or choroid (Booij et al. 2010). The Bruch’s 
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membrane, separating the RPE cells from the blood supply in the choroid, is 
collagen-rich, and is likely to be a target for HTRA1-mediated remodelling.   
Murwantoko and co-workers (2004) have shown that COL3A1 is degraded by 
recombinant HTRA1 in vitro, suggesting that HTRA1 does have a role in 
remodelling the ECM.  
Changes to the ECM may play a role in drusen development and disease 
progression.  Histopathological analysis indicates that alterations in the collagen and 
elastin layers of Bruch’s membrane occur in AMD (Spraul et al. 1999; Chong et al. 
2005).  As HTRA1 is expressed by RPE cells and appers to possess extracellular 
matrix remodelling activity in normal tissue, tumour progression and invasion, and in 
arthritis (Hu et al. 1998; Baldi et al. 2002), HTRA1 remains an attractive candidate 
gene for AMD. 
Fibronectin (FN) was detected by mass spectrometry of HTRA1 interactors 
from TAP eluates in two experiments (Table 3.4). The interaction between these 
proteins has been previously reported, and may play a role in cartilage degradation, 
arthritis pathology and in matrix mineralization (Grau et al. 2006; Hadfield et al. 
2008). Fibronectin can be degraded by full-length mouse HtrA1 in vitro (Hadfield et 
al. 2008). Fibronectin fragments, generated by the action of various proteases 
including MMPs, increase the expression of fibronectin, promote cellular 
transformation and are pro-inflammatory (Labat-Robert 2002). Fibronectin levels 
increase with age (Labat-Robert et al. 1981). Soluble fi ronectin upregulates VEGF 
in RPE cells and can promote angiogenesis (Mousa et al. 1999).  The physiological 
relevance of an interaction between fibronectin and HTRA1, and a relationship to 
AMD pathology, is unknown.  
Thrombospondin-1 (THBS1) was identified by mass spectrometry in the first 
analysis of TAP eluates as a potential binding partner of HTRA1 in conditioned 
media. As such, the interaction between HTRA1 and thrombospondin-1 was the first 
to be investigated further. Thrombospondin-1 is a homotrimeric glycoprotein with 
disulfide-linked subunits, arising from a precursor protein of 129 kDa. 
Thrombospondin-1 is secreted by a variety of cells during development, tissue 
remodelling and wound healing. In the eye, thrombospondin-1 is secreted by the 
RPE and is predominantly localised to the basement mbrane (Carron et al. 2000; 
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Miyajima-Uchida et al. 2000; Hiscott et al. 2006). Following secretion, THBS1 is 
incorporated in the ECM as a matricellular protein, bi ding to matrix components 
including heparin, fibronectin, fibrinogen, plasminogen and collagen. It binds to a 
variety of extracellular proteins (including proteas s, growth factors) and to cell-
surface receptors, allowing the formation of multi-protein signalling complexes 
(Bornstein 2001).  
A variety of biological roles have been attributed o thrombospondin-1, 
including regulation of cell-matrix interactions and cellular behaviour, both anti-
angiogenic and pro-angiogenic properties, activation of TGF-β, inhibition of VEGF 
signalling, inhibition of MMP2 and MMP9, modulating RPE cell migration and 
maintenance of immune privilege in the eye (Good et al. 1990; Murphy-Ullrich et al. 
1992; Nicosia and Tuszynski 1994; Gupta et al. 1999; Bein and Simons 2000; 
Rodriguez-Manzaneque et al. 2001; Sheridan et al. 2002; Zamiri et al. 2005). Any 
alteration in levels of THBS1 will affect these processes. For example, a reduction in 
thrombospondin-1 could lead to an increase in protease activity of MMP2 and 
MMP9 in the ECM. Matrix metalloproteinases degrade components of the ECM and 
basement membrane during tissue remodelling and in pathological processes, 
including the development of coronary disease and in AMD (Guo et al. 1999; Kamei 
and Hollyfield 1999; Blankenberg et al. 2003; Auge et al. 2004). In experimental 
models of choroidal neovascularisation (CNV), MMP2 and MMP9 play a role in the 
development of new vasculature (Lambert et al. 2002; Lambert et al. 2003). 
Mutations in the gene encoding tissue inhibitor of metalloproteinases-3 (TIMP3) 
cause Sorsby’s fundus dystrophy, a rare inherited form of macular degeneration 
associated with deposits in the Bruch’s membrane and sub-retinal neovascularisation 
(Weber et al. 1994). More recently, TIMP3 has also been associated with AMD in a 
large genome-wide association scan (Chen et al. 2010). An association between 
variants in MMP9 and AMD (Fiotti et al. 2005) has not been replicated in large 
genome-wide association studies (Chen et al. 2010; Yu et al. 2011). 
Interestingly, although expression of THBS1 in the retina increases with age 
(Chowers et al. 2003), reduced levels of thrombospondin-1 have been detected in 
AMD eyes (Uno et al. 2006; Bhutto et al. 2008). Thrombospondin-1 is anti-
angiogenic in most tissues. However, pro-angiogenic activity of thrombospondin-1 in 
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the subretinal space has been suggested in an in vitro study using RPE cells (Mousa 
et al. 1999). Clearly, thrombospondin-1 is involved in the modulation of 
inflammatory responses, largely via the activation of TGF-β, and regulation of 
intraocular vasculature. Indeed, these seem to be vital roles of thrombospondin-1 in 
maintaining a healthy eye, as reviewed by Hiscott et al. (2006). Thus, the potential 
interaction between thrombospondin-1 and HTRA1 is of great interest.  
An in vitro pull-down assay, using a recombinant form of HTRA1 and 
thrombospondin-1 purified from human platelets, was used to verify the interaction 
(Figure 3.13C). Moreover, a protease activity assay using the same recombinant 
HTRA1 protein shows that thrombospondin-1 is subjected to proteolytic degradation 
by the serine protease in vitro. Further experiments are required to determine the 
significance of this. The interactions, and resultant activities, of thrombospondin-1 
may be disrupted by aberrant proteolytic degradation by HTRA1. For example, 
HTRA1 is known to inhibit TGF-β signalling, with some in vitro experiments 
indicating that TGF-β itself is not degraded by the protease (Oka et al. 2004). 
Degradation of thrombospondin-1 may affect the activ tion of TGF-β, preventing 
downstream signalling, leading to dysregulation of a number of processes which are 
involved in AMD pathogenesis, including ECM deposition and inflammation. 
Alternatively, pro-angiogenic fragments of thrombosp ndin-1 may be generated.  
Furthermore, thrombospondin-1 is known to interact with CFH, potentially providing 
a link between two AMD susceptibility genes (Vaziri-Sani et al. 2005).  
Two clones encoding fibulin-1 (FBLN1) have been isolated as interactors of 
HTRA1 in a yeast two-hybrid screen performed in a placental cDNA library. Fibulin-
1 is a calcium-binding secreted glycoprotein, widely expressed in basement 
membranes of epithelial cells and in blood vessels. The protein is incorporated into 
the extracellular matrix via binding to fibronectin, nidogen, aggrecan, and versican 
(Argraves et al. 1989; Aspberg et al. 1999).  
A mutation in the fibulin-3 gene (also known as EFEMP1) causes autosomal 
dominant drusen or Doyne’s honeycomb retinal dystrophy, an early onset Mendelian 
disease with similar pathological features to AMD (Stone et al. 1999). Variants in 
fibulin-6 (HEMICENTIN-1) and in fibulin-5 have been associated with AMD 
(Schultz et al. 2003; Stone et al. 2004). Subsequently, doubts have been cast upon the 
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contribution of variants in fibulin-6 towards AMD risk at the chromosome 1q31 
locus, due to the close proximity to CFH (Fisher et al. 2007). Although fibulin-1 is 
expressed in RPE cells, no variants were identified n the FBLN1 gene on 
chromosome 22q13 that were significantly associated with AMD in a case-control 
study (Stone et al. 2004). However, the fibulins remain an interesting family of 
proteins to investigate with respect to AMD, and a potential interaction with HTRA1 
may contribute towards AMD pathology. Additionally, fibulin-1 interacts with CFH 
and with ARMS2 in yeast two-hybrid screens which may indicate a role in AMD 
development (Kortvely et al. 2010). 
Three clones encoding osteonectin (SPARC; secreted protein, acidic and rich 
in cysteine) were found to interact with HTRA1 in the yeast two-hybrid screen. 
Sequence alignment with osteonectin suggests that the minimal binding region 
required for an interaction between the two proteins involves the Kazal-type 
inhibitory domain present at the N-terminus of ostenectin (data not shown). This 
has interesting implications for the regulation of HTRA1, which also contains a 
Kazal-type inhibitory domain which appears to be involved in self-regulation and is 
often cleaved in vivo (Chien et al. 2006). Like thrombospondin-1 and CTGF, 
osteonectin is a matricellular protein which mediates cell interactions and signalling 
(Bornstein and Sage 2002), and may have a role in the migration of RPE cells 
(Sheridan et al. 2002). Osteonectin is a 32 kDa phos protein, largely found in 
bone but expressed by endothelial cells in response to injury (Termine et al. 1981; 
Goldblum et al. 1994). Osteonectin binds to type 1 collagen fibrils, and modulates 
the activity of MMPs, PDGF, VEGF and FGF-2 (reviewed by (Brekken and Sage 
2001). Although the full-length protein is considered anti-angiogenic, fragments of 
osteonectin can stimulate angiogenesis and promote w und healing (Bornstein and 
Sage 2002). Indeed, a role for osteonectin in regulation of VEGF signalling in 
choroidal neovascularisation  has previously been suggested (Nozaki et al. 2006b).  
Further work remains to determine whether osteonecti , and a potential interaction 
with HTRA1, have physiological significance under normal conditions or in AMD. 
Connective tissue growth factor (CTGF) is a cysteine-r ch protein of 38 kDa, 
produced by a variety of cell types and secreted into the extracellular environment. 
This protein was identified as a potential interactor of HTRA1 in TAP experiments 
   
 138 
and in a yeast two-hybrid screen (Table 3.1, Table 3.4, Figure 3.8). The domains of 
CTGF, shown schematically in Figure 3.15A, are separated by hinge regions which 
are susceptible to cleavage by proteases (Brigstock et al. 1997). 
  CTGF is expressed during development and is induce  during wound healing, 
embryo implantation and is overexpressed in fibrosis (Igarashi et al. 1993; Surveyor 
et al. 1998). CTGF associates with components of the ECM and with cell surface 
receptors. TGF-β induces expression of CTGF, leading to the hypothesis that CTGF 
is a downstream mediator of TGF-β signalling (Grotendorst 1997). However, 
expression of CTGF can occur independently of TGF-β. CTGF may be induced by 
thrombin and angiotensin II, suppressed by TNF-α and cAMP, and under the control 
of glucose (Murphy et al. 1999; Abraham et al. 2000; Chambers et al. 2000; 
Finckenberg et al. 2003). The precise action of CTGF is unknown, but 
overexpression of CTGF leads to fibrosis by promoting he expression of ECM 
proteins including fibronectin and type IV collagen (Ruiz-Ortega et al. 2006). 
Fibrosis is considered to be important in many diseases, with a role for CTGF being 
proposed in disorders including cancer, atherosclerosis, Crohn’s disease, vitroeretinal 
disorders and in AMD (Oemar and Luscher 1997; Koliopanos et al. 2002; He et al. 
2003; Beddy et al. 2006; Kuiper et al. 2006). In vitro CTGF, together with additional 
growth factors and cytokines, also promotes a range of activities, including matrix 
production, photoreceptor cell survival and angiogenesis (Frazier et al. 1996 ; Shimo 
et al. 1999; Hauck et al. 2008).  
He et al. (2003) used a variety of methods to show that CTGF was expressed 
by RPE cells of patients with wet AMD but not by the RPE in healthy eyes. CTGF 
was localised to the choroidal neovascular membrane in the AMD eye. Furthermore, 
CTGF stimulates tube formation by choroidal endothelial cells in vitro, potentially 
promoting angiogenesis n vivo (He et al. 2003). A similar study by Watanabe and 
co-workers co-localised TGF-β and VEGF with CTGF to CNV membrane 
(Watanabe et al. 2005). Recent work has shown that CTGF is present in the Bruch’s 
membrane, in basal deposits and in drusen in human macula, and increases 
expression of matrix proteins in ARPE-19 cells (Nagai et al. 2009). Interestingly, 
CTGF is upregulated by oxidative stress, a process that has been implicated in AMD 
pathogenesis (Matsuda et al. 2005). Additionally, CTGF activates MMP2, which has 
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been shown to degrade ECM components and promote nevascularisation (Yang et 
al. 2007). CTGF may also play a role in inflammatory response, inducing a range of 
genes including chemokine [C-X-C motif] ligand 1 (CX L1), chemokine [C-X-C 
motif] ligand 6 (CXCL6), interleukin 6 (IL6), and interleukin 8 (IL8) in primary 
human tenon fibroblasts (Seher et al. 2011).  
An interaction between HTRA1 and CTGF was verified in a GST-pulldown 
assay (Figure 3.15C), complementing the results of he yeast two-hybrid screen and 
TAP experiments. CTGF is also known as IGFBP8 (insul -like growth factor-
binding protein 8), and contains a conserved N-terminal IGFBP motif also seen in 
HTRA1. However, this domain is removed in the N-terminally truncated form of 
HTRA1 used in the assay, suggesting that the interaction between these proteins is 
not dependent on the IGFBP domain. In an in vitro protease assay, CTGF appears to 
be subjected to partial cleavage by HTRA1 (Figure 3.15B). In addition to a potential 
role in angiogenesis, fragments of CTGF seem to increase ECM deposition and 
fibrovascular scarring - pathological characteristics of AMD.  This is an attractive 
candidate for further study in relation to AMD.  
The involvement of inflammatory processes in AMD has been indicated by 
the identification of variants in several components (CFH, C2, C3, CFB, CFHR1 and 
CFHR3 genes) of the complement pathway that influence the risk of AMD 
development (Conley et al. 2005; Edwards et al. 2005; Hageman et al. 2005; Haines 
et al. 2005; Klein et al. 2005; Magnusson et al. 2005; Gold et al. 2006; Hughes et al. 
2006; Yates et al. 2007). Numerous plasma and cell-surface proteins are involved in 
the complement system, activating and regulating the innate immune response and 
facilitating adaptive immunity (reviewed by Walport, 2001). C3 is the most abundant 
of these proteins. Cleavage of C3 plays a central role in complement activation in the 
classical pathway, the lectin pathway and the alternative complement pathway 
(Walport, 2001). Although C3 is produced mainly by the liver, C3 mRNA is detected 
in numerous other cells and tissues, including the retina, choroid and RPE cells 
(Mullins et al. 2000). 
A potential interaction between C3 and HTRA1 was detect d by mass 
spectrometry of TAP eluates (but has yet to be verified ndependently, Figure 3.14). 
However, due to the central role of this protein in the complement cascade, a 
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previous association with AMD and evidence that C3 is found in drusen (along with 
HTRA1), an interaction between these two proteins is potentially very interesting 
(Mullins et al. 2000; Yang et al. 2006; Yates et al. 2007). 
Aside from connective tissue growth factor and an enrichment for ECM 
components, there is little overlap between the potntial binding partners of HTRA1 
that have been identified by TAP and those identified by the yeast two-hybrid screen. 
Both systems use fusion proteins, coupling HTRA1 to a Strep-FLAG tag in the case 
of TAP, or to a promoter-specific DNA-binding domain in the yeast two-hybrid 
screen. The conformation of a fusion protein may differ from that of the native 
protein, resulting in altered activity, inaccessibility of binding sites and modified 
functionality. The small size (6 kDa) of the TAP tag is believed to lead to a minimal 
impact on correct folding of the fusion protein (Gloeckner et al. 2007).  An 
additional benefit of tandem affinity purification from a human cell line is that 
HTRA1 and interacting proteins are likely to undergo correct post-translational 
modifications, which may not occur in a heterologous system such as the yeast two-
hybrid system. Modifications such as the formation of disulphide bridges, 
glycosylation and phosphorylation may not occur in yeast in the same manner as in 
mammalian cells. If protein-protein interactions were dependent on such 
modifications, a yeast two-hybrid approach would be unlikely to detect them. 
Thrombospondin-1, for example, undergoes acetylation, glycosylation and 
disulphide cross-linking. This may explain why a potential interaction with HTRA1 
was detected by TAP, but not in an extensive yeast two-hybrid screen. Additionally, 
the protease activity assay using recombinant GST ∆N HTRA1 suggests that the 
modified form of thrombospondin-1 is particularly susceptible to degradation by the 
protease, relative to the unmodified form of the protein (Figure 3.13B). 
The yeast two-hybrid screen using HTRA1 as a bait protein identified 
numerous components of the ECM as potential interacting partners, including 
collagens, fibulin-1 and osteonectin (Figure 3.8, and Table 3.1 and Table 3.2). 
However, as the two-hybrid system detects interactions that occur in the yeast 
nucleus, it is possible that interactions with some extracellular proteins or proteins 
that contain strong targeting signals are not detect d. Furthermore, indirect 
interactions occurring in multi-protein complexes cannot be detected using a yeast 
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two-hybrid approach. Mass spectrometry analysis of TAP eluates does not 
discriminate between direct interactions between two proteins and a multi-protein 
complex which arises as a result of numerous interac ions between multiple proteins. 
A large number of potential interacting partners for HTRA1 were identified 
using a combination of TAP and yeast two-hybrid approaches. Many of these 
potential interactors remain to be verified, by back-transformation in the yeast two-
hybrid screen, and by additional methods including pull-downs and 
immunoprecipitation experiments. The biological relevance of all interactions 
remains to be shown. Some interactions may be an artefact of the experimental 
procedures - that is, although two proteins are ablto interact, they would never be 
found in close proximity to each other within the cell. HTRA1 is a secreted protein, 
and yet numerous proteins that are localised to distinct subcellular compartments are 
identified as potential binding partners of the protease in both the yeast two-hybrid 
screen and in TAP experiments (particularly TAP performed in cell lysate, in which 
the subcellular compartments are disrupted). 
Neither yeast two-hybrid (a heterologous system) nor HEK293T cells are 
physiologically relevant to AMD. TAP was performed in RPE1 cells to partially 
address this issue. It is encouraging to note that many of the extracellular proteins 
identified as potential interactors with HTRA1 are secreted by cultured primary RPE 
cells (An et al. 2006). Furthermore, differential expression of several interacting 
proteins - including COL1A1, COL3A1, fibronectin-1 and osteonectin - between 
RPE derived from AMD cases and normal controls was observed (An et al. 2006).   
Any of these putative interactors of HTRA1 could play a role in AMD 
susceptibility, given the range of roles in inflammation, angiogenesis and matrix 
remodelling. Aside from C3, none of the genes encoding these proteins have shown 
genetic associations with AMD in recent large genome-wide association studies 
(Chen et al. 2010; Yu et al. 2011). This suggests that common variants in these genes 
are not important influences in disease susceptibility – extensive further work is 
required to characterise the role of these proteins in AMD. One putative interactor 
was selected for such study in this thesis. The interaction between CFD and HTRA1 
(Table 3.1, Figure 3.8) is characterised in Chapter 5, and a role for CFD in 
influencing the genetic susceptibility to AMD is investigated in Chapter 4. 
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4.1  Introduction  
The alternative complement pathway is thought to contribute to the chronic 
inflammatory state observed in the AMD eye. Previous studies have identified strong 
association between AMD-susceptibility and genes encodi g components of the 
alternative complement pathway. The CFH gene on chromosome 1 has been 
identified as a major AMD-susceptibility locus (Edwards et al. 2005; Hageman et al. 
2005; Haines et al. 2005; Klein et al. 2005). This gene encodes Complement Factor 
H, which regulates activation of the pathway and dampens down an inflammatory 
response. Variants in additional components of the alternative complement pathway 
are also associated with altered disease-risk, including CFB/C2, C3, CFI, CFHR1 
and CFHR3 (Gold et al. 2006; Hughes et al. 2006; Yates et al. 2007; Fagerness et al. 
2009). Additionally, inflammatory peptides have been identified in drusen (Hageman 
et al. 2001; Crabb et al. 2002; Johnson et al. 2002), and are expressed at altered 
levels in AMD cases compared to disease-free controls (Hakobyan et al. 2008; Scholl 
et al. 2008; Reynolds et al. 2009; Hecker et al. 2010). Thus, it is clear that 
dysregulation of the alternative complement pathway as a result of environmental or 
genetic factors has a key role in development and progression of AMD. 
Complement factor D (CFD; also known as adipsin) is a member of the 
chymotrypsin family of serine proteases and regulates  key step in the activation of 
the alternative complement pathway (Volanakis and Narayana 1996; Xu et al. 2001). 
CFD is expressed in several tissues and cell types, but the major source of plasma 
CFD in humans is adipose tissue, in which it is secret d by both mature adipocytes 
and macrophages (Whaley 1980; Barnum and Volanakis 1985; White et al. 1992). 
CFD becomes transiently active following removal of an activation peptide, and 
upon conformational change when bound to Factor B. This allows CFD to cleave 
factor B into Ba and Bb fragments. This is a rate limiting step in formation of the 
C3bBb complex or C3 convertase, which is crucial to activation and amplification of 
the alternative complement pathway (Volanakis and Narayana 1996).  
Plasma CFD concentrations have been reported to be very low (1-2 µg/ml) 
(Barnum et al. 1984). This is much lower than other complement proteins, including 
plasma C3 (1-2 mg/ml) or factor B (200µg/ml) (Schreiber and Müller-Eberhard 
1978). This means that CFD only ceases to be limiting at 9-10 times the 
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concentration generally found in plasma. Given the importance of proper regulation 
of the alternative complement pathway in AMD pathogenesis, it is in some ways 
surprising that CFD has not previously been implicated in the disease. This chapter 
investigates whether CFD may contribute to the genetic and molecular basis of 
AMD, by analysis of genetic association, copy number variation and plasma CFD 
concentrations. 
 
4.2  Testing SNPs in CFD for an association with AMD 
In order to test the contribution of variants in CFD towards genetic susceptibility to 
AMD, a SNP association study was performed. Several SNPs were genotyped and 
tested for an association with disease in a Scottish AMD case-control cohort (the 
discovery cohort, UK1). Subsequently, one or two SNPs were investigated in five 
additional “replication” cohorts from the UK, USA and one combined European 
cohort from Holland and Germany. 
 
4.2.1  SNP selection 
CFD maps to chromosome 19p13.3, spans 3.9 kb and contains 5 exons (Figure 4.1).  
Three SNPs in CFD- rs3826945, rs1683564 and rs1683563 - with a minor allele 
frequency >10% in the CEPH Caucasian reference population were identified. 
TaqMan 5’ nuclease SNP genotyping assays were ordered fo  these SNPs from 
Applied Biosystems. The position of the SNPs on chromosome 19, and in relation to 
CFD, is shown in Figure 4.2. Due to their intronic locations, these SNPs are unlikely 
to play a functional role in CFD activity (unless they act to alter expression levels), 
but may be in linkage disequilibrium (LD) with novel or rare functional variants. The 
Tagger-pairwiseTagging algorithm (http://hapmap.ncbi. lm.nih.gov/) identified 








Figure 4.1 Selection of SNPs in CFD on chromosome 19. 
The International HapMap Project (http://hapmap.ncbi. lm.nih.gov/) was used to 
identify variants in CFD for investigating an association between CFD and AMD 
(HapMap Data Release 27, Phase 2 and 3 data, Feb09, NCBI Build 36 assembly, 
dbSNP126). There are 25 known SNPs in the region chr19: 810,014 to 815,259 
(dbSNPs). The majority of these are rare variants or have not been genotyped in 
reference populations used by the HapMap project (Genotyped SNPs). Populations in 
which the SNPs were genotyped are: A: African ancestry in Southwest USA, C: Utah 
residents with Northern and Western European ancestry from the CEPH collection, 
H: Han Chinese in Beijing, China, D: Chinese in Metropolitan Denver, Colorado, G: 
Gujarati Indians in Houston, Texas, J: Japanese in Tokyo, Japan, L: Luhya in 
Webuye, Kenya, M: Mexican ancestry in Los Angeles, California, K: Maasai in 
Kinyawa, Kenya, T: Tuscan in Italy, Y: Yoruban in Ibadan, Nigeria. Three SNPs 
with a minor allele frequency (red portion of chart in Genotyped SNPs panel) greater 
than 10% in the CEPH population were identified andselected for use in this study. 
These SNPs are rs1683564, rs1683563 and rs3826945. 
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Figure 4.2 Location of SNPs selected for genotyping  within the CFD 
gene. 
TaqMan SNP genotyping assays were obtained for the in ronic variants rs1683564, 
rs1683563 and rs3826945. These alignment maps, obtained from Applied 
Biosystems, show the location of each SNP, the polym rphism detected by the assay 
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The degree of linkage disequilibrium between the thr e SNPs was investigated using 
data from the HapMap3 Genome Browser release #2 (Phase 3 - genotypes, 
frequencies & LD), accessed through the Internationl HapMap Project 
(http://hapmap.ncbi.nlm.nih.gov/).  Pair-wise LD betw en the SNPs is reported in 
Table 4.1. As shown by LOD (Log of Odds) scores of >2 between pair-wise 
combination of the SNPs, there is some LD between SNPs. There is strong LD 
between rs3826945 and rs1683563 (D’=1). However, th SNPs are not in perfect LD 
(r2=0.314), indicating that the alleles for the two SNPs are not correlated on the three 
possible haplotypes (ab, AB, aB, where A is the minor allele of rs3826945, and b is 






position 2 Population Marker1 Marker2 D' r^2 LOD 
810214 812593 CEU rs1683564 rs1683563 0.764 0.184 4.12 
810214 813912 CEU rs1683564 rs3826945 0.745 0.476 11.3 
812593 813912 CEU rs1683563 rs3826945 1 0.314 7.48 
 
Table 4.1  Linkage disequilibrium between SNPs in CFD. 
Pair-wise linkage disequilibrium between the rs1683564, rs1683563 and rs3826945 
SNPs in CFD has been tested in the CEPH population, and is avalable through the 
HapMap project. Measures of LD are D’ (Complete LD =1), r2 (perfect LD=1) and 
Log of Odds (LOD). 
 
4.2.2  Discovery and replication AMD case-control c ohorts  
The characteristics and demographic information for the AMD case-control series 
used in this study are shown in Table 4.2. The Scottish AMD cohort was the first to 
be genotyped, and represents the discovery cohort (UK1).  
Replication cohorts from Cambridge, England (UK2), Michigan, USA 
(USA1), NIH, USA (USA2), Tufts University (USA3) and Nijmegen, Holland 
(Nijmegen) were used. Replication cohorts had a grete  proportion of late AMD 
cases (>85%) than the discovery cohort. Ages of cases nd controls were not 
significantly different between cohorts (data not shown; Table 4.2). 
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Table 4.2  Cohort characteristics.   
Late AMD includes cases of geographic atrophy (GA) and neovascular AMD (CNV). Grading was based on the Clinical Age-Related 
Maculopathy Grading System (CARMS) (Bird et al. 1995). Grading was performed by an ophthalmologist and refers to the worst eye. 
Controls were also examined. All cohorts were made up of Caucasian individuals. The numbers shown in the main text refer to the number 
of individuals that were successfully genotyped for CFD SNPs. 
 
Sex 
Cohort Status N % Grading % 
Mean 
age 
(years)  SD Male % Female % 
Control 351 41     78 8.5 152 43.8 199 57.3 
Case 505 59 Late AMD 48.3 77.9 9.2 190 38.1 315 63.1 
UK1 Total 846   
Control 421 32.1     75.6 7.7 171 40.6 232 55.1 
Case 891 67.9 Late AMD 100 78.7 7.2 377 42.3 472 53 
UK2 Total 1312   
Control 311 33.8     76.6 5.1 143 46 168 54 
Case 608 66.2 Late AMD 85.9 79.3 7.3 222 36.5 386 63.5 
USA 1 Total 919   
Control 378 42.1     75.6 7.9 177 46.8 203 53.7 
Case 520 57.9 Late AMD 100 80 8.5 206 39.6 314 60.4 
USA 2 Total 898   
Control 887 40.1     75.4 6.1 394 44.4 501 56.5 
Case 1326 59.9 Late AMD  100  80.7 6.3 583 44 758 57.2 
USA 3 Total 2213   
Control 562 31.9     72.7 6.6 245 43.6 314 55.9 
Case 1201 68.1 Late AMD 91.3 75.9 8.2 456 38 744 61.9 
Nijmegen  Total 1763   
   
 149 
4.2.3   CFD SNP Genotyping in UK1 case-control cohort 
A schematic representation of TaqMan SNP genotyping is shown in Figure 4.3. Of 
the three single nucleotide polymorphisms selected for genotyping, only two of the 
genotyping assays performed satisfactorily. Representative genotype plots for each 
SNP, obtained from plate reads on the Applied Biosystems HT7900, are shown in 
Figure 4.4. One assay, for rs1683564, failed to achieve sufficient discrimination 
between genotype clusters to permit accurate assignment of genotype (Figure 4.4C). 
As a result, this SNP was not genotyped.  
Allelic discrimination was achieved by the two remaining assays, with clear 
genotype clusters observed for the major allele homozygotes, heterozygotes and 
minor allele homozygotes (Figure 4.4A and B). 
 In addition to visual checking of genotyping cluster plots, the quality of genotyping 
data was assessed by call rate and deviation from Hardy-Weinberg equilibrium 
(HWE). Minimum call rate was found to be 93%. This is likely to represent poor 
DNA quality for individuals who failed to genotype, rather than a preferential assay 
failure for a given genotype as the same samples did not amplify for both the SNPs 
tested in the UK1 cohort. Hardy-Weinberg disequilibrium was not observed for 
either polymorphism in cases and controls (p > 0.05).   
Genotype and allele frequencies obtained in the UK1case-control cohort are 









Figure 4.3 Schematic representation of TaqMan SNP g enotyping 
technology. 
TaqMan SNP Genotyping is performed by amplification of the target DNA using 
sequence-specific primers and two allele-specific TaqMan® MGB probes. The 
probes are labelled with either VIC or FAM fluorophores at the 5’ end; whilst the 
probe is intact, fluorescence is quenched by a 3’ quencher. During amplification, if 
the probe anneals to the polymorphic sequence, the 5’ nuclease activity of Taq 
polymerase degrades the probe, releasing the fluoroph e. This causes a detectable 
fluorescent signal during amplification of each allele. Source: 
www.appliedbiosystems.com.


































Figure 4.4  Representative genotyping plots obtaine d for SNPs in CFD. 
TaqMan SNP genotyping uses fluorescent probes to detect SNP genotype. 
Representative genotyping plots for the three SNPs in CFD are shown. Assays for 
genotyping rs3826945 (A) and rs1683563 (B) performed w ll, generating distinct 
clusters for homozygous individuals, located at the Y (blue) or X (red) axis, whilst 
heterozygotes cluster in the centre (green). The assay for rs1683564 (C) did not 
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   Cohort 
SNP 
AMD 
Status Genotype frequency UK1 UK2 USA1 USA2 USA3 Ni jmegen 
TT  0.42 0.45 0.41 0.45 0.46 0.47 
CT  0.47 0.46 0.47 0.45 0.42 0.42 
CC  0.10 0.09 0.11 0.09 0.12 0.11 
Cases 
Minor allele frequency 0.34 0.32 0.35 0.32 0.33 0.32 
TT  0.47 0.50 0.48 0.46 0.45 0.51 
CT  0.41 0.41 0.43 0.41 0.44 0.39 
CC  0.11 0.09 0.10 0.12 0.11 0.10 
rs3826945 
Controls 
Minor allele frequency  0.32 0.29 0.31 0.33 0.33 0.29 
  HWE p-value 0.72 0.31 0.46 0.93 0.19 0.16 
GG  0.37 0.36 0.37 0.34 - - 
CG  0.49 0.47 0.48 0.50 - - 
CC  0.14 0.17 0.15 0.16 - - 
Cases 
Minor allele frequency  0.38 0.40 0.39 0.41 - - 
GG  0.42 0.35 0.35 0.33 - - 
CG  0.44 0.50 0.49 0.48 - - 
CC  0.14 0.16 0.16 0.19 - - 
rs1683563  
Controls 
Minor allele frequency  0.36 0.40 0.41 0.43 - - 
    HWE p-value 0.91 0.88 0.60 0.77 - - 
 
 
Table 4.3  Genotype and allele frequencies of rs382 6945 and rs1683563 in six AMD case-control series. 
Two SNPs in CFD - rs3826945 and rs1683563 - were genotyped in multiple AMD case-control series. UK1 was the discovery cohort; 
UK2, USA1-3 and Nijmegen were the replication cohorts. No cohort showed a significant deviation from Hardy-Weinberg Equilibrium 
(HWE) using Chi2 test. 
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4.2.3.1 SNPs in CFD are associated with AMD in a British 
discovery cohort 
Association analysis was carried out in a Scottish AMD case-control cohort (UK1) in 
the first instance. The UK1 series consisted of 351 controls and 505 cases (of which 
48% had late AMD). The average age of cases was 77.9±9.2 years (SD) and 
78.0±8.5 years (SD) for controls (Table 4.2). All individuals were unrelated and of 
Scottish ethnicity. Disease status and AMD grading criteria were described in 
Section 2.3.5.   
 The association between genotype at rs3826945 and rs1683563 with AMD 
was investigated by binomial logistic regression implemented in the statistical 
software package SPSS version 17. Odds ratios (OR) were calculated using the 
coefficient of the logistic regression (β). AMD status was included as a categorical 
dependant variable (AMD or disease-free control). Using a dominant genotypic 
model for regression, SNP genotype was categorised a  0=major allele homozygote, 
or 1=minor allele homozygote or heterozygote. Smoking status (ever/never), age and 
sex were also included in the analyses as known risk-modifiers for AMD. Smoking 
status and sex were categorical variables. Age was a continuous variable. 
 The results of the case-control association analyses of rs3826945 and 
rs1683563 in the UK1 cohort are summarised in Table 4.4. In this Scottish cohort, 
rs1683563 was suggestively associated with AMD (p=0.07). The minor allele of the 
rs3826945 SNP was significantly associated with AMD, increasing risk of AMD in 
carriers of the minor allele (OR 1.44, 95% C.I. 1.04-2.00, p=0.028).  
 The UK1 series was split by gender for regression analysis. As shown in 
Table 4.4, the association with AMD was observed only in females, who showed an 
OR of 1.70 (95% C.I. 1.11-2.63, p=0.016). This may represent a loss of power to 
detect an effect in males, due to a reduction in sample size (N male cases=175, N 
female cases=287). 
 Similar results were obtained using an additive model for logistic 
regression. SNP genotypes were categorised as 1 =major allele homozygote, 2 
=heterozygote, 3 =minor allele homozygote. Minor allele homozygotes of rs3826945 
were significantly associated with increased risk of AMD using this model (OR 
1.403, 95% C.I. 1.008-1.953, p=0.045). 








controls Total OR 95% CI p 
Discovery cohort 
UK1 males 175 143 318 1.224 0.739-2.026 0.432 
UK1 females 287 182 469 1.704 1.105-2.629 0.016 
UK1 combined 462 325 787 1.442 1.041-1.998 0.028 
Replication cohorts 
UK2 males 343 154 497 1.202 0.778-1.856 0.407 
UK2 females 430 208 638 1.898 1.262-2.855 0.002 
UK2 combined 773 362 1135 1.546 1.151-2.076 0.004 
              
USA 1 males 210 137 347 1.093 0.668-1.788 0.725 
USA 1 females 370 159 529 1.463 0.967-2.214 0.071 
USA 1 combined 580 296 876 1.303 0.950-1.786 0.101 
              
USA 2 males 205 172 377 1.080 0.678-1.721 0.746 
USA 2 females 307 199 506 0.882 0.580-1.342 0.522 
USA 2 combined 512 371 883 0.974 0.714-1.329 0.870 
              
USA 3 males 527 354 881 0.982 0.833-1.261 0.817 
USA 3 females 684 436 1120 0.952 0.719-1.260 0.731 
USA 3 combined 1211 790 2001 0.955 0.784-1.163 0.647 
              
Nijmegen males 449 226 675 1.105 0.799-1.528 0.547 
Nijmegen 
females 
725 300 1025 1.017 0.769-1.345 0.907 
Nijmegen 
combined 
1174 526 1700 1.052 0.852-1.299 0.637 
Meta-analysis 
All males  1932 1196 3128 1.043 0.901-1.207 0.571 
All females  2833 1497 4330 1.180 1.036-1.344 0.012 
All  4765 2693 7458 1.112 1.009-1.225 0.032 
 
 
Table 4.4 SNP association results for CFD SNP rs3826945 .   
A dominant additive model was used to assess the associ tion of the minor allele of 
rs3826945 to AMD in a total of six cohorts. Analyses were controlled for age, sex 
and smoking. UK1, UK2, USA1 and USA2 cohorts were also genotyped for 
rs1683563, which was not significantly associated with AMD when included as a 
covariate in the analysis of these cohorts. 
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4.2.3.2        Power calculation 
Based on the odds ratios of the association between AMD and rs3826945 in the UK1 
cohort (OR 1.44, 95% C.I. 1.04-2.00), retrospective power calculations were 
performed to determine the appropriate sample size to d tect an effect of this 
magnitude with a 95% confidence level. The Genetic Power Calculator programme 
was utilised for this analysis (Purcell et al 2003). Prevalence of AMD was reported 
as 1.47% in the population aged above 40 years (The Eye Diseases Prevalence 
Research 2004). The calculation was performed to allow for a 1% threshold for type 
I errors. Assuming a control:case ratio of 0.7, the number of cases required to detect 
an effect of this size with 95% power was calculated as 1876 cases using the 
dominant model, and 4332 cases using an allelic model. 
 
4.2.4  Association analysis of CFD rs3826945 in 5 replication   
cohorts 
Given that the Scottish AMD cohort had low power to eliably detect such a small 
effect upon AMD risk, both SNPs were genotyped in alarger set of case-controls 
(Table 4.2). Some individuals in these cohorts were not successfully genotyped; the 
number of genotyped cases and controls is indicated in the following text. Minor 
allele frequencies and genotype frequencies are shown in Table 4.3. 
The first round of replication cohorts consisted of an additional UK series 
from Cambridge, England (UK2; 773 genotyped cases (all with severe AMD) and 
362 examined controls) and two North American cohorts (USA1, USA2). USA1 
(University of Michigan) included 580 genotyped cases (86% severe AMD) and 296 
examined controls while USA2 (National Eye Institute) included 512 genotyped 
cases (100% severe AMD) and 371 examined controls). All cohorts comprise 
unrelated Caucasian individuals.  
The minor allele (C) of rs3826945 was found to be associated with an 
increased risk of AMD in a second British AMD case-control cohort (UK2; p=0.004, 
OR 1.54, 95% C.I. 1.151-2.076; Table 4.4). Once again, in analysis stratified by 
gender, the association with AMD remained significant in females (p=0.002, OR 
1.90, 95% C.I. 1.262-2.855), but not in males (p=0.40). Age and smoking history 
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were also significantly associated with AMD-risk in this cohort. The average age of 
individuals in this cohort was 78.7±7.2 years (SD) for cases and 75.6±7.7 years (SD) 
for controls. A small increase in risk for each year of age was observed (p=8.9x10-12, 
OR 1.06, 95% C.I. 1.04-1.08). This reflects the repo ted increased prevalence of 
AMD in older individuals which is 1.47% in the population aged over 40 years, 15% 
in white females aged over 80 years (The Eye Diseases Prevalence Research 2004). 
A current or former smoker (ever smoked) in this cohort had an increased risk of 
AMD, relative to never having smoked (OR 1.38, 95% C.I. 1.04-1.82, p=0.025). 
SNP genotyping for USA1 and USA2 was performed in America. The USA1 
cohort was genotyped by dye-termination Sanger sequencing. The USA2 cohort was 
genotyped for rs1683563 and rs3826945 using TaqMan, as described for the UK1 
and UK2 series in Section 2.3.6.1. Genotype and minor allele frequencies are shown 
in Table 4.3. There were no significant deviations from HWE. 
Table 4.4 summarises the results of the binary logistic regression analysis 
performed in the USA1 and USA2 replication cohorts. Regression analysis was 
performed as described for the British cohorts, both c mbining males and females, 
and splitting the series by gender. The minor allele of rs3826945 showed no 
significant association with AMD in either of the USA 1-2 replication cohorts 
(p=0.10 and p=0.87 respectively). However, when stratified by gender, there was a 
suggestively significant association of the minor allele of rs3826945 with AMD in 
females from the USA1 cohort only (p=0.07, OR 1.46, 95% C.I. 0.97-2.21). 
Age was significantly associated with AMD-risk in these cohorts. The 
average age of individuals in the USA1 cohort was 79.3±7.3 years (SD) for cases and 
76.6±5.1 years (SD) for controls. In USA2, the averg  age of cases was 80.0±8.5 
years (SD), and for controls, 75.6±7.9 years (SD). As expected, both series exhibited 
a small increase in risk for each year of age (USA1: p= .1x10-8, OR 1.07, 95% C.I. 
1.04-1.09; USA2: p=2.2x10-12, OR 1.06, 95% C.I. 1.04-1.08). Smoking history was 
not significantly associated with AMD in the analysis of either USA1 or USA2 series 
(data not shown). The USA1 series showed a significa t association between gender 
and AMD, with males appearing to be protected from AMD (p=3.8x10-4, OR 0.57, 
95% C.I. 0.42-0.78). This is likely to reflect the composition of the cohort, with 
unequal distribution of males and females between cases and controls (Table 4.2). 
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Rs1683563 was not significantly associated with AMD in any of these three cohorts 
(UK2, p=0.265; USA1, p=0.911, USA2, p=0.311). 
Due to the lack of conclusive replication of the association between 
rs3826945 and AMD that was observed in two British co orts (UK1, UK2) in two 
North American cohorts (USA1, USA2), additional cohorts were investigated. The 
second replication group included a further large case-control series from USA 
(USA3, Tufts University) and another from Europe (Nijmegen, a Dutch-German 
series). Due to the absence of association detected between rs1683563 and AMD in 
the four earlier cohorts, these cohorts were genotyped for rs3826945 only. In the 
USA3 series, rs3826945 was genotyped using the Sequenom iPLEX assay (Yu et al 
2011). The Nijmegen series was genotyped using the TaqMan 5’ nuclease SNP 
genotyping assay for rs3826945. 
 The USA3 cohort consisted of 1211 genotyped cases (all with severe AMD) 
and 790 examined controls. The average age of individuals in USA3 was 80.7±6.3 
years (SD) for cases and 75.4±6.1 years (SD) for controls (Table 4.2).  In the 
Nijmegen series, 1174 cases (91.3% with severe AMD) and 526 examined controls 
were genotyped. The average age of cases was 75.9±8.2 years (SD), whilst controls 
were generally younger (72.7±6.6 years (SD)). Neither of these series showed 
evidence of association between rs3826945 and AMD (USA3, p=0.647; Nijmegen, p 
=0.637), as shown in Table 4.4.  
Once again, advancing age was a significant AMD-risk factor; in USA3, p= 
3.8x10-60, OR 1.16, 95% C.I. 1.14-1.18, and in Nijmegen, p=1.64x10-13, OR 1.05, 
95% C.I. 1.04-1.07. The USA3 series, but not the Dutch series, showed a significant 
association between gender and AMD, with males appearing to be protected from 
AMD (p=1.4x10-5, OR 0.63, 95% C.I. 0.51-0.78). Smoking history was also a 
significant covariate in these analyses (in USA3, p=7.0x10-9; in Nijmegen,  
p=5.9x10-6). Individuals who had ever smoked were at increased risk of AMD. 
The minor or risk allele frequency (C allele) for rs3826945 varied from 0.31 
to 0.35 in AMD cases across the individual case-control series, and from 0.29-0.33 in 
controls (Table 4.3).  These very similar minor allele frequencies observed in the 
UK1 (0.34) and replication series obtained from both the UK and abroad indicate 
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that allele frequency differences in the various populations are unlikely to account 
for differences between cohorts.  
 
4.2.5 Meta-analysis of rs3826945 in six AMD case-co ntrol 
cohorts 
The contribution of rs3826945 towards AMD risk was as essed in all of the six 
cohorts combined in a single meta-analysis. This wa expected to increase statistical 
power to detect an effect of small magnitude. The combined cohorts comprised of 
4765 cases and 2693 controls. The mean age of cases w  78.7±7.8 (SD) years and 
the mean age of the controls was 75.4±7.1 (SD) years (Table 4.2).  
The combined cohort for the meta-analysis was analysed by binary logistic 
regression using a dominant model, as previously described for the individual 
cohorts. The results of the regression are shown in Table 4.4. The odds ratio (and 
95% confidence interval) obtained for each of the individual cohorts, together with 
the combined data set, are summarised in the Forest Plot shown in Figure 4.5. 
Overall, there was a significant association between AMD and rs3826945 (OR=1.11, 
C.I. 1.01-1.23, p=0.032). As seen in the UK1-2 cohorts, and suggested in the USA1 
cohort, analysis of the combined cohorts found a significant effect in females 
(OR=1.18, 95% C.I.1.04-1.34, p=0.012) but not in males (OR=1.04, 95% C.I. 0.90-
1.21, p=0.57) for the minor allele of rs3826945. Similar results were obtained using 
an additive model for regression analysis, although this model has less power to 
detect the association (data not shown). 






Figure 4.5  Forest plot of the results of meta-anal ysis for the 
association between CFD SNP rs3826945 and AMD. 
Six AMD case-control cohorts were tested for an association between rs3826945 and 
AMD. Association varied between the three US and three European case-control 
series. Meta-analysis of the combined cohorts, consisti g of 4765 cases and 2693 
controls, showed a significant association in the combined sexes (OR=1.11, p-
value=0.032) and in combined females (OR=1.18, p-value=0.012). No significant 
association between rs3826945 and AMD was detected in males. 
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4.2.6  Gene-environment interactions for CFD in AMD 
AMD was associated with increasing age, smoking and gender (in some cohorts), as 
described in Section 4.2.1.6. For some of the replication cohorts (UK2, USA3, 
Nijmegen), body mass index (BMI) scores were available. A BMI score greater than 
30 was significantly associated with AMD in these combined cohorts where data 
were available (p=0.037, OR 1.357, 95% C.I. 1.019-1.807).  
The possibility of interactions between genotype at rs3826945 and BMI, 
smoking status, age or sex affecting the association w th AMD was evaluated. 
Multinomial logistic regression was performed using a custom/stepwise approach to 
investigate an interaction between rs3826945*smoking (ever/never), rs3826945*age, 
rs3826945*sex and rs3826945*BMI (categorised as <25, 25-29.99, or >30). Models 
in which an interaction was included did not influenc  the association with AMD, 
compared to independent inclusion of both covariates for age and smoking (Table 
4.5). In agreement with results obtained by regression analysis performed in females 
only, females appear to be more susceptible to AMD when they carry the risk allele 
of rs3826945 (OR 1.304, 95% C.I. 1.142-1.489 for the interaction; increased from 
OR 1.236, 95% C.I. 1.117-1.367 for females without accounting for genotype). 
There was no increase in AMD susceptibility for carriers of the rs3826945 
minor allele in combination with BMI. In fact, the interaction between high BMI 
(>30) and rs3826945 removed the significant associati n of BMI with AMD 
(p=0.037, OR 1.357, 95% C.I. 1.019-1.807 was reduce to OR 0.878, 95% C.I. 
0.551-1.397, p=0.582 for the interaction). 











rs3826945 0.106 0.049 4.595 1 0.032 1.112 1.009 1.225 
Exact_Age 0.056 0.003 292.949 1 1.13x10-65 1.058 1.051 1.065 
Exact_Age * rs3826945 CT/CC 0.056 0.003 264.125 1 2.17x10-59 1.057 1.050 1.065 
Sex (female) 0.212 0.051 16.984 1 3.77x10-5 1.236 1.117 1.367 
Sex (female)* rs3826945 CT/CC 0.266 0.068 15.394 1 8.73x10-5 1.304 1.142 1.489 
Smoker2 (never) 0.043 0.051 0.728 1 0.394 1.044 0.945 1.154 
rs3826945* Smoker2 (never) 0.053 0.069 0.580 1 0.446 1.054 0.920 1.207 
BMICAT(>30) 0.305 0.146 4.368 1 0.037 1.357 1.019 1.807 
BMICAT(>30) * rs3826945 CT/CC -0.130 0.237 0.303 1 0.582 0.878 0.551 1.397 
 
Table 4.5 Interactions between rs3826945 and age, s moking or BMI do not increase susceptibility to AMD . 
Multinomial logistic regression was performed using a custom/stepwise approach to investigate an interaction between 
rs3826945*smoking (ever/never), rs3826945*age, rs3826945*sex and rs3826945*BMI (categorised as <25, 25-29.99, or >30). An 
interaction between female gender and the risk allele resulted in an increased susceptibility to AMD. An interaction between high BMI and 
risk genotype resulted in a non-significant relationship of BMI and SNP genotype to AMD. 
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4.2.7            Searching for novel variants in CFD 
The intronic SNPs used to search for association with AMD are unlikely to have a 
functional effect on the protein, unless they affect CFD expression. In order to 
investigate the possibility that novel variants in CFD were responsible for the 
association with AMD identified in theUK1 and UK2 series, a subset of cases and 
controls were subjected to sequencing and testing for copy number variation.  
 
4.2.7.1          Optimisation of CFD sequencing primers 
Primers were designed to span all 5 exons of CFD, together with the intron-exon 
boundaries. Primer sequences and optimised conditios for PCR amplification of 
each exon are shown in Table 2.3.  
 
4.2.7.2          Sequencing of CFD 
Genomic DNA from 95 AMD cases and from 95 disease-fre  controls was used to 
sequence the exonic and flanking regions of CFD. Sequence analysis was performed 
using Mutation Surveyor to identify variants in relation to the CFD reference 
sequence (ENSG00000197766), obtained from Ensembl (http://www.ensembl.org).  
No novel variants in CFD were identified in these cases or controls. All of the 
variants identified by sequencing, shown in Figure 4.6, are reported in dbSNP 
(www.ncbi.nlm.nih.gov/projects/SNP/). Three variants are intronic. Two of the 
intronic variants (rs1629038 and rs1626564) are in high linkage disequilibrium with 
one another, commonly occurring on the same haplotye in both cases and controls. 
One coding change was identified, changing the glutama e (E) at position 69 in CFD 
to lysine (K). E69 is located close to the histidine residue (H66) of the catalytic triad 
of CFD. It is conceivable that altering a negatively charged amino acid (E) for a 
positively charged amino acid (K) may affect the active site of the enzyme. One 
control sample was homozygous for the E69K variant, d one AMD case was 
heterozygous for the same variant. Representative chromatograms for the variants are 
shown in Figure 4.6.  
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The SNPs identified by sequencing were tested for association with AMD. 
Two-by-two contingency tables and Fisher’s exact tests determined that there is no 
significant difference between the frequency of these polymorphisms in CFD in 





Figure 4.6 Sequencing identified known variants in CFD. 
The exons and flanking regions of CFD were sequenced in 96 AMD cases and 96 
controls from the UK1 cohort. No novel variants in CFD were identified by 
sequencing. The polymorphisms detected are included in the dbSNP database 
(www.ncbi.nlm.nih.gov/projects/SNP). Only one - rs35186399 – resulted in a coding 
change in CFD (E69K). Representative sequence chromatograms for the major allele 
homozygotes, heterozygotes and the minor allele homozygotes for each variant are 
shown. Minor allele frequencies (MAF) were calculated for cases and controls. There 
were no significant differences in MAF between cases and controls assessed with 
Fisher’s exact test (p-value is shown). 
 
4.3          Copy number variation at chromosome 19 p13.3 
The Database of Genomic Variation (http://projects.t ag.ca/variation/; (Iafrate et al. 
2004)) was used to screen the human genomic assembly (Build 36, March 2006) for 
previously reported variations in copy number near CFD. A copy number variation 
(Variation_30054) was identified using “CFD” as the search term (Figure 4.7). 
Located on chromosome 19, positions 791984-850978, Variation_30054 spans 
almost 60 kb covering the genes PRTN3, MED16, ELANE, CFD and C19orf22. It 
was identified as a loss of copy number in one individual in 485 control samples in 
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the Human Genome Diversity Panel, using the Illumina HumanHap550 BeadChip 




Figure 4.7 Copy number variation in the CFD locus.  
The Database of Genomic Variation (http://projects.t ag.ca/variation) was screened 
for reported variations in copy number in CFD in the human genomic assembly 
(Build 36, March 2006). Variation_30054 is spans almost 60 kb covering the genes 
PRTN3, MED16, ELANE, CFD and C19orf22. The TaqMan Copy Number Variation 
assay (Hs01536182_cn) spans the exon 3-intron 4 boundary in CFD was selected to 




4.3.1   Measuring copy number variation at CFD 
Due to the copy number variation spanning CFD, it was proposed that copy number 
variation might play a role in AMD susceptibility. To assess this, TaqMan Copy 
Number Variation assays for Variation_30054 (Hs01536182_cn) and an RNAseP 
reference assay were used in a multiplex reaction to measure copy number. 311 
AMD cases and 329 controls from the UK1 (Scottish AMD) case-control series were 
assayed in triplicate for each sample. Predicted copy number was calculated using 
Copy Caller software from Applied Biosystems. This calculates the difference in 
threshold cycle (CT) values measured during amplification for CFD and RNAseP.  CT 
is considered proportional to the number of copies of the target gene. Alterations in 
CFD copy number are reflected by deviation of CT ratio from 1. A CT ratio of 0.5 
indicates a reduction of one copy (compared to the normal two copies), whilst an 
increase in CT ratio to 1.5 indicates an increase in CFD copy number to 3 copies. A 
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conservative CT threshold value of 32 was used across all plates, with samples 
showing amplification later than cycle 32 excluded from the analysis.  
Predicted copy number was used to calculate the proporti n of AMD cases and 
controls with deletions or duplications spanning CFD. Copy number variation was 
identified in 4 out of 311 AMD cases (2 with a single copy and 2 with three copies) 
and 9 out of 329 controls (1 with zero copies, 5 with a single copy and 3 with three 
copies) (Figure 4.8). There was no significant difference in the frequency of 
duplication or deletion of CFD between cases and controls (1.3% of AMD cases and 




Figure 4.8 Duplication and deletion of CFD in AMD c ases and 
controls. 
Copy number variation in the CFD gene was detected in AMD cases and controls.  
Decreased copy number was slightly more common in controls (N=329, 1 with zero 
copies, 5 with a single copy) than AMD cases (N=311, 2 with a single copy). 
Increased copy number was identified in 2 out of 311 AMD cases 3 out of 329 
controls. There was no statistically significant difference in copy number variation 
between AMD cases and controls.
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4.4   Plasma CFD  
Plasma CFD concentrations are reported to be elevatd in AMD cases, relative to 
controls, in some but not all studies of complement pro eins in plasma in small 
cohorts (Scholl et al. 2008; Reynolds et al. 2009; Hecker et al. 2010). Plasma CFD 
was measured in the UK1 and UK2 series to test for an association with AMD, and 
with CFD SNP genotype. 
 
4.4.1  Optimisation of the CFD ELISA 
The Duoset ELISA development kit for human CFD from R&D Systems is a 
sandwich ELISA developed for measuring CFD in cell u ture supernatants. The 
concentration of CFD in plasma is higher than in cell culture supernatants. In order to 
use the mouse anti-CFD Capture antibody (4 µg/ml) and the biotinylated goat anti-
CFD Detection antibody (200 ng/ml) at the recommended ilution, the optimal 
dilution of plasma was determined. Serial dilutions f three internal control plasma 
samples (P1, P2 and P3) were made, ranging from 1/400 to 1/4,000 to determine the 
appropriate dilution to achieve measurements in the linear range of the ELISA. The 
standard curve was made by serial dilutions of recombinant human CFD, ranging 
from 0 - 2.5 ng/ml. A representative 6-point standard curve is shown in Figure 4.9. 
Average absorbance at 450 nm for the three plasma sa ples at each dilution ± SD is 
shown in Figure 4.10.   
Plasma CFD concentrations in the range of 1-3 µg/ml have previously been 
reported (Reynolds et al 2010). In this range, a plasma dilution of 1/4,000 (0.00025) 
was determined to be suitable for the assay. 
 
4.4.2   Inter- and intra-assay variation for the CF D ELISA 
The internal control plasma samples P3, P6 and P9 were measured multiple times 
within the same assay, and measurements obtained wer  us d to assess intra-assay 
variability for the CFD ELISA. Figure 4.11A shows the mean measurement of 
plasma CFD obtained for each plasma sample (±s.e.m.) from at least 5 replicates. 
Coefficients of variation (CV) were around the 5% threshold or below, indicating 
that there was no significant difference between replicates.  
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Figure 4.9 Representative standard curve for CFD EL ISA. 
A standard curve for CFD was obtained by serial dilution of purified recombinant 
human CFD of known concentration, included in the R&D DuoSet ELISA kit. The 
standard curve also included a blank control to obtain background absorbance at 450 
nm. The equation of the line-of-best fit was obtained by polynomial regression in 
Microsoft Excel. Goodness of fit was assessed using the squared correlation 
coefficient (R2). The standard curve was used to calculate the concentration of CFD 



















Figure 4.10 Optimisation of plasma dilutions for CF D ELISA. 
The optimal dilution of human plasma samples for use with the pre-developed CFD 
DuoSet ELISA kit antibodies was determined. Dilutions of three human plasma 
samples were made, in the range of 1/400 to 1/4,000 and used in the ELISA 
following the recommended protocol. Plasma CFD was expected to be in the range 
of 1-3 µg/ml. The average absorbance at 450 nm for the three plasma samples at each 
dilution ± standard deviation shows that a dilution of 1/4,000 allows detection of 






























Figure 4.11 Inter- and Intra-assay variation of CFD  ELISA. 
A. Intra-assay variation was measured within replicates of three human plasma 
samples P3. P6 and P9. Each point represents at least five replicates ±s.e.m. 
Coefficients of variation (CV) are shown below each point. 
B. Inter-assay variation was measured based on the mean of two or more 
replicates from at least five different assays. Each point represents the mean 




The internal control plasma samples P3, P6 and P9 were also used to assess inter-
assay variation. The samples were measured multiple times in different assays, and 
measurements obtained were used to assess inter-assay variability for the CFD 
ELISA as described in Section 2.5.3. Figure 4.11B shows the mean measurement of 
plasma CFD obtained for two replicates of each plasma ample in a minimum of five 
assays (±s.e.m.), and indicates the coefficient of variation for each sample. There was 
minimal variation observed between assays (CV < 10%).  
 
4.4.3 Plasma CFD measurements in UK1 and UK2 AMD ca se-
control cohorts 
The plasma CFD concentration was measured in 751 AMD cases and 474 controls 
from the UK1 and UK2 case-control series for which plasma was available. 
Measurements were carried out in duplicate and mean values were corrected for 
inter-assay variation using two internal controls (P3 and P6).  
The plasma CFD measurements in the two British case- ontrol cohorts 
showed a slight positive skew, leading to a small deviation from normal distribution 
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(Figure 4.12). To account for the deviation from normal distribution, non-parametric 
tests were used to investigate the relationship between plasma CFD and AMD. The 
effect of age, gender, smoking history and body mass index (where available, in 
UK2) upon plasma CFD was also investigated using non-parametric testing. The 
relationship of quartiles of plasma CFD with AMD status was further investigated 
using logistic regression, including AMD-risk factors as covariates. Plasma 
measurements in the UK1 and UK2 cohorts were analysed independently. 
Additionally, as there was no significant differenc in the observations made in each 




Figure 4.12  Distribution of plasma CFD measurement s in combined 
UK1 and UK2 series. 
The distribution of unadjusted plasma CFD measurements (µg/ml) in the combined 
UK1 and UK2 AMD case-control series. Normal distribut on has a kurtosis value of 
less than 0.8: these data show a deviation from noral, as indicated by a kurtosis 
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4.4.3.1  Analysis of AMD-risk factors as covariates  
Expression of CFD has been reported to increase with advancing age (Reynolds et al 
2010). This was confirmed in the analysis of plasma CFD measurements in the two 
UK cohorts combined. As shown in the box plots in Figure 4.13, there was a 
significant increase in plasma CFD with increasing age. The median values of 
plasma CFD in the group aged less than 60 years was 1.96±0.14 (s.e.m.) µg/ml. The 
median increased to 2.09±0.04 (s.e.m.) µg/ml in individuals aged 60-79.99 years, and 
again to 2.35±0.05 (s.e.m.) µg/ml in individuals aged over 80 years. This reflected a 
significant difference in the distribution of plasma CFD measurements in the three 
age groups (p <0.001; Kruskal-Wallis test). A similar effect of increasing age upon 
plasma CFD was observed in AMD cases and controls analysed separately (data not 
shown). 
Both UK cohorts exhibited a gender-specific differenc  in plasma CFD 
concentrations, with females having a lower median co centration (2.09±0.04 
(s.e.m.) µg/ml) compared to males (2.26±0.05 (s.e.m.) µg/ml) in the combined 
cohorts. A Mann-Whitney U test identified a significant difference in the distribution 
of plasma CFD measurements between males and females (p=0.002, Figure 4.14). 
When the gender groups were split into AMD cases and co trols, the significant 
difference in plasma  
CFD was observed in controls (p=0.001), and not in cases (p=0.254).  
Smoking history was categorised as never smoked, currently smokes or ex-
smoker. As shown in Figure 4.15, neither of the UK cohorts showed a significant 
difference in plasma CFD measurements as a result of sm king history (UK1, 
p=0.84; in UK2, p=0.224).  
Adipose tissue is a leading source of CFD (White et al. 1992). BMI scores 
were available for the UK2 cohort. Non-parametric testing was used to assess the 
association between plasma CFD and BMI category (BMI<25, 25-29.99, >30) in this 
series. Plasma CFD was found to be significantly elevated in individuals with BMI 
>30 (Figure 4.16). In this group, the median plasma concentration was 2.11±0.07 
(s.e.m.) µg/ml, compared to lower median values in the groups for BMI <25 
(1.77±0.06 (s.e.m.) µg/ml) and BMI 25-29.99 (1.91±0.04 (s.e.m.) µg/ml). The 
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difference in plasma CFD between individuals with a e lthy BMI (BMI <25) and 




Figure 4.13  Plasma CFD increases with age. 
Non-parametric testing identified a significant relationship between elevated plasma 
CFD concentration and increasing age (p=<0.001; Kruskal-Wallis test). Age in the 
combined UK1 and UK2 cohorts was categorised as <60 years (0), 60-80 years (1) 
and >80 years (2). A similar relationship was also observed in AMD cases and in 




Figure 4.14  Plasma CFD has altered distribution in  females. 
Mann-Whitney U testing of ranked plasma CFD concentrations (µg/ml)  identified a 
significant difference (p=0.002) in the distribution f CFD measurements in females 
compared to males. Females had significantly lower m dian plasma CFD 
concentrations than males (mean rank=625.75 compared to a mean rank of 691.36 in 
males); this effect was most pronounced in controls. 
 




Figure 4.15  Smoking history does not affect plasma  CFD. 
Smoking history (categorised as current smoker, ex-smoker, or never smoked) was 
not found to influence plasma CFD concentrations in the combined UK1 and UK2 







Figure 4.16  BMI affects plasma CFD. 
BMI was found to have a significant relationship with elevated plasma CFD 
concentrations using non-parametric testing. Body mass index scores were 
categorised as BMI<25 (healthy), 25-29.99 (overweight) and >30 (obese). There was 
a highly significant difference in median plasma CFD concentrations between 
individuals with a BMI <25 and a BMI >30 (p=3×10-6). 
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4.4.3.2  Association of AMD status with plasma CFD 
 Plasma CFD was elevated in AMD cases compared with controls in the UK1-2 
series assessed by non-parametric testing (Table 4.6). In the combined cohorts, the 
median plasma CFD concentration in cases was 2.31±0043 (s.e.m.) µg/ml and 
2.08±0.046 µg/ml in controls (p=3.95x10-6; Figure 4.17). When samples were 
stratified by gender, plasma CFD was significantly greater in AMD females than 
control females (p=3.76x10-6) but there was no significant difference between AMD 
males and control males. (p=0.112; Figure 4.17).  
To correct for the confounding impact of age, sex and BMI, these were 
included as covariates in logistic regression analyses to assess the association of 
plasma CFD quartiles with AMD. In agreement with the results of non-parametric 
testing, elevated plasma CFD was significantly associated with AMD, and this 
association was found only in females. The odds ratio for those of both sexes in the 
highest versus lowest quartile of plasma CFD when age and smoking (ever/never) 
was included as a covariate was 1.81 (95% C.I. 1.27-2 5 ; p=0.001). In females only, 
the corresponding odds ratios were 2.15 (95% C.I. 1.35-3.44; p=0.001), and in males 
only, 1.42 (95% C.I. 0.82-2.47; p=0.215).  
BMI was included as a covariate in regression analysis for 272 controls and 
402 AMD cases from the UK2 series. The OR for the 4th versus 1st quartile of plasma 
CFD was 2.03 (95% C.I. 1.26-3.27; p=0.004).  
 
4.4.3.3  Association of CFD genotype with plasma CFD 
The minor allele of the CFD SNP rs3826945 was associated with increased risk of 
AMD. Reflecting the female-specific association betw en SNP genotype and AMD, 
there was also a female-specific association with plasma CFD and AMD. The 
intronic SNP rs3826945 may be in LD with an unidentified variant that affects 
expression of CFD. However, genotype at rs3826945 was not found to be associated 
with plasma CFD in the combined UK case-control cohorts (p=0.309).  
There was no significant association between copy number variation at CFD 
and plasma CFD (p=0.857). 
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    Controls Late AMD 
    
Median (25th-75th 
Percentile) Median (25th-75th Percentile) P* OR (95% CI) P 
UK1 Series 
All 2.51 (2.02 - 3.09) 2.78 (2.12 - 3.6) 0.001 1.32 (1.07 - 1.62)  0.010 
Males 2.77 (2.22 - 3.36) 2.97 (2.28 -3.93) 0.170 1.19 (0.82 - 1.72) 0.366 
CFD 
(µg/ml) 
Females 2.30 (1.99 - 2.94) 2.68 (2.06 -3.42) 0.002 1.39 (1.08 - 1.80) 0.011 
              
UK2 Series 
All 1.82 (1.43 - 2.25) 1.99 (1.57 - 2.60) 0.0004 1.18 (0.99 - 1.39) 0.060 
Males 1.98 (1.56 - 2.38) 2.07 (1.60 - 2.70) 0.218 1.07 (0.84 - 1.37) 0.574 
CFD 
(µg/ml) 
Females 1.69 (1.34 - 2.17) 1.95 (1.55 - 2.51) 0.001 1.28 (1.01 - 1.63) 0.046 
              
UK1 and UK2 Series 
All 2.08 (1.59 - 2.70) 2.31 (1.76 - 3.06) 3.95 x 10
-6 1.81 (1.27 - 2.57) 0.0010 
Males 2.21 (1.74 - 2.87) 2.38 (1.78 - 3.07) 0.112 1.42 (0.82 - 2.47) 0.2150 
CFD 
(µg/ml) 
Females 2.01 (1.51 - 2.55) 2.25 (1.74 - 3.06) 3.76 x 10
-6 2.15 (1.35 - 3.44) 0.0004 
 
 
Table 4.6  Plasma CFD is elevated in AMD cases comp ared to controls. 
Plasma CFD was measured by ELISA in 751 AMD cases and 474 controls in two British AMD case-control series. Significant differences 
in the distribution of plasma CFD measured in late AMD cases (CNV and GA), determined by Mann-Whitney U testing (*), were observed 
in both series independently and when they were combined. When the series were split by gender, the significant difference was seen only 
in females. Logistic regression was used to account for the confounding effects of age and smoking history upon plasma CFD; the fourth 
quartile of plasma CFD measurements was significantly ssociated with AMD compared to the first quartile. This was also seen only in 
females when the cohort was split by gender. BMI was included as a covariate for the UK2 cohort in addition to age and smoking; the 
fourth quartile of plasma CFD remained significantly associated with AMD (data not shown). 




Figure 4.17 CFD is elevated in the plasma of AMD ca ses relative to 
controls. 
Plasma CFD concentrations in age-related macular degeneration (AMD) and control 
subjects in the combined UK1 and UK2 series were measured by ELISA. The 
difference was statistically significant both in the combined sexes (p=3.95x10-6) 
(upper Figure) and in females (p=3.76x10-6) but not in males using Mann-Whitney U 
testing. P-values indicated on the figures were obtained by regression analysis, 
correcting for age, BMI and gender. 
The 4th quartile of plasma CFD concentrations was significantly associated with 
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4.4.3.4  Power Calculations for the CFD ELISA 
Having observed a 10% difference in median plasma CFD between AMD cases and 
controls (Table 4.9), the power of the study to identify a significant difference 
(p=0.05) of this magnitude at 80% power was assessed. As previously described, the 
plasma CFD measurements showed a slight deviation from normal distribution and 
were assessed using non-parametric testing. Calculation of power using the Altman 
Nomogram assumes that data are normally distributed. This was achieved by log-
transforming the plasma CFD measurements in SPSS (Figure 4.18). Log-transformed 
plasma CFD remained significantly elevated in AMD cases relative to controls, using 
non-parametric tests (p=0.001) and logistic regression (4th quartile, p=0.001, OR 
1.78, 95% C.I. 1.26-2.50).  
 
 
Figure 4.18  Normalisation of plasma CFD distributi on by log 
transformation.   
Plasma CFD measurements in the combined UK1 and UK2 series showed a 
leptokurtic distribution. Log-transformation of raw CFD concentrations reduced 
kurtosis, normalising distribution. 
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The difference in mean of log plasma CFD in AMD cases (0.368) and controls 
(0.318), and the observed standard deviation (0.19) were used to calculate the 
standardised difference. The standardised differenc was applied to an Altman 
Nomogram. A sample size of 450, comprising an equal n mber of cases and controls 
would be sufficient to successfully identify a difference in plasma CFD of this 
magnitude with 80% power. Given that this study involved 751 AMD cases and 474 
controls, the study is adequately powered.   
 
4.5   Discussion 
Genetic association studies and proteomic approaches implicate uncontrolled 
activation of the alternative complement pathway in the pathogenesis of AMD. This 
chapter describes investigation of Complement factor D, the central activator of the 
alternative pathway, as a candidate for a role in AMD. 
A commercially available ELISA for measuring CFD was optimised for use 
in plasma samples from two British AMD case-control series. In agreement with 
previous reports (Scholl et al. 2008), median plasma CFD was 2.16±1.13 (SD) µg/ml 
across these series. The median value of plasma CFD was significantly raised (11% 
increase, p-value=0.001) in 751 AMD cases compared with 474 disease-free 
controls, correcting for age (Figure 4.17).  
The levels of complement components and activation fragments in the plasma 
of AMD cases and controls have previously been investigated. These studies have 
provided clear evidence that activation products, such as Ba, Bb, C3a and C5a, are 
elevated in AMD cases (Reynolds et al. 2009; Hecker et al. 2010).  This is consistent 
with the hypothesis that AMD pathogenesis involves chronic activation of the 
alternative complement pathway, perhaps spilling over into the systemic circulation 
from the eye. Although two studies reported elevated levels of CFD (Scholl et al. 
2008; Hecker et al. 2010), one study did not identify any significant difference in 
plasma CFD between 120 AMD cases (all with severe dis ase) compared to 60 
controls (Reynolds et al. 2009). These previous studies were performed in small 
series. The present study was conducted in a substantially larger number of cases and 
controls, and has much greater power to detect a small difference in CFD (> 80% 
power to detect a difference of this magnitude). Of the 751 cases, 82% of the 
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combined UK1 and UK2 cases had severe AMD (GA or CNV), so disease severity is 
unlikely to affect comparison between studies. This study confirms that CFD, the 
central activator of the alternative pathway, is elevated in AMD cases compared to 
controls. This has important implications on alternative pathway activity in AMD, 
further contributing to the activation observed during normal ageing and in those 
with high BMI.  
Increasing age has a significant effect upon the concentration of CFD in 
plasma (Hecker et al. 2010). In agreement with this, plasma CFD concentrations 
were significantly higher in individuals aged 60-79.9  years, and higher again in 
individuals aged over 80 years, compared to those aged less than 60 years (p <0.001; 
Figure 4.13). Plasma CFD increased with age, regardless of AMD status. Controls 
have lower plasma CFD than cases in each age category, reflecting both an age-
related and AMD-related increase in complement activ tion. 
In addition to an effect of advancing age, females had a significantly lower 
median concentration of plasma CFD (2.09±0.04 (s.e.m.) µg/ml) than males 
(2.26±0.05 (s.e.m.) µg/ml) in the combined cohorts (p=0.002, Figure 4.14). The 
significant difference in plasma CFD measurements be ween genders was only 
observed in controls (p= 0.001). This is consistent with female cases, and to a lesser 
extent male cases, having elevated levels of CFD regardless of gender when 
suffering from AMD (Figure 4.17).  
The majority of complement components circulating i the plasma are 
synthesised by the liver, with the exceptions of CFD and C1q (Morgan and Gasque 
1997). The major source of plasma CFD is adipose tissue (White et al. 1992). The 
most abundant cell type in adipose tissue is adipocytes. Bone-marrow derived 
macrophages are also present, possibly recruited by chemokines such as monocyte 
chemoattractant protein -1 (MCP-1) that are expressed by adipocytes. Both 
adipocytes and macrophages are known to synthesise CFD, although adipocytes 
appear to be the major source of plasma CFD in normal individuals. Consistent with 
this, there is a clear relationship between increased body fat (indicated by BMI score) 
and increasing plasma CFD measurements in the UK2 cohort (Figure 4.16). Median 
plasma CFD was significantly higher in obese individuals compared to those with a 
BMI <25 (p=0.000003). Fat is increasingly regarded as an endocrine organ, secreting 
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a variety of hormones, such as leptin, as well as immune and inflammatory 
mediators, including CFD and tumor necrosis factor-α (Fantuzzi 2005). Reynolds et 
al. (2009) report an association between high BMI and elevated C3, CFB, and CFH, 
in addition to elevated concentrations of complement activation fragments Bb, C3a, 
and iC3b.  
Although BMI was significantly associated with plasma CFD in the UK2 
cohort, plasma CFD level remained significantly associated with AMD when BMI 
was included as a covariate. Similarly, the contribu ion of advancing age to plasma 
CFD did not remove the significant association with AMD.  
CFD is constitutively secreted at a high level, but is rapidly catabolised in 
tissues such as the kidney (White et al. 1992; Volanakis and Narayana 1996). The 
fractional catabolic rate of plasma CFD has been estimated to be 60% per hour 
(Pascual et al. 1988), contributing to its low serum concentrations. No information 
regarding kidney function (e.g. creatinine levels) was available for the UK cohorts. 
High CFD concentrations in plasma as a result of impaired renal function in some 
individuals cannot be excluded. Given the large number of individuals involved in 
this study, this is unlikely to play a significant role in elevating CFD in AMD cases 
compared to controls. 
   Plasma CFD is elevated in AMD cases compared to controls (Table 4.6). This 
seems likely to result in activation of the alternative complement pathway in AMD. 
Uncontrolled complement activity appears to have detrim ntal effects in AMD. 
However, the source of elevated CFD in AMD remains u clear. Although the 
majority of circulating CFD is synthesised by adipose tissue, non-adipose sources of 
plasma CFD include circulating monocytes/macrophages, lung, placenta, muscle, 
synovial tissue and brain astrocytes (White et al. 1992; Morgan and Gasque 1997). 
The blood-retinal barrier may restrict entry of theCFD in plasma to the neural retina, 
although the RPE and choroid are exposed to systemically available complement 
proteins. Systemic and locally expressed complement components in the eye may 
contribute to the chronic inflammatory process observed in AMD.   
Anderson et al (2010) investigated the expression of CFD in the eye using 
quantitative real-time PCR (qPCR). In tissue isolates, choroidal cells were shown to 
express CFD at over tenfold higher levels than either neural retina or RPE (Anderson 
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et al. 2010).  The complement regulators CFH, DAF and CFI and the initial 
components of both the alternative and classical complement pathways, including C3 
and factor B, are also expressed more highly in the choroid than in RPE or neural 
retina. Macrophages and the choroidal capillaries adjacent to Bruch’s membrane may 
express alternative complement pathway proteins, including CFD, in the choroid, 
although this remains unconfirmed.  
Regardless of the cellular source, CFD, factor B and C3, are co-expressed in 
choroidal tissue. However, alternative complement pathway activation mediated by 
CFD requires the deposition of C3 and factor B on a surface upon which control by 
CFH, CFI, DAF, MCP and complement receptors can be evaded (Walport 2001). 
Drusen deposits, characteristic of AMD, are considere  by-products of a chronic 
inflammatory response at the Bruch’s membrane which contributes to the 
pathogenesis of AMD (Mullins et al. 2000; Hageman et al. 2001; Anderson et al. 
2002). Druse form between the RPE and Bruch’s membrane, and contain most 
components of both the classical and alternative complement pathways and their 
regulators. Whilst drusen do not contain CFD, this may be a consequence of low 
levels of CFD in relation to other complement proteins in circulation.  Thus, a high 
level of complement activation occurring in the choriocapillaris-Bruch’s membrane-
RPE region in response to an unknown trigger may contribute to both tissue damage 
locally, and to the elevated plasma CFD concentration measured in AMD cases 
compared with controls systemically. Alternatively, AMD may be a systemic disease 
which manifests itself at the tissues most vulnerabl  to attack by complement, 
including the macula. 
A genetic association between AMD and variation within the CFD gene was 
observed in several AMD case-control series, and in a meta-analysis, including 4765 
predominantly severe AMD cases and 2693 examined controls. The association was 
detected with a single non-coding SNP, rs3826945, located in intron 4 of the CFD 
gene. The region in chromosomal region 19p13.3 in which CFD spans 3.9 kb has a 
high gene density, high levels of recombination andrelatively low linkage 
disequilibrium (http://hapmap.ncbi.nlm.nih.gov). This suggests that the association 
may not extend far on either side of rs3826945. The effect size of the association in 
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the meta-analysis was small (odds ratio 1.11) and almost confined to females (Table 
4.4, Figure 4.5).  
Zeng et al (2010) investigated SNPs in CFD for an association with AMD in 
a smaller AMD cohort (178 cases and 161 controls). They did not identify an 
association between rs3826945 and AMD (although minor allele frequencies in cases 
and controls - 35% and 31% respectively -   were comparable to those observed in 
the UK1 and UK2 series (Table 4.3)). The small study (Zeng et al. 2010) would lack 
power to detect an effect of the size observed in the meta-analysis described within 
this chapter (OR 1.11). Furthermore, their analysis did not account for confounding 
factors such as age, sex, smoking history or BMI. Although no interaction was 
observed between environmental factors and rs3826945 in the study described in this 
chapter, only partial BMI information was available. BMI is a modifiable factor, 
which has previously been associated with AMD-susceptibility. Furthermore, BMI 
affects levels of inflammatory biomarkers in addition to CFD (Seddon et al. 2006a; 
Reynolds et al. 2009), and may also modify genetic susceptibility. This raises the 
possibility that BMI may contribute to the variability in replication across case-
control series used in the SNP association study, as there may be differences in BMI 
between populations. This cannot be excluded, as BMI data were only available in 
some series (UK2, USA1, Nijmegen).  
Both the genetic and proteomic association between CFD and AMD appear to 
have a greater impact on females than males. The coorts investigated generally had 
a greater proportion of females than males, so this may reflect a loss of power to 
detect the small differences observed in males. However, sex differences in the 
heritability of complex traits are common (Weiss et al. 2006). This may indicate that 
an unidentified variant in linkage disequilibrium with rs3826945 regulates plasma 
CFD levels in females. There was no significant association between rs3826945 in 
CFD and plasma CFD measurements. Almost 5,000 cases wer  required to show the 
genetic association with AMD, so this study is likely underpowered to detect such an 
effect. Deletions and duplications of CFD could affect expression, although no 
significant difference in frequency of these was oberved between AMD cases and 
controls (Figure 4.8). No correlation could be made between copy number and 
plasma CFD.  Furthermore, sequencing of the exonic a d flanking regions of CFD in 
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95 cases and 95 controls did not identify any candidate regulatory variants. However, 
such variants may be identified in the future by re-sequencing of additional samples 
and would be subject to functional studies to examine the effects on CFD expression 
in adipocytes or macrophages. 
The genetic association between rs3826945 in CFD and AMD may 
contribute only a small increase in risk for AMD, but further implicates the 
alternative pathway in AMD pathogenesis. Ablation of CFD is neuroprotective and 
reduces photoreceptor cell death in response to light-induced damage in a CFD −/− 
mouse model (Rohrer et al. 2007). The central role of CFD in the alternative 
complement pathway makes this an attractive candidate for therapeutic intervention, 
regardless of whether plasma CFD is a cause or a secondary effect of the disease. 
Partial (or local) inhibition of CFD in individuals at high genetic risk of AMD might 
reduce the risk of development and progression of disease by minimising tissue 
damage.  Recent studies have suggested the variants in complement genes (CFH and 
C3) are associated with risk of developing geographic atrophy, but not with disease 
progression in humans (Scholl et al. 2009; Klein et al. 2010). However, animal 
models using laser damage to induce neovascularisation from the choroid have 
shown that complement components including C5a are important in development of 
CNV (Bora et al. 2005). It therefore remains to be se n whether the inhibition of 
complement would be an effective therapy for treating late forms of the disease. One 
such complement inhibitor, an anti-complement factor D antibody fragment 
(FCFD4514S) is currently in Phase I clinical trials using intravitreal injections 
(Genentech / Roche; ClinicalTrials.gov identifier: NCT00973011).  







5: Chapter 5 
 
Functional relevance of the 
interaction between HTRA1 
and CFD 
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5.1  Introduction 
This chapter describes the validation and characterisation of an interaction between 
HTRA1 and complement factor D (CFD).  The interaction was identified in a yeast 
two-hybrid screen, and selected for further study due to the role of CFD in the 
alternative complement pathway. Variation in genes such as CFH, CFB, C3 and FI 
deregulate this pathway and contribute to AMD pathogenesis (Edwards et al. 2005; 
Haines et al. 2005; Klein et al. 2005; Gold et al. 2006; Yates et al. 2007; Fagerness et 
al. 2009). CFD (also known as adipsin (White et al. 1992)) is a serine protease with a 
key role in this pathway, cleaving factor B when it is bound to C3b to form the C3 
convertase (Götze and Müller-Eberhard 1971; Müller-Eberhard and Götze 1972 ; 
Vogt et al. 1974). Altered CFD activity caused by an interaction between HTRA1 
and CFD may affect systemic and local inflammation, which has been implicated in 
AMD pathogenesis. 
CFD is expressed as a prepropeptide. The N-terminal s gnal peptide is 
cleaved to form an inactive zymogen, proCFD (White et al. 1992; Kim et al. 1994; 
Yamauchi et al. 1994; Jing et al. 1999). Subsequently, the 5-6 amino acid N-terminal 
activation domain in humans is removed, either within e secretary pathway or it 
may be rapidly cleaved in plasma. >99% of plasma CFD is CFD rather than proCFD 
(Fearon et al. 1974; Lesavre and Müller-Eberhard 1978; Yamauchi et al. 1994). The 
mature peptide becomes active as a result of a conformational change which occurs 
when it binds C3bB, a complex of factor B, magnesium ons and complement 
component 3b (C3b) (Volanakis and Narayana 1996; Jing et al. 1999). 
A number of serine proteases are able to cleave the activation peptide from 
proCFD (Fearon et al. 1974; Yamauchi et al. 1994). A physiological role for serine 
proteases in serum, such as thrombin, in the activation of mouse proCFD was 
excluded by Takahashi et al. (2010).  This group proposed a role for mannose-
binding lectin-associated serine protease-1 (Masp1), a component of the lectin 
pathway. Masp1-/- null mice have defective activation of the alternative pathway, 
with proCFD rather than mature CFD circulating in serum. This suggests that Masp1 
is responsible for activation of proCFD to mature CFD in serum in mice. In humans, 
cleavage of proCFD is thought to occur during CFD maturation and secretion 
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(Yamauchi et al. 1994), rather than post-secretion as proposed for Masp1 in the 
mouse (Takahashi et al. 2010). Masp1 is not expressed in adipose tissue, the leading 
source of CFD in humans (White et al. 1992; Takahashi et al. 2010). Thus, the 
enzyme(s) responsible for activation in human tissue , including blood, adipose 
tissue and the eye remain unknown.  
The mechanism(s) by which the chromosome 10q26 AMD-susceptibility 
locus increases risk of AMD remain elusive. In addition to verifying the interaction 
between HTRA1 and CFD in vitro, a novel ability of HTRA1 to activate CFD by 
specific cleavage of the activation peptide was uncovered in this study, using a 
variety of biochemical approaches. This provides a biologically plausible mechanism 
for HTRA1 involvement in AMD pathogenesis. 
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5.2  Validation of the interaction between CFD and HTRA1 
A putative interaction was identified between CFD and HTRA1 in a yeast two-
hybrid screen (described in Chapter 3). A back-transformation experiment, with bait 
and prey plasmids isolated from the initial positive clones, confirmed an interaction 
between these proteins in the yeast two-hybrid system. Purified and recombinant 
proteins were used to further verify the interaction and to identify CFD as a novel 
substrate for HTRA1 in vitro.  
 
5.2.1   CFD interacts with HTRA1 in a yeast two-hyb rid screen 
Of the numerous potential interactors of HTRA1 that were identified by yeast two-
hybrid screening in a placental cDNA library and by tandem affinity purification in 
RPE1 and HEK293T cells, CFD was selected for further study. The specificity of the 
initial interaction was tested by back-transformation of the isolated bait (pBD-DEST-
HTRA1) and prey plasmid (pACT2-CFD) into PJ69–4A yeast cells. Growth of co-
transformed yeast on selective media of increasing tringency (-WHL and -WHLA) 
indicates a positive interaction between CFD and HTRA1 (Figure 5.1). Back-
transformation of the isolated plasmids was performed by Dr. Elod Kortvely 
(Helmholtz Zentrum, Munich, Germany). 
 
5.2.2  The minimal binding site of the CFD:HTRA1 in teraction 
Sequences obtained from the three CFD clones identified were aligned to the human 
full-length CFD cDNA reference sequence (NM_001928.2), using Clusta W 
(www.ebi.ac.uk/clustalw/). This defined the minimal sequence required for a positive 
interaction between the active HTRA1 bait and CFD prey (Figure 5.2). The minimal 
binding region for the interaction lies at the N-terminal portion of the CFD, 
overlapping the activation peptide sequence of proCFD (bold text in NM_001928 
reference sequence, Figure 5.2). 





Figure 5.1 Back-transformation of HTRA1 and CFD pla smids into 
PJ69–4A cells. 
Prey plasmids containing CFD cDNA (pACT2-CFD) and the HTRA1 bait construct 
were back-transformed into PJ69–4A cells, and tested for growth. Yeasts that were 
co-transformed with pACT2-CFD and pBD-DEST-HTRA1 were capable of growth 
on selective media of increasing stringency (-WHL and -WHLA), indicating a 
positive interaction. No growth was observed in yeast that were co-transformed with 
the HTRA1 bait construct and empty prey plasmid. Supplements missing from the 
SD media are tryptophan (W), leucine (L), histidine (H) and adenine (A). Images and 
back-transformations were produced by Dr. Elod Kortvely. 
 
 
Figure 5.2  Minimal binding region of CFD isolated in the yeast-two 
hybrid screen. 
Prey plasmid sequences from the three positive yeast clones for CFD were aligned 
with a reference sequence for human CFD (NM_001928). Asterisks indicate 
complete sequence agreement. Numbering refers to length of isolated sequence for 
the positive clones, and to nucleotide position in the full-length cDNA sequence for 
CFD for the reference sequence.  CFD is translated s a prepropeptide; grey text 
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5.2.3   HTRA1-mediated cleavage of the N-terminus o f CFD  
A peptide spanning 30 amino acid residues at the N-t rminal end of proCFD, 
corresponding to the minimal binding site for HTRA1 in the yeast-two hybrid screen, 
was synthesised. The sequence of the CFD_Y2H peptide is shown in Table 5.1. The 
CFD_Y2H peptide (20 µM) was tested as a substrate for recombinant HTRA1 in an 
in vitro protease activity assay with increasing amounts of recombinant HTRA1 (0.1-
1 µg).  Following incubation at 37oC for 16 hours, samples were subjected to 
reducing gel electrophoresis.  A significant decrease in the amount of substrate, 
relative to synthetic peptide in the absence of protease, was observed in a 
Coomassie-stained gel (Figure 5.3A). Specificity of the proteolysis was confirmed by 
incubation of CFD_Y2H with the inactive mutant HTRA1 (S328A); under the same 
conditions, no degradation of the substrate was observed (lane 2, Figure 5.3A).   
The intensity of Coomassie-stained bands was quantified by densitometry 
(ImageQuantTL), and plotted as band intensity relative to the untreated peptide 
(Figure 5.3B). Incubation with 0.1 µg, 0.5 µg or 1 µg of GST ∆N HTRA1 resulted in 
decreased band intensity for CFD_Y2H, corresponding to a reduction of 68±1 
(SD)% with 1 µg GST ∆N HTRA1 compared to untreated (p = 0.0094; t-test, n=2). 
Similar results were obtained by comparison of band intensity to the inactive S328A 
mutant HTRA1-treated peptide (data not shown).   
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 Name of 
peptide  Sequence (N – C) 
Molecular 
Weight 
(Da)  Purity   Modification  
CFD_Y2H PPRGRILGGREAEAHARPYMASVQLNGAHL 3225.71 85%  
Act_pep_MCA PPRGR 738.84 88% C-terminal MCA 
Random_MCA DSVLA 660.72 88% C-terminal MCA 
 
Table 5.1 Synthetic peptides. 
Synthetic peptides corresponding to regions of CFD were generated. CFD_Y2H corresponds to the N-terminal amino acid sequence 
identified as the minimal binding region in the yeast-two hybrid screen, including the activation peptide. Act_pep_MCA corresponds to the 
activation peptide of proCFD, conjugated to a C-terminal MCA group. Random_MCA corresponds to the last 5 amino acids of the C-
terminal end of CFD, conjugated to a C-terminal MCA moiety.





Figure 5.3  The CFD peptide sequence identified by yeast-two hybrid 
screening is subject to proteolysis by HTRA1 in vitro . 
A. A synthetic peptide corresponding to the CFD activation peptide and N-
terminal portion of CFD isolated in the yeast two hybrid screen 
(PPRGRILGGREAEAHARPYMASVQLNGAHL) was tested as a sub trate 
for recombinant HTRA1. The 3.2 kDa peptide was incubated with increasing 
amounts of recombinant HTRA1 (0.1-1 µg).  A Coomassie- tained gel of the 
reactions showed a decrease in the amount of substrate, relative to synthetic 
peptide in the absence of protease or when incubated wi h the inactive mutant 
GST ∆N HTRA1 S328A.   
B. Analysis of band density in Coomassie-stained gels showed that increasing 
amounts of HTRA1 resulted in a significant (p<0.05) decrease of synthetic 
substrate, determined by a one tailed t-test, relative to the untreated substrate 
or substrate treated with an inactive mutant of HTRA1. Data is mean of two 
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5.2.4  GST ∆N HTRA1 interacts with, but does not cleave, mature  
CFD 
A GST-pulldown assay using catalytically inactive GST-tagged ∆N HTRA1 S328A 
(amino acids 157-480), GST HTRA1 ∆C (amino acids 21-157) or GST alone, and 
mature CFD, purified from human plasma, was performed. Schematic domain 
structures of these proteins are shown in Figure 5.4. The S328A mutant of HTRA1 




Figure 5.4 Schematic domain structure of recombinan t and purified 
proteins used to verify the CFD-HTRA1 interaction in vitro . 
The domain structure of proteins assayed for an interac ion. CFD was purified from 
human plasma, and is the mature form of the protein, lacking the activation peptide. 
HTRA1 has an N-terminal secretory signal sequence (SP), an insulin-like growth 
factor binding domain (IGFBP), a Kazal-type serine protease inhibitor domain 
(which may be involved in self-regulation), a characteristic trypsin-like catalytic 
domain and a C-terminal PDZ domain. Recombinant GST-tagged forms of HTRA1, 
corresponding to the N-terminal domains (GST HTRA1 ∆C) and to the C-terminal 
domains (GST ∆N HTRA1) were expressed and purified from E. coli. S328A (*) is 
an inactive mutant of HTRA1. GST was expressed and purified from E. coli to test 
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5.2.4.1   Optimisation of wash conditions for the G ST pulldown  
Following a standard protocol for performing a GST pulldown, GST HTRA1 ∆C , 
GST ∆N HTRA1 and free GST were bound to Glutathione Sepharose beads, which 
were pre-equilibrated in TEN150 Buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl). 
An equimolar amount of CFD (0.5 µg) was added to each, nd to Glutathione 
Sepharose beads alone. Following incubation at 4oC for 2 hours, the beads were 
washed extensively in TEN150 buffer. Bound proteins were eluted from the 
Glutathione Sepharose in 1 x LDS Buffer and 1 x Reducing Agent. Eluates were 
analysed by reducing gel electrophoresis and immunoblotting using anti-CFD (C-16) 
and anti-GST-HRP antibodies (data not shown). 
An interaction between CFD and GST ∆N HTRA1 was observed. However, 
under these wash conditions, there was a non-specific interaction between CFD and 
GST, and between CFD and Glutathione Sepharose in th  absence of any 
recombinant protein (data not shown).  
In order to reduce the background-binding of CFD to the beads, and to GST, 
the stringency of the wash conditions was increased by the addition of 0.1% NP40 to 
TEN150 Buffer for the washes. Additionally, the number of washes was increased 
from three to four washes, for a total of 160 times the bead volume. 
 
5.2.4.2   Validation of the interaction between CFD  and HTRA1  
The previously observed interaction between GST ∆N HTRA1 and CFD was 
confirmed using the more stringent wash conditions (Figure 5.5). Minimal binding 
was observed between the N-terminal portion of HTRA1 (GST HTRA1 ∆C) and 
CFD. This indicates that CFD interacts with HTRA1, and that the binding site for 
CFD on HTRA1 is located in the C-terminal portion of the protease, spanning the 
protease domain and the PDZ domain (Figure 5.4).  Minimal binding of CFD to GST 
alone was observed using the more stringent wash conditi ns, thus excluding the 
possibility that the interaction was a result of binding to the GST tag; similarly, there 
was no observed binding of CFD to Glutathione Sepharose beads alone (Figure 5.5). 




Figure 5.5 CFD interacts with GST ∆N HTRA1 in a GST pulldown 
assay. 
An interaction between GST ∆N HTRA1 S328A and CFD was observed (lane 6) 
when GST or GST-tagged forms of HTRA1 were immobilised on glutathione-
sepharose beads (or beads alone) and incubated with 2µg of CFD. Minimal binding 
was observed between the N-terminal portion of HTRA1 (GST HTRA1 ∆C) and 
CFD, between GST alone and CFD, and between Glutathione Sepharose beads and 
CFD. Samples, including 10% of input only samples (anes 1-4) were subjected to 
electrophoresis and western blot following elution of bound proteins from 




5.2.5    Mature CFD is not a substrate for GST ∆N HTRA1 in vitro  
Following confirmation of the interaction between CFD and the C-terminal domains 
of HTRA1 (including the protease domain; Figure 5.4), the ability of GST ∆N 
HTRA1 to cleave mature CFD was assessed by a protease assay. Mature CFD (1 µg) 
was tested as a substrate for HTRA1 by incubation with 0.5 µg proteolytically active 
GST ∆N HTRA1 overnight at 37oC. Samples were subjected to reducing gel 
electrophoresis and subsequent Coomassie staining or Western blotting. There was 
no evidence of cleavage or degradation of mature CFD by HTRA1, as shown by a 
representative anti-CFD (C-16) immunoblot in Figure 5.6. This, together with the 
observation that the CFD_Y2H peptide is cleaved by HTRA1 (Figure 5.3), indicates 
that the propeptide region of CFD is subject to cleavage by HTRA1. 
 






Figure 5.6  Mature CFD is not a substrate for GST ∆N HTRA1 in vitro. 
CFD purified from plasma is not a substrate for HTRA1, in an in vitro assay of 
protease activity. No cleavage of CFD was observed in the presence of active GST 
∆N HTRA1.  
 
5.3  Production of recombinant proCFD 
In order to confirm the requirement for the propeptide sequence (PPRGR) for 
HTRA1-mediated cleavage of CFD, and to test the functio al consequences of the 
cleavage upon CFD activity, recombinant proCFD was produced. A bacterial 
expression vector, encoding an N-terminal cleavable GST-tag, was used for protein 
expression in E. coli. The GST-tag was utilised for purification and then cleaved 
using PreScission Protease, to release proCFD with a short (27 amino acids) linker 
peptide remaining at the N-terminus. 
 
5.3.1  Cloning proCFD for bacterial expression 
An Ultimate ORF clone encoding the full-length preproCFD cDNA sequence was 
obtained from Invitrogen. The sequence encoding proCFD was sub-cloned from the 
Ultimate ORF. 
 
5.3.1.1 PCR amplification of the proCFD insert 
ProCFD cDNA was cloned from the CFD Ultimate ORF (Invitrogen) by PCR using 
attB-containing primers to amplify the sequence encoding amino acids 21-253 of the 
CFD peptide (proCFD, lacking the signal peptide from amino acids 1-20 of the 
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preproprotein). PCR products, generated by Phusion polymerase in the presence of 
10% DMSO, were separated by agarose gel electrophoresis, as shown in Figure 5.7. 
The band of approximately 800 bp was excised and gel purified. 
 
5.3.1.2  Creation of the proCFD Gateway Entry Vecto r  
Gateway cloning technology was utilised for creation of the proCFD entry vector. 
Gel purified attB-flanked proCFD sequence was inserted into the attP-containing 
donor vector pDONR221 using BP Clonase II. The resulting entry vector, pENTR 
proCFD, was selected by kanamycin resistance, and propagated in E. coli TOP10 
cells. Sequencing with M13 and CFD-specific forward and reverse primers 
confirmed the presence, and sequence fidelity, of the proCFD insert in the entry 
vector (data not shown). 
 
5.3.1.3  Sub-cloning of proCFD into Gateway Destina tion Vector 
Gateway cloning technology was utilised for creation of the proCFD bacterial 
expression vector. The attL-proCFD-containing entry vector pENTR proCFD was 
used in a Gateway LR recombination reaction to insert th  proCFD sequence into the 
destination vector pGEX6P1-DEST. This plasmid (a kind gift from Dr Martin 
Reijns) is a Gateway-modified form of pGEX6P1, contai ing the attR recombination 
cassette, to allow IPTG-inducible expression of recombinant proteins with a 
cleavable GST-tag at the N-terminus. Ampicillin-resistance was used to select for 
destination vector clones containing the proCFD insert. Four clones were selected for 
screening for the insert into the destination vector by restriction digestion of the 
plasmids with ApaI or MluI. Figure 5.8 shows the separation of the digests by 
agarose gel electrophoresis. 
ApaI cuts the pGEX6P1-DEST vector backbone twice, and the proCFD insert 
twice. As shown in Figure 5.8A, clones 1, 3 and 4 have the correct pattern of 
digestion with ApaI to confirm that proCFD has been inserted into the pGEX6P1-
DEST vector. Clone 2 does not show the pattern of ApaI digestion that is 
characteristic for the pGEX6P1-DEST vector.  
   
 196 
Figure 5.8B shows the pattern of restriction digest generated by MluI. This 
enzyme cuts the pGEX6P1-DEST vector backbone once, does not cut the proCFD 
insert and cuts the entry vector twice. Clones 1, 3 and 4 show the pattern of digestion 
with MluI expected for pGEX6P1-DEST containing the proCFD insert. Clone 2 
shares the restriction digest pattern of the entry vector, CFD Ultimate ORF, 
indicating that the LR recombination step was not successful in this instance. 
pGEX6P1-DEST proCFD clones 1, 3 and 4 were sequenced using gene-
specific primers to confirm that the inserts matched the published proCFD sequence 
(NM_001928.2). 
 
5.3.2   Expression and purification of recombinant proCFD  
The pGEX6P1-DEST proCFD construct is an E. coli expression vector, with an 
IPTG-inducible lacIq promoter controlling expression of the recombinant protein. In 
addition to a GST-tag at the N-terminus, the vector encodes the recognition sequence 
for specific cleavage by PreScission Protease, between the GST domain and the site 
of the Gateway cloning system compatible DEST cassette. This allows sequential 
purification using the GST-tag on Glutathione Sepharose, followed by site-specific 
removal of the GST-tag by PreScission Protease. 
 
5.3.2.1 Expression of recombinant proCFD 
The E.coli strain BL21(DE3) pLysS was used for the expression of GST-tagged 
proCFD.  
 
5.3.2.2 Purification of recombinant proCFD 
Recombinant proCFD was purified from the soluble fraction of the cell lysate using 
the affinity of the GST-tag for Glutathione Sepharose resin. Following extensive 
washing of the glutathione sepharose under stringent conditions (0.5% Triton-X100 
in the wash buffer) to remove contaminants from the immobilised proCFD protein, 
PreScission Protease was added.   
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PreScission Protease cleaves the GST fusion proCFD between the Gln and 
Gly residues of the recognition sequence Leu-Glu-Val-Leu-Phe-Gln-Gly-Pro. As 
seen in the flow-through (FT) in Figure 5.9A, B and C, the action of PreScission 
Protease releases free proCFD (27 kDa) from the GST tag (25 kDa), which together 
comprise the 54 kDa GST fusion proCFD observed in the input fraction of the anti-
CFD and anti-GST immunoblots shown in Figure 5.9B and C respectively. The GST 
tag remains bound to the Glutathione Sepharose resin, and is seen following elution 
from the resin by reduced glutathione (Figure 5.9A, lane 2). The PreScission 
Protease (47 kDa) also has a GST tag, allowing it to be removed from the purified 
cleaved proCFD by binding to Glutathione Sepharose. Following elution with 
reduced glutathione, PreScission Protease was released, s shown in Figure 5.9A 
(lane 2) and in the anti-GST immunoblot shown in Figure 5.9C. 





Figure 5.7  PCR amplification of the proCFD insert.  
The cDNA sequence encoding amino acids 21-253 of the CFD peptide (proCFD, 
lacking the signal peptide from amino acids 1-20 of the preproprotein) was amplified 
using attB-containing primers. PCR products were separated by agarose gel 
electrophoresis and the appropriate band (800 bp) was excised and gel purified. 
 
Figure 5.8 Restriction digests to verify presence o f proCFD insert in 
the pGEX6P1-DEST vector. 
Four clones containing the destination vector were sc ened for the insert by 
restriction digestion with ApaI or MluI, and separated by agarose gel electrophoresis. 
DNA Molecular Weight Marker III was used to calculate the size of restriction 
fragments. 
A. Clones 1, 3 and 4 have the correct pattern of digestion with ApaI to confirm that 
proCFD has been inserted into the pGEX6P1-DEST vector. Clone 2 does not show 
the pattern of ApaI digestion that is characteristic for the pGEX6P1-DEST vector.  
B. Clones 1, 3 and 4 have the correct pattern of digestion with MluI for pGEX6P1-
DEST containing the proCFD insert. Clone 2 has the restriction digest pattern as the 
entry vector, CFD Ultimate ORF, confirming that proCFD was not successfully 
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Figure 5.9  Purification of recombinant proCFD and removal of GST-
tag.  
A. A Coomassie-stained gel showing that PreScission Prtease cleaves GST-
tagged proCFD, releasing free proCFD (27 kDa) from the GST tag (25 kDa) 
in the flow-through (FT) fraction observed on. The GST tag remains bound to 
the Glutathione Sepharose resin, a d can be eluted using reduced glutathione 
(Elution). 
B. Anti-CFD immunoblot confirms the cleavage of GST-tagged proCFD (54 
kDa) in the input fraction by PreScission Protease re ults in release of free 
proCFD (27 kDa) in the flow-through (FT) fraction, and to a lesser extent, in 
the Elution. 
C. Anti-GST immunoblot confirms the cleavage of GST-tagged proCFD (54 
kDa) in the input fraction by PreScission Protease, leaving the GST tag (25 
kDa) and PreScission Protease (47 kDa, with a GST-tag) bound to 
Glutathione Sepharose resin until eluted with reduc glutathione.  
D. A Coomassie-stained gel showing the removal of contaminating proteins 
(bands at 60 kDa and 66 kDa) from the proCFD preparation. A YM50 spin 
column was used to separate the proteins larger than 50 kDa from the smaller 
proCFD (27 kDa) in the flow-through from the PreScission Protease step 
(YM50 Input).  
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5.2.2.3 Further purification of recombinant proCFD 
As seen in the flow-through (FT) fraction of the proCFD purification procedure in 
Figure 5.9A, there are some contaminating proteins in the purified proCFD 
preparation (bands at 60 kDa and 66 kDa). The presenc  of a weak band at 66 kDa in 
the FT fraction on the anti-GST western blot shown in Figure 5.9C suggests that one 
contaminant has some similarity to GST and thus is likely to remain bound to 
Glutathione Sepharose under the stringent wash conditi s. Alternatively, as these 
contaminants are released in the mild conditions of the PreScission Protease cleavage 
buffer, they may be bound to proCFD. 
As the contaminating proteins (60 kDa and 66 kDa) were larger than proCFD 
(27 kDa), an additional round of purification was performed on the FT from the 
PreScission Protease step. A YM50 spin column separated the proteins by size. 
Proteins larger than 50 kDa are less able to pass through the pores of a filter 
membrane and are retained above the membrane. Smaller proteins, such as proCFD, 
pass through the filter. Figure 5.9D shows a Coomassie-stained gel of the input to the 
YM50 column (i.e. the FT from the PreScission Protease cleavage step) in lane 1, 
and in lane 2, the YM50 FT containing proCFD. The contaminating bands at 60 kDa 
and 66 kDa are removed. The reduction in the amount f proCFD observed 
following processing in the spin column is due to incomplete passage of proCFD 
through the filter membrane and the unavoidable loss of sample within the column. 
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5.4  HTRA1 cleaves recombinant proCFD  
Recombinant proCFD was tested as a substrate for HTRA1, and peptide mass 
fingerprinting was used in an attempt to identify the site of cleavage in the resulting 
fragments of proCFD. 
 
5.4.1  HTRA1 cleaves, rather than degrades, proCFD 
Increasing amounts of GST ∆N HTRA1 (0.1-1 µg) were incubated with proCFD 
overnight at 37 oC in order to assess whether HTRA1 is able to proteolytically 
process proCFD in vitro. Figure 5.10A shows immunoblot analysis of the digest. 
There is a clear shift in molecular weight of CFD in the presence of active HTRA1, 
which does not occur in the absence of the protease, or in the presence of the inactive 
mutant form of HTRA1 (Figure 5.10B). This indicates hat cleavage of proCFD is 
specific to active HTRA1 in this assay. A linker peptide of 27 amino acids remains at 
the N-terminal end of the recombinant proCFD following the action of PreScission 
Protease (shown in Figure 5.10D). This linker peptide appears to contribute to the 
detectable shift in molecular weight of proCFD upon c version to CFD following 
HTRA1 activity, corresponding to a loss of 3.5 kDa. This is the predicted molecular 
weight for the linker peptide (2.9 kDa) and the activation peptide (0.6 kDa). The 
distinct cleavage pattern was also detected by SDS-PAGE followed by staining with 
InstantBlue Coomassie stain (Figure 5.10C).  
 
5.4.2  Peptide Mass finger printing to confirm HTRA 1-mediated 
cleavage of proCFD 
Bands corresponding to CFD and proCFD were excised from a Coomassie-stained 
gel (Figure 5.10C) for analysis by mass spectrometry. In-gel digests on destained gel 
slices were performed by Dundee Cell Products, using the V8 Protease, also known 
as Endoproteinase Glu-C (EC 3.4.21.19). This serine protease from Staphylococcus 
aureus V8 specifically cleaves the peptide and ester bonds at the carboxylic side of 
Glu, or both Glu and Asp, depending on the buffer used. The reaction buffer 
(50 mM Tris-HCl, 0.5 mM Glu-Glu, pH 8.0) utilised for the in-gel digest strongly 
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favours cleavage at glutamic acid residues. Figure 5.10D shows the sequence of 
proCFD, and indicates the expected sites of cleavage by HTRA1 and by the V8 
protease. The N-terminal activated CFD fragment ILGGRE, unique to activated CFD 
following removal of the activation peptide PPRGR, was of particular interest. 
Peptides derived from CFD following V8 protease digest are indicated in 
bold text in Figure 5.10D. For both bands – proCFD and putative activated CFD – 
the same two peptides were detected by mass spectrometry. These peptides -
AHARPYMASVQLNGAHLCGGVLVAE and QWVLSAAHCLE- are located 
immediately adjacent to one another at the N-terminal e d of activated CFD, and 
provide 13.8 % coverage of the complete peptide sequence of proCFD.  
In agreement with the anti-CFD immunoblot shown in Figure 5.10A, 
detection of these CFD-specific peptides in the putative activated CFD band confirm 
that there is a change in molecular weight of proCFD as a result of HTRA1 activity. 
As the ILGGRE peptide was not detected, it was not possible to confirm activation of 
proCFD by HTRA1 directly using mass spectrometry. However, taken together with 
the cleavage of a synthetic peptide corresponding to the N-terminus of proCFD 
(Figure 5.3) and the absence of cleavage of mature CFD which lacks the propeptide 
sequence (Figure 5.6) by HTRA1 in vitro, it seems likely that HTRA1 cleaves the N-
terminal end of proCFD at, or near to, the activation peptide. 
 




Figure 5.10  ProCFD is a substrate for HTRA1 in an in vitro  protease 
assay. 
A. ProCFD was incubated with increasing amounts of recombinant GST ∆N 
HTRA1. Immunoblotting with anti-CFD antibody (lower panel) revealed 
bands at 27 kDa and at 24 kDa – corresponding to the predicted mass of 
proCFD and activated CFD. Self-cleavage of HTRA1 generated multiple 
lower molecular weight bands, in addition to the band t 64 kDa in the upper 
panel, probed with anti-HTRA1 PDZ. 
B. The absence of CFD cleavage when increasing amounts f the inactive 
mutant (S328A) of HTRA1 was incubated with proCFD in the lower panel 
(anti-CFD) indicates that active HTRA1 is responsible for the processing of 
proCFD seen in A. 
C. Following the specific cleavage of proCFD by GST ∆N HTRA1, bands 
corresponding to proCFD and the putative activated CFD were excised from 
a Coomassie-stained gel for analysis by mass spectrome y. 
D. The amino acid sequence of proCFD. The linker peptid  is shown in blue. 
The activation peptide is highlighted in yellow. The expected site of cleavage 
by HTRA1 is indicated by a red arrow.  In-gel digests were performed using 
V8 protease, which specifically cleaves at the carboxyl side of Glu and Asp 
(indicated by a black arrow). Mass spectrometry analysis of the peptide 
fragments identified the same two peptides for both proCFD and putative 
activated CFD; these are indicated in bold text, with one peptide also 
underlined.  
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5.5  HTRA1 specifically cleaves the CFD activation peptide 
sequence  
The ability of HTRA1 to specifically cleave the activation peptide sequence of 
proCFD in vitro was assessed using a synthetic activation peptide (PPRGR), coupled 
to a C-terminal methyl coumaric acid (MCA). A measurable increase in fluorescence 
only occurs following cleavage of the synthetic peptide at the amino acid residue 
immediately adjacent to the MCA group, to release fre AMC.   
 
5.5.1  Development of the fluorescent peptide assay  
A fluorescent peptide assay was developed to test whe her the human CFD activation 
peptide was a substrate for HTRA1 in vitro. MCA-labelled synthetic peptides are 
shown in Table 5.1. Recombinant GST ∆N HTRA1 and proCFD were freshly 
purified to avoid loss of activity as a result of storage at -80oC, and were diluted in 
TBS to the appropriate concentration for each assay.  Thrombin, purified from 
human plasma, was used as a positive control for cleavage of the activation peptide. 
The optimal pH for HTRA1 activity was determined. All assays were incubated at 
37oC. 
 
5.5.1.1 pH optimisation 
The ability of recombinant GST ∆N HTRA1 to specifically cleave the five amino 
acid activation peptide of CFD was studied over a pH range of 6-8.5 in TBS.  50 nM 
of active enzyme was incubated with 20 µM fluorescent peptide for 24 hours. The 
final reaction volume was 50 µl. Following cleavage at the amino acid immediately 
adjacent to the MCA group, free AMC is released. Free AMC increases fluorescence 
measured at excitation wavelength of 355 nm and an emission wavelength of 460 
nm. Assays were performed in duplicate, and the data shown in Figure 5.11 
represents the mean ± SD of three independent experiments. Optimal cleavage 
activity for HTRA1, reflected by the highest measurement of relative fluorescent 
units (Rfu) as a result of released AMC, was obtained at pH 7.5 (Figure 5.11). 
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5.5.1.2  Validation of HTRA1 cleavage specificity 
The specificity of the MCA-peptide assay was validate  by comparing the relative 
fluorescent units generated by HTRA1-mediated cleavage of the CFD activation 
peptide-MCA peptide (PPRGR-MCA) and DSVLA-MCA, corresponding to the C-
terminal five amino acid sequence of mature CFD. The relative fluorescence 
(corresponding to nanomoles of AMC released, Figure 5.14) increased over time for 
the CFD activation peptide-MCA, DSVLA-MCA did not generate detectable 
fluorescence over background measured when the peptide was incubated in the 
absence of protease (Figure 5.12). This indicates that HTRA1 could not cleave 
DSVLA-MCA and cleaves the activation peptide of CFD specifically. 
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Figure 5.11 pH optimisation of the fluorescent pept ide assay. 
A range of pH conditions were tested in order to determine the optimal pH for ∆N 
HTRA1-mediated cleavage of PPRGR-MCA. AMC release,  a consequence of 
proteolysis of the fluorescent peptide, was measured aft r 6 hours. The optimal pH 
for HTRA1 activity was pH 7.5. Values are the mean relative fluorescent units (Rfu) 




Figure 5.12   Specificity of the fluorescent peptide assay.  
The specificity of the MCA-peptide assay was tested by measuring the relative 
fluorescent units (Rfu) generated by HTRA1-mediated cl avage of DSVLA-MCA. 
This is a fluorescently labelled peptide corresponding to the C-terminal sequence of 
mature CFD. HTRA1 could not cleave DSVLA-MCA, as there was no increase in 
fluorescence relative to the background Rfu measured when the peptide was 
incubated in the absence of protease. This indicates that HTRA1 cleaves the 
activation peptide of CFD specifically. Values are the mean Rfu obtained in two 
independent experiments ± SD. 
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5.5.1.3  The AMC standard curve 
Serial dilutions of 7-amino-4-methyl coumarin (AMC) in the range of 0.05-50 µM 
were used to create a standard curve of AMC fluorescence (Figure 5.13). A 
concentration dependent, linear (R2=0.9979) increase in AMC fluorescence was 
observed in the concentration range tested. The AMC standard curve was used to 
calculate the concentration of AMC released as a function of a measurable increase 
in fluorescence (Rfu) above background. Non-specific background fluorescence was 
measured in the absence of enzyme, and was used to calculate AMC release due to 
protease activity.  
 






















Figure 5.13 An AMC Standard Curve. 
A standard curve of AMC fluorescence in the range of 0.05-50 µM was generated by 
serial dilutions of 7-amido-4-methyl coumarin (AMC). There was a concentration 
dependent, linear (R2=0.9979) increase in AMC fluorescence observed in the 
concentration range tested, with little change in fluorescence over time.  This 
standard curve was used to calculate the amount of AMC released as a function of 
increased in fluorescence (Rfu). 
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5.5.1.4  Enzyme concentration dependent increase in  fluorescence 
A range of enzyme concentrations were tested to determine the minimum amount of 
enzyme required for a detectable increase in fluorescence as a result of AMC release 
following peptide cleavage. Any increase in fluorescence generated by enzyme 
concentrations less than 10 nM was below the limits of sensitivity of the assay (data 
not shown). Within the range of 10-200 nM of active HTRA1 (assessed by 
zymography, data not shown), there was an enzyme concentration-dependent 
increase in free AMC over time (Figure 5.14). 50 nMof active enzyme was selected 
for use in subsequent assays with a range of substrate concentrations (0-240 µM, 





Figure 5.14 An enzyme concentration-dependent incre ase in 
fluorescence. 
Increasing concentrations of active recombinant ∆N HTRA1 were used to cleave 
PPRGR-MCA. Fluorescence emission corresponded to the amount of cleavage 
product, with a clear relationship between increasing enzyme concentrations and an 
increase in AMC release over time. Results are shown as relative fluorescence units 
(Rfu), corrected for non-specific background of substrate alone. Each data point 
represents a minimum of three observations ±SD. 
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Figure 5.15 Substrate concentration-dependent incre ase in 
fluorescence. 
HTRA1 is able to cleave the synthetic activation peptide across a range of substrate 
(0-240 µM) concentrations. A substrate concentration-dependent increase in free 
AMC over time was observed, with 50 nM of active ∆N HTRA1 approaching 
saturation at higher concentrations of substrate.   
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 5.5.2   HTRA1 cleaves the synthetic activation pep tide 
50 nM of active ∆N HTRA1 (generated by self-cleavage of the GST tag)or the 
S328A mutant was incubated with increasing concentrations of the CFD activation 
peptide PPRGR-MCA (0-240 µM) for 96 hours at 37 oC, following an initial 
incubation of 4 hours at 37oC to increase solubility of the enzyme in solution. 
Confirming results obtained during optimisation of the assay, HTRA1 cleaves the 
synthetic activation peptide (Figure 5.15). There was substrate concentration-
dependent increase in free AMC over time, with the enzyme approaching saturation 
at higher concentrations of substrate.    
Using a substrate concentration of 20 µM, and 50 nM of active ∆N HTRA1, 
the proteolysis of substrate by HTRA1 was observed to be of sustained duration, 
acting in a processive manner to release AMC in a lear fashion over the course of 
96 hours of study (Figure 5.16). This is in contrast to the same experiment using 50 
nM thrombin in the place of HTRA1, in which rapid generation of free AMC was 
observed for 1 hour, then no further increase in free AMC over the next 4 days 
(Figure 5.16). The inactive mutant of HTRA1, S328A, exhibited no ability to cleave 
the synthetic substrate, showing no increase in fluorescence above background 
(Figure 5.16).  
Michaelis Menton kinetics were used to calculate the maximum velocity of 
the reaction (Vmax) of 19.88 nanomoles AMC/hour/mg active enzyme. TheKm was 
calculated as 183 µM. The Lineweaver Burk plot is shown in Figure 5.17. 




Figure 5.16 Processive cleavage of the fluorescent peptide over time 
by HTRA1. 
50 nM active recombinant ∆N HTRA1 is able to cleave the synthetic substrate in a 
linear fashion for a sustained period (96 hours). This is in contrast to the activity of 
50 nM thrombin, which cleaves the substrate rapidly, before reaching a plateau after 
one hour of reaction. There is no measurable increase in fluorescence when the 
fluorescent peptide is incubated with 50 nM inactive recombinant ∆N HTRA1 








Figure 5.17 Characterisation of enzyme kinetics usi ng a Lineweaver-
Burk plot. 
The cleavage reaction was performed with 50 nM active recombinant ∆N HTRA1 in 
the presence of increasing concentrations of PPRGR-MCA (1.25-240µM). Rate (V) 
was calculated as nM AMC released/hour/nM active ∆N HTRA1. Vmax and KM were 
calculated using Michaelis Menton kinetics. 
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5.6 Functional relevance of the interaction between  HTRA1 and 
CFD 
Recombinant HTRA1 specifically cleaves the activation peptide of proCFD.  In vitro 
assays of alternative complement pathway activation were utilised to determine the 
functional impact on CFD activity of HTRA1-mediated cleavage. Such assays have 
been described previously (Biesma et al. 2001; Carroll et al. 2009; Takahashi et al. 
2010), and were adapted for use with HTRA1.  
The alternative complement pathway is amplified by the C3 convertase. C3b 
binds to Factor B, which is subsequently bound and cleaved to Ba and Bb by 
activated CFD to form C3bBb, the C3-convertase. Upon formation of the convertase, 
there is a downstream cascade of complement activation leading to the formation of 
the membrane attack complex and lysis of invading pathogens. The C3 convertase 
will only be formed when active CFD is present.  The activity of the C3 convertase 
was assessed by visualising the cleavage of factor B  Ba and Bb, both in vitro and 
in normal and CFD-depleted human sera. Alternative complement pathway activity 
was measured directly by monitoring heamolysis of sheep erythrocytes in normal and 
CFD-depleted human sera supplemented with purified and recombinant proteins. 
 
5.6.1  Reconstitution of the C3 convertase in vitro  
The first assay determined whether a functional C3 convertase could be formed using 
purified human factor B, CVF (a structural homologue of C3b) and either CFD 
purified from plasma, or with recombinant proCFD which had been pre-treated with 
HTRA1. HTRA1 does not cleave either factor B or C3 in vitro (Figure 5.18). Thus, 
the proteolytic activity of HTRA1 is specific to proCFD under the conditions used in 
the subsequent assays.  
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Figure 5.18  HTRA1 does not cleave factor B or C3 in vitro. 
The C3-convertase of the alternative complement pathway is formed when C3b binds 
Factor B, to form C3bB. Bound Factor B is subsequently cleaved to Ba and Bb by 
activated CFD to form C3bBb, the C3-convertase. The ability of HTRA1 to cleave 
Factor B and C3 was tested in in vitro protease assays, with neither protein subject to 
proteolysis by HTRA1. This is a requirement for subequent assays, in which the 
proteolytic activity of HTRA1 must be specific to proCFD. 
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5.6.1.1 C3 convertase is formed with proCFD activat ed by HTRA1 
in vitro  
0.2 µg of recombinant proCFD was incubated overnight with an equal amount of 
active GST ∆N HTRA1 to allow cleavage of proCFD (Figure 5.10). HTRA1-treated 
proCFD was added to purified plasma factor B, in the presence or absence of 1 µg of 
CVF at 37oC overnight. Concurrently, HTRA1, proCFD or CFD purified from 
plasma was incubated with factor B and 1 µg of CVF. The final reaction volume was 
20 µl, in TBS supplemented with 5 mM MgCl2 and 5 mM CaCl2.  Formation of the 
C3 convertase was determined by cleavage of Factor B (83 kDa) to Ba (26 kDa) and 
Bb (57 kDa), as seen in a non-reducing Coomassie-sta ned gel (Figure 5.19).  
HTRA1-treated proCFD or CFD purified from plasma form the C3 
convertase with factor B and CVF in vitro, resulting in cleavage of factor B to Ba 
and Bb (lanes 6 and 10, Figure 5.19). Reflecting the p ysiological situation, all three 
components of the C3 convertase are required for cleavage of factor B to occur. 
HTRA1-treated proCFD incubated with factor B without CVF does not result in 
cleavage of factor B (lane 5). No cleavage of Factor B was observed when proCFD 
or HTRA1 alone were mixed with Factor B and CVF (lanes 7 and 8), indicating that 
the specific cleavage of proCFD by HTRA1 results in formation of mature CFD, 
necessary for formation of the C3 convertase.   
 
5.6.1.2  Mg2+ ions are required for the formation of the C3 
convertase 
Divalent magnesium ions have a co-factor role in the formation of the C3 convertase 
of the alternative complement pathway, both in vitro and in vivo. Calcium ions are 
required in the classical complement pathway. The requi ement for magnesium 
and/or calcium ions in the formation of the C3 convertase by HTRA1-treated 
proCFD, factor B and CVF was assessed.  The assay was performed as above, 
including Mg2+ (2 -20 mM) or 10 mM Mg2+ and 10 mM Ca2+ in TBS. Mg2+ is 
required for the formation of the C3 convertase and cleavage of factor B to Ba and 
Bb. Ca2+are not required (Figure 5.20). 
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Figure 5.19 HTRA1 activates proCFD in an in vitro  reconstitution 
experiment. 
The C3-convertase was reconstituted in vitro, using purified complement 
components and recombinant proCFD and HTRA1. Cobra Venom Factor (CVF) is a 
homologue of C3b. Before the addition of CVF and Factor B, 0.2µg proCFD was 
preincubated with 0.2µg HTRA1 (lane 5 and 6). Samples were incubated at 37oC for 
16 hours and then subjected to electrophoresis under non-reducing conditions, 
followed by Coomassie-staining. Cleavage of Factor B to Ba and Bb - a requirement 
for formation of the C3-convertase - indicates thatactivated CFD is present. Bb and 
Ba were detected only when Factor B was incubated with CVF in the presence of 
either proCFD treated with HTRA1 (lane 6) or with CFD purified from plasma (lane 
10). Results shown are representative of three independent experiments. 
 
      1     2    3    4    5     6     7    8     9   10  11 
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Figure 5.20 Mg 2+ ions are required for the formation of the C3 
convertase 
The ability of HTRA1-activated CFD to cleave Factor B in the presence and absence 
of magnesium and calcium ions was assessed. All lanes in the Coomassie-stained gel 
contain proCFD, pre-treated with HTRA1, in addition t  CVF and Factor B. There is 
no cleavage of Factor B in the absence of both cations. Magnesium ions are required 
for the cleavage of Factor B to Ba and Bb in vivo, and also in this in vitro assay. 
Calcium ions are not an absolute requirement for the formation of the convertase, as 
Factor B is cleaved when calcium ions are not included in the reaction.  
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5.6.2  Normal alterative complement pathway activit y can be 
restored to CFD-depleted sera 
In order to test formation of the C3 convertase from endogenous plasma components 
and HTRA1-treated proCFD, normal and CFD-depleted human sera were required. 
 
5.6.2.1 CFD-depleted sera 
Human serum was obtained from five healthy volunteers and pooled to provide a 
“normal” serum sample. CFD-depleted sera were obtained from a commercial source 
(Quidel) and by production of depleted serum on affinity columns. The monoclonal 
CFD-specific antibodies GAU-008-01 or MAB#255719 were coupled to CNBr-
activated Sepharose 4B, equilibrated in veronal buffered saline (VBS). Fresh serum 
was passed over each column twice. The least dilute fractions of depleted sera, 
assessed visually by colour, were collected and pooled f r each antibody. 
BioRex70 chromotography was also used to deplete CFD from serum 
(Østerud and Eskeland 1982). The cation-exchange resin was equilibrated in VBS, 
and incubated for 1 hour with normal serum to adsorb CFD. Depleted-serum was 
obtained by centrifugation to remove the BioRex70 resin. 
Depletion of CFD in serum was confirmed by CFD-specific ELISA (Table 
5.2) and by Western blotting with anti-CFD (Figure 5.21A). All methods of depletion 
resulted in a decrease in detectable CFD in sera, by immunoblot analysis with anti-
CFD and by ELISA. 
 
5.6.2.2 Assessment of depletion in CFD-depleted ser a 
The completeness of CFD-depletion in sera was tested by assessment of residual 
haemolytic activity of sheep red blood cells (RBCs), compared to normal pooled 
human serum. Sera were diluted 1 in 5 with 1x108 neuraminidase-treated RBCs 
resuspended in 10mM ethylene glycol-bis(2-aminoethyl er)-N,N,N,N’-tetraacetic 
acid (EGTA), 7mM MgCl2, 2.1mM sodium barbital, 59mM NaCl, 2.08% (w/v) 
glucose, 0.08% (w/v) gelatin, pH 7.4  (DGVB-MgEGTA), and incubated for 1 hour 
at 37 oC.  Haemolysis was measured in the supernatant by absorbance at 412 nm. 
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CFD-depleted sera showed a large reduction in haemolytic activity compared to 
normal serum (Figure 5.21B). Generally, there was a correlation between the 
proportion of retained haemolytic activity in the CFD-depleted sera and the CFD 
ELISA measurement and signal intensity on the anti-CFD immunoblot (Table 5.2; 
Figure 5.21A). The serum depleted using the monocloal antibody GAU 008-01 
showed a 56.1% reduction in CFD (0.54 µg/ml compared to 1.23 µg/ml) measured 
by ELISA, corresponding to a 65.6% reduction in haemolytic activity (Figure 
5.21B). Likewise, the CFD-depleted sera obtained from Quidel and by depletion 
using the monoclonal antibody #255719 both had >85% reduction in CFD measured 
by ELISA, corresponding with an almost total loss of haemolytic activity compared 
to normal serum. 
One exception was the depleted serum generated by asorption of CFD to 
BioRex70; this showed a small depletion of CFD by ELISA (a reduction of 23.6%, 
from 1.23 µg/ml to 0.94 µg/ml) and an almost total loss of haemolytic activity.  
The specificity of the serum depletion was assessed by monitoring the degree 
of haemolysis when purified CFD from plasma was added to the depleted sera. The 
three depleted sera with the least residual haemolytic activity (depletion methods, 
MAB#255719, BioRex70 and Quidel, Figure 5.21B) were supplemented with 0.1 µg 
CFD, or used alone in haemolysis assays, and compared to normal serum and to 
heat-inactivated serum. Figure 5.22 shows that onlythe CFD-depleted serum 
purchased from Quidel can be restored to normal levels of haemolytic activity by 
supplementation with CFD. Heat inactivated serum, and sera depleted by 
MAB#255719 and BioRex70, show no restoration of lytic activity in response to 
supplementation with CFD. The depletion of CFD in the CFD-depleted sera 
generated by MAB#255719 and BioRex70, and the observed loss of haemolytic 
activity in these samples, is most likely due to dilution, non-specific depletion of 
other complement components, or exhaustive activation of complement on the 
column during depletion. 
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Figure 5.21  Assaying depletion in CFD-depleted ser a. 
Normal human serum was depleted of CFD using affinity columns, using BioRex70 
chromotography or by coupling the monoclonal CFD-specific antibodies GAU-008-
01 or MAB#255719 to CNBr-activated Sepharose 4B. CFD-depleted serum was also 
obtained from Quidel. 
A. The depletion of CFD in sera was confirmed by western blotting with anti-CFD 
(C-16). The intensity of the CFD-specific band (24 kDa) in all depleted sera was 
decreased relative to the normal pooled serum sample.  
B. The degree of haemolysis of sheep red blood cells was used to assess the 
specificity of the serum depletion. A reduction in CFD leads to a corresponding 
decrease in the haemolytic activity. All methods of depleting CFD reduced the 
residual haemolytic activity relative to normal serum. 
 




Sera Depletion method          CFD µg/ml 
CFD-depleted serum A GAU 008-01   0.54 
CFD-depleted serum B MAB#255719 0.14 
CFD-depleted serum C BioRex70 0.94 
Normal pooled serum   1.23 
CFD-depleted serum D QUIDEL 0.13 
 
Table 5.2 CFD measured in human serum by ELISA. 
The effectiveness of CFD-depletion in human sera using a variety of methods was 
assessed using a CFD-specific ELISA. Depletion was determined by comparison to 






Figure 5.22  Restoration of normal alternative comp lement activity to 
CFD-depleted sera 
Depleted sera with the least residual haemolytic activity (depletion methods, 
MAB#255719, BioRex70 and Quidel) were used alone or supplemented with 0.1 µg 
CFD, and compared to normal serum and to heat-inactivated serum. Heat inactivated 
serum, and sera depleted by MAB#255719 and BioRex70, show no restoration of 
haemolytic activity when supplemented with CFD. Supplementation with CFD was 
able to restore normal levels of haemolytic activity to the CFD-depleted serum 
purchased from Quidel.  
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5.6.2.3  Restoration of alternative complement path way activity in 
CFD-depleted serum by HTRA1-treated proCFD 
Having verified that the completeness and specificity of the depletion of CFD in the 
depletion serum purchased from Quidel, this serum was used in subsequent assays. 
The haemolysis of RBCs by the alternative complement pathway in normal human 
serum, in heat-inactivated normal serum and in CFD-depleted serum was assessed, 
with and without the addition of purified proteins. The assay is specific for the 
alternative complement pathway. EGTA in the reaction buffer chelates any calcium 
ions present, preventing activation of the classical pathway. 1 µg of CVF was added 
to all samples, including 0% and 100% lysis in water to allow reactive lysis of RBCs. 
Haemolysis in normal serum after 1 hour incubation at 37 oC was considered 
as 100%; this activity was removed by heat-inactivation and in CFD-depleted serum 
(Figure 5.23). The addition of recombinant proCFD or HTRA1 alone did not restore 
haemolysis, although proCFD alone was able to induce slight haemolysis in the 
CFD-depleted serum. Addition of 0.05 µg of CFD, or of 0.2 µg proCFD pre-treated 
with HTRA1, restored heamolysis in CFD-depleted serum to levels observed in 
normal serum (data is the mean of two independent experiments ± SD). 0.2 µg of 
proCFD was used, compared to the 0.05 µg of CFD, to acc unt for the incomplete 
cleavage of proCFD by HTRA1 to the lower molecular weight form of the 
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Figure 5.23 HTRA1 activates proCFD in vitro, and re stores complement 
activity in CFD-depleted serum.  
The degree of haemolysis of sheep red blood cells was assessed in normal, heat-
inactivated or CFD-depleted sera with and without the addition of purified proteins. 
The addition of 0.05 µg of CFD, or of 0.2 µg proCFD pre-treated with HTRA1, 
results in the restoration of haemolytic activity in CFD-depleted serum. Neither 
proCFD, nor HTRA1 alone restored haemolysis to levels s en in normal serum. 
Results shown are the mean level of haemolysis achieved relative to normal serum in 
two independent experiments ± SD. 
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5.6.2.4 Restoration of C3 convertase activity in CF D-depleted 
serum in vitro by HTRA1-treated proCFD 
Normal levels of haemolysis are restored to CFD-deplet d serum upon the addition 
of proCFD that had been pre-treated with HTRA1. To confirm that this was a result 
of formation of the C3 convertase and resultant activ tion of the alternative 
complement pathway, the specific cleavage of factor B to Bb in sera was investigated 
by Western blotting. 
The optimal conditions for Western blotting using the anti-Bb antibody were 
determined. 250 ng of purified factor B, from human plasma, could be detected using 
a 1:500 dilution of the primary antibody (data not shown). Under reducing 
conditions, no Bb-specific signal was obtained from serum on an immunoblot 
performed using a 1:500 dilution of the primary antibody (Figure 5.24A). Under non-
reducing conditions, a clear signal for both factor B, and for Bb upon addition of 
CFD and CVF, was obtained from 1µl serum using a 1:500 dilution of the primary 
antibody (Figure 5.24B). 
The ability of recombinant proCFD to restore C3 convertase activity to serum 
which was depleted of CFD was subsequently assessed. To ensure that availability of 
C3b was not a limiting factor in the reaction, normal and CFD-depleted sera were 
supplemented with 1 µg of CVF, together with either 0.2 µg of CFD purified from 
plasma, 0.2 µg of recombinant proCFD, 0.2 µg of HTRA1 or 0.2 µg proCFD which 
had been pre-treated with 0.2 µg of HTRA1. In normal serum, after incubation for 3 
hours at 37oC, cleavage of endogenous Factor B to Bb was detected in both the 
presence and absence of CVF (Figure 5.25). As seen in la e 3, Bb was dramatically 
increased following addition of purified CFD and CVF. In CFD-depleted serum, 
there was no cleavage of endogenous Factor B to Bb without supplementation with 
activated CFD. Both proCFD pre-treated with HTRA1 (lane 6) and CFD from 
plasma (lane 7) were able to restore C3 convertase activity to the CFD-depleted 
serum. HTRA1 (lane 8) or proCFD alone (lane 9) did not restore the alternative 
pathway convertase (Figure 5.25).  
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Figure 5.24 Optimisation of conditions for immunobl otting with anti-Bb 
A. Reducing gel electrophoresis of normal human serum s pplemented with 1 
µg CVF, 1 µg Factor B and 0.1 µg of CFD, followed by immunoblotting 
using a 1:500 dilution of anti-Bb. No Bb-specific sgnal was detected under 
reducing conditions.  
B. Non-reducing gel electrophoresis of normal human serum supplemented with 
1 µg CVF, 1 µg Factor B and 0.1 µg of CFD, followed by immunoblotting 
using a 1:500 dilution of anti-Bb. Both Factor B and Bb were detected using a 
1:500 dilution of anti-Bb.  
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Figure 5.25 HTRA1 activates proCFD in vitro , and restores cleavage of 
Factor B to Bb in CFD-depleted serum.  
Endogenous Factor B in serum is cleaved when activated CFD is present. Normal 
serum or CFD-depleted serum was supplemented with CVF and purified CFD, 
proCFD and HTRA1 as indicated. After incubation at 37oC for 3 hours, samples 
were subjected to non-reducing gel electrophoresis and western blot. Immunoblotting 
with anti-Bb antibody detected both Factor B and the cleavage product Bb. Addition 
of CFD purified from plasma (lane 7) or proCFD pre-tr ated with HTRA1 (lane 6) 
but not with proCFD (lane 9) or HTRA1 (lane 8) alone resulted in cleavage of Factor 
B in CFD-depleted sera. This reflects the cleavage of Factor B observed in normal 
human serum (lanes 1-3) Results shown are representativ  of two independent 
experiments. 
 
 1    2    3    4    5    6    7   8    9 
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5.6.3  Reduced alternative complement pathway activ ity in 
CARASIL patients with mutations in HTRA1 which affect 
protease activity 
Cerebral autosomal recessive arteriopathy with subcortical infarcts and 
leukencephalopathy (CARASIL) is an ischemic, non-hypertensive small vessel 
disease associated with spondylosis and alopecia. Recently, missense and nonsense 
mutations in HTRA1 have been associated with CARASIL (Hara et al. 2009). 
Professor Osamu Onodera kindly provided serum samples from three Japanese 
CARASIL patients and two Japanese disease-free controls.  
Sera were tested for their relative ability to lyse sh ep RBCs in the presence 
of CVF, as an indication of alternative complement pathway activity. The CARASIL 
sera showed significantly reduced haemolytic activity compared to normal 
ethnically-matched sera (or to normal pooled sera from Caucasian individuals) in 
three independent experiments (Figure 5.26A). The haemolysis assays were 
performed without knowledge of the HTRA1 mutation carried by the CARASIL 
patients. Subsequent identification of the mutations confirm that the patient whose 
serum showed the lowest haemolytic activity (CARASIL2, 15.7±4.1 (SD) % relative 
to normal sera) carries the R370X mutation in HTRA1. This mutation leads to 
nonsense-mediated decay of the HTRA1 transcript and a lack of protein in patient 
fibroblasts (Hara et al 2009). The two remaining CARASIL patients carry mutations 
which appear to reduce activity of the protease to <30% of wild-type activity in vitro 
without altering protein expression (CARASIL1; V297M, and CARASIL 3; R302X; 
Hara et al. 2009). CFD concentrations in the CARASIL and control sera were 
measured by ELISA, and determined to be within the normal range for both proteins 
(data not shown). 
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Figure 5.26  Alternative complement pathway activit y in CARASIL sera. 
A. Alternative complement pathway-specific reactive lysis of sheep RBCs induced 
by a 1 in 5 dilution of CARASIL sera were significantly reduced, compared to lysis 
in control sera. Data represent mean % heamolysis±SD obtained in 3 independent 
experiments, in which each sample was assayed 4 times. Significant differences were 
determined using t-tests to compare mean heamolysis. 
B. Cleavage of factor B to Bb in CARASIL serum compared to normal serum was 
investigated in the presence of CVF and increasing Mg2+ concentration. The amount 
of factor B in the assay was equalised by using 1 µl of control serum or 3 µl of 
CARASIL3 serum. Bb appears less abundant in CARASIL3 serum. A high 
molecular weight complex, corresponding to the predict  molecular weight of the 
CVF-factor B complex (~240 kDa) was observed in CARASIL3 serum, but not in 
control serum. Data is representative of 2 independent experiments, probed with anti-
Bb. 2 independent experiments using equal volumes (1 µl) of CARASIL3 and 
normal serum gave similar results. The complex was also observed in CARASIL1 
and CARASIL2 sera (data not shown). 
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5.7  Co-expression of HTRA1 and CFD 
HTRA1 is a stress-responsive gene, widely expressed in a ra ge of tissues (De Luca 
et al. 2003). The functional data presented in Section 5.6 indicates that HTRA1 is 
capable of activating proCFD in vitro. However, a number of serine proteases, 
including thrombin, can activate CFD (Fearon et al. 1974; Yamauchi et al. 1994; 
Takahashi et al. 2010). To determine whether HTRA1 and CFD are present in the 
same cellular environment, thereby increasing the chan es of similar activity in vivo, 
the expression of HTRA1, CFD, and of other genes implicated in local activation of 
the alternative complement pathway, was investigated. Expression of these genes 
was studied in a human tissue cDNA panel, and in the cell lines THP-1 and hTERT 
RPE1. THP-1 cells are a human macrophage-like cell-lin , which can be 
differentiated from a monocyte-like cell by treatment with PMA. hTERT RPE1 is a 
telomerase-immortalised human retinal pigment epithlial cell line. These cell lines 
were investigated due to a proposed role for these c lls in the development and 
progression of AMD pathogenesis. 
 
5.7.1   Screening a cDNA panel by RT-PCR 
Commercially available cDNA from a range of human tissues, including retina, 
brain, adipose, liver, kidney, skeletal muscle, thymus and peripheral blood 
monocytes, was screened for the expression of gene-specific transcripts. HTRA1-
specific transcripts were detected by RT-PCR in cDNA derived from retina, brain, 
adipose, liver and skeletal muscle. No HTRA1 transcripts were detected in cDNA 
from the kidney or peripheral blood monocytes (Figure 5.27). HTRA1 has previously 
been reported to be expressed in these tissues (De Luca et al 2003). GAPDH was 
used as a control, and was found to be expressed across all tissues screened. CFD-
specific transcripts were detected in all the tissue  screened (Figure 5.27). Variations 
in band intensity were observed, which is likely to reflect variations in the amount of 
CFD-specific transcripts within the 10 ng of cDNA used as template in the 
amplification reactions. Adipose cells, for example, are known to express high levels 
of CFD, correlating with high band intensity in Figure 5.27 (Cook et al. 1985; White 
et al. 1992).  
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Expression of MASP1, encoding an enzyme able to activate murine proCFD 
(Takahashi et al. 2010), was also tested. In contrast with the overlapping expression 
patterns of CFD and HTRA1 across a range of tissues, MASP1 transcripts were only 
detected in cDNA purified from the liver (Figure 5.27). 
 
 
Figure 5.27  Human cDNA panel screened for HTRA1 an d other genes. 
Co-expression of HTRA1, CFD and MASP1 was investigated by RT-PCR in cDNA 
from a range of human tissues. HTRA1-specific transcripts were detected in cDNA 
derived from retina, brain, adipose, liver, thymus and skeletal muscle. CFD-specific 
transcripts were detected in all the tissues screened, with variations in expression 
level observed. MASP1 transcripts, encoding an enzyme able to activate murine 
proCFD, were detected only in the liver. GAPDH was used as a control, and was 
found to be expressed across all tissues screened. 
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5.7.2  RPE1 cells 
The human RPE cell line hTERT-RPE1 (RPE1) was used to investigate the 
expression of HTRA1, and other genes, in a cell line of physiological relevance to 
AMD. HTRA1 transcripts were found to be constitutively expressed by RPE1 cells 
(Figure 5.29), in agreement with previous reports of HTRA1 expression in primary 
RPE cells derived from human eyes (Yang et al. 2006; An et al. 2010). Expression of 
CFD was not detected in RPE1 cells in the absence of cllular stress. 
 
5.7.2.1 Stress conditions for RPE1 cells 
In TAP experiments performed in RPE1 cells (Chapter 3, Section 3.3), CFD was not 
identified as an interactor of a tagged form of HTRA1. Following the observation 
that HTRA1 is expressed by RPE1 cells, the concomitant expression of the interactor 
CFD was investigated. As shown in Figure 5.29, there was no CFD-specific 
transcript detected in RPE1 cDNA under normal culture conditions. Similarly, no 
CFD was detected by ELISA in the conditioned media from RPE1 cells (Figure 
5.30).  
The pathological processes underlying AMD are thougt to involve 
dysregulation of the retinal pigment epithelium in response to a variety of triggers. In 
order to investigate whether stressed RPE1 exhibit an altered expression profile for 
CFD, RPE1 cells were treated with H2O2 to induce oxidative stress, or with 
lipopolysaccharide to mimic bacterial infection. 
 
5.7.2.1.1  Hydrogen peroxide treatment 
Hydrogen peroxide-treatment of cells is used to assess usceptibility to, and the 
response to oxidative stress (Cho et al. 2011). Oxidative stress is proposed to play a 
role in the degeneration of the retinal pigment epihel al cells in AMD, leading to 
cellular dysfunction and death, resulting in death of photoreceptor cells. The 
cytotoxic effects of a range of H2O2 concentrations (250-2,000 µM) upon RPE1 cells 
in culture was assessed in a 96-well plate format by monitoring the reduction of the 
yellow tetrazole MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
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bromide) to the purple formozan product. This provides an indication of cell viability 
as a reflection of reductase activity. 
  After 24 hours of treatment with 250 µM H2O2, cell viability was equivalent 
to that of untreated cells (Figure 5.28A). At higher concentrations of H2O2, decreased 
cellular metabolic activity as a consequence of increased cell death was observed. 
250 µM H2O2 was used in subsequent experiments to investigate the non-cytotoxic 
effects of oxidative stress on RPE1 cells. 
 
5.7.2.1.2  Lipopolysaccharide (LPS) treatment 
LPS is a constituent of the cell wall of Gram-negative bacteria, and is an endotoxin 
commonly used to induce an immune response in experimental models (Cho et al. 
2011). Bacterial infection may contribute to the chronic inflammatory state observed 
in the AMD eye (Ishida et al. 2003; Kalayoglu et al. 2003; Robman et al. 2005). A 
dose-response curve of LPS (1.25-80 µg/ml) was performed to determine an 
appropriate concentration for induction of an immune response without causing 
death of RPE1 cells. In the range of LPS concentrations tested, cytotoxicity was 
minimal (Figure 5.28B). A concentration of 10 µg/ml was selected for use in 
subsequent experiments to induce complement activation.  
 
5.7.2.1.3 Constitutive expression of HTRA1 and induction of CFD 
RPE1 cells were cultured under standard conditions in a 6-well dish until confluency 
was achieved. Serum-free media was added to the cells, ontaining either 10 µg/ml 
LPS, 250 µM H2O2 or with no supplementation in the case of the untreated cells. 
Following treatment for 24 hours, the cells were harvested and RNA purified. RPE1 
cDNA was synthesised by reverse transcription using ra dom hexamer primers.  
50 ng of cDNA was used as the template for amplification of transcripts 
specific to HTRA1, GAPDH and C3. 250 ng of cDNA was used for the template for 
amplification of the CFD transcript. GAPDH is constitutively expressed by RPE1 
cells (Figure 5.29). Similarly, HTRA1 and C3 transcripts were detected in RPE1 
cDNA regardless of treatment with LPS or H2O2. A transcript specific to CFD was 
detected only weakly using 50 ng of cDNA as template (data not shown). However, 
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when 250 ng of cDNA was used as the template for amplification, it became 
apparent that expression of the CFD transcript is not constitutive in RPE1 cells, but 
is induced by both oxidative stress and by treatmen with LPS (Figure 5.29). 
Constitutive expression of C3 - the central component of the alternative complement 
pathway, by RPE1 cells - suggests that expression of CFD may be rate-limiting in 
alternative complement pathway activity in this cellular environment.  
Conditioned media from the untreated and treated RPE1 cells was analysed 
using an ELISA specific for CFD. Figure 5.30 shows that CFD is detected at low 
levels in the media following treatment with LPS (2.08±0.79 (SD) pg/ml) or with 
H2O2 (3.09±1.59 (SD) pg/ml, but is not detected when the cells have not been treated 
to induce a stress-response. 
 




Figure 5.28  Optimisation of stress conditions for RPE1 cells. 
A. Cell viability assay for RPE1 cells treated with H2O2 (250-2,000 µM). 250 
µM H2O2 in the cell culture media did not cause a significant decrease of cell 
viability. Data are expressed as mean cell viability assessed by the MTT 
assay in three independent experiments (± SD), relativ  to the untreated 
control cells.   
 
B. Cell viability assay for RPE1 cells treated with LPS (1.25-80 µg/ml). 
Concentrations in the media of 1.25 to 80 µg/ml of LPS did not cause a 
significant decrease of cell viability, assessed by the MTT assay in three 
independent experiments (± SD), relative to the untreated control cells.  
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Figure 5.29 Expression of HTRA1, CFD and C3 in RPE1  cells. 
HTRA1 transcripts were endogenously expressed in RPE1 cells.  CFD was induced 
following treatment with LPS (to mimic bacterial infection) or H2O2 (to mimic 
oxidative stress). C3 was detected in untreated RPE1 cells, suggesting that CFD is 
rate-limiting in activation of the alternative complement pathway in the local 
environment of the RPE. Retinal cDNA was included as a positive control. GAPDH 




Figure  5.30  CFD is detected by ELISA in condition ed media from RPE1 
cells treated with LPS or H 2O2. 
CFD is not detected in conditioned media from untreated RPE1 cells using a CFD-
specific ELISA. Following treatment with LPS or with H2O2, CFD is detected at low 
levels in the conditioned media, suggesting that CFD is induced in response to stress.  
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 5.7.3  THP-1 cells 
The physiological relevance of the HTRA1-CFD interaction was also investigated by 
analysis of co-expression of the genes encoding HTRA1 (HTRA1) and CFD (CFD) 
in THP-1 cells. These are monocyte-like cells that can be induced by phorbol 
myristate acetate (PMA) to differentiate into macrophage-like cells. Figure 5.31 
shows the morphological changes observed in THP-1 cells following treatment with 




Figure 5.31  Morphological changes of THP-1 cells t reated with PMA.  
THP-1 cells are a Human acute monocytic leukaemia cell line, which can be 
differentiated to a macrophage-like cell by treatment with 200 nM phorbol myristate 
acetate (PMA). The monocyte-like cells grow in suspension and are characterised by 
large, round, single cells. DMSO alone did not induce differentiation of these cells. 
200 nM PMA, resuspended in DMSO, induces differentiation to a macrophage-like 
cell. Morphological changes can be observed, including increased adherence of cells 
to the cell culture plate, and an increase in cytoplasmic volume.    
 
In THP-1 cells, CFD transcripts were highly expressed in both monocyte and 
macrophage-like cells (Figure 5.32A), whilst HTRA1 mRNA was only detected 
following differentiation into macrophage-like cells (Figure 5.32A). Conditioned 
media from monocyte and macrophage-like cells containi g 20 µg of protein was 
subjected to immunoblotting to detect CFD and HTRA1. CFD was highly expressed 
at the protein level in both undifferentiated and differentiated THP-1 cells (Figure 
5.32B). HTRA1 was detected in the conditioned media from the differentiated 
macrophage-like THP-1 cells (Figure 5.32B). This is in agreement with the 
observation that HTRA1 transcripts were detected only in differentiated macrophage-
like cells (Figure 5.32A).  




Figure 5.32  Co-expression of HTRA1 and CFD in THP-1 cells. 
A. CFD transcripts were detected by RT-PCR in cDNA from both the monocyte 
and macrophage-like cells which are induced to differentiate by treatment 
with PMA in the macrophage-like cell-line THP-1. HTRA1 mRNA was 
detected only in the macrophage-like cells following treatment with PMA. 
Human retinal and brain cDNA were used as controls. GAPDH transcripts 
were amplified as a control.  
B. The macrophage-like cell-line THP-1 was found to expr ss high levels of 
CFD protein in both monocyte and macrophage-like cells. In agreement with 
the RT-PCR data in (A), HTRA1 protein was detected only in the 
macrophage-like cells following treatment with PMA. 
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5.8  Discussion 
This chapter describes the validation and characterisation of a putative interaction 
between HTRA1 and CFD that was identified in a yeast two-hybrid screen. A novel 
function for HTRA1 was discovered – the ability to cleave the activation peptide of 
CFD to generate the active zymogen of the central component of the alternative 
complement pathway.  CFD is expressed as a prepropetide, from which a signal 
peptide and five amino acid activation peptide are sequentially cleaved  (Volanakis 
and Narayana 1996). The minimal binding sequence identified by sequence 
alignment of the CFD prey sequences with the CFD reference sequence indicates that 
the interaction occurs at the N-terminus of the CFD zymogen, overlapping the 
activation peptide (Figure 5.2). HTRA1 is a trypsin-like serine protease, and proCFD 
can be activated by several such serine proteases (Fearon et al. 1974; Yamauchi et al. 
1994) although the enzyme(s) responsible for physiolog cal activation in humans 
remain unknown. This led to speculation that HTRA1 may be able to activate 
proCFD to generate mature CFD, which is known to be the rate-limiting component 
of the alternative complement pathway (Lesavre and Müller-Eberhard 1978; 
Volanakis and Narayana 1996).  
Using in vitro assays, the interaction between HTRA1 and CFD was 
confirmed and localised to the C-terminal portion of HTRA1, spanning the protease 
domain and the PDZ domain (Figure 5.5). Although a synthetic peptide 
encompassing the minimal region of CFD was a substrate for HTRA1, there was no 
cleavage of mature CFD purified from human plasma by HTRA1 (Figure 5.6). 
However, recombinant proCFD (27 kDa) was susceptible o cleavage, giving rise to 
a cleavage product of the expected molecular weight of CFD (24kDa; Figure 5.10A 
and C). This suggests a requirement for the propeptide sequence of CFD for HTRA1 
to cleave CFD.  
This was investigated further using a synthetic fluorescently labelled 
activation peptide (PPRGR-MCA), which was specifically cleaved by HTRA1 to 
release free AMC. This site of cleavage corresponds to the position at which the 
activation peptide is removed from the mature CFD zymogen in vivo. This shows 
that the propeptide of CFD is both necessary and sufficient for HTRA1-mediated 
cleavage. PPRGR-MCA was also cleaved by thrombin, as has previously been 
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shown by Takahashi et al. (2010) in their analysis of CFD activation in the Masp1-/- 
mouse. However, there was a striking difference in the kinetics of the cleavage of 
PPRGR-MCA by thrombin and HTRA1 (Figure 5.16). HTRA1 had a slower rate of 
reaction, as indicated by the Vmax of 19.88 nanomoles AMC/hour/mg of active 
protease. HTRA1 acts as a trimeric, cage-forming protease, and the minimal peptide 
length to effectively bridge the active site is 10 amino acid residues (Truebestein et 
al. 2011). This, together with the observations that some members of this family of 
proteases require substrate binding to the PDZ domain to induce remodelling of the 
active site and that the bacterial homologue DegP creates very few cleavage products 
of 5 residues (Murwantoko et al. 2004; Krojer et al. 2008) indicate that PPRGR-
MCA is a far from optimal substrate for HTRA1.  This may account for the slow rate 
of reaction. However, whilst thrombin activity with e synthetic peptide ceased after 
one hour, HTRA1 continued to cleave the synthetic substrate for 96 hours (the 
duration of the experiment). It is not clear why thrombin activity reaches a plateau 
while HTRA1 processively cleaves the substrate over 96 hours, as the substrate is not 
a limiting factor. Whilst the synthetic activation peptide utilised in this study is not 
an optimal substrate, there is clear evidence that HTRA1 is able to cleave the 
synthetic activation peptide of CFD specifically.  
The alternative complement pathway is one of three b anches of the innate 
immune response, and kills invading microorganisms by disrupting cell membranes. 
The alternative complement pathway is triggered by the spontaneous hydrolysis of 
C3 to C3a and C3b. When C3b binds to a “foreign” tissue surface, a conformational 
change allows formation of C3bB by binding Factor B. In the presence of Mg+2 ions, 
C3-bound factor B is cleaved to Ba and Bb by activated CFD to form C3bBb, the 
C3-convertase. Upon formation of the convertase, there is a downstream cascade of 
complement activation leading to the formation of the membrane attack complex and 
lysis of invading pathogens. CFD-catalysed cleavage of Factor B is the key 
activating step in this pathway, and is regarded as being rate limiting due to serum 
concentrations of CFD that are about nine-fold lower than C3 or factor B (Barnum et 
al. 1984). 
Takahashi et al. (2010) report that MASP1 is responible for the activation of 
proCFD in mice, but the enzyme responsible for the activation of CFD in humans has 
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not been described. The functional consequence of HTRA1-mediated cleavage upon 
proCFD was assessed in a variety of in vitro assays of alternative complement 
activity. In agreement with the proposed removal of the activation peptide, the 
HTRA1-treated proCFD was active in all assays of complement activity. A C3 
convertase formed with Cobra Venom Factor, purified human Factor B and proCFD 
which had been pre-treated with HTRA1, had equivalent activity to that observed 
with an equal quantity of active CFD purified from plasma (Fig. 5.20). This confirms 
that recombinant proCFD can be activated by HTRA1 to generate a mature CFD 
protease. Further evidence was obtained by restoration of normal levels of alternative 
complement pathway activity to CFD-depleted serum, both by the specific cleavage 
of endogenous Factor B to Bb in human serum and in a haemolysis assay (Fig. 5.24 
and 5.26). 
Haemolysis assays were also used to test the alterntive complement activity 
in sera from CARASIL patients. CARASIL is caused by homozygous mutations in 
HTRA1, which appear to either result in almost total absence of the protein due to 
nonsense-mediated decay, or to a severe reduction in the protease-activity of the 
enzyme (Hara et al. 2009). This causes uncontrolled activation of TGF-β signalling 
and results in cerebral small vessel disease in early adulthood. A deficiency in 
alternative complement pathway activity has not been d scribed for these patients. 
However, sera from three CARASIL patients showed a dramatic reduction (ranging 
from 15-53%, Figure 5.26) in the reactive lysis of sheep RBCs, relative to ethnically-
matched disease-free control sera.  Due to the mutations in HTRA1, sera from 
CARASIL patients are naturally deficient (although not entirely lacking) in the active 
HTRA1 enzyme. The reduction in alternative complement pathway activity in these 
patients is strong evidence for HTRA1 having a rolein the activation of this 
pathway.  
As a result of the identification of a major susceptibility factor in CFH, which 
is known to modulate complement activation by inhibiting the formation of the C3-
convertase and dampening the inflammatory response, i flammation is considered to 
play an important role in the degeneration of the macula and in AMD pathogenesis 
(Edwards et al. 2005; Haines et al. 2005; Klein et al. 2005). Several other 
components of the complement pathway, including C3, CFB and CFI have been 
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implicated in AMD, providing further evidence for the damage caused by aberrant 
regulation of inflammatory processes in the eye (Gold et al. 2006; Yates et al. 2007; 
Fagerness et al. 2009). As the rate-limiting component in the activation of the 
alternative complement pathway, any alterations in activation of CFD may result in 
an increase in alternative complement activity and consequent inflammation 
(depending on the amount of C3 and factor B deposited on tissue surfaces, and the 
complement regulators present). In agreement with the elevated plasma CFD 
concentrations in AMD cases compared to controls described in Chapter 4, several 
groups have reported elevated levels of plasma CFD and downstream activation 
products in AMD cases compared to controls (Scholl et al. 2008; Reynolds et al. 
2009; Hecker et al. 2010). It is not clear whether t is represents a systemic increase 
in complement activity, spill-over from the AMD eye or both. 
Others have suggested a link between HTRA1 over-expession and regulation 
of the complement pathway based on its effects on other complement regulators 
(clusterin, vitronectin, fibromodulin), or upon inflammation (An et al. 2010; Yasuma 
et al. 2010).  This is the first evidence however that HTRA1 can directly activate the 
central component of the alternative complement pathw y by cleaving the activation 
peptide from proCFD. 
Takahashi et al.  (2010) proposed a role for mannose-binding lectin-
associated serine protease-1 (Masp1), a component of the lectin pathway, in 
activation of proCFD to mature CFD in serum in mice. However, Masp1 is not 
expressed in adipose tissue in mice (Takahashi et al. 2010), the major source of CFD 
in the circulation (White et al. 1992). Most of the CFD circulating in human plasma 
consists of mature CFD, although a small amount of pr CFD can be detected (Fearon 
et al. 1974). Cleavage of proCFD in humans is therefore thought to occur during 
maturation and secretion of the protein (Kim et al. 1994; Yamauchi et al. 1994), 
rather than after secretion as proposed for Masp1 in the mouse (Takahashi et al. 
2010).  The co-expression of HTRA1 with CFD was investigated to assess whether 
the enzymes were likely to be present in the same tissues. Expression data from a 
panel of human tissues, including blood, adipose tissue and the eye, suggest that 
HTRA1 is a strong candidate for the activation of proCFD, as there is substantial 
overlap in the expression of the two genes (Figure 5.27). Expression of CFD in 
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adipose tissue was high, which may contribute to the correlation between obesity and 
systemic inflammation as a result of adipose-expressed pro-inflammatory adipokines 
(Hotamisligil et al. 1995; Yudkin et al. 1999; Weyer et al. 2002). Obesity is also 
associated with an increased risk of developing AMD (Seddon et al. 2003a). HTRA1 
expression was detected in adipose tissue cDNA. However, in agreement with the 
expression data from Takahashi et al. (2010) of Masp1 in mouse adipose tissue, 
MASP1 transcripts were not detected in adipose tissue (or indeed, any tissue except 
the liver which is a minor producer of CFD in humans (Morgan and Gasque, 1997, 
Figure 5.27). MASP1 synthesised by the liver is likely to be the major source of 
MASP1 measured in human serum (1-12 µg/ml), where active MASP1 is rapidly 
neutralised by C1 esterase inhibitor (Terai et al. 1997; Matsushita et al. 2000).   
There is co-expression of HTRA1 and CFD in the human cell-lines hTERT-
RPE1 and THP-1 macrophages (Figure 5.29, 5.32). These are cell-lines with 
physiological relevance to AMD, given the role of RPE cells and macrophages in the 
disease. Interestingly, expression of CFD was only detected in RPE1 cells following 
the application of cellular stress, either with LPS to mimic bacterial infection, or with 
H2O2, to mimic oxidative stress (Figure 5.29, 5.30). RPE cell dysfunction is 
considered a key factor in the development of AMD, leading to the loss of 
photoreceptor function. Both oxidative stress (for example, caused by cigarette 
smoking (Fujihara et al. 2008)) and infection with C. pneumoneiae have been 
suggested as triggers for RPE cell degeneration (Ishida et al. 2003; Kalayoglu et al. 
2003; Robman et al. 2005). Constitutive expression of C3 in RPE1 cells suggests 
that, as in plasma where the concentration of CFD is nine-fold lower than of other 
complement components (Lesavre and Müller-Eberhard 1978), CFD may be limiting 
in order to prevent activation of the alternative complement pathway under normal 
cellular conditions. This is in agreement with low expression levels of CFD in RPE 
cells and the choroid, relative to other complement components (Anderson et al. 
2010). 
Tight regulation of inflammatory processes is important in delicate tissues 
such as the eye to avoid tissue damage. The contribution of the alternative 
complement pathway to tissue damage as a consequence of cellular stress was 
recently explored by microarray analysis of the Cfd-/- mouse retina when subjected to 
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light-induced damage (Rohrer et al. 2007). Cfd-/- mice are protected from 
degeneration of the photoreceptors compared to wild-type mice, implicating the 
complement pathway activity that results from activation of CFD in AMD 
pathogenesis. Interestingly, Htra1 (also known as protease, serine, 11 (Igf binding)), 
a stress-responsive protein (Clausen et al. 2002), is significantly upregulated in the 
microarray analysis of the Cfd-/- mouse retina when subjected to light-induced 
damage (Rohrer et al. 2007). Oxidative stress, induce  in cell cultures of ARPE-19 
cells by H2O2, has also been shown to contribute to RPE cell injury mediated by the 
complement pathway (Thurman et al. 2009). 
Inflammation as a consequence of activation of the alternative complement 
pathway is clearly involved in the pathobiology of AMD. However, the cellular 
events which lead to activation of complement are not fully understood.  In addition 
to the contribution of RPE cells, a role for circulating monocytes and infiltrating 
macrophages has been proposed. This is based on theidentification of macrophages 
associated with drusen and with CNV membranes in AMD eyes (Killingsworth et al. 
1990; Lopez 1991; Penfold et al. 2001; Grossniklaus et al. 2002). Although the 
accumulation of macrophages in AMD lesions may be acontributory factor to the 
development of AMD, the dynamic nature of macrophage recruitment makes 
studying their contribution to pathology in humans difficult. Studies in animal 
models have shown that depletion of macrophages can dimi ish severity of CNV in 
laser-induced models (Espinosa-Heidmann et al. 2003; Sakurai et al. 2003). This 
may be due to a reduction in VEGF, which is secreted by macrophages. Conflicting 
data from (Apte et al. 2006) found that increased recruitment of macrophages inhibits 
laser induced CNV in IL-10 deficient mice. It seems likely that macrophages have 
multiple roles in the eye; some are anti-inflammatory and are recruited to clear 
drusen, whilst others are pro-inflammatory and contribu e to chronic and damaging 
inflammation. 
Macrophages are a source of CFD in humans (but not in mice; White et al. 
(1992)). In agreement with this, the human monocytic cell-line THP-1 expresses high 
levels of CFD at both the mRNA and protein level (Figure 5.31A and B) in both 
monocyte and differentiated macrophage-like cells. Interestingly, expression of 
HTRA1 was not detected in the monocytes, but there was a significant up-regulation 
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of both HTRA1 mRNA and protein following treatment with PMA. If HTRA1 is 
indeed able to activate proCFD in vivo, this is consistent with activated macrophages 
having a pro-inflammatory role, and contributing to activation of the alternative 
complement pathway, in AMD pathology. 
HTRA1 and CFD are likely to be expressed in the same cells, and more 
specifically, in cells with a known role in AMD pathogenesis, either endogenously or 
in response to stress. Co-expression of HTRA1 and CFD in adipose tissue, as well as 
in cell lines with physiological relevance to AMD, makes the in vivo activation of 
CFD by HTRA1 an exciting possibility to explore in the future.  Certainly, the 
reduced level of alternative complement pathway activity in the sera from CARASIL 
patients supports a role for HTRA1 in activating proCFD in vivo. Activation of 
proCFD by HTRA1 may contribute to both systemic andlocal activation of the 
alternative complement pathway. Although work remains to determine the 
physiological relevance of this interaction, there is a link between activation of the 
alternative complement pathway and one of the major genetic-risk factors for AMD.  







6: Chapter 6 
 
Systemic and local levels of 
HTRA1 
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6.1   Introduction 
An AMD-risk haplotype on chromosomal region 10q26, comprising the strongly 
associated indel in the 3’ UTR of ARMS2 and the minor alleles of the SNPs 
rs10490924 (T) in ARMS2, and rs11200638 (A), a putative HTRA1 promoter 
polymorphism has been reported (Fritsche et al. 2008). Given the intractable nature 
of identifying the variants responsible for increasd risk at this locus because of 
strong LD, recent studies have investigated the expression of ARMS2 and HTRA1. 
The effect of the risk haplotype upon expression of the two proteins has been 
controversial. There is evidence that loss of ARMS2 is necessary, but not sufficient, 
for disease (Yang et al. 2010). HTRA1 appears to be upregulated in carriers of the 
risk haplotype in some studies (Dewan et al. 2006; Yang et al. 2006; Chan et al. 
2007; Yang et al. 2010) but not all (Kanda et al. 2007; Chowers et al. 2008; Kanda et 
al. 2010; Wang et al. 2010a; Wang et al. 2010b). These studies have been localised to 
specific tissues, such as the RPE (Yang et al. 2006), the retina (Kanda et al. 2007; 
Kanda et al. 2010; Wang et al. 2010b), placenta (Kanda et al. 2010) and blood (Yang 
et al. 2006; Chowers et al. 2008), and have failed to replicate consistently. Thus, it 
remains unclear whether the risk haplotype, or indeed a single variant on the risk 
haplotype, is linked to alterations in the expression of either gene.  
The systemic concentration of HTRA1 in plasma has not been reported, but 
may reflect small changes at the local level. This c apter describes the development 
and optimisation of an enzyme-linked immunosorbent assay (ELISA) for measuring 
HTRA1 in plasma. The aim was to determine whether t risk haplotype was 
associated with a difference in plasma HTRA1.  
The effect of covariates that are known to influence susceptibility to AMD 
upon plasma HTRA1 was also assessed (Klein et al. 2004). Body mass index (BMI) 
was identified as a significant covariate for plasm HTRA1. High BMI has been 
associated with increased risk of developing AMD (Seddon et al. 2003b). The 
contribution of BMI and genotype at the chromosome 10q26 locus to the expression 
of HTRA1 was also investigated in a small number of adipose tis ue biopsies.  
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6.2  Optimisation of an ELISA to measure the system ic levels of 
HTRA1 in plasma 
The expression level of HTRA1 in specific tissues or cell lines has previously been 
associated with risk genotype at the chromosome 10q26 locus, although this remains 
controversial. In order to investigate the systemic level of HTRA1 in relation to risk 
genotype at this locus, plasma HTRA1 was measured in the UK2 AMD case-control 
cohort, genotyped for the rs10490924 SNP.  Antibodies specific to HTRA1 were 
kindly provided by Dr Jeremy Chien (Rochester, Minnesota) for use in development 
of a sandwich ELISA to measure HTRA1 in human plasm amples.  
 
6.2.1  Testing HTRA1 antibodies in an indirect ELIS A 
The antibodies that were used in the development of the optimised HTRA1 ELISA 
are shown in Table 6.1. Three antibodies were provided; one purified polyclonal 
antibody raised in rabbit (HTRA1**) and two monoclonal antibodies (MAb 4.1 and 
MAb 10) which were obtained as unpurified supernatats from murine hybridoma 
cell cultures. All were raised against a recombinant purified protein spanning amino 
acids 140-480 of human HTRA1. Precise epitopes are unknown.  
The ability of the HTRA1 antibodies to specifically bind and detect a 
recombinant purified form of HTRA1 was initially test d by indirect ELISA. Figure 
6.1 shows the standard curves obtained by indirect ELISA in the range of HTRA1 
concentration from 0.312-5 ng/ml. As seen in Figure 6.1A, the polyclonal antibody 
HTRA1** (1 in 100 dilution) generates a linear stand rd curve (R2= 0.9923). The 
monoclonal antibodies were tested as a 1:1 mixture, and also individually. 
Polynomial regressions fitted to the standard curves show that MAb 10 is able to 
detect HTRA1 in the range of 0.312-5 ng/ml (R2=0.987; Figure 6.1C), but MAb 4.1 
did not detect HTRA1 (Figure 6.1D). The mixture of monoclonal antibodies did 
detect HTRA1, but provided no greater sensitivity than using MAb 10 alone (Figure 
6.1B).
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Figure 6.1  Testing the performance of anti-HTRA1 a ntibodies by 
indirect ELISA. 
Three antibodies raised against unknown epitopes of rec mbinant human HTRA1 
were tested in indirect ELISA for the ability to specifically bind and detect a 
recombinant purified form of HTRA1. The standard curves obtained by indirect 
ELISA in the range of HTRA1 concentration from 0.312-5 ng/ml are shown. The 
equation of the line-of-best fit was obtained by polyn mial regression in Microsoft 
Excel. Goodness of fit was assessed using the squared co relation coefficient (R2).  
A. The purified rabbit polyclonal antibody HTRA1** generates a linear standard 
curve (R2= 0.9923).  The monoclonal antibodies MAb10 and MAb 4.1 were tested as 
a 1:1 mixture (B), and also individually (C and D respectively). The mixture of 
monoclonal antibodies did detect HTRA1 (B).  MAb 10 is able to detect HTRA1 in 
the range of 0.312 -5ng/ml (R2=0.987; C), but MAb 4.1 did not detect HTRA1 (D).  
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6.2.2  Testing HTRA1 antibodies by Western blotting  
The polyclonal antibody HTRA1** and the monoclonal antibody MAb 10 were able 
to detect purified recombinant HTRA1 in an indirect ELISA. These antibodies were 
used to assess the purity of the recombinant HTRA1 standard, GST ∆N HTRA1 
S328A by Western blotting. The inactive mutant of HTRA1 was used for the 
standard to avoid degradation of the protease and antibodies by the active protease. 
Figure 6.2A shows a Coomassie-stained gel of 2 µg of the purified GST ∆N HTRA1 
S328A. The recombinant protein has a predicted molecular weight of 64 kDa and is 
visualised as the major band at approximately 62 kDa in the Coomassie-stained gel. 
1 µg of protein was immunoblotted with anti-HTRA1** (Figure 6.2B), anti-HTRA1 
MAb10 (Figure 6.2C), or with anti-HTRA1-PDZ (Figure 6.2D). Anti-HTRA1 PDZ 
is the antibody used throughout this thesis to detect HTRA1 in Western blots, and is 
shown as a control.  
Both HTRA1** (1:1,000 dilution) and MAb 10 (1:100 dilution) were able to 
detect the recombinant protein by Western blot. In agreement with the Coomassie-
stained gel, the predominant HTRA1-immunoreactive band for each antibody is 
observed at approximately 64 kDa. Minor HTRA1-immunoreactive bands are 
observed at 51 kDa (also seen in the Coomassie-stained gel) and at approximately 
130 kDa and 200 kDa. The higher molecular weight bands are thought to result from 
incomplete reduction of HTRA1 dimers and trimers. HTRA1 is thought to 
oligomerise via interactions at the C-terminus (Truebestein et al. 2011), thus only the 
monomer is detected by anti-HTRA1 PDZ, which recognises the PDZ domain of the 
protease. 
Figure 6.2 also shows that no HTRA1-specific signal w s observed in 5 µl of 
human plasma or serum by Western blotting. This maybe due to the low abundance 
of HTRA1 in serum and plasma. 
   
 250 
 
Figure 6.2  Testing anti-HTRA1 ELISA antibodies in Western blots. 
A. A Coomassie-stained gel of 2 µg of the purified GST ∆N HTRA1 S328A 
(predicted molecular weight of 64 kDa). GST ∆N HTRA1 S328A, human plasma 
and human serum was separated by reducing SDS-PAGE and then immunoblotted 
with anti-HTRA1** (B), anti-HTRA1 MAb10 (C) or anti-HTRA1-PDZ (D) and 
appropriate secondary antibodies. Anti-HTRA1 PDZ is the antibody used throughout 
this thesis to detect HTRA1 in Western blots, and is shown as a control.  The 
predominant HTRA1-immunoreactive band for each antibody is observed at 
approximately 64 kDa. Minor HTRA1-immunoreactive bands are observed at 51 
kDa (also seen in the Coomassie-stained gel) and at approximately 130 kDa and 200 
kDa in B and C. The higher molecular weight bands are thought to result from 
incomplete reduction of HTRA1 oligomers. None of the antibodies were able to 
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6.2.3  Optimisation of the HTRA1 ELISA 
A sandwich ELISA for HTRA1 was developed, modifying the suggested protocol 
provided by Dr Jeremy Chien. The polyclonal antibody HTRA1** was used as a 
capture antibody, and the monoclonal antibody MAb 10 was used as a detection 
antibody. The appropriate dilution of each antibody to detect HTRA1 in plasma was 
determined, along with the optimal dilution of anti-mouse IgG HRP-conjugate and a 
suitable plasma dilution. A schematic representation of the optimised assay is shown 
in Figure 6.3. 
 
 6.2.3.1  Capture Antibody HTRA1** 
A dilution series of HTRA1** was used to capture a range of concentrations of GST 
∆N HTRA1 S328A (0.78-50 ng/ml) by sandwich ELISA. The optimal dilution of 
HTRA1** is able to capture all of the HTRA1 present at the highest concentration of 
HTRA1. Figure 6.4 shows that a dilution of 1:100 of the antibody is sufficient to 
capture 50 ng/ml of the protein, without the antibody becoming saturated. 
 
6.2.3.2  Detection Antibody MAb 10 
 The optimal dilution of the MAb 10 detection antibody for use in the sandwich 
ELISA was determined using a dilution series against a range of GST ∆N HTRA1 
S328A (0.78-50ng/ml), captured with HTRA1**. Figure 6.5 shows that a 1:10 
dilution of the murine hybridoma culture supernatant is sufficient to detect 50ng/ml 
HTRA1, without saturation of the detection antibody. In agreement with the results 
from the indirect ELISA to test the specificity of the antibodies, MAb 4.1 did not 
detect any HTRA1 captured by HTRA1** in a sandwich ELISA (Figure 6.5). A 
corresponding decrease in the sensitivity of detection was observed using a 1:1 mix 
of the monoclonal antibodies MAb10 and MAb 4.1. 
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Figure 6.3  Schematic representation of the HTRA1 s andwich ELISA. 
A polyclonal anti-HTRA1 antibody (HTRA1**) was used as the capture antibody, in 
combination with a monoclonal detection antibody (MAb10). Precise epitopes of the 
antibodies are unknown. The detection antibody was recognised by horse radish 
peroxidise (HRP)-conjugated anti mouse IgG. Absorbance at 450 nm was used to 
detect the HRP-mediated conversion of TMB substrate and allow quantitation of 




Figure 6.4  Optimisation of the polyclonal capture antibody. 
The polyclonal antibody HTRA1** was tested for the ability to detect purified 
recombinant HTRA1 in the range expected in human plsma (<50 ng/ml). 
Fluorometric detection at 450 nm was used to measur HTRA1. Data points 
represent different concentrations of HTRA1, detected using HTRA1** diluted in the 
range of 1 in 100 to 1 in 1,000. The optimal dilution of HTRA1** was determined as 
1 in 100, as this was not saturated at higher HTRA1 concentrations. 
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Figure 6.5  Optimisation of the monoclonal detectio n antibody. 
Monoclonal antibodies MAb10 and MAb4.1 were obtained as hybridoma cell culture 
supernatants. The supernatants were tested (undiluted, or diluted in the range of 1 in 
2 to 1 in 25) to detect recombinant purified HTRA1 in the range expected in human 
plasma (<50 ng/ml). Fluorometric detection at 450 nm was used to measure HTRA1. 
MAb 4.1 (orange) did not detect HTRA1. A 1:1 mixture of MAb4.1 and MAb10 






Figure 6.6  Optimisation of anti-mouse IgG HRP. 
Rabbit anti-mouse IgG HRP was optimised for the purpose of detecting HTRA1 in 
human plasma by sandwich ELISA. A dilution series of HRP-conjugated antibody 
was used to detect binding of MAb10 to HTRA1 captured by HTRA1** in two 
internal control plasma samples, P8 and P9. Lower dilutions of IgG HRP-conjugate 
generated falsely high measurements of plasma HTRA1. High dilutions of IgG HRP 
were saturated by the secondary detection antibody. Dilutions in the range of 
1:25,000 to 1:75,000 were considered optimal for the accurate detection of HTRA1 
by sandwich ELISA.  
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6.2.3.3  Anti-mouse IgG HRP 
The detection antibody in this sandwich ELISA is unlabelled, so acts as a primary 
detection antibody. A secondary detection antibody, specific to the primary detection 
antibody but not the capture antibody, is required to generate an output signal 
corresponding to the detection of HTRA1. In this asay, the output signal is the blue 
colour arising from the oxidation of tetramethylbenzidine (TMB) chromagen, 
catalysed by HRP in the presence of hydrogen peroxide. 
Rabbit anti-mouse IgG HRP was optimised for the purpose of detecting 
HTRA1 in human plasma by sandwich ELISA. Two internal control plasma samples, 
P8 and P9, were diluted 1 in 10 and assayed for HTRA1 using the optimised 
antibody dilutions for capture and detection. A dilution series of HRP-conjugated 
antibody was used to detect binding of MAb10 to HTRA1 from plasma which had 
been captured by HTRA1** (Figure 6.6). Lower dilutions of IgG HRP-conjugate 
generated falsely high measurements of plasma HTRA1, as a result of non-specific 
binding of the secondary detection antibody. High dilutions of IgG HRP generated 
falsely low measurements of plasma HTRA1 as a result of saturation of the 
secondary detection antibody. Dilutions in the range of 1:25,000 to 1:75,000 were 
considered optimal for the accurate detection of HTRA1 by sandwich ELISA. 
1:25,000 was selected for use in the assay to ensur that any high plasma HTRA1 
levels encountered would not saturate the secondary detection antibody. 
   
6.2.3.4  Inhibition of the sandwich ELISA in human plasma 
The optimised antibody dilutions were used in a sandwich ELISA to detect HTRA1 
in a dilution series of plasma samples, ranging from undiluted plasma to a 1 in 100 
dilution. Neat plasma and low dilutions of plasma were found to inhibit the assay, 
decreasing the amount of HTRA1 measured in plasma (dat  not shown). To further 
investigate the plasma inhibition of the assay, an HTRA1 standard curve, ranging 
from 0.312 to 50 ng/ml of GST ∆N HTRA1 S328A was measured in either the 
standard dilution buffer (1% BSA/TBST) or diluted in plasma (P7), either 1:10 or 
1:50 in 1% BSA/TBST. The standard curves for each dilution buffer are shown in 
Figure 6.7A, B and C. Inhibition of the assay was ob erved when recombinant 
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HTRA1 was diluted in a 1 in 10 dilution of plasma (Figure 6.7B). Direct comparison 
of the measured absorbance at 450 nm (minus background f the appropriate zero 
standard) is shown in Figure 6.7D. The ability of the assay to detect a known amount 
of HTRA1 in a 1 in 50 dilution of plasma was roughly equivalent to detection of the 
same amount of HTRA1 diluted in 1% BSA/TBST. In order to minimise the 
inhibition of the assay when measuring endogenous plasma HTRA1, plasma samples 
were subsequently diluted 1 in 50. 
 
6.2.3.5  Analysis of intra-assay variation 
The internal control plasma standards P8 and P9 were m asured multiple times 
within the same assay, and measurements obtained wer  us d to assess intra-assay 
variability for the optimised HTRA1 sandwich ELISA. Figure 6.8A shows the mean 
measurement of plasma HTRA1 obtained for each plasma sample (±s.e.m.) from at 
least 5 replicates. Coefficients of variation (CV) were around the 5% threshold, 
indicating that there was no significant difference between replicates.  
 
6.2.3.6  Analysis of inter-assay variation 
Internal control plasma standards P8 and P9 were used to assess inter-assay variation. 
The samples were measured multiple times in different assays, and measurements 
obtained were used to assess inter-assay variability for he HTRA1 sandwich ELISA 
as described in Section 2.5.3. Figure 6.8B shows the mean measurement of plasma 
HTRA1 obtained for two replicates of each plasma sample in a minimum of five 
assays (± s.e.m.), and indicates the coefficient of variation for each sample. There 
was minimal variation observed between assays (CV<10%). Previous work by 
Morad Ansari has shown that variation of this magnitude can be caused by pipetting 
error. 
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Figure 6.7  Optimisation of plasma dilution for the  HTRA1 ELISA. 
Inhibition of the ELISA was observed in plasma diluted 1 in 10.  
A. An HTRA1 standard curve, ranging from 0.312 to 50 ng/ml of GST ∆N 
HTRA1 S328A was measured in the standard dilution buffer (1% 
BSA/TBST).  
B. An HTRA1 standard curve, ranging from 0.312 to 50 ng/ml of GST ∆N 
HTRA1 S328A was measured in 1 in 10 in plasma (P7) in 1% BSA/TBST. 
Inhibition of the assay was apparent compared to (A). 
C. An HTRA1 standard curve, ranging from 0.312 to 50 ng/ml of GST ∆N 
HTRA1 S328A was measured in 1 in 50 in plasma (P7) in 1% BSA/TBST. 
D. Direct comparison of the measured absorbance at 450 nm (minus background 
of the appropriate zero standard) for each standard curve A-C. The 
performance of the assay is approximately equivalent in a 1 in 50 dilution of 
plasma and in 1% BSA/TBST.  
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Figure 6.8 Intra- and Inter assay variability of th e HTRA1 ELISA. 
A. Intra-assay variation was measured within replicates of four human plasma 
samples P6. P7, P8 and P9. Each point represents at least five replicates ±s.e.m. 
Coefficients of variation (CV) are shown below each point. 
B. Inter-assay variation was measured based on the mean of two or more 
replicates of four human plasma samples P6. P7, P8 and P9 from at least five 
different assays. Each point represents the mean of replicates ±s.e.m. Coefficients of 
variation (CV) are shown below each point.  
 
6.3  Plasma HTRA1 measurements 
In healthy human tissues, HTRA1 is widely expressed, with strongest expression in 
the epidermis, liver and kidney tubules (De Luca et l. 2003). Systemic levels of 
HTRA1 in plasma are likely to result from spill-over from tissues. The effect of 
genotype at the chromosome10q26 haplotype on plasma levels of HTRA1, as a 
reflection of expression of HTRA1systemically, was investigated by measuring 
plasma HTRA1 in 769 individuals from a British AMD case-control cohort, UK2. 
680 of these individuals were genotyped for rs10490924; missing genotypes were 
due to assay failure or missing DNA for these individuals. Table 6.2 shows the 
characteristics of the genotyped individuals. Measurements were carried out in 
duplicate. Mean values were corrected for inter-assay variation using two internal 
controls. In addition to the effect of genotype, the contribution of age, sex, smoking 
and body mass index (BMI) to plasma HTRA1 in this cohort was investigated. 
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Table 6.2 Demographic characteristics for the UK2 c ase-control 
series genotyped for rs10490924. 
Demographic characteristics for the UK2 case-control series are shown according to 
rs10490924 genotypes. Statistically significant differences between GG and GT/TT 
groups were identified between mean age and % AMD. Exact test of Hardy–
Weinberg equilibrium (number), t-test (mean age and mean BMI), exact test (gender, 
smoking history and % AMD) and median test (median HTRA1 (ng/ml)) were 
applied to calculate p-values. Abbreviations: SD, standard deviation; BMI, body 
mass index.  
 
UK2 Case-Control Series 
Genotype Total GG GT/TT p-value  
Number 680 284 396 <0.0001 
Mean age (yrs) 78.0 77.6 79.0 
SD 7.9 7.9 7.5 0.013 
Mean BMI 27.48 27.25 27.49 
SD 5.15 5.17 5.01 0.537 
% Males 44.5 45.6 43.7 0.819 
Smoking     
never 257 110 147 
former 374 158 216 
current 46 15 31 0.653 
AMD (%) 59.5 42.0 72.1 2.92x10-14 
Median HTRA1 (ng/ml) 20.81 18.05 22.26 0.062 
 
 
6.3.1   Analysis of plasma HTRA1 by genotype  
The rs10490924 SNP encodes a serine to alanine change at position 69 of ARMS2, 
and is in high linkage diseqilibrium (r2>0.88) with other variants on the risk 
haplotype, including an indel and a putative HTRA1 promoter polymorphism 
(Fritsche et al. 2008). Some, but not all, reports have suggested increased HTRA1 
expression at the local level in individuals carrying risk alleles at the chromosome 
10q26 locus (Yang et al 2010; Wang et al 2010, Fritsche et al 2008, Friedrich et al 
2011, An et al 2010, Yang et al 2006, Chan et al 2007, Kanda et al 2007, Tuo et al 
2008, Chowers et al 2008, Wang et al 2010b).   
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6.3.1.1 Confirmation of haplotype by PCR amplificat ion of indel  
Genotyping of these samples for rs10490924 had previously been performed by 
Susan Campbell using a TaqMan SNP genotype assay. PCR amplification of the 
indel-spanning region in the 3’ UTR of ARMS2 was used to confirm that rs10490924 
genotype tagged the indel correctly in a subset of individuals (Figure 6.9).  
Consistent with previous reports of high LD (D’ 0.99) between these variants (Wang 
et al. 2010b), the wild-type, non-risk, G allele of rs10490924 was always associated 
with a haplotype in which the indel was absent (band of 600 bp; Figure 6.9), whilst 
the risk allele (T) was associated with a haplotype in which the indel was present 
(band of 200 bp; Figure 6.9). 
 
Figure 6.9 The ARMS2 3’ UTR indel is linked to SNP genotype. 
680 samples in the UK2 cohort were genotyped at SNPrs10490924. This SNP 
genotype was used to tag the AMD-risk haplotype covering SNP rs10490924 in 
ARMS2, 3’ UTR indel in ARMS2 and  rs11200638 in HTRA1 (Fritsche et al. 2008, 
Wang et al. 2010). To confirm the association of SNP genotype with the indel, the 
region spanning the indel was amplified by PCR. Expected PCR products are 598 bp 
for the wild-type allele and 209 bp for the indel allele. Five samples for each 
genotype of rs10490924 were amplified by PCR and subjected to gel electrophoresis. 
All GG samples show a single band at 600 bp, TT homozygotes show a single band 
at 200 bp and heterozygotes show two bands, representing the wild-type and risk 
allele of the indel. 
 
6.3.1.2 Analysis of raw plasma HTRA1 by rs10490924 genotype 
Plasma HTRA1 measured by ELISA was used to assess whether genotype was 
associated with alterations in plasma HTRA1. Due to the low frequency of minor 
allele homozygotes (12.4%), minor allele (T) homozygotes and heterozygotes were 
combined (n=396) for comparison with major allele (G) homozygotes (n=284).  
The plasma HTRA1 measurements in the British case-control cohort showed 
a leptokurtic distribution. There was a significant deviation from normal, as indicated 
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by a skewedness factor of 5.93±0.088 (standard error of skewedness). Skewedness is 
a measure of departure from normality: normally distributed data has a value of zero. 
The positive or right-skewed nature of these data is mostly due to the wider range of 
plasma HTRA1 measured in GT/TT individuals. This is upported by the high 
kurtosis measure for GT/TT data (85.8±0.245 standard error of kurtosis) compared to 
samples with a GG genotype (4.27±0.288). Exclusion of extreme outliers (mean±3 
SD; seven samples) reduced kurtosis but did not otherwise affect the subsequent 
analysis. Figure 6.10 shows the distribution of plasm  HTRA1 measurements 
following exclusion of extreme outliers. 
 
Figure 6.10 Distribution of plasma HTRA1 measuremen ts.  
The distribution of unadjusted plasma HTRA1 measurements (ng/ml) in the UK2 
AMD case-control series, trimmed for extreme outliers (mean ±3 SD). These data 
show a deviation from normal, as indicated by a kurtosis value of 1.91 (S.E. 0.177) 
and skewedness value of 1.25 (S.E. 0.088).  
 
To account for the deviation from normal distribution, non-parametric tests were 
used to investigate the relationship between genotype and plasma HTRA1. As shown 
in the box plot in Figure 6.11, there was a suggestiv ly significant (p=0.06) increase 
in median level of HTRA1 measured in carriers of one r two copies of the T risk 
allele (22.26 ±1.76 (s.e.m.) ng/ml) compared to GG homozygotes (18.05 ±1.56 
(s.e.m.) ng/ml). The range of plasma HTRA1 measured was significantly wider in 
GT/TT individuals, compared to GG homozygotes (Moses test of extreme reaction, 
in which data was trimmed for extreme outliers, p=0.045).  




Figure 6.11  The risk allele of rs10490924 is assoc iated with elevated 
plasma HTRA1 concentrations in the UK2 cohort. 
Plasma HTRA1 was measured by ELISA in 680 samples from a British AMD case-
control cohort which were genotyped for rs10490924. Logistic regression was used 
to test the association between genotype at rs10490924 (GG or GT/TT) and plasma 
HTRA1, accounting for the confounding effect of age and BMI. The 3rd (p=0.03) and 
4th (p=0.04) quartiles of plasma HTRA1 were significantly associated with carriers of 
the T allele, which is associated with risk of AMD in this cohort (p=2.73x10-13). 
Extreme outliers are indicated by *. 
 
 
6.3.1.3 Analysis of AMD-risk factors as covariates 
The known AMD risk factors of increasing age, gender and smoking history 
(reviewed by Klein et al 2004) showed no correlation with alterations in plasma 
HTRA1 using non-parametric tests of median, range and distribution for categorical 
variables (Table 6.3). For non-parametric testing, age was categorised as <65 years, 
65-80 years, or >80 years of age. The median HTRA1 level in plasma for the 
individuals aged <65 years (N=46) was 17.87 ±11.9 (s.e.m.) ng/ml compared to a 
median of 21.27±1.19 (s.e.m.) ng/ml in the 65-80 years category (N=395), and to 
20.16±1.54 (s.e.m.) ng/ml in the >80 years category (N=331).  Due to the small 
number of individuals aged <65 years, an effect of increasing age on plasma HTRA1 
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cannot be completely excluded. Smoking was categorised as ever/never, and was 
also assessed in terms of packyears (the number of cigarettes smoked per day 
multiplied by the years of smoking; none, <20, >20).  
Body mass index (BMI) was significantly associated with an alteration in the 
distribution of plasma HTRA1 measurements (Figure 6.12A). Individuals with BMI 
> 30 had a median HTRA1 level in plasma of 25.65 ±2.64 (s.e.m.) ng/ml compared 
to a median of 19.2±1.41 (s.e.m.) ng/ml for individuals with a BMI<25 (p=0.022). 
There was also a significant difference between the BMI groups at the extremes of 
distribution, as indicated by the Moses test of extreme reaction (p=<0.001).  
Stratifying analysis by BMI category showed that the largest difference in 
median plasma HTRA1 by genotype was observed in individuals with a BMI<25 
(Figure 6.12B, Table 6.3). In individuals with BMI<25, the median HTRA1 level in 
plasma for the GG non-risk genotype (N=99) was 17.9 ±2.17 (s.e.m.) ng/ml 
compared to a median of 21.53±2.15 (s.e.m.) ng/ml for individuals with GT/TT 
genotype (N=120; p=0.374).  Stratifying the samples by BMI causes lossof power 
so that the differences in median are not significant. However, the range of plasma 
HTRA1 concentrations between genotypes was significa tly different in this BMI 
group (p=0.038). In the BMI>30 group, the proposed effect of genotype upon plasma 
HTRA1 was barely observed, with only a slight (and not statistically significant) 
elevation in median plasma HTRA1 between genotype groups (Table 6.3). 







Figure 6.12 BMI is a confounding factor in the asso ciation between 
genotype and plasma HTRA1 in the UK2 cohort. 
A. The distribution of plasma HTRA1 measurements were significantly different 
(p=0.022) between BMI categories (<25, 25-29.99, >30), as assessed by non-
parametric tests using SPSS v17. 
B. The association between rs10490924 genotype and median plasma HTRA1 
concentration was affected by BMI. The difference in median plasma HTRA1 
was most obvious in BMI<25 (although this was not sta i tically significant), 
and was barely apparent in the BMI>30 category. Error bars represent 
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    plasma HTRA1 ng/ml       

















Combined   769 680 20.81 5.29 - 37.91 497.13 1.11         
Male 308 303 20.79 4.63 - 38.83 497.13 2.1 
Gender Female 380 317 20.78 5.90 - 38.06 257.87 1.33   0.821 1 0.005 
Ever 471 422 20.08 5.23 - 36.05 497.13 1.51 
Smoking Never 297 258 21.95 5.92 - 39.11 257.87 1.6   0.341 0.266 0.008 
0 260 259 21.04 5.71 - 38.97 257.87 1.75 
<20 221 217 22.63 5.46 - 43.32 497.13 2.66 
Pack years >20 207 204 17.52 5.22 - 31.56 171.65 1.7   0.2 0.193   
GG 284 284 18.05 4.95 - 39.81 171.65 1.53 
3rd Quartile 
0.03 
rs10490924 GT/TT 396 396 22.26 6.49 - 37.97 497.13 1.76 
4th Quartile 
0.04 0.307 0.062 0.031 
<65 years 42 31 17.87 5.83 - 38.36 497.13 11.91  
65-80 
years 395 349 21.27 6.28 - 39.95 168.62 1.19 
3rd Quartile 
0.94 
Age >80 years 331 300 20.16 4.35 - 35.35 257.87 1.54 
4th Quartile 
1.0 0.552 0.253 (< 0.001) 




(65-80 years) GT/TT   198 21.59 6.31 - 39.07 114.07 1.61 
4th Quartile 
0.457 0.893 0.478 0.062 




(>80 years) GT/TT  184 24.1 6.89 - 38.06 257.87 2.16 
4th Quartile 
0.064 0.171 0.033 0.127 
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<25 248 219 19.2 4.56 - 32.01 120.27 1.41 
3rd Quartile 
0.041 
25-29.99 327 287 19.3 5.65 - 39.11 497.13 1.85 
4th Quartile 
0.062 




(0.057) (< 0.001) 




(BMI <25) GT/TT  120 21.53 6.03 - 33.96 120.27 2.15 
4th Quartile 
0.713 0.463 0.374 0.038 




(BMI >30) GT/TT   95 24.7 7.92 - 40.64 257.87 3.69 
4th Quartile 
0.465 0.867 0.872 0.2 
Control 277 274 18.43 5.64 - 40.22 120.8 1.36 
3rd Quartile 
0.019 
AMD Status Case 411 406 21.68 5.30 - 36.90 497.13 1.78 
4th Quartile 
0.065 0.728 0.244 < 0.001 
Else 341 274 19.36 6.22 - 39.43 120.8 1.21 
3rd Quartile 
0.032 






(0.086) (< 0.001) 
CNV Any CNV 319 307 22.63 6.00 - 38.06 497.13 2.21         
 
 
Table 6.3 Plasma HTRA1 analysis in the UK2 series. 
Plasma HTRA1 concentrations were tested for an association with gender, smoking history, age, BMI and AMD status, in addition to 
rs10490924 genotype. Raw plasma HTRA1 (ng/ml) was tested using non-parametric tests to account for skewed distribution. Quartiles of 
plasma HTRA1 were tested for an association with genotype, correcting for age and BMI by logistic regrssion. P-values shown in 
brackets are calculated for comparisons of the following groups: age, <65 years, >80 years; BMI, <25, >30; CNV, Else, any CNV.
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Increasing age was not shown to be a confounding effect upon plasma HTRA1 
concentration. However, when the cohort was split into age categories (<65 years, 
65-80 years, or >80 years), the association between elevated median plasma HTRA1 
and risk genotype at rs10490924 was most significant in the group aged over 80 
years. Table 6.3 shows the median and quartile ranges of plasma HTRA1 
measurements for each age group, split by genotype. In the group aged 65-80 years, 
the difference in median plasma HTRA1 is suggestively significant (p=0.06; 19.76 
±1.91 (s.e.m.) ng/ml for GG genotype compared to 21.59±1.61 (s.e.m.) ng/ml for 
GT/TT genotype). In individuals aged over 80 years, there is a more significant 
difference between median plasma HTRA1 in individuals with a GG genotype 
(17.02±2.62 (s.e.m.) ng/ml), compared to individuals carrying a risk allele 
(24.10±2.16 (s.e.m.) ng/ml), p=0.033. There was no ignificant difference in mean 
BMI between age groups, suggesting that the confounding effect of BMI is not 
responsible for this observation (data not shown).  
 
6.3.1.4 Analysis of plasma HTRA1 quartiles 
To account for the skewed distribution of plasma HTRA1 and the large number of 
low plasma HTRA1 measurements, quartiles of plasma HTRA1 were tested for an 
association with SNP genotype. Quartiles were calcul ted for the combined data set, 
and plasma HTRA1 measurements were classified as 1st quartile (1), 2nd quartile (2), 
3rd quartile (3) or 4th quartile (4) for analysis. Quartile ranges for thecombined data 
are shown in Table 6.3, and for the cohort split by genotype in the box plot shown in 
Figure 6.11. Using a dominant model of logistic regression, the 3rd and 4th quartiles 
of plasma HTRA1 were significantly associated with carriers of the HTRA1 
rs10490924 minor allele (for each quartile, p=0.036, OR 1.608, 95% C.I, 1.032-
2.504).   
BMI was included as a covariate in binary logistic regression analysis to 
correct for the confounding effect of high BMI upon plasma HTRA1. The upper 
quartiles of plasma HTRA1 remained significantly associated with carriers of the 
HTRA1 rs10490924 minor allele (3rd quartile, p=0.03; 4th quartile, p=0.04), 
independent from the contribution of high BMI to plasma HTRA1. The addition of 
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age as a covariate had little effect upon the associati n of upper plasma HTRA1 
quartiles with risk genotype (3rd quartile, p=0.029; 4th quartile, p=0.046). 
 
6.3.1.5 Association of plasma HTRA1 with AMD 
The genotype of rs10490924 was significantly associated with AMD in this cohort 
(GT/TT, p=2.73x10-13, OR 3.618 (95% C.I. 2.56–5.11)). Median plasma HTRA1 in 
controls was 18.43±1.36 ng/ml, which was lower than in AMD cases (21.68±1.78 
ng/ml). This was not significantly different when assessed by non-parametric tests 
(p=0.244, Table 6.3). However, binary logistic regression of plasma HTRA1 
quartiles, including the known AMD-risk factors of age, sex, smoking history and 
BMI, indicate that higher plasma HTRA1 measurements are significantly or 
suggestively associated with AMD (3rd quartile, p=0.015, 4th quartile p=0.063). 
These analyses may indicate that there is a confounding factor affecting the 4th 
quartile of plasma HTRA1 which is not corrected for, r alternatively, insufficient 
power.  
The chromosome 10q26 risk locus has been suggested to increase the risk of 
development and progression of wet AMD, possibly as a consequence of HTRA1 
activity promoting choroidal neovascularisation (CNV; Dewan et al. 2006; Sobrin et 
al. 2011; Chen et al. 2011). The risk locus tagged by rs10490924 was significantly 
associated with CNV in this cohort (GT/ TT, p=2.99 x10-17, OR 4.445 (95% C.I. 
3.145 – 6.284)). The relationship between plasma HTRA1 and CNV was assessed 
using non-parametric tests and logistic regression.  
As shown in Table 6.3, individuals with CNV had a higher median plasma 
HTRA1 (22.63±2.21 ng/ml) compared to individuals with only geographic atrophy 
(16.65±2.33 ng/ml) or to disease-free controls (19.36±1.21 ng/ml). Due to the 
smaller number of GA cases (N=98) potentially affecting power, CNV cases 
(N=307) were compared to controls (N=274). There was a significant difference in 
the distribution of plasma HTRA1 concentrations measured in controls compared to 
AMD cases with CNV (p=0.044). The range of plasma HTRA1 concentrations was 
also significantly different between controls and CNV cases (p<0.001). Binary 
logistic regression of plasma HTRA1 quartiles, including the known AMD-risk 
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factors of age, sex, smoking history and BMI, confirmed that higher plasma HTRA1 
measurements are significantly or suggestively associated with AMD (3rd quartile, 
p=0.03, 4th quartile p=0.083). 
 
6.3.2 Association of rs10490924 risk allele with el evated plasma 
CFD 
Plasma CFD was shown to be significantly elevated in AMD cases compared to 
controls in Chapter 4.4.3.2. In light of the interaction between HTRA1 and CFD at 
the protein level, the association between plasma CFD and rs10490924 genotype was 
assessed. The median plasma CFD concentration in individuals with the GG 
genotype was 1.82±0.049 µg/ml); in GT/TT individuals, median plasma CFD was 
1.95±0.053 µg/ml). The risk allele (T) was associated with higher plasma CFD 
measurements (p=0.005, Mann Whitney U).  
AMD status is a confounding factor, given that plasm  CFD was elevated in 
AMD cases compared to controls (p =0.00025). BMI is also a confounding factor, as 
shown in Chapter 4.4.3.1. Logistic regression, including age, sex, smoking, BMI and 
AMD status as covariates, was performed to test for an association between elevated 
plasma CFD and rs10490924 genotype. When comparing the 1st to 4th quartiles of 
plasma CFD, there was a significant association with the risk allele (GT/TT; p=0.01, 
OR 1.96, 95% C.I. 1.18-3.26). Furthermore, there was no association between the 
CFH Y402H variant (rs1061170) and plasma CFD (p=0.345). This suggests that the 
association of plasma CFD with AMD may reflect a contribution (by an unknown 
mechanism) of the chromosome 10q26 locus to systemic inflammation. 
 
6.4  Power calculations for HTRA1 ELISA 
There are no published reports of plasma HTRA1 measur ments. Having observed a 
difference in mean and median plasma HTRA1 between g notype groups 
corresponding to a 8.1 % increase in the median plasma HTRA1 concentration in 
carriers of the risk haplotype (Table 6.3), the power of the study to identify a 
significant difference (p=0.05) of this magnitude at 80% power was assessed. 
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6.4.1   Normalisation of plasma HTRA1 measurements  
Plasma HTRA1 measurements showed a considerable deviation from normal 
distribution, as shown in Figure 6.10. A combination of non-parametric testing and 
quartile normalisation was used to allow for this in the analysis of the data. However, 
in order to calculate power, normal distribution of data is required. 
Cube root (√3) transformation of the detectable plasma HTRA1 
measurements was performed to achieve normalisation of the plasma HTRA1 
measurements for analysis of a relationship with rs10490924 genotype. As shown in 
Figure 6.13A, normal distribution is achieved following cube root transformation of 
detectable HTRA1. This is also seen in the Q-Q plot (Figure 6.13B). There was no 
significant difference between the proportion of plasma samples with HTRA1 below 
the detectable limits of the ELISA between genotype groups (p=0.345). 
 
6.4.2  Calculation of required sample size using th e Altman 
Nomogram 
Mean values of cube root (√3) transformed plasma HTRA1 were used to calculate the 
required sample size to detect a significant difference in plasma HTRA1 between 
genotype groups. The mean value of √3transformed plasma HTRA1 in the 
rs10490924 GG group (N=283) was 2.33±0.081 (s.e.m.), compared to 2.43±0.066 
(s.e.m.) in the GT/TT group (N=394). The difference in means and the observed 
standard deviation (1.33) were used to calculate the s andardised difference. The 
standardised difference was then applied to an Altman Nomogram (Figure 2.1). This 
indicates that a sample size of 4,000 would be requi d to identify a difference in 
plasma HTRA1 of this magnitude with 80% power (p=0.05)  
 






Figure 6.13 Normalisation of the distribution of pl asma HTRA1 
measurements in UK2. 
A. Detectable HTRA1 (measurements above zero) were cub root (√3) 
transformed to attain a normal distribution. Skewedness and kurtosis were 
reduced.  
B. A Q-Q plot showing that cube root transformation successfully normalises 
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6.4.3  Confounding effect of BMI 
High BMI is significantly associated with elevated plasma HTRA1 (p=0.022, Table 
6.3, Figure 6.12A). Although the effect of BMI does not remove the significant 
association between higher plasma HTRA1 measurements and the risk haplotype on 
chromosome 10q26, it does act to reduce the significa ce of the association, 
particularly with the 4th quartile of plasma HTRA1 measurements. Thus, the 
inclusion of individuals with high BMI is a confounding factor in the power of the 
study to identify a significant association between g otype and plasma HTRA1. The 
measured difference in mean cube root-transformed plasma HTRA1 in GG versus 
GT/TT individuals stratified by BMI group (< 25, 25-29.99, >30) was used to 
calculate the standardised difference for each group. Application of these data to the 
Altman Nomogram (Figure 2.1) indicates that in indivi uals with BMI<25, as few as 
500 samples would be sufficient to detect a significant difference (p=0.05) of the 
expected magnitude with 80% power. Substantially more samples are required in 
groups with higher BMI. 
 
6.4.4  Plasma HTRA1 was measured in a Scottish coho rt with 
BMI<25 
In order to minimise the confounding effect of increasing body mass, and to increase 
the power to detect a significant difference in plasm  HTRA1 between genotype 
groups, EDTA-plasma samples from an additional 210 individuals with BMI<25 
were obtained. These samples are disease-free SOCCS controls, and were kindly 
provided by Prof. Malcolm Dunlop. The characteristic  of this series are shown in 
Table 6.4. Mean age was substantially lower than in the UK2 cohort used for the 
initial plasma HTRA1 measurements (50.9±6.8 (SD) years, compared with 79.0±7.5 
(SD) years in the UK2 series). Mean BMI was 22.6±1. (SD). 
Genotyping the SOCCS samples for rs10490924 was performed by Susan 
Campbell, using a TaqMan SNP genotyping assay. Genotype frequencies are shown 
in Table 6.4. Eight samples were not successfully genotyped for the SNP.  
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Table 6.4 Demographic characteristics for the SOCCS  series 
genotyped for rs10490924. 
Demographic characteristics for the SOCCS series are hown according to 
rs10490924 genotypes. No statistically significant differences between GG and 
GT/TT groups were identified. Exact test of Hardy–Weinberg equilibrium (number), 
t-test (mean age and mean BMI), exact test (gender, smoking history) and median 
test (median HTRA1 (ng/ml)) were applied to calculate p-values. Abbreviations: SD, 
standard deviation; BMI, body mass index.  
 
SOCCS  
Genotype Total GG GT/TT p-value  
Number 200 119 81 0.796 
Mean age (yrs) 50.9 50.9 50.9 
SD 6.8 6.7 6.8 0.96 
Mean BMI 22.64 22.79 22.51 
SD 1.6 1.46 1.72 0.227 
% Males 43.0 42.0 44.4 0.773 
Smoking     
never 100 61 39 
former 51 30 21 
current 48 28 20 0.946 
AMD (%) Not examined  
Median HTRA1 (ng/ml) 10.85 10.36 11.79 0.223 
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6.4.4.1 Plasma HTRA1 measurements in SOCCS 
Plasma HTRA1 was measured in the SOCCS samples as previously described for the 
UK2 cohort. Internal control plasma samples P8 and P9 were included on all plates 
to ensure the assay performed in a consistent manner cross the two series. Median 
plasma HTRA1 concentrations in this cohort (10.85±1.22 (s.e.m.) ng/ml) were lower 
than in the UK2 cohort (20.81±1.11 (s.e.m.) ng/ml). 
Plasma HTRA1 concentrations in the SOCCS series showed a leptokurtic 
distribution, with measurements ranging from 0-84.2 ng/ml (Figure 6.14). Non-
parametric tests were used to investigate associatins between plasma HTRA1 
concentrations with rs10490924 genotype (GG versus GT/TT). 
 
Figure 6.14  Distribution of plasma HTRA1 measureme nts in SOCCS 
cohort. 
The distribution of unadjusted plasma HTRA1 measurements (ng/ml) in the SOCCS 
control series. These data show a deviation from normal, as indicated by a kurtosis 
value of 1.81 (S.E. 0.336) and skewedness value of 1.42 (S.E. 0.169).  
 
   
 274 
6.4.4.2  Analysis of raw plasma HTRA1 measurements by 
rs10490924 genotype in SOCCs 
The median level of HTRA1 measured in GG homozygotes (N=121) was 10.36±1.17 
(s.e.m.) ng/ml, which was lower than in carriers of one or two copies of the T risk 
allele (N=81; 11.79±2.28 (s.e.m.) ng/ml). This was not statistically significant 
(p=0.31). However, the range of plasma HTRA1 measured was significantly wider in 
GT/TT individuals than in GG homozygotes (Moses test of extreme reaction, in 
which data was trimmed for extreme outliers, p< 0.001).  
 
6.4.5 Combined analysis of UK2 and SOCCS plasma HTR A1 
measurements 
The plasma HTRA1 measurements made in UK2 and SOCCS cohorts were 
combined for analysis. This allowed further assessment of the relationship between 
the confounding factors of BMI, age and AMD status upon plasma HTRA1. There 
was also an increase in power to detect a significat difference in plasma HTRA1 
concentration by genotype in the BMI<25 group (N=418). 
 
6.4.5.1 Analysis of raw plasma HTRA1 by rs10490924 in the 
combined cohorts 
The relationship between genotype and plasma HTRA1 in the combined UK2 and 
SOCCS cohorts was assessed using non-parametric tesing to account for the 
deviation from normal distribution (skewedness 1.32±0.078 standard error of 
skewedness). As shown in the box plot in Figure 6.15, there was a significant 
(p=0.045) increase in median level of HTRA1 measured in carriers of one or two 
copies of the T risk allele (20.56±1.05 (s.e.m.) ng/ml) compared to GG homozygotes 
(14.81 ±1.10 (s.e.m.) ng/ml). This reflected a signif cant difference in the distribution 
(p=0.017) and range (p<0.001) of plasma HTRA1 measur d in GT/TT individuals, 
compared to GG homozygotes (Table 6.5). 
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Figure 6.15 Elevated plasma HTRA1 is associated wit h risk genotype in 
BMI<25 goup for combined cohorts. 
Plasma HTRA1 was measured by ELISA in 418 samples with BMI<25 which were 
genotyped for rs10490924.  Non-parametric testing performed in SPSS v19 
identified a significant (p=0.045) increase in median level of HTRA1 measured in 
GT/TT individuals compared to GG homozygotes. Signif cant differences in the 
distribution (p=0.017) and range (p<0.001) of plasm were also identified. 
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genotyped Median  
25th-75th 















HTRA1 208 202 10.85 1.34 - 24.89 84.23 1.22         
Male 90 86 12.90 1.13 - 25.84 61.01 1.76 
Gender 
Female 118 114 8.69 1.13 - 22.4 84.23 1.68 
  0.268 0.05 0.016 
current 52 48 10.96 0.00 - 21.4 52.66 2.28 
former 54 51 10.19 0.00 - 18.47 77.27 2.30 Smoking 
never 101 100 11.12 2.88 - 26.29 84.23 1.84 
 0.598 0.827  
GG   119 10.36 2.52 - 21.04 59.86 1.17   
rs10490924 
GT/TT   81 11.79 0.25 - 32.68 84.23 2.28   
0.223 0.313 <0.001 




973 916 17.37 4.57 - 34.9 130.75 0.72         
Male 396 387 17.79 3.84 - 35.16 130.75 1.15   
Gender 
Female 497 490 16.36 4.93 - 35.07 120.80 1.00   
0.556 0.482   
Current 104 357 14.82 0.42 - 24.77 63.25 1.59   
Former 470 425 17.48 5.14 - 35.46 130.75 1.05  Smoking 
Never 397 94 18.15 4.61 - 36.95 120.80 1.16   
0.05 0.158   
GG   402 14.81 3.78 - 31.03 120.80 1.10 
rs10490924 
GT/TT   475 20.56 5.32 - 37.26 130.75 1.05 
4th Quartile 
0.143 0.017 0.045 <0.001 
 <65 years 247 228 10.88 2.48 - 26.22 93.94 1.27 
65-80 years 395 349 21.27 6.28 - 39.95 168.62 1.19 Age 
 >80 years 
331 300 20.16 4.35 - 35.35 257.87 1.54 
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<25 455 418 14.72 3.01 - 29.7 120.85 0.96 
25-29.99 329 287 19.10 4.47 - 39.08 99.31 1.15 BMI 
>30 176 158 24.94 6.44 - 41.9 30.75 2.06 
  <0.001 0.002   
GG   217 12.72 3.37 - 25.0 97.41 1.21 rs10490924 
(BMI <25) GT/TT   201 16.08 2.30 - 32.96 120.27 1.59 
4th Quartile  
0.026 0.048 0.063 <0.001 
GG  283 13.21 3.46 - 27.88 120.80 1.23 rs10490924 
(disease 
free only) GT/TT   191 16.09 4.37 - 39.05 89.36 1.51 
4th Quartile  
0.045 0.097 0.223 <0.001 
 
 
Table 6.5  Plasma HTRA1 analysis in the SOCCS serie s, and in the UK2 and SOCCS combined series. 
 
Plasma HTRA1 concentrations were tested for an association with gender, smoking history, age, and BMI, in addition to rs10490924 
genotype. Raw plasma HTRA1 (ng/ml) was tested using non-parametric tests to account for skewed distribution. Quartiles of plasma 
HTRA1 were tested for an association with genotype, correcting for age and BMI by logistic regression
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6.4.5.2  Analysis of AMD-risk factors as covariates  in the combined 
cohorts 
A significant difference between plasma HTRA1 concentrations was observed 
between genotype groups in the combined cohorts. The potential confounding effect 
of age, sex, smoking history and BMI was assessed uing non-parametric testing as 
described for the UK2 cohort. As was seen in analysis of the UK2 cohort alone 
(Table 6.3) using non-parametric tests, there was no ignificant relationship between 
plasma HTRA1 and sex (p=0.525), or between plasma HTRA1 and smoking history 
(p=0.158) in the combined UK2 and SOCCS cohorts (Table 6.5).  
The SOCCS cohort has a mean age of 50.9±6.8 (SD) years, which increases 
the ability to identify a relationship between plasma HTRA1 and increasing age in 
the combined cohorts. Age was categorised as less than 65 years, 65-80 years, or 
aged over 80 years of age for non-parametric testing. The median HTRA1 level in 
plasma for the individuals aged<65 years in the combined cohort (N=249) was 
10.88±1.26 (s.e.m.) ng/ml. Comparison of this to a median of 21.27±1.19 (s.e.m.) 
ng/ml in the 65-80 years category (N=395), and to 20.16±1.54 (s.e.m.) ng/ml in the 
>80 years category (N=331) identified a significant relationship between increasing 
age and increasing plasma HTRA1, irrespective of rs10490924 genotype (p< 0.001; 
Figure 6.16A, Table 6.5).   
The relationship between increasing age and plasma HTRA1 may be 
confounded by the lower mean BMI in the group aged<65 years (due to the inclusion 
of the SOCCS cohort). In the two groups with BMI<30, the effect of age remained 
significant, and was most pronounced in individuals with BMI<25 (p=0.003, 
Kruskal-Wallis test; Figure 6.16B). In the combined cohorts, the median HTRA1 
level for individuals with a BMI<25 was 14.7±0.96 (s.e.m.) ng/ml (Table 6.5). This 
group showed a significant alteration in distribution compared to the group with 
BMI>30 who had a median of 24.94±2.06 (s.e.m.) ng/ml (p<0.001). 
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Figure 6.16 Increasing age is associated with eleva ted plasma HTRA1. 
A.Increasing age was significantly associated with elevated plasma HTRA1, 
irrespective of genotype (p<0.001, Kruskal-Wallis te t) in the combined UK2 and 
SOCCS cohort.  
B. The association between increasing age and plasma HTRA1 in the combined 
cohorts remained significant in individuals with BMI<25 (p=0.003, Kruskal-Wallis 
test). 
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6.4.5.3 Analysis of plasma HTRA1 quartiles in the c ombined 
cohorts 
To account for the skewed distribution of plasma HTRA1 and the confounding 
factors of age, BMI and AMD status, quartiles of plasma HTRA1 were tested for an 
association with SNP genotype by logistic regression. Quartiles of plasma HTRA1 
measurements were calculated for the combined cohorts. Quartile ranges for the 
combined data are shown in Table 6.5, and for the co ort split by genotype in the 
box plot shown in Figure 6.15. Using a dominant model of logistic regression, 
including age, sex, smoking history, BMI and AMD status as covariates, the 4th 
quartile of plasma HTRA1 was not significantly associated with the HTRA1 
rs10490924 minor allele (p=0.132). 
Based on the previous observation that the effect of genotype upon plasma 
HTRA1 appears most obvious in the BMI<25 group, the combined cohorts were 
stratified by BMI category for analysis. A dominant model of logistic regression was 
used, including age, sex, smoking history and AMD status as covariates. As was 
previously predicted in the power calculations for the HTRA1 ELISA, there was a 
lack of power to detect a significant difference between genotypes in the groups with 
BMI >25.  However, in the BMI<25 group, the 4th quartile of plasma HTRA1 was 
significantly associated with the HTRA1 rs10490924 minor allele (p=0.026, OR 
2.03, 95% C.I, 1.09-3.78), corrected for confounding factors.   
Similar results were obtained when only disease-fre individuals (either 
controls from the UK2 AMD case-control cohort, or SOCCs controls) were 
investigated (Table 6.5). The median level of HTRA1 measured in 283 GG 
homozygotes was 13.21 ±1.23 (s.e.m.) ng/ml while risk (T) allele carriers (N=191) 
had a slightly higher median level of 16.09±1.51 (s.e.m.). In a regression analysis, 
including age and BMI as covariates, the upper quartile of plasma HTRA1 was 
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6.4.5.4 Retrospective power calculation for plasma HTRA1 in 
BMI<25 
The distribution of plasma HTRA1 measurements in the combined cohorts was 
normalised by √3-transformation of detectable HTRA1. The standardise  difference 
was calculated using the difference in mean transformed HTRA1 measurements 
(GG=2.57±0.056 (s.e.m.), GT/TT 2.86±0.063 (s.e.m.)) and the standard deviation of 
the measurements. Application of the standardised difference to the Altman 
Nomogram (Figure 2.1) indicate that a sample size of 230 individuals would be 
sufficient to identify a difference in plasma HTRA1 of this magnitude with 80% 
power (p=0.05). In the combined UK2 and SOCCS cohorts, plasma HTRA1 
measurements were made in 217 individuals with a GG genotype for rs10490924, 
and 201 individuals with either a GT or TT genotype. This indicates that the study is 
adequately powered to detect a significant difference i  plasma HTRA1 by genotype, 
given that confounding factors of increasing age, AMD status and BMI are corrected 
for by regression analysis. 
 
6.5  Local expression of HTRA1 in adipose tissue 
Due to the confounding effect of high body mass index upon plasma HTRA1 
concentrations, expression of HTRA1 in adipose tissue was investigated further to try 
to clarify the role of genotype upon expression of HTRA1. As shown in Figure 5.27, 
HTRA1 transcripts were detected in cDNA derived from adipose tissue. The local 
expression of HTRA1 in adipose tissue in relation t BMI and rs10490924 genotype 
(as a tag for the risk haplotype) was assessed by anal sis of microarray data from 
eleven adipose tissue biopsies, kindly shared by Professor Brian Walker. 
 
6.5.1  Expression of HTRA1 in adipose tissue biopsi es 
Expression of HTRA1 in adipose tissue correlates with elevated plasma HTRA1 in 
individuals with high BMI (Chapter 6.3.1.3, Table 6.3). As adipose tissue appears to 
contribute significantly to the systemic level of HTRA1, the expression of HTRA1 
was investigated in eleven adipose biopsy samples by microarray analysis of adipose 
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cDNA, provided by Professor Brian Walker. Figure 6.17A shows the HTRA1 
transcript intensity detected, showing a trend for elevated levels of HTRA1 in relation 
to increasing BMI. The mean intensity detected for HTRA1 transcripts in individuals 
with a BMI<25 was 5495±542 (SD), compared to an aver g  of 5813±305 (SD) for 
individuals with a BMI >30. This difference of 6% in the mean HTRA1 intensity 
from the microarray, although not statistically significant (p=0.27), reflects the 
observed effect of high BMI upon plasma HTRA1 in the ELISA measurements.  
These individuals were genotyped for the ARMS2 3’ UTR indel by PCR to 
investigate whether the risk haplotype was associated with higher HTRA1 expression 
in this tissue, as was seen systemically in plasma. Of the 11 individuals, 6 were 
homozygous wild-type for the indel (and presumed homozygous for the non-risk 
haplotype).Five individuals were heterozygous, carrying one copy of the indel 
variant associated with AMD-susceptibility. No homozygous carriers of the risk 
allele were identified. There was no significant difference in the intensity of HTRA1 
between genotype groups (non-risk, 5462±372 (SD); risk, 5542±668 (SD), p=0.80). 
The contribution of genotype within the BMI groups <25 and >30 upon 
HTRA1 expression is summarised in Figure 6.17B. In the BMI<25 group, three 
individuals were homozygous wild-type and three were heterozygous. There was no 
significant difference between mean HTRA1 intensity by genotype in this group 
(non-risk, 5630±78 (SD); risk, 5359±821 (SD), p=0.60)  In the BMI >30 group, one 
person was homozygous wild-type and two were heterozygous. There was no 
significant difference between mean HTRA1 intensity by genotype in this group 
(non-risk, 5809; risk, 5815±431 (SD).   
 




Figure 6.17  Microarray data revealed no significan t relationship 
between BMI, genotype and HTRA1 intensity. 
A. HTRA1 expression in adipose biopsy samples obtained from 11 individuals (N=6, 
BMI<25; N= 2, BMI 25-29.99, N=3, BMI>30), provided by by Professor Brian 
Walker, was investigated using the Affymetrix probe set 201185_at. A possible trend 
for increased HTRA1 intensity in relation to BMI was observed. 
B. HTRA1 expression in adipose biopsy samples genotyped for the ARMS2 3’ UTR 
indel on the chromosome 10q26 risk haplotype, divided into BMI categories. There 
was no clear relationship between genotype and HTRA1 intensity in this small 
sample size (BMI<25, WT N=3, Het N=3; BMI>30 WT N=1, Het N=2). 
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6.6   Discussion 
The AMD-risk haplotype in chromosome 10q26 may be associated with alterations 
in the expression of one of, or both, ARMS2 and HTRA1genes. Early studies 
proposed that increased HTRA1 activity, as a consequence of increased HTRA1 
expression, may increase susceptibility to AMD. The risk haplotype, tagged by 
rs11200638, was suggested to result in up-regulation of HTRA1 by the AA genotype 
compared with the GG genotype (Dewan et al. 2006). Increased levels of HTRA1 
mRNA and protein were detected in RPE from four AMD-affected individuals 
carrying the AA risk allele (Yang et al. 2006). Subsequent studies have failed to 
replicate these findings consistently, with several studies showing no significant 
difference in HTRA1 mRNA or protein in retina and placental samples of known 
genotype, and no increased promoter activity by luciferase assays (Kanda et al. 2007; 
Chowers et al. 2008; Kanda et al. 2010; Friedrich et al. 2011).  However, others have 
shown that there is a difference in promoter activity, mRNA and protein levels for 
HTRA1 in carriers of the risk haplotype using similar techniques (An et al. 2010; 
Yang et al. 2010).  
The concentration of HTRA1 in human plasma has not previously been 
reported. This chapter describes the development and optimisation of a sandwich 
ELISA to measure HTRA1 in EDTA-plasma. The optimised assay was used to 
measure plasma HTRA1 in 769 individuals from a British AMD-case control cohort 
and subsequently, in an additional 208 Scottish disease-free controls. This allowed 
investigation of an association between plasma HTRA1 and the AMD-risk haplotype 
on chromosome 10q26. In the UK2 cohort, measurements in plasma ranged from no 
detectable HTRA1 to 497 ng/ml (mean 25.94, median 20.81, s.e.m. 1.11, SD 30.85). 
In the SOCCS cohort, the range was between 0- 84.2 ng/ml HTRA1 (mean 16.02 
ng/ml, median 10.85 ng/ml, s.e.m. 1.21, SD 17.55). Measurements in each cohort, 
and in the cohorts combined, showed a leptokurtic distribution. Exclusion of 
significant outliers (mean±3 SD) reduced the range of plasma HTRA1 measurements 
to below 118 ng/ml, and reduced kurtosis (1.21, standard error of kurtosis 0.18). 
Due to the deviation from normal distribution, the effects of categorical 
covariates on plasma HTRA1 were assessed using non-parametric tests. There was 
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no significant difference observed in plasma HTRA1 concentrations between genders 
in either cohort, with males having a median of 20.79±2.10 (s.e.m.) ng/ml, compared 
to a median value of 20.78± 1.33 (s.e.m.) ng/ml in females in UK2. Median values of 
plasma HTRA1 were lower in the SOCCS cohort for both sexes; there was no 
significant difference between measurements made in males and females (p=0.268). 
Advanced age is known to increase risk of AMD development, and was 
associated with increased plasma HTRA1 concentrations in people aged >65 years in 
this cohort (p<0.001; age classified as <65 years, 65-80 years, and aged >80 years, 
Figure 6.16). Individuals aged <65 years had lower m dian plasma HTRA1 (N=249, 
10.88±1.26 (s.e.m.) ng/ml) than older individuals (N=395, 21.27±1.19 (s.e.m.) ng/ml 
in the 65-80 years category, p=0.55). 
The effect of smoking history upon plasma HTRA1 concentrations was also 
assessed by non-parametric testing. Schmidt et al. (2006) reported that the risk 
genotype of rs10490924 conferred a more substantial risk of AMD to smokers than 
to non-smokers, although no biological mechanism was proposed. Subsequent 
studies have not shown the same gene-environment int raction, so smoking is 
generally considered to be an independent risk factor for AMD (Hughes et al. 2007; 
Seddon et al. 2009; Chen et al. 2011). However, smoking increases oxidative stress, 
and is proposed to have damaging effects on retinal p gment epithelial cells and 
Bruch’s membrane during the early events of AMD development (Espinosa-
Heidmann et al. 2006; Fujihara et al. 2008). HTRA1 is rapidly up-regulated following 
oxidative stress (Zurawa-Janicka et al. 2008) and so the effect of smoking history 
upon plasma HTRA1 concentration was investigated.  
Smoking is a significant risk factor for AMD in this British AMD cohort (for 
each additional packyear, OR 1.02, 95% C.I. 1.01-1.3, p= 0.0002) and in other 
studies (Hughes et al. 2007; Seddon et al. 2009; Chen et al. 2011). The effect of 
smoking history on plasma HTRA1 concentration was tested both as ever/never 
smoked, and by pack years (0 pack years, less than 20 pack years, and more than 20 
pack years). There was no significant difference in the median or distribution of 
plasma HTRA1 concentrations between these groups of sm king history, in either 
the UK2 cohort (Table 6.2) or the SOCCS cohort (Table 6.4).  Therefore, it appears 
that smoking history has little effect on plasma HTRA1 levels, although it remains to 
   
 286 
be tested whether up-regulation of HTRA1 expression as a response to smoking 
occurs in specific tissues such as the RPE and choroid. 
  High fat diets and a high body mass index have been r ported as risk factors 
for AMD (Cho et al. 2001; Seddon et al. 2001; Seddon et al. 2003b; Seddon et al. 
2003c). BMI is not associated with increased susceptibility to AMD in this UK2 
cohort (p=0.32). However, adipose tissue is a major sou ce of a variety of pro-
inflammatory adipokines, including tumour necrosis factor (TNF) and interleukin-6 
(IL6). This leads to both local adipose inflammation and systemic inflammation, 
rendering obesity a pro-inflammatory state. In agreem nt with this, in Chapter 
4.4.3.1, BMI was identified as a significant confounding effect upon plasma CFD 
concentrations. In the current chapter, obese individuals (BMI >30) had significantly 
higher median plasma HTRA1 concentration 24.94±2.06 (s.e.m.) ng/ml), compared 
to individuals with a BMI in the healthy range (BMI<25; 14.7±0.96 (s.e.m.); 
p<0.001) in the combined UK2 and SOCCS cohorts. In the UK2 cohort stratified by 
BMI, the BMI<25 group showed the largest difference in median plasma HTRA1 
concentrations in relation to rs10490924 genotype (GG, 17.91±2.17 (s.e.m.) ng/ml; 
GT/TT, 21.53±2.15 (s.e.m.) ng/ml). Although this difference was not statistically 
significant, this likely reflected a lack of power due to reduced sample size.  
This was confirmed by the subsequent inclusion of plasma HTRA1 
measurements from 208 additional disease-free controls with BMI<25. In individuals 
with BMI<25 in the combined data, the median plasma HTRA1 concentration of 
individuals with a GG genotype was 12.72±1.21 (s.e.m ) ng/ml. This is significantly 
lower than median HTRA1 measured in GT/TT individuals (16.08±1.59 (s.e.m.) 
ng/ml) (p=0.048). Increasing age, BMI and AMD status were identified as 
confounding factors, all raising plasma HTRA1 concentrations. However, in logistic 
regression correcting for these covariates, the 4th quartile of plasma HTRA1 
measurements remained significantly associated with the risk allele of rs10490924 
(p=0.026, OR 2.03, 95% C.I, 1.09-3.78) in the BMI<25 group. Conversely, including 
only disease-free controls from either UK2 or SOCCS and correcting for BMI and 
age in logistic regression also found a significant association between plasma 
HTRA1 and risk genotype (p=0.045, N=485). Power calcul tions confirmed that the 
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study was sufficiently well powered to detect a signif cant difference in plasma 
HTRA1 measurements in this BMI category. 
In the BMI >30 group, the link between genotype andplasma HTRA1 
concentration was reduced (Table 6.3), suggesting that increased fat mass leads to 
higher systemic levels of plasma HTRA1, regardless of genotype. In order to test this 
hypothesis, data from a microarray experiment performed in the laboratory of 
Professor Brian Walker was obtained. HTRA1 expression in adipose biopsy samples 
obtained from 11 individuals (N=6, BMI<25; N= 2, BMI 25-29.99, N=3, BMI>30) 
was investigated using the Affymetrix probe set 201185_at. As shown in Figure 
6.17A, there was a suggestion of increased intensity of HTRA1 expression detected 
in individuals with higher BMI (mean intensity for BMI<25, 5494.7±543.4, mean 
intensity for BMI>30, 5813.1±304.4). The biggest difference in plasma HTRA1 
measurements by rs10490924 genotype was observed in the BMI<25 group. 
However, there was no obvious relationship between genotype (for the indel variant 
in ARMS2) and intensity of HTRA1 detected in the microarray (Figure 6.17B).  
The small number of samples involved affects the power of this microarray 
study to detect a significant difference in HTRA1 expression level by genotype. A 
minimum of six biological replicates has been suggested to ensure that statistically 
significant conclusions can be drawn from a microarray (Lee and Saeed 2007). Using 
genotype and BMI as categories for analysis reduces the number of samples in this 
study to below this threshold. Moreover, HTRA1 expression in healthy RPE from 
aged human donors exhibits intermediate levels of inter-individual variation (Booij et 
al. 2009). Although Booij et al. did not investigate HTRA1 expression in relation to 
genotype, the work of Wang et al. (2010) and Frederich et al. (2011) confirms that 
HTRA1 expression can be highly variable, irrespective of genotype. HTRA1 is up-
regulated in response to ageing, cellular stress and in diseases such as arthritis (Ly et 
al. 2000; Grau et al. 2006). The data shown in this c apter identify BMI as an 
additional confounding variable. These factors vary between individuals, and will 
complicate the analysis of a genotypic effect upon HTRA1 expression. This 
highlights the benefit of using a large cohort of samples, which have been well 
characterised for confounding factors such as age, BMI and disease, to generate more 
robust results.    
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Elevated plasma HTRA1 concentration in ARMS2/HTRA1 risk haplotype 
carriers compared with non-carriers supports a role for HTRA1 rather than ARMS2 
in AMD susceptibility. In the UK2 cohort, there was significant or suggestively 
significant association between AMD and the upper quartiles of plasma HTRA1 (3rd 
quartile, p= 0.015, 4th quartile p =0.063), when correcting for AMD-risk factors of 
age, sex, smoking history and BMI. The association between plasma HTRA1 and 
AMD is not simply a reflection of the increased susceptibility of AMD for carriers of 
the rs10490924 risk allele in this cohort (GT/TT, p=2.73x10-13, OR 3.618 (95% C.I. 
2.56 – 5.11)), as the association differs from thatseen between genotype and plasma 
HTRA1 in the same cohort. There was also some evidence that plasma HTRA1 
concentrations are higher in AMD cases with choroidal neovascularisation 
(22.63±2.21 ng/ml) compared to individuals with only geographic atrophy 
(16.65±2.33 ng/ml). This is in keeping with the more significant association of the 
risk allele of rs10490924 with CNV, compared to all AMD cases in the UK2 cohort 
(GT/ TT, p=2.99 x10-17, OR 4.445 (95% C. I. 3.145-6.284)). Previous studies have 
also suggested that the chromosome 10q26 risk-locus in reases the risk of 
development and progression of wet AMD (Dewan et al. 2006; Chen et al. 2011; 
Sobrin et al. 2011).  However, the relatively small number of GA cases in these 
studies may affect this conclusion, given that other studies find no difference 
between AMD sub-types and susceptibility as a consequence of chromosome 10q26 
haplotype (Cameron et al. 2007). 
  Interrogation of a microarray data set for a selection of 11 adipose tissue 
biopsies for variation in HTRA1 expression level as a function of chromosome 10q26 
haplotype and BMI category proved inconclusive (Figure 6.17A and B). However, a 
high BMI appears to influence plasma HTRA1 concentration. Microarray data, and 
RT-PCR performed in Chapter 5 (Figure 5.27), detect HTRA1 transcripts in human 
adipose tissue cDNA. The precise cellular source of these HTRA1 transcripts is 
unclear. Adipose tissue is composed of adipocytes, fibroblasts and macrophages. De 
Luca et al. (2003) could not detect expression of HTRA1 in adipocytes. However, 
HTRA1 expression ratio is high in adipocytes in the GNF Expression Atlas 2 Data 
from U133A and GNF1H Chips (http://genome.ucsc.edu/cgi-bin). High HTRA1 
levels have been detected in fibroblasts using immunohistochemistry (De Luca et al. 
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2003), and HTRA1 transcripts were detected in macrophage-like THP-1 cells 
(Chapter 5). It is therefore likely that the elevation of plasma HTRA1 observed in 
individuals with high BMI is a result of increased number of fat cells, macrophages 
and fibroblasts, all of which may express HTRA1. Obesity is associated with an 
increased risk of developing AMD (Seddon et al. 2003b). The role that increased 
HTRA1 expression plays in this increased risk of AMD, as a consequence of obesity, 
remains to be tested. However, if HTRA1 is able to activate CFD, this would 
contribute to the systemic inflammatory state that is characteristic of obesity (Mathis 
and Shoelson 2011). 
HTRA1 and CFD appear to be expressed in the same cellular contexts and the 
proteins interact with each other in vitro (Chapter 5). The relationship between 
rs10490924 genotype and plasma CFD in the UK2 cohort was tested using logistic 
regression, including age, sex, smoking, BMI and AMD status as covariates. The risk 
allele was significantly associated with the 4th quartile of plasma CFD (GT/TT; 
p=0.01, OR 1.96, 95% C.I. 1.18-3.26). Although AMD status is a confounding 
factor, there was no association between the CFH Y402H variant (rs1061170) and 
plasma CFD (p=0.345). This suggests that the chromos e 10q26 locus may 
contribute to systemic inflammation by elevating CFD, although the mechanism is 
unclear. This has previously been suggested for another systemic inflammatory 
marker, C-reactive protein (CRP). Elevated CRP has been associated with increased 
risk of AMD progression (Seddon et al. 2010). A recent report suggests that the risk 
haplotype in chromosome 10q26 is associated with elevated CRP in the serum of 476 
Japanese people without macular degeneration (Yasuma et al. 2010). This was most 
pronounced in individuals aged over 60 years, and is the first report of a link between 
the chromosome 10q26 AMD-risk locus and chronic inflammation. The association 
between the rs10490924 risk allele and elevated plasma CFD levels in the UK2 
AMD case-control cohort provides an additional possibility to explore in considering 
the contribution of this locus to AMD susceptibility. Furthermore, evidence has 
emerged that complement activation (indicated by an elevated ratio of C3/C3d) is 
observed in AMD cases carrying only the rs10490924 risk allele, without additional 
variants in complement genes (personal communications, Dr. Anneke den 
Hollander). 
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Further investigation of the relationship between the chromosome 10q26 
locus, elevated plasma HTRA1 and systemic and chronic inflammation is required. It 
is also necessary to determine whether elevated plasma HTRA1 concentrations 
reflect expression at the tissue level. This is especially important in the context of the 
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7.1   Introduction 
Age-related macular degeneration is the leading cause of registered blindness in 
developed countries, affecting an estimated 50 million people worldwide 
(VanNewkirk et al. 2000). Despite the considerable impact upon sufferers, effective 
therapeutic options for this progressive loss of central vision remain elusive. A better 
understanding of the genetic and molecular basis of AMD is necessary. Increased 
knowledge of the biological and pathological processes behind the disease may 
identify new therapeutic targets. Furthermore, identification of genetic risk-factors 
may allow early identification of at-risk individuals, allowing therapeutic 
intervention before photoreceptor cell death occurs, thus preventing irreversible loss 
of vision. 
In addition to environmental risk-factors, such as smoking and diet, family 
history of AMD is one of the most significant epidemiologically identified risk-
factors (Klein et al. 2004). Since 2004, considerable progress has been made towards 
identifying genes in which variants can alter AMD susceptibility. Family-based 
linkage studies, case-control association studies and, more recently, genome-wide 
association scans, have led to the identification of components of the complement 
cascade – CFH, C2, C3, CFB, CFI, CFHR1 and CFHR3 genes -  as containing risk-
modifying variants for AMD (Conley et al. 2005; Edwards et al. 2005; Hageman et 
al. 2005; Haines et al. 2005; Klein et al. 2005; Magnusson et al. 2005; Zareparsi et al. 
2005a; Gold et al. 2006; Hughes et al. 2006; Yates e  al. 2007; Fagerness et al. 2009). 
This has strongly implicated the aberrant regulation of inflammation in the disease 
process, providing important insights into the pathogenesis of the disease. 
An additional locus on chromosome 10q26 has been significantly associated 
with AMD risk in numerous studies (Majewski et al. 2003; Seddon et al. 2003d; 
Weeks et al. 2004; Fisher et al. 2005). Three genes (PLEKHA1, LOC387715/ARMS2 
and HTRA1) lie in a region spanning 220 kb; controversy over which of these genes 
contains causative variants has been on-going sincethe initial reports by Jakobsdottir 
et al. and Rivera et al. in 2005. Recently, a deletion and insertion in the 3’ UTR of 
ARMS2 which leads to rapid RNA decay of the ARMS2 transcript has been 
identified. The indel occurs along with rs10490924 and rs11200638 in a previously 
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identified risk haplotype for AMD, and has led to attention being refocused on 
ARMS2 as the AMD susceptibility gene (Fritsche et al. 2008). However, the indel is 
not always associated with loss of ARMS2 expression (Wang et al. 2010b) and loss of 
ARMS2 expression is not sufficient to explain the increased risk of AMD at this locus 
(Yang et al. 2010). 
Meanwhile, variants in HTRA1 cannot be excluded as susceptibility alleles 
for AMD. Analysis of allele frequency alone is insufficient to discriminate between 
potential causative variants in ARMS2 and those in HTRA1, due to the strong linkage 
disequilibrium between the genes (D’= 0.99; Dewan et al. 2006). Correlating 
expression data in AMD cases and controls, and a more complete understanding of 
the function of each protein is vital to determining which gene contributes to AMD 
susceptibility. This study investigated the expression and function of HTRA1, in 
order to elucidate the role of the protease in healt  and disease. 
 
7.2   Summary of results 
In this study, interacting partners of HTRA1 were id ntified using a combination of 
yeast two-hybrid screening and tandem affinity purification (TAP). This identified a 
large number of potential interactions, some of which have proposed roles in AMD 
pathogenesis (Chapter 3). One such interactor, CFD, was selected for further study 
and was found to be significantly associated with AMD at the genetic and protein 
level (Chapter 4). The interaction between CFD and HTRA1 was investigated in 
vitro and resulted in activation of CFD and consequently, the alternative complement 
pathway (Chapter 5). Consistent with this, serum from patients with CARASIL – 
caused by reduced activity of HTRA1 – showed deficin es in alternative 
complement pathway activity. Finally, plasma HTRA1 was found to be significantly 
elevated in carriers of the chromosome 10q26 AMD-risk haplotype, and in relation to 
other AMD-risk factors (Chapter 6). These data are consistent with HTRA1 
contributing to AMD susceptibility. 
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7.2.1 Plasma HTRA1 is elevated in carriers of the c hromosome 
10q AMD-risk haplotype  
There has been controversy about the expression level of both HTRA1 and ARMS2 
in relation to the AMD-risk haplotype on chromosome 10q26. An ELISA was 
developed to measure HTRA1 in human plasma. The ELISA was used to measure 
plasma HTRA1 in 979 individuals, including AMD cases, AMD-free controls and 
non-examined disease-free controls. Advancing age, hi h BMI and AMD status were 
significantly associated with elevated plasma HTRA1 measurements, irrespective of 
genotype at the chromosome 10q26 locus. Regression analysis was used to correct 
for these confounding factors, and a significant association between elevated plasma 
HTRA1 and genotype at rs10490924 was uncovered. Further investigation of the 
haplotype at this locus is required. However, this is the first report of elevated plasma 
HTRA1 in carriers of a risk genotype on chromosome 10q26, and adds substantial 
weight to the argument that HTRA1 may contribute to the pathogenesis of AMD. 
It is interesting to note that advancing age and high body mass have been 
identified as AMD-risk factors. These factors are significantly associated with 
elevated plasma HTRA1 measurements independently of genotype at rs10490924. 
Normal age-related changes are known to contribute greatly to the development of 
AMD, and increased expression of HTRA1 may constitute another age-related 
change. Likewise, high body mass and high fat diets significantly increase the 
susceptibility of an individual to AMD. The detection of HTRA1-specific transcripts 
in adipose tissue cDNA, together with expression data from microarray analysis of 
11 adipose tissue biopsies, confirms that HTRA1 is expressed in adipose tissue. This 
is of particular relevance as CFD, an interactor of HTRA1 identified in this study, is 
abundantly expressed in adipose tissue. CFD contributes to the systemic 
inflammatory state observed in obesity. Systemic inflammation has been observed in 
AMD cases relative to controls (Hakobyan et al. 2008; Scholl et al. 2008; Reynolds 
et al. 2009; Hecker et al. 2010). 
The identification of confounding factors for HTRA1 expression levels may 
help to explain some of the discrepant findings previously reported for HTRA1 
expression levels in relation to genotype (Dewan et al. 2006; Yang et al. 2006; 
Kanda et al. 2007; Chowers et al. 2008; Kanda et al. 2010). These studies used small 
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numbers of tissue samples, and did not account for age, BMI or other potential 
confounding factors in their analyses. Although measuring the systemic 
concentration of HTRA1 in plasma is a long way away from the site of the AMD 
lesion, this study has substantial power to detect differences of this magnitude, 
corrected for confounding factors.  
 
7.2.2   The extracellular HTRA1 Interactome  
HTRA1 is a stress-induced serine protease with a poorly characterised interactome 
and substrate specificity. Interacting partners of HTRA1 were identified in a yeast 
two-hybrid screen performed in a placental cDNA library, and by tandem affinity 
purification of tagged-HTRA1 and interactors from the cell lysate and conditioned 
media of HEK293T cells and from RPE1 cells. More than 100 potential interactors 
were identified using these two methods. Several of these confirmed previously 
identified interactions (tubulin A1, COL3A1, COL1A1), but many potential 
interactions had not previously been reported.  
 HTRA1 is a secreted serine protease, and the majority of interactors 
identified are localised to the ECM and extracellular environment. A proposed 
extracellular interactome for HTRA1 was constructed (Figure 3.8). An abundance of 
ECM structural constituents were identified as interacting with HTRA1 (including 
COL1A1, COL3A1, FBLN1, FN, SPARC, THBS1). Many of these are expressed by 
RPE cells and are found in the Bruch’s membrane (Figure 1.4). There was substantial 
overlap between the HTRA1 interactome shown in Figure 3.8 and the network of 
proteins which are differentially expressed in AMD and disease-free primary RPE 
cells (An et al. 2006). Many of these proteins have known roles in angiogenesis, 
TGF-β signalling and regulation of matrix metalloproteas ctivity. Furthermore, 
expression of several of these interactors in the eye has been reported to increase 
with age, or to be altered in AMD.  This suggests that ECM remodelling mediated by 
HTRA1 activity may influence a variety of pathways involved in AMD 
pathogenesis, although further work is required to confirm the mechanisms of action.  
 Several of the novel interactions identified in the yeast two-hybrid screening 
or by TAP were validated using GST-pulldown assays and protease assays using 
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recombinant proteins. Thrombospondin-1, identified as an interactor of HTRA1 
using TAP, was shown to interact with, and to be a substrate for HTRA1 (Figure 
3.13B). Thrombospondin-1 has been shown to localise to the basement membrane of 
RPE cells, and to play a role in activating TGF-β signalling, inhibiting the action of 
VEGF, MMP2 and MMP9 in the ECM. The interaction with connective tissue 
growth factor, which is also involved in VEGF and TGF-β signalling pathways, was 
similarly validated (Figure 3.15). CTGF expression is elevated in AMD eyes, and 
plays a role in photoreceptor survival, ECM remodelling and fibrovascular scarring. 
It is encouraging to note that both CTGF and THBS1 have previously been 
implicated in AMD (He et al. 2003; He et al. 2006; Uno et al. 2006; Bhutto et al. 
2008). Further investigation of these proteins is warranted, both as substrates for 
HTRA1 and as independent risk-factors for disease.  
 Complement Factor D (CFD) was also identified as aput tive interactor of 
HTRA1 in the yeast two-hybrid screening. This is the first report of a direct 
interaction between an activator of the alternative complement pathway and HTRA1. 
The minimal binding site for the interaction incorpated the 5 amino acid pro-
peptide of CFD, which must be cleaved to activate the mature CFD protein. In vitro 
GST-pulldown assays confirmed an interaction between th  mature CFD protein and 
HTRA1; however, the activation peptide was both necessary and sufficient for CFD 
to be a substrate for HTRA1. 
 
7.2.3  The contribution of CFD to AMD-susceptibilit y 
The alternative complement pathway is accepted to play a major role in the 
pathogenesis of AMD. Complement proteins have been id tified in drusen 
(Hageman et al. 2001; Crabb et al. 2002). Variants in several alternative complement 
pathway genes have been associated with AMD susceptibility (Conley et al. 2005; 
Edwards et al. 2005; Hageman et al. 2005; Haines et al. 2005; Klein et al. 2005; 
Magnusson et al. 2005; Zareparsi et al. 2005a; Gold et al. 2006; Hughes et al. 2006; 
Yates et al. 2007; Fagerness et al. 2009). Activated components of the alternative 
pathway are elevated in plasma from AMD cases compared to controls (Hakobyan et 
al. 2008; Scholl et al. 2008; Reynolds et al. 2009; Hecker et al. 2010). However, 
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previous studies had not shown association between variants in CFD and AMD, 
although this was confounded by small numbers of cases nd controls (Zeng et al. 
2010). Two intronic variants in CFD were genotyped in a UK case-control cohort, 
and the minor allele of rs3826945 SNP was found to be significantly associated with 
an increased risk of AMD (OR 1.44, 95% C.I. 1.04-2.00, p=0.028). Subsequently, a 
further UK series, three case-control series from the USA and one comprised of 
Dutch and German individuals was also genotyped for this SNP. None of the four 
additional cohorts showed a significant association with AMD independently, but 
meta analysis of the combined cohorts (4765 cases and 2693 controls) identified a 
significant association between AMD and the minor allele of rs3826945 (OR=1.11, 
C.I. 1.01-1.23, p=0.032). This variant has a small effect on AMD-risk (OR =1.1) and 
is unlikely to explain much of the population-attributable risk of AMD. The apparent 
differences between the two UK series, and the seri f om North America and 
Europe is difficult to account for. Similar minor allele frequencies were observed 
between cases and controls in all series (and in the previously reported investigation 
of CFD variants in relation to AMD). This suggests that population substructure is 
unlikely to account for the differences observed. This is consistent with an earlier 
study which did not find this region on chromosome 19 to be subject to population 
stratification within the UK (WTCCC 2007). It seems likely that incomplete BMI (or 
other phenotypic characteristics) information for all cohorts may help to explain the 
discrepancies between series. Recent genome-wide associ tion scans have not 
identified variants in CFD as AMD-susceptibility loci (Chen et al. 2010; Yu et al. 
2011). A potential benefit of investigating an association between AMD with 
variants in a specific gene is that the stringent thresholds used in correction for 
multiple testing are not required. This may allow the positive identification of 
variants with a small effect on disease risk to be identified.  
 The variant in CFD that was associated with AMD is located in intron 4. This 
SNP is not predicted to affect exon splicing, as has been reported for other intronic 
variants in genes associated with AMD (Kralovicova and Vorechovsky 2009). 
Sequencing of the coding region of CFD did not identify coding changes in LD with 
rs3826945 that might result in altered function of CFD. A reasonable hypothesis is 
that this variant is in linkage disequilibrium with an unidentified variant(s) that 
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affects expression levels of CFD. This would be consistent with the observation of 
elevated plasma CFD concentrations in AMD cases relativ  to controls, and also to 
systemic inflammation having a role in AMD. The current study is underpowered to 
detect differences in CFD expression in relation to SNP genotype, due to the small 
effect size and confounding factors of age, sex and AMD. 
Copy number variation is becoming increasingly well studied in relation to 
diseases, including systemic lupus erythematosus, auti m, rheumatoid arthritis and 
cardiovascular disease (Fanciulli et al. 2010). Copy number variation affecting CFD 
was observed in a small number of AMD cases and controls; however, there was no 
significant difference in the frequency of duplicatons or deletions between groups. 
Further investigation into the role of copy number va iation (as has been seen with 
CFHR1 and CFHR3) in AMD genetics may be useful to develop a complete 
understanding of the genetic basis of the disease. 
 
7.2.4  HTRA1 activates CFD in vitro: implications i n AMD 
CFD was identified as an interactor of HTRA1 in a yeast-two hybrid screen. The 
minimal binding site required for the interaction encompasses the five amino acid 
activation peptide of CFD. Subsequent experiments using synthetic peptides and 
purified CFD showed that the activation peptide is necessary and sufficient for 
HTRA1-mediated cleavage of CFD. The mature CFD protein, which lacks the 
activation peptide, is not subject to cleavage by HTRA1 in vitro. 
 The functional consequences of HTRA1 cleaving recombinant proCFD were 
investigated in several assays of alternative comple ent pathway activity. In each 
assay, proCFD that had been pre-treated with HTRA1 was able to activate the 
alternative complement pathway in vitro. This was determined by monitoring the 
cleavage of Factor B, or by the formation of the MAC and subsequent lysis of red 
blood cells.  
 The finding that HTRA1 is able to activate proCFD in vitro is intriguing, 
given that the protein responsible for the activation of proCFD in humans remains 
unidentified. A recent study found that Masp1 is reponsible for the activation of 
proCFD in mice (Takahashi et al. 2010). However, in humans, CFD is thought to be 
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activated during secretion, and MASP1 transcripts were not detected in adipose tissue 
or in other major sources of CFD production. HTRA1 is expressed in these tissues, 
and in cell-lines with physiological relevance to AMD. Co-expression is required for 
the in vivo interaction of the proteins, and CFD and HTRA1 appear to be co-
expressed in a wide range of tissues.  
 
7.2.5 Reduced HTRA1 activity correlates with reduce d 
alternative complement pathway activity 
Several serine proteases have been found to activate proCFD in vitro, although these 
are not considered candidates for the in vivo activation (Fearon et al. 1974; 
Yamauchi et al. 1994). The relationship between HTRA1 activity and alternative 
complement pathway activation (as a reflection of pr CFD activation) was assessed 
in the sera from CARASIL patients. These individuals have mutations in HTRA1 
which cause reduced function of the protease (Hara et al. 2009). Reduced HTRA1 
activity causes uncontrolled TGF-β signalling, thickening of cerebral arteries and 
ischeamic stroke. There have been no reports of increased susceptibility to bacterial 
infection in CARASIL patients, such as would suggest a deficiency in the alternative 
complement pathway.  
However, in the sera from three patients with mutations in HTRA1, reactive 
lysis of sheep red blood cells mediated by the alternative complement pathway was 
significantly reduced, relative to disease-free controls. This does not seem to reflect a 
systemic deficiency in alternative complement pathway components: CFD 
concentrations measured by ELISA were within the normal range previously 
reported (Hiemstra et al. 1989). Factor B concentrations, as seen in Western blots, 
were variable, but this is also consistent with the wide range of CFB that has been 
reported in healthy individuals (Reynolds et al. 2009; Scholl et al. 2008; Hecker et al. 
2009). Sera were supplemented with Cobra Venom Factor (a C3b analogue), so C3 
deficiency is not a factor. Additionally, the convertase formed by CVF is not subject 
to inhibition by CFH or CFI; high concentrations of the endogenous inhibitors of 
complement activation cannot explain the differences observed in CARASIL sera.  
Cleavage of endogenous factor B in CARASIL sera was assessed by Western 
blotting of sera supplemented with CVF. Conversion of Factor B to Bb did not 
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appear to be grossly affected, although may be slightly reduced as a proportion of 
total factor B. However, a high molecular weight complex was recognised by the 
anti-Factor B antibody in all of the CARASIL sera, and not in control sera. The 
molecular weight is consistent with the CVF(C3b)-Factor B complex. This is the 
labile pro-C3 convertase, in which Factor B is held in an “open” conformation to 
allow cleavage by CFD (Forneris et al. 2010). The presence of this pro-C3 
convertase in the sera of CARASIL patients is consistent with reduced CFD-
mediated cleavage of Factor B to form the C3bBb convertase, implicating HTRA1 in 
activation of proCFD. Given that the CARASIL sera retain the ability to activate 
factor B and the C3 convertase, it is unsurprising that alternative complement 
pathway deficiency has not been described in CARASIL patients. Previous studies of 
CFD deficiencies caused by mutations in CFD have found that increased 
susceptibility to bacterial infection appears to affect only some individuals with a 
complete absence of CFD. Individuals who are heterozyg us for loss of function 
mutations in CFD are not reported to have increased susceptibility to infection, and 
sera are normal in complement assays (Hiemstra et al. 1989; Biesma et al. 2001; 
Sprong et al. 2006). 
 
7.3 Proposed roles for HTRA1 in AMD pathogenesis 
Plasma HTRA1concentration was significantly elevated in disease-free carriers of 
the chromosome 10q26 risk haplotype. The effect of the risk haplotype on the 
neighbouring protein ARMS2 remains unclear, but this implicates HTRA1 in AMD 
susceptibility. In plasma, the concentration of HTRA1 increases with age and high 
BMI – factors associated with increased risk of developing AMD. Elevated plasma 
HTRA1 concentrations were also measured in AMD cases relative to controls.  
This study has identified a number of potential substrates for the protease. 
These suggest a role for HTRA1 in neovascularisation, wound healing following 
chronic inflammation, complement regulation and thickening of Bruch’s membrane 
with age.  The proposed contribution of HTRA1 to disease is summarised in Figure 
7.1. 
 







Figure 7.1  Proposed involvement of HTRA1 in AMD pa thogenesis. 
The formation of drusen and subsequent development of AMD pathology is 
increased by, and contributes to, local and systemic inflammation.  Ageing, 
environmental factors and genetic factors alter susceptibility to disease. HTRA1 is 
elevated in carriers of the chromosome 10q26 AMD-risk haplotype, with increasing 
age, and by high BMI, and may contribute to a variety of stages in AMD 
pathogenesis, indicated by green arrows. Figure adapte  from Anderson et al. (2010). 
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7.3.1 Remodelling of the Bruch’s membrane by HTRA1 
The interactome identified by TAP and yeast two-hybrid screening showed that 
HTRA1 interacts with a broad range of ECM proteins. The potential roles of several 
of these interactions in health and disease were discussed in Chapter 3. Many of the 
proteins are important components of Bruch’s membrane (BM) (Booij et al. 2010), 
suggesting that the BM may be particularly susceptible o the activity of HTRA1. 
This is consistent with the expression of HTRA1 by RPE cells.  Changes to the 
Bruch’s membrane ECM may play a role in drusen formation and in initiating AMD 
(Spraul et al. 1999; Chong et al. 2005).    
 In agreement with previous reports (De Luca et al. 2004; Murwantoko et al. 
2004), several types of collagen were identified as interactors of HTRA1 (COL1A1, 
COL3A1, COL5A2, COL12A1). These are abundant throughout Bruch’s membrane, 
but particularly in the collagenous layers. Fibronectin was also previously reported as 
an interactor and substrate of HTRA1. Fibronectin is a component of the collagenous 
layers of the BM, and is also important in the formation of blood vessels. Novel 
interactions with Laminin alpha 4, and with thrombosp ndin-1 were identified. 
These proteins are found abundantly in the basement mbrane of both the RPE and 
choroidal epithelium (Carron et al. 2000; Miyajima-Uchida et al. 2000; Booij et al. 
2010).  
BM is vital to maintaining healthy RPE, playing a cru ial role in the 
exchange of biomolecules from the choroid and the photoreceptors. Damage to 
Bruch’s membrane – for example, caused by age-related changes or oxidative 
damage – compromises the RPE layer, and has detrimen al consequences for the 
overlying photoreceptors. Indeed, age-related changes in BM are a contributing 
factor for the development of AMD. It is possible tha  HTRA1-mediated degradation 
or cleavage of some components of the BM may further exacerbate such damage. 
Such a sequence of events has previously been suggested as a result of the 
proteolysis of vitronectin and clusterin by HTRA1 (An et al. 2010). These proteins 
inhibit the formation of the terminal complex of the complement pathway. Their 
degradation may result in increased RPE cytolysis and inflammation. For example, 
expression of THBS1 increases in the retina with age (Chowers et al. 2003) but is 
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decreased in AMD eyes (Uno et al. 2006; Bhutto et al. 2008). If reduced THBS1 
expression is pathogenic in AMD as has been suggested, the activity of HTRA1 may 
contribute further to the associated processes.  
Thrombospondin-1 is a multi-functional protein. It is feasible that the 
cleavage of thrombospondin-1 by HTRA1 may affect a diverse array of processes in 
the eye including ECM deposition and turnover (through inhibiting MMP2 and 
MMP9), RPE cell-matrix interactions and regulation of inflammation. Furthermore, 
this protein has both anti-angiogenic and pro-angiogenic properties, including 
inhibition of VEGF signalling and activation of TGF-β signalling (Good et al. 1990; 
Murphy-Ullrich et al. 1992; Nicosia and Tuszynski 1994; Gupta et al. 1999; Bein and 
Simons 2000; Rodriguez-Manzaneque et al. 2001; Sheridan et al. 2002; Zamiri et al. 
2005). Dysregulation of these processes following aberrant proteolysis may have 
profound effects, in relation to both the dry and wet forms of AMD.   
 A second possibility is that HTRA1 cleaves components of the ECM, 
releasing peptide fragments that have different roles to the full-length protein. This 
has been observed with fragments of CTGF and THBS1, amongst others. If the 
balance of proteolysis is disturbed – by increased levels of HTRA1 as a result of 
genotype, age, or BMI – it may have detrimental effects. Fragments of CTGF have 
fibrotic activity, and lead to deposition of additional ECM components (Ruiz-Ortega 
et al. 2006). This has been implicated in fibrovascular scarring but may also have a 
role in the pathological thickening of the BM.  Given that CTGF has been reported to 
enhance survival of photoreceptor cells in vitro (Hauck et al 2008), the activity of 
HTRA1 towards this particular substrate may also affect photoreceptor cells directly.  
 Thirdly, cleavage of ECM components such as collagen may have a direct 
effect on signalling pathways, via the release of ligands which are normally bound to 
matrix proteins. MMP9-mediated cleavage of collagen fibres releases mature TGF-β 
from the latency associated peptide (LAP) and TGF-β–binding protein (LTBP) 
which are responsible for sequestering the ligand in the ECM (Taipale et al. 1994; 
Yu and Stamenkovic 2000; Dallas et al. 2002). In addition to MMPs, serine proteases 
can also release TGF-β from the ECM, so it is feasible that HTRA1 activity may 
affect signalling pathways.   
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7.3.2  Regulation of TGF- β signalling by HTRA1 
The TGF-β signalling pathway has many roles during development, and in adult 
tissues. In addition to regulating cell function, proliferation, differentiation, and 
migration (Massague 1990), TGF-β signalling is also involved in modulating 
inflammation, immune homeostasis and wound repair (Wan and Flavell 2007). The 
TGF-β superfamily includes TGF-βs, bone mophogenic proteins (BMPs) and growth 
differentiation factors (GDFs). Members of each of these families of ligands have 
been found to interact with HTRA1 intracellularly and extracellularly, resulting in 
inhibition of TGF-β signalling temporally and spatially (Oka et al. 2004; Shiga et al. 
2011). GDF15 was identified as an interactor of HTRA1 in this study, although 
further experiments were not performed. However, HTRA1 appears to be an 
important antagonist of TFG-β signalling, as shown when the activity of the protease 
is reduced in CARASIL (Hara et al. 2009). Protease ctivity is important to the 
regulation of TGF-β by HTRA1 (Oka et al. 2004; Hara et al. 2009; Shiga et l. 
2011). Reduced HTRA1 activity leads to uncontrolled TGF-β signalling and 
thickening of cerebral small vessels by deposition of fibronectin (Hara et al. 2009).  
 The proTGF-β proprotein is processed in the trans-Golgi network by 
proprotein convertases such as furin, to generate mure TGF-β and a latency-
associated peptide (LAP). Dimers of TGF-β form a non-covalent complex with LAP, 
which then binds to LTBP (Miyazono et al. 1991). This complex is secreted from the 
cell, where it becomes anchored to the ECM. Once sequestered in the ECM, mature 
TGF-β can be released into the extracellular space by the action of MMPs, serine 
proteases and acidic microenvironments (Annes et al. 2003). As hypothesised earlier, 
HTRA1 may be involved in the release of TGF-β from the ECM, activating 
signalling in this pathway.  
 Conversely, recent work by Shiga et al. (2011) has shown that HTRA1 
directly cleaves the pro-domain of proTGF-β1 in the endoplasmic reticulum (ER). 
This results in degradation of the processed TGF-β1 product by the ER-associated 
degradation (ERAD) system, reducing the amount of mature TGF-β1. This novel 
mechanism of regulating TGF-β1 may be specific to the tissues affected by 
CARASIL, which include human cerebral small vessels, but may also have 
   
 305 
implications in AMD where HTRA1 appears to be up-regulated, particularly in 
carriers of a risk genotype on chromosome 10q26.  
The contribution of HTRA1 to dysregulation of TGF-β signalling becomes 
more complex with the consideration of thrombospondin-1 and CTGF, two 
substrates for HTRA1 identified in this study. Thrombospondin-1 binds the growth 
factor in its active and latent forms, and also activ tes TGF-β signalling (Schultz-
Cherry and Murphy-Ullrich 1993). CTGF is a downstream mediator of the signalling 
pathway. Hypothetically, increased amounts of HTRA1 may reduce the amount of 
mature TGF-β secreted to the extracellular space. Cleavage of thr mbospondin-1 
may independently reduce activation of the pathway further. Inhibiting TGF-β 
signalling has been implicated in increased vascular and neural cell apoptosis in the 
mouse retina, resulting in decreased retinal functio  (Walshe et al. 2009). 
Conversely, minimising TGF-β has also been suggested to be beneficial in reducing 
senescence-associated changes (such as the expression of CTGF and fibronectin) in 
human RPE, such as is seen in early AMD (Yu et al. 2009).  HTRA1 may also be 
responsible for increased release of mature TGF-β from the ECM by degrading ECM 
components, including thrombospondin-1, fibronectin and decorin (Canfield et al. 
2007) thus activating the pathway.  CTGF cleavage may result in the formation of an 
active fragment which increases fibrosis as a result of TGF-β signalling.   
Without knowing the consequences of HTRA1-mediated cl avage upon 
protein function, it is difficult to speculate how TGF-β signalling may be affected. 
However, several components of the HTRA1 interactome may influence TGF-β 
signalling positively or negatively in a complicated loop. This is likely to affect 
processes including inflammation, ECM deposition and photoreceptor survival, and 
may contribute towards AMD pathogenesis.   
 
7.3.3  Alterations in VEGF signalling by HTRA1 
Wet AMD is a severe form of AMD, in which neovascularisation occurs from the 
choroid in the sub-macular region. The new blood vessels are fragile and prone to 
breakage. This can lead to leading to bleeding in the sub-retinal space, causing RPE 
and photoreceptor cell death and irreversible loss of central vision and fibrovascular 
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scarring. Under normal conditions, the choroidal vasculature is maintained by VEGF, 
which stimulates angiogenesis, and PEDF, which suppresses angiogenesis. 
Neovascularisation inwards from the choroid is thought to occur as a result of 
imbalances of these growth factors (Witmer et al. 2003).  
Normally, RPE cells constitutively express VEGF from the basal side, 
towards the choroid. PEDF is expressed in the opposite direction, towards the 
photoreceptors (Maminishkis et al. 2006). This maintains the choroidal vasculature 
and the avascular nature of the inner retina. For unknown reasons - possibly as a 
consequence of RPE dysfunction - this balance appears to change with age and in 
AMD.  
In wet AMD cases, VEGF expression is increased and PEDF expression is 
suppressed (Kvanta et al. 1996; Bhutto et al. 2006). This is also observed in 
experimental CNV induced by photocoagulation, when n ovascularisation occurs for 
several days following treatment (Renno et al. 2002). However, once the RPE cells 
repopulate the surface of the lesion (within a few weeks), PEDF expression increases 
and VEGF expression decreases. This results in resolution of the new vessels (Miller 
et al. 1990). When RPE cells are killed by injection of sodium iodate at the same 
time as photocoagulation, no new vessels form. If sodium iodate is used to kill the 
RPE cells 4 days later, the new vessels continue to grow rather than regressing 
(Yamagishi et al. 1988). Thus, RPE cells obviously play a key role in regulating 
vascularisation in the choroid. 
The significant contribution of VEGF to wet AMD has been shown by the 
success of treatment with anti-VEGF agents (Boyer et al. 2007; Kaiser et al. 2007). 
In addition to suppressing CNV, anti-VEGF therapy may also directly counteract the 
VEGF-mediated loss of tight junction integrity on the apical surface of RPE in 
confluent culture (Ablonczy and Crosson 2007). Anti-VEGF agents such as Lucentis 
and Avastin not only influence CNV, but also RPE cell integrity.  
However, regulation of pro- and anti-angiogenic growth factors involves not 
only the expression of these factors by the RPE and response by endothelial cells, but 
also the ECM (Folkman and Shing 1992). Proteins and proteoglycans of the ECM, 
and biologically active fragments of these components generated by proteolysis, can 
affect angiogenesis directly (Davis et al. 2000). Sequestered angiogenic factors are 
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also released from the matrix by proteolysis (Taipale and Keski-Oja 1997; Iozzo and 
San Antonio 2001), leading to rapid and local signalling cascades. Several of the 
interactors of HTRA1 in the ECM that were identified in this study have been shown 
to influence angiogenesis. For example, soluble fibronectin up-regulates VEGF in 
RPE cells, which can promote angiogenesis (Mousa et al. 1999). Fragments of 
osteonectin can stimulate angiogenesis (Bornstein and S ge 2002), and have 
previously been implicated in VEGF-induced CNV (Nozaki et al. 2006b). CTGF has 
been shown to co-localise with TGF-β and VEGF to CNV membranes in AMD eyes 
(Watanabe et al. 2005), and to promote angiogenesis (He et al. 2003). 
Thrombospondin-1 appears to directly bind to and inhibit VEGF, and competes with 
VEGF for binding to heparan sulphate on endothelial cell surfaces to inhibit 
angiogenesis (Gupta et al. 1999). Thrombospondin-1 also appears to have pro-
angiogenic activity in the sub-retinal space, based on evidence from an i  vitro study 
using RPE cells (Mousa et al. 1999). This contradicts a predominantly anti-
angiogenic role for thrombospondin-1 in other tissues (Good et al. 1990).  
In this study, HTRA1 cleaved thrombospondin-1 in vitro. Thrombospondin-1 
contains both pro- and anti-angiogenic domains (Good et al. 1990; Taraboletti et al. 
1990; Taraboletti et al. 2000); differential cleavage may explain these contradictory 
roles. Further work is required to determine the consequences of this upon the 
activity of thrombospondin-1 in relation to angiogenesis. However, it is plausible that 
cleavage of thrombospondin-1 in Bruch’s membrane may release the pro-angiogenic 
fragment of the protein, and/or release sequestered VEGF. This is likely to disrupt 
the balance of angiogenic signalling at the interface between the RPE and choroid, 
and may contribute to CNV. Similar theories may be proposed for other substrates of 
HTRA1 in the ECM that have been implicated in angiogenesis. In humans, the 
chromosome 10q26 risk haplotype is associated with increased susceptibility to both 
wet and dry forms of AMD (Cameron et al. 2007). However, mouse models over-
expressing HTRA1 in the RPE may suffer from more sever  CNV induced by laser 
injury (personal communications, Dr. Yingbin Fu). This is consistent with the 
protease exacerbating wet AMD in some cases. 
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7.3.4 Activation of the alternative complement path way by 
HTRA1  
There is overwhelming evidence that the alternative complement pathway is 
involved in the pathogenesis of AMD. This includes g netic association with variants 
in CFH, C2/CFB, C3 and FI (Edwards et al. 2005; Haines et al. 2005; Klein et al. 
2005; Gold et al. 2006; Yates et al. 2007; Fagerness et al. 2009). Proteomic studies 
have identified complement proteins in drusen, the c aracteristic hallmark of AMD 
(Hageman et al. 200; Crabb et al. 2002; Johnson et al. 2002), and more recently, 
systemic activation of complement has been reported in the plasma of AMD cases 
relative to controls (Scholl et al. 2008; Reynolds et al. 2009; Hecker et al. 2010). In 
this study, an intronic variant in CFD – the central activator of the alternative 
complement pathway – was associated with increased susceptibility to AMD. 
Additionally, plasma CFD concentrations were significantly higher in AMD cases 
than controls. This is consistent with chronic activation of complement contributing 
to AMD pathogenesis. 
In this study, HTRA1 was found to specifically cleav  the activation peptide 
of proCFD.  The specificity of cleavage was somewhat surprising, given the 
previously reported role for HtrA proteins in degrading mis-folded proteins (Clausen 
et al. 2002). However, consistent with this dual role, bacterial HtrA family members 
are involved in pro-peptide processing and in maturation of a native host protein 
during secretion, in addition to degradation of misfolded proteins (Poquet et al. 
2000). 
The action of HTRA1 upon proCFD resulted in the activ tion of the 
alternative complement pathway in vitro assays performed using CFD-depleted 
human serum. Conversely, in sera from CARASIL individuals with reduced HTRA1 
activity, the alternative complement pathway was les  active than in normal sera. 
This is an exciting discovery, given that the enzyme responsible for the conversion of 
the inactive zymogen proCFD to the mature CFD which c rculates in the blood in 
humans is unknown (Fearon et al. 1974; Lesavre and Müller-Eberhard 1978; 
Yamauchi et al. 1994). Furthermore, this is the first report of a link between a major 
genetic risk factor for AMD (of largely unknown function) and alternative 
complement pathway activation.  
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Can clues regarding the role of HTRA1 in activating CFD, and hence the 
alternative complement pathway, be gleaned from other pathological conditions? 
HTRA1 is highly expressed in the placenta, where it is proposed to be involved in 
extensive tissue remodelling (De Luca et al. 2003; De Luca et al. 2004). Complement 
pathways are activated during normal pregnancy (Abramson 1992). Excessive 
activation of the alternative pathway has been associated with complications of 
pregnancy. These include spontaneous abortion in mice with high levels of 
adipsin/Cfd (Takeshita et al. 2010). In humans, elevat d levels of Bb, produced by 
CFD-mediated cleavage of C3b-bound factor B, have been found in pre-eclampsia 
(Lynch et al. 2008) and pre-term labour (Vaisbuch et al. 2009). Excessive activation 
of the alternative complement pathway can also lead to pregnancy-associated 
atypical hemolytic uremic syndrome (Fakhouri et al. 2010). 
Of these conditions, over-expression of HTRA1 has previously been 
implicated in pre-eclampsia (Ajayi et al. 2008; Lorenzi et al. 2009). Interestingly, 
risk variants in complement regulatory genes, including MCP and CFI, have recently 
been shown to predispose women to the condition (Salmon et al. 2011). Other known 
risk factors for pre-eclampsia include older maternal age, obesity, oxidative stress 
and smoking. Thus, there are striking parallels betwe n risk factors for pre-eclampsia 
and AMD, both conditions in which the alternative pathway appears to be 
pathologically activated and in which HTRA1 concentrations are elevated. Given 
that the interaction between HTRA1 and CFD was ident fi d in yeast two-hybrid 
screening performed in a placental cDNA library, it would be fascinating to test for a 
genetic association between the chromosome 10q26 risk haplotype and pre-
eclampsia; such investigations have not been reportd to date. 
 
7.4  Future work 
It is unclear whether genetic variants in HTRA1 influence risk for AMD, or whether 
the genetic association with AMD on chromosome 10q26 can be attributed to 
variants in the gene encoding the largely uncharacte ized ARMS2 protein. In 
addition to showing that HTRA1 is elevated in the plasma of individuals carrying the 
risk haplotype at this locus, this study also implicates HTRA1 in a variety of 
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processes which are dysregulated in AMD pathogenesis. Perhaps the most intriguing 
finding of the study is that HTRA1 is capable of activating proCFD in vitro. 
 Although alternative complement pathway dysregulation plays a key role in 
the pathogenesis of AMD, and other diseases, there is still much to discover about 
the regulation and activation of the pathway. This is of particular importance at sites 
such as the RPE/choroid and retina, which are subject to attack in AMD, but also the 
source of systemic activation in the human body.  
A key issue is the identity of the enzyme responsible for the activation of the 
proCFD zymogen into the mature CFD which circulates in the blood. Several serine 
proteases can convert the propeptide into mature CFD in vitro when present in 
catalytic excess (Fearon et al. 1974; Yamauchi et al. 1994).  These proteases, 
including thrombin and trypsin, are not thought to be physiologically responsible 
(Takahashi et al. 2010). Recent work by Takahashi et al. has suggested that the 
mannose-binding lectin-associated serine protease-1 (Masp1), a component of the 
lectin pathway, is responsible for activating CFD in mice. However, in humans, 
MASP1 expression does not correlate with the major sites of CFD expression (White 
et al. 1992). It is possible that this is a fundamental difference between mouse and 
human complement pathways. Indeed, the alternative complement pathway of mice 
and humans is known to differ (Holers et al. 1992). CFD itself shares only 72% 
identity between mouse and human, and the activation peptide for the two species 
differs by one amino acid. Mouse CFD is heavily glycosylated and this appears 
essential for activity (Rosen et al 1989), whilst human CFD is not modified in this 
way. These differences may alter substrate recogniti n by various proteases. 
Alternatively, it may suggest that several proteases ar  responsible for activating 
proCFD in a variety of contexts. This is supported by the observation that one of the 
CARASIL patients (CARASIL2) has a premature stop codon in HTRA1 (R370X), 
resulting in nonsense mediated decay and absence of th protein in fibroblasts (Hara 
et al. 2009). This individual shows 15% of the normal level of alternative 
complement pathway-specific red blood cell lysis. Therefore, some active CFD is 
present in their serum. This may represent proCFD that escapes activation by 
HTRA1 during maturation and secretion, and is activted by MASP1 in the plasma. 
This could be addressed using mass spectrometry to quantitate proCFD in CARASIL 
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sera, relative to normal sera. This was not possible using Western blotting due to the 
difficulty of resolving the small shift in molecular weight resulting from activation of 
the 5 amino acid activation peptide. Mass spectrometry could also be utilised to 
identify the high molecular weight complex containing factor B that is detected in 
CARASIL sera following addition of CVF. These two pieces of data would provide 
powerful evidence that HTRA1 is involved in the activa ion of CFD in humans.  The 
remaining alternative complement components should also be measured in these 
samples to confirm that there is no deficiency of C3 or factor B or excess of 
inhibiting factors (CFH, CFI). Normal levels of MASP1 should also be confirmed. It 
is worth noting that variants in MASP1 have not been associated with AMD (Ennis et 
al. 2008) 
In addition to the potential impact upon the alternative complement pathway, 
investigation of HTRA1-mediated changes in Bruch’s membrane remodelling, 
drusen formation, TGF-β signalling and angiogenesis should be performed. Sveral 
of the other interactors of HTRA1 that were identified in this study – for example, 
thrombospondin-1 and connective tissue growth factor – may have relevance to 
AMD pathogenesis, and are suitable targets for further investigation. It would be 
useful to study protein interactions and co-localisation in human eyes (and placental 
tissue), although these are understandably difficult to obtain. Cell culture systems 
utilising siRNA knock-down of HTRA1 and transfection to over-express the protease 
could be used to investigate the effect of protease activity upon signalling. However, 
it seems likely that the complex layered structure of the retina, specifically the 
interplay between the choroid, Bruch’s membrane and RPE, may be important in 
elucidating the whole picture. A recent report has shown that stem cells can 
differentiate to form early retinal structures in vitro (Eiraku et al. 2011). However, 
such in vitro organogenesis not easily achieved, and has yet to be developed for 
human eyes. Rather, valuable information may be obtained from mice in which 
HTRA1 is absent or over-expressed. Although such anim ls have yet to be reported, 
they are available (personal communications, Dr. Elod Kortvely, Dr. Ulrich 
Luhmann).  
A specific inhibitor of HTRA1 would be a useful tool f r investigating this 
protease, both in cell-culture and in animal models. This may also have therapeutic 
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potential in AMD in the future, although there are cl ar risks associated with reduced 
HTRA1 activity, as observed in CARASIL. The potential for partial inhibition of the 
specific cleavage of proCFD by HTRA1 may provide a better therapeutic target, with 
fewer “off-target” effects than inhibition of the either HTRA1 or activated CFD. The 
therapeutic potential of inhibiting CFD is already being explored in clinical trials.  
The data presented in this study strongly suggest that HTRA1 plays a role in 
AMD pathogenesis, expanding considerably upon the roles of this protease in AMD. 
However, these data do not exclude a role for ARMS2 in disease, as HTRA1 may be 
up-regulated by the risk haplotype that either results in loss of ARMS2 protein, 
and/or contains the A69S coding change in ARMS2 (Yang et al. 2010). The current 
confusion regarding the effect of the indel upon ARMS2 expression complicates this 
issue. If the indel does result in loss of ARMS2 protein (Fritsche et al. 2008; Zang et 
al 2010), some 40% of individuals of Caucasian ancestry will have only half the 
normal level of ARMS2 protein. Individuals who are homozygous for the indel 
(approximately 2-5% of Caucasians) will have no detectable ARMS2 (Allikmets and 
Dean 2008). Further confusing the potential impact of a deficiency of ARMS2 in 
relation to AMD risk is the observation that another variant (R38X) in ARMS2, 
which should also lead to nonsense-mediated decay of the transcript, occurs on a 
haplotype which is considered neutral or weakly protective for the disease (Allikmets 
and Dean 2008). However, if the indel does not result in loss of ARMS2 as has 
recently been suggested (Wang et al. 2010b), then att tion must be given to the 
functional effect of the A69S variant in addition to the consequences of HTRA1 up-
regulation. Although the role of ARMS2 remains to be clarified, the multi-functional 
serine protease HTRA1 seems likely to affect the balance of BM remodelling, 
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